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The Department of Environmental Protection Policy #WSC/ORS- 142-92 is a package of
material which consists of three items:
(1) Computer spreadsheet software entitled Risk Assessment ShortForm -
Residential Scenario (1 disk);
(2) A document entitled User's Guide to the Risk Assessment ShortForm -
Residential Scenario (» 30 pages); and
(3) A document entitled Documentation for the Risk Assessment ShortForm -
Residential Scenario (« 450 pages).
This package makes available a software program and guidance intended to streamline the
human health risk characterization required under the Massachusetts Contingency Plan
(310 CMR 40.00). While this risk assessment tool has been developed primarily for use at
C.21E sites where the current or foreseeable use includes residential use, it may be
generalized to other high exposure situations or employed as a screening mechanism at
other, non-residential locations. The information provided in this guidance may be used in
whole or in part by the risk assessor.
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FOREWORD
RISK ASSESSMENT SHORTFORM - RESIDENTIAL SCENARIO
The Residential ShortForm is an optional tool which has been developed by the
Massachusetts Department of Environmental Protection's Office of Research and Standards
in conjunction with the Bureau of Waste Site Cleanup to fill a perceived need for a
streamlined method of evaluating potential human health risks at state superfund sites.
The ShortForm is a LOTUS 1-2-3 (or Quattro Pro) spreadsheet incorporating standard
assumptions for a residential exposure and formulae which are used to estimate human
health risk (including estimated Excess Lifetime Cancer Risks, Subchronic Hazard Indices
and Chronic Hazard Indices). Forty-nine chemicals are currently incorporated in the
ShortForm. The Residential ShortForm evaluates potential exposures via direct contact with
soil, ingestion of garden fruits and vegetables, use of drinking water and inhalation of indoor
air. The only site specific parameters required to run the ShortForm are the exposure point
concentrations for soil, drinking water and/or indoor air. The output of the Residential
ShortForm is a package of eight summary tables which describe the exposure point
concentrations, toxicity information and potential chemical-specific, medium-specific and total
health risks. These tables would be submitted as part of a site characterization report.
The MA DEP Office of Research and Standards has also prepared a User's Guide to the Risk
Assessment ShortForm and a Documentation for the Risk Assessment ShortForm - Residential
Scenario. The Documentation... details each assumption and equation contained in the
ShortForm, develops Relative Absorption Factors and provides standardized Toxicity Profiles
for each of the 49 chemicals.
While the Residential ShortForm was developed specifically to meet the requirements of the
Massachusetts Contingency Plan (MCP) for the evaluation of state superfund sites, it has
found several additional applications, including: the calculation of site-specific target cleanup
levels; the evaluation of public water supply wells; the development of allowable
concentrations for land applied septage sludge; as a screening tool for determinations ofNo
FurtherAction Required (NFA); and as a teaching tool for university risk assessment courses.
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The Risk Assessment ShortForm, all its companion documentation and other
poUcies/information of interest will be made available to the public and the regulated
community through the State Bookstore (617-727-2834), and via a dial-in computer bulletin
board system (Modem #: 617-292-5546) being established for this purpose. Please call the
Office of Research and Standards at (617) 292-5570 for more information.
The Office of Research and Standards maintains a mailing list of companies and individuals
interested in the use of risk assessment in environmental regulation in Massachusetts. The
ORS uses this list to inform the regulated community about anticipated changes in
regulations or policies, updates of lists of standards and guidelines, and the publication of
new documents. If you would like to add your or your company's name to the mailing list,
please send a note to:
Massachusetts Department of Environmental Protection
Office of Research and Standards
ATTN: Risk Assessment Mailing List
1 Winter Street, 3rd FL
Boston, MA 02108
The policies and procedures established in this document are intended
solely as guidance. They are not intended and cannot be relied upon
to create any right, substantive or procedural, enforceable by any party
in any administrative or judicial proceeding with the Commonwealth.
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1.0 PURPOSE
This Risk Assessment ShortForm - Residential Scenario (also known as the Residential
ShortForm) and accompanying documentation is presented by the Department of
Environmental Protection as a tool for streamlining the assessment and remediation of
disposal sites in the Ch. 2IE waste site clean-up program. The Residential ShortForm will
be part of a set of ShortForms which is expected to include a number of exposure scenarios,
including Office/Commercial and Industrial/Construction spreadsheets. The ShortForms
streamline the process by providing a rapid, low cost procedure for assessing health risks.
The ShortForms are "off the shelf packages containing procedures and assumptions which
have already been approved by DEP for use in decision-making at many disposal sites.
Chapter 2IE of the Massachusetts General Laws is the Massachusetts Oil and Hazardous
Material Release Prevention and Response Act, which became law in 1983 and was amended
as a result of citizens' initiative Number 4 in 1986, and by an act of the legislature in July,
1992. This risk-based statute identifies requirements for action at disposal sites and
describes the liability issues related to disposal sites. The statute requires that the
Department ofEnvironmental Protection (DEP) ensure that actions be taken at disposal sites
as necessary to eliminate or abate "significant or otherwise unacceptable risk of harm to
health, safety, public welfare or the environment" associated with oil or hazardous materials
(OHM).
The DEP promulgated the Massachusetts Contingency Plan in 1988. Those regulations
provide the legally enforceable procedures for the implementation of the Ch. 2IE statute.
Subpart E of these regulations specifies, for disposal sites, a phased approach for assessing
the nature and magnitude of releases of OHM and their associated risks as well as for the
development and selection of remedial alternatives. If, in the absence of remediation,
significant risk exists or would exist, considering reasonably foreseeable uses of the disposal
site and surrounding environment that may be affected by OHM at the site or in the
surrounding environment, then development, evaluation and selection of remedial
alternatives is indicated. The statute requires that a "permanent solution" ultimately be
implemented at all disposal sites requiring remediation. Such a solution eliminates
significant risk for the foreseeable future.
In the Subpart E process, risk assessments can be conducted for three main reasons: first,
to determine if remediation is needed; second, to identify target clean-up levels which meet
the risk requirements; and third, to evaluate the effectiveness of remedial alternatives in
eliminating significant health risk. Therefore, the ShortForm has been designed specifically
for those purposes as described in the Phase II and Phase III sections of Subpart E.
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The ShortForm should also be useful, provided there is adequate site information available,
to evaluate if a No Further Action (NFA) determination is appropriate at other chronological
points in the process. In particular, the ShortForm can be used to determine if Short Term
Measures (STM) or Interim Measures (IM) have eliminated significant health risk. It should
be noted that an NFA determination cannot be made solely on the basis of a health risk
assessment - risks of harm to safety, public welfare, and the environment must also be
evaluated. The ShortForm may also be used to develop criteria for making imminent hazard
determinations based on health risk.
This version of the Residential ShortForm was developed for use under
the existing Massachusetts Contingency Plan.
As a result of the July 1992 legislative amendments to M.G.L. Chapter
21E, the Department's Waste Site Cleanup program is currently being
redesigned in a manner which will result in significant changes in the
MCP. As these changes are implemented, the Residential ShortForm
and its Documentation shall be revised to reflect the new program.
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
2
2.0 APPLICABILITY
This version of the ShortForm is intended for use at "residential" sites which are to be
evaluated via the health risk assessment method set forth in section 40.545(3)(g)3.b. of the
MCP, and described as a "Method 3b" risk characterization in the Department's Guidance for
Disposal Site Risk Characterization... (MA DEQE, 1989a). Method 3b risk assessments are
specifically for multi-media disposal sites. These multi-media situations are ones in which
a given receptor is exposed to contaminant situations which would not normally be dealt with
by a single medium-specific program within DEP. Examples of DEP medium-specific
programs are the Division of Water Supply, the Division of Air Quality Control, and the
Division of Water Pollution Control.
It is expected that a set of ShortForms will be developed to identify health- or risk-based
guidelines for use in evaluating the risk of harm to human health for "single-medium"
disposal sites evaluated via Method 3a of the MCP (40.545(3)(g)3.a). These guidelines may
serve as health-based clean-up levels.
2.1 Land Use
The term "residential" does not limit the applicability of this ShortForm to those disposal
sites currently in use as a residential property.
"Residential" disposal sites are those sites for which the current or reasonably foreseeable use
has been determined to be residential (see Section 5.0), or those sites which are evaluated
with an assumption that use could be residential (even though this use is not necessarily
foreseeable); or sites "surrounded" by residential properties.
Examples of locations which could be evaluated with the Residential ShortForm include:
single family homes, multiple family homes, condominiums, apartment complexes, and vacant
lots adjacent to residential property.
Residential property does not necessarily involve SOIL exposure! If there is no accessible
soil (either currently or for the foreseeable future), then soil exposures may not be counted
as an exposure medium when determining if there is a multi-media site for which the short
form is applicable.
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2.2 Exposure Scenarios
The Residential ShortForm scenario applies to disposal sites where the receptor of concern
may be exposed via one of the combinations of pathways described in Table 2-1. This figure
describes the most common "multi-media" residential scenarios. It should be noted that the
term "multi-media" should not be interpreted literally to mean where there is OHM in more
than one medium. The term is used to refer to situations where the nature of combined
exposures indicates that a single medium-specific program within DEP would not usually
handle by itself. Therefore, a "multi-media" site is actually any site which is not a "single-
medium" site - those sites which would normally be handled by one medium-specific program
within DEP. Examples of those "single-medium" sites include: exposure to OHM from in-
home use of drinking water only; exposure to OHM from indoor air vapors only.
Table 2-1
APPLICABILITY OF THE RESIDENTIAL SHORTFORM
FOR VARIOUS EXPOSURE SCENARIOS
MULTI-MEDIA SCENARIOS SINGLE-MEDIUM SCENARIOS
Use the ShortForm Do NOT Use the ShortForm
Soil and indoor air Soil and vegetables
Soil and drinking water Soil only
Soil, vegetables and indoor air Indoor air only
Soil, vegetables and drinking water Drinking water only
Soil, vegetables, indoor air and
drinking water
Vegetables only
Drinking water and indoor air
Drinking water and vegetables
2.3 Adequate Site Characterization
As is the case with any health risk assessment activity, the risk assessment results can only
be as meaningful as the site information which serves as the basis of the assessment.
Therefore, in most circumstances, the ShortForm is applicable (in a formal regulatory sense)
when the site has been adequately characterized. There are minimum information
requirements which must be met before a ShortForm risk assessment can be conducted with
the intent of using the results to characterize the health risks of the site for purposes of
showing that "no significant health risk" exists.
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USER HINT: One could use the ShortForm to conclude that remediation is
required at a site without completely characterizing the site if there is enough
information available to generate exposure point concentrations for some OHM
which are present at significant concentrations OR by running lowest reported
concentration for each OHM with risk estimates which exceed total site risk
limits. The latter approach could be used to determine that remediation is
required, but it would not necessarily be an adequate baseline health risk
assessment.
The minimum information requirements for conducting a ShortForm risk assessment, the
results of which would be used as an official health risk characterization for Phase II, Phase
EI, or for an NFA demonstration after an STM or an IM include (but are not limited to):
1. Nature and extent of the released) of OHM fully characterized.
2. All migration pathways for OHM released fully characterized.
3. All current and potential receptors or receptor groups identified.
4. All activities likely to occur at the location identified. For current and foreseeable uses of land and waters.
5. Exposure points have been identified.
6. Representative sampling and analysis of environmental media at exposure points has been conducted.
7. Background levels of OHM in appropriate media have been identified.
Section 40.545 of the MCP should be consulted to expand upon the information needs listed
above.
2.4 ShortForm Uses
2.4.1 Rough Screening
A rough screening may be conducted to get a general picture of the seriousness of a
site. This would be done when some site information is available, but the site is not
"adequately" characterized. One could determine that a site definitely requires
remediation, may require remediation, or is unlikely to require remediation. Such
an analysis could use lowest reported concentrations of each OHM in each exposure
pathway, average or mid-range values, or highest reported concentrations of each
OHM in each exposure pathway respectively. Such a screening evaluation could not
be used to make a No Further Action determination since the site characterization
is incomplete or otherwise inadequate.
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2.4.2 Phase II Baseline Health Risk Characterization
The ShortForm has been developed specifically for the purpose of conducting a
baseline health risk characterization as required in section 40.545(3)(g)3.b. For
"multi-media" sites which have been adequately characterized per the other
requirements of 40.545, the ShortForm is used to conduct the appropriate risk
characterization which serves, in part, as the basis for decisions concerning the need
for remediation. Representative exposure point concentrations are inputs to the
ShortForm.
2.4.3 Phase IH Derivation of Target Clean-up Levels
The ShortForm can be used, for multi-media sites, to identify combinations of
chemical and medium-specific concentrations which would meet applicable standards
and Total Site Risk Limits. At a given site, there may be an infinite number of
combinations which could meet the Total Site Risk Limits. In those cases, target
concentrations can be developed in a way which maximizes risk reduction and
niinimizes cost. It can also identify situations where background concentrations
prevent achievement of the Total Site Risk Limits.
2.4.4 Phase HI Evaluation of Effectiveness of Remedial Alternatives
When remedial alternatives utilizing known technologies are proposed, it is often
possible to project the effectiveness of those technologies in reducing exposure point
concentrations. When the capability of a given technology is described in terms of
likely residual exposure point concentrations, then those concentrations can quickly
be evaluated by the ShortForm to determine if that technology alone is capable of
achieving the Total Site Risk Limits.
2.4.5 No Further Action after STM or IM
Short Term Measures (STM) and Interim Measures (IM) often reduce concentrations
ofOHM at exposure points, prevent additional migration ofOHM to exposure points,
or prevent access to exposure points. Subsequent to the completion of such
measures, it may be appropriate to evaluate the risks which remain. The ShortForm
can perform this evaluation provided adequate exposure point concentrations which
are representative of foreseeable exposures can be identified based on post-STM or
post-IM sampling and analytical results. The ShortForm addresses only health risk,
but a No Further Action demonstration must also show that there is no significant
or otherwise unacceptable risk ofharm to safety, public welfare and the environment.
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2.4.6 Derivation of Method 3A clean-up levels
At "single-medium sites", Method 3.a. is used to assess human health risks. That
method utilizes, where they exist, applicable or suitably analogous public health
standards, guidelines and policies to evaluate the significance of exposure point
concentrations. Where such a standard, guideline, or policy does not exist for an
OHM of concern, a health- or risk-based guideline is to be developed. Each chemical-
and medium-specific guideline "shall be set so that the daily receptor dose resulting
from exposure to the concentration specified in the guideline shall not exceed twenty
percent (20%) of the appropriate Reference Dose or other allowable daily dose
specified by the Department and shall not be associated with an excess lifetime cancer
risk greater than one in one million."
The ShortForm can be used in an iterative manner to identify such health- or risk-
based guidelines for individual OHM. This is most easily accomplished one chemical
at a time. By entering one value in the data input section for either soil, drinking
water or indoor air for a given chemical and viewing the Risk Summary table (not the
medium-specific summary table), it is possible in a couple of minutes to identify the
concentration which meets the guideline requirements specified in the MCP.
Subsequent versions of the ShortForm may include an option to automatically
calculate such guidelines.
2.4.7 Evaluation of the existence of Imminent Hazards to Health
The Department is currently developing specific criteria which will be used to
determine what situations constitute an imminent hazard to health. In the near
future, it may be possible to use the ShortForm as part of the Imminent Hazard
evaluation process.
For example, if the total excess lifetime cancer risk for an assumed lifetime exposure
associated with contamination in an operating water supply (public or private) exceeds one
in ten-thousand, that water could be deemed unsuitable for any residential use per the
procedures in "Guide to the Regulation of Toxic Chemicals in Massachusetts Waters" (MA
DEP, 1990a).
The Drinking Water Summary Table from the ShortForm would contain the ELCR
estimate which would be compared to such a risk management criterion.
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2.4.8 Use of ShortForm as Part of a Larger Assessment
The ShortForm results by themselves adequately characterize health risks for a
receptor or receptor group only if that receptor has no exposure pathways which are
not included in the ShortForm. In circumstances where a receptor or receptor group
has additional exposure pathways not included in the ShortForm, the ShortForm
could still be applicable, provided the additional exposure pathways are evaluated and
the risks for those pathways are combined with the risk estimates from the
ShortForm to calculate Total Site Risks.
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3.0 RISK ANALYSIS PROCESS
Environmental protection often involves the regulation of situations which pose risks to
human health, safety, public welfare or the environment. During the last decade, achieving
the goals of environmental protection have increasingly relied on the process of risk analysis.
Risk analysis encompasses a broad array of techniques, combining the disciplines of science,
engineering and statistics to estimate and evaluate the probability and magnitude of health
or environmental risk. Given the frequent limitations in available, relevant information, the
challenge in risk analysis has been to make the best possible use of data and expert
assumptions or judgments to estimate adverse affects and determine appropriate measures
of protection.
The term Risk Analysis has often been used synonymously with risk assessment. However,
it is important to recognize that risk analysis involves both methods of risk assessment as
well as methods to use the resulting information for environmental decision making. This
latter process is often referred to as risk management.
The National Research Council (NRC, 1983) in the widely accepted and often quoted
document, Risk Assessment in the Federal Government: Managing the Process
describes the process of risk analysis and provides insight into the relationship and
distinction between risk assessment and risk management. In that document, the NRC
describes the two distinct elements of risk analysis as follows:
Regulatory actions are based on two distinct elements, risk assessment, the
subject of this study, and risk management. Risk assessment is the use of the
factual base to define the health effects ofexposure to individuals orpopulations
to hazardous materials and situations. Risk management is the process of
weighing policy alternatives and selecting the most appropriate action,
integrating the results of risk assessment with engineering data and with
social, economic and political concerns to reach a decision.
More recently, the Council on Environmental Quality (CEQ, 1989) explored the use of risk
analysis as a regulatory framework in the publication Risk Analysis: A Guide to
Principles and Methods for Analyzing Health and Environmental Risks . The
following discussions of risk assessment and risk management are drawn from these
documents to clarify the use of risk analysis techniques in environmental protection and the
investigation and cleanup of hazardous waste sites in Massachusetts (see Section 4.0 - Risk
Analysis Requirements).
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3.1 Risk Assessment
The risk assessment process defined by the NRC generally describes the methods employed
by the Commonwealth of Massachusetts and the federal government for the regulation of
environmental contaminants. According to the NRC, the risk assessment process involves
four steps: hazard identification, dose-response assessment, exposure assessment and risk
characterization.
Hazard Identification determines whether a substance causes adverse effects and
identifies those effects. This step describes why the substance is of regulatory
concern.
The Dose-Response Assessment describes the relationship between the level of
exposure and the likelihood and/or severity of an adverse effect. Simply speaking,
the dose-response information describes the toxicity of the substance.
The Exposure Assessment involves identifying potential routes of exposure;
characterizing the populations exposed; and determining the frequency, duration and
extent of exposure.
The last step of the risk assessment process is the Risk Characterization which
combines information from the other three steps to describe the type (e.g.,
carcinogenic or non-carcinogenic) and magnitude of risks to exposed populations. It
also identifies the uncertainty in the characterization of risks. The results ofany risk
assessment reflect scientific uncertainty resulting from limitations in available data
and assumptions that are made in the absence of such data. These assumptions and
limitations should be discussed.
Each of these risk assessment steps as it applies to the Residential ShortForm is described
in detail in separate sections of this document.
It is important to remember that risk estimates generated in the risk assessment are not
measures of actual or absolute risks. Rather, risk assessments are a tool - a method of
providing valuable information regarding potential risks to public health and the
environment. Risk assessment is used throughout the regulatory process to provide such
information, whether it is to determine "How clean is clean enough?" at a waste disposal site,
to develop drinking water standards for public water supplies, or to evaluate a proposed
facility seeking a source permit.
While ideally risk assessment is an objective analytic process based solely on scientific
considerations, subjective decisions are often made when available evidence is not conclusive
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or when assumptions need to be made. These judgments inevitably draw on both scientific
and policy decisions. The NRC makes a point to distinguish between these risk assessment
policy judgments from "judgments and choices from the broader social and economic policy
issues that are inherent in risk management decisions." It has long been recognized that
some of the controversy surrounding regulatory decisions such as what level of cleanup at
a site is appropriate, have resulted from a blurring of the distinction between the process of
risk assessment and risk management.
3.2 Risk Management
If risk assessment gives us the answer to the question "What is the risk?" then risk
management is the method for determining what to do about it. Risk management is the
decision-making process that usually considers the risk assessment results along with any
relevant political and social values and economic or engineering information. According to
the NRC, risk management involves three steps: development and evaluation of regulatory
options, selection and implementation of one or more options, and evaluation of the
effectiveness of the selected option or options.
This decision-making process necessarily requires the use ofvalue judgments on such issues
as the acceptability of the risks and the reasonableness of the costs of control. Social and
political considerations may vary from community-to-community and from year-to-year.
Factors such as engineering feasibility, while considered to be somewhat more objective, still
may change as technology progresses. In any event, it is not surprising and should be
expected that regulatory programs operating under different legislative mandates and
addressing various environmental contamination situations appear to require inconsistent
levels of control when measured by residual risk alone. Remember that the health risk
assessment is only one piece of information considered in the risk management process.
People perceive risks differently depending on the nature of the risks, their individual
experiences and the social, political or cultural context of the risk. Risk perceptions are
influenced by whether they have voluntarily agreed to bear them and whether or not they
have control over the source and management of the risks, and trust in those seen as
responsible for the risk or control of risks. Other factors affecting risk perception and
ultimately "acceptability" include such issues as fairness, equity, and the distribution of risks
versus benefits. These differences in risk perception may not affect the risk assessment
process, but clearly they can have impacts on the management and communication of risks.
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Thus concepts such as "significant risk" or "acceptable risk" do not have universal definitions,
nor are the definitions necessarily based solely on risk assessment. Many factors go into the
definition of "significant risk" which should be considered part of the risk management
decision.
The next section examines the specific legislative mandates of M.G.L. Chapter 2IE and the
regulatory requirements of the Massachusetts Contingency Plan.
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
12
4.0 MCP RISK ANALYSIS REQUIREMENTS
The Massachusetts Oil and Hazardous Material Release Prevention and Response Act,
Massachusetts General Laws Chapter 2IE (the statute) sets forth requirements for the
assessment and remediation of State Superfund sites. The statute requires that "permanent
solutions" be achieved at all disposal sites, a permanent solution being defined as one that
achieves, at a minimum, a level of "no significant risk". Permanent solutions must eliminate
any significant or otherwise unacceptable risk ofharm to health, safety, public welfare or the
environment during any foreseeable period of time, and reduce concentrations of oil or
hazardous materials to levels which would exist in the absence of the disposal site when
feasible.
The Massachusetts Contingency Plan (MCP) was promulgated under Chapter 2IE on
October 3, 1988. Similar to the National Contingency Plan (NCP) under the federal
Superfund program, the MCP sets forth the specific requirements to implement Chapter
2IE. The MCP establishes requirements and procedures for identifying, evaluating and
cleaning up releases of oil or hazardous materials to the environment.
4.1 Risk Assessment
The MCP specifies a risk assessment process that is consistent with the methods adopted
by the EPA for use on federal Superfund sites. While the basic approach and methodology
for performing risk assessments is similar in both the state and federal program, the
definition ofwhat constitutes a "significant" risk or answers the question "how clean is clean"
is unique to Massachusetts. This difference is, in fact, the result of specific risk management
decisions, and is discussed further in Section 4.2 below.
Under the MCP, the assessment and remediation of Chapter 2IE disposal sites is carried out
in a phased approach. As stated at 310 CMR 40.545, the Phase II - Comprehensive Site
Assessment has three objectives:
• characterize the type and quantity of oil or hazardous materials released at or
from the disposal site;
• characterize and evaluate the risk of harm that the disposal site poses to
human health, safety, public welfare, and the environment; and
• provide data necessary to develop remedial response alternatives as required
in 310 CMR 40.546 (Phase HI).
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Phase II investigations collect information to support development of a risk characterization.
The purpose of the characterization is to evaluate the extent to which compounds present
at a site present or may present a significant risk to health, safety, public welfare or the
environment within the meaning of the MCP. The Phase II risk characterization process
provides a framework for detennining (1) whether remediation at a disposal site is required;
and (2) the extent of remediation needed to maintain a temporary or permanent solution.
To provide more detailed guidance on how Phase II risk characterizations are performed,
DEP published a guidance document - "Guidance for Disposal Site Risk
Characterization and Related Phase II Activities - in support of the Massachusetts
Contingency Plan" (MA DEQE, 1989a). The guidance document focuses primarily on the
characterization of the risk to human health. The evaluation of risk to safety, public welfare
and the environment currently relies upon the comparison of site specific conditions to
existing standards and guidelines.
To recognize the variability of conditions commonly found at disposal sites, the MCP and the
Guidance Document describe four methods that can be used to characterize risk of harm to
human health at disposal sites. Only one of the four methods for characterizing risk is
appropriate for a given disposal site, and the Guidance Document should be consulted for
criteria to be used in method selection. The Residential ShortForm has been designed to
meet the requirements of a Method 3b (multi-media) human health risk characterization
required under the MCP, although it may have additional applications (Section 2.4).
Method 3b is appropriate when human receptors may be exposed to the oil or hazardous
materials (OHM) at or from the disposal site by more than one contaminated media, and if
there are not existing standards applicable to each OHM in every medium to which persons
might be exposed, or specific promulgated sets of cleanup levels for the site category.
In Method 3b, exposure point concentrations are compared to applicable or suitably analogous
public health standards promulgated under existing regulations, and in addition, a site
specific risk assessment is conducted. The results of the risk characterization are threefold:
(1) documentation of any comparisons to standards which were conducted, (2) an estimate
of Total Excess Lifetime Cancer Risk for each receptor group associated with the disposal
site, and (3) estimate(s) of Total Site Non-cancer Risk (as measured by a Hazard Index) for
each receptor group associated with the disposal site.
The ShortForm Risk Assessment - Residential Scenario can be incorporated into the site-
specific risk characterization required at the end of the MCP Phase II Investigation. The
Residential ShortForm is a lower cost option and a rapid tool that can be used to estimate
risks (both cancer and non-cancer) for a residential receptor assumed to live on or near a
disposal site. The ShortForm results are calculated in a manner consistent with guidance
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published by the Department (MA DEQE, 1989a) and may be directly compared to the MCP
risk management criteria (risk limits) detailed in 310 CMR 40.545(3)(g)3.b. and described in
Section 4.2 below.
4.2 Risk Management
While risk assessment and risk management are two distinct processes, how and when they
are applied can vary depending upon the application or circumstances. Oftentimes the two
steps overlap, but it is still important to recognize the differences. The risk assessment gives
us information on the level of risk associated with exposures at a site. The risk management
process defines whether those risks are considered "significant", and thus require
remediation. If remediation is necessary, the risk management process defines the level of
remediation required to achieve a permanent or temporary solution.
Permanent solution is defined in the statute and regulations, and the attainment of a
permanent solution requires the elimination of "significant risk" of harm to human health,
safety, public welfare and the environment for all current and foreseeable future uses of the
disposal site and surrounding area. In addition, & permanent solution should reduce, to the
extent possible, the level of oil or hazardous material in the environment to the level that
would exist in the absence of the disposal site - commonly referred to as "background". A
temporary solution must be implemented if a permanent remedy is not feasible at the
present time. A temporary solution eliminates "significant risk" until a permanent solution
is in place. While "Significant Risk" has no universal definition, the enactment of Chapter
2IE and the promulgation of the Massachusetts Contingency Plan required that the
Department provide a working definition. This definition forms the basis of the risk
management decisions at disposal sites.
Consistent with M.G.L. Chapter 2IE, a risk management philosophy was developed for the
MCP which: (1) recognized the legislative and referendum mandate to protect human
health, safety, public welfare, and the environment, (2) was consistent with existing state
regulatory programs, and (3) restored sites to background conditions whenever feasible. The
MCP risk characterization process was designed to ensure that this risk management
philosophy is consistently applied at all disposal sites.
Central to the Method 3b risk characterization process is the comparison of estimated Total
Site Risks to the Total Site Risk Limits contained in the regulations. These risk limits, in
combination with any applicable or suitably analogous standards, essentially define whether
a site poses a significant risk to human health. The Total Site Cancer Risk Limit is one in
one hundred thousand (1 x 10*); the Total Site Non-cancer Risk Limit is a Hazard Index
equal to 0.2.
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The MCP is explicit in its interpretation of the significance of the risk estimates. The risk
management philosophy inherent in the establishment of the risk limits is to ensure that
no potential receptor groups would experience an excess lifetime cancer risk greater than the
risk limit, regardless of the number of chemicals or exposure routes that exist at a site. The
noncancer risk limit reflects a risk management decision that exposures related to a disposal
site not contribute more than 20% of an estimated "allowable" dose - a dose which would not
result in adverse health effects. This 20% source allocation reflects the fact that everyone
is exposed to chemicals at home, at work and play, and in the ambient air. It ensures that
the combination of site- and non-site-related exposures would not be likely to result in
adverse health effects.
The risk based approach is clearly the foundation for disposal site cleanup decisions.
Remediation of the disposal site is required if: (1) Exposure Point Concentrations exceed
any applicable or suitably analogous public health standards, or (2) the estimated cancer or
non-cancer risks associated with exposure to OHM at or from the disposal site exceed the
Total Site Risk Limits (310 CMR 40.545(3)(i)). Remedial alternatives must be evaluated to
determine if they eliminate "significant risk" as defined in the MCP (310 CMR 40.546).
The Residential ShortForm was developed to provide the site manager, site owner, DEP staff
or the general public with a risk assessment tool which is compatible with the risk
management criteria contained in the Massachusetts Contingency Plan. The ShortForm can
be used to determine the need for remediation by comparing Exposure Point Concentrations
to standards and the estimated Total Site Risks to the MCP Total Site Risk Limits.
Remedial Alternatives may also be identified and target cleanup levels developed in a manner
which clearly demonstrates that they meet the MCP risk management criteria.
The risk management criteria described in this section concerns the potential
risk of harm to human health. Under the Massachusetts Contingency Plan
remediation is also required to eliminate any nsignificant risk* to safety, public
welfare or the environment. Such risks must be identified and evaluated per
the MCP, and are part of the selection criteria for remedial alternatives.
The Residential ShortForm estimates only the risk of harm to human health,
and can not be substituted for the entire risk characterization required under
the MCP. Specifically, the ShortForm meets the requirements of 310 CMR
40.545(3)(g), and does not fulfill the requirements of 310 CMR 40.545(3)(h).
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5.0 CURRENT AND REASONABLY FORESEEABLE USE
The ultimate goal of the site assessment and remediation process mandated under M.G.L.
Chapter 2IE and the Massachusetts Contingency Plan is the attainment of a "permanent
solution* which is protective of public health, safety, welfare and the environment. By
definition such a permanent solution must consider not only the current use of the site
and the surrounding area, but also any uses which may occur in the reasonably
foreseeable future.
LAND USE
The Risk Assessment ShortForm -Residential Scenario has been
developed for disposal sites whose current and/or reasonably
foreseeable future land use is determined to be residential.
GROUNDWATER USE
The Residential ShortForm may be used to evaluate disposal sites
for which the current and/or foreseeable future use of the
groundwater either is or is not drinking water.
The current and reasonably foreseeable uses of a site and the surrounding area help
define the potential receptor groups which must be evaluated and the activities by which
they may be exposed to the oil or hazardous materials. (It may be helpful to think of the
term "use" as relating to activities and exposure which may occur at a given location,
rather than as a zoning or urban planning term.) The determination of use plays a role
in both the baseline risk assessment and the selection of the remedial alternative. The
baseline risk assessment (performed as part of the Phase II investigation) answers the
question "What are the potential human health risks associated with this site as it stands
now and if it were to remain unremediated into the future?" Remedial alternatives must
be evaluated (in Phase HI) to determine if they eliminate significant risk for the current
and future uses of the site and the surrounding area.
As part of the Waste Site Cleanup program redesign, the Department
is developing a policy which will assist a site manager in determining
the reasonably foreseeable future use of a site and surrounding area.
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Determinations of current and future use must be made for both the use of the land and
the groundwater, and these determinations are independent of each other. Table 5-1 lays
out some possible exposure combinations of residential land use and groundwater use.
While the Residential ShortForm is intended for the evaluation of the residential use of a
disposal site, there is some flexibility within this use category to tailor the evaluation
considering site-specific exposures. The following sections briefly describe the options
available to the risk assessor within the limits of the residential use of the location.
5.1 Land Use Is Residential
5.1.1 Potential For Soil Contact
For disposal sites where there is potential for direct soil contact, the Residential
ShortForm version 1.6a assumes that exposure to the potential residential receptor
will occur via the incidental ingestion of soil, dermal contact with the soil, and via
the ingestion of fruits and vegetables grown in the soil. (Version 1.6b assumes the
same potential exposures with the exception of the ingestion of homegrown fruits
and vegetables.) Exposure assumptions (described in Section 8.7) consistent with
the residential use of the location were developed for this scenario and are
embedded in the spreadsheet. These assumptions cannot be modified by the risk
assessor.
If the ingestion of homegrown fruits and vegetables can be eliminated as a
pathway (either by documenting site-specific conditions which would prevent
gardening or the imposition of institutional controls which could effectively restrict
such gardening), then the Residential ShortForm version 1.6b would be considered
for use. Version 1.6b can be used to assess risks associated with direct contact
with contaminated soil, use of contaminated drinking water and/or inhalation of
contaminated indoor air.
For those disposal sites with no potential of exposure to contaminated soils, the
direct contact pathways (soil ingestion and dermal absorption) and the homegrown
fruits and vegetables pathway may be eliminated from consideration. In this case
no soil exposure point concentrations would be entered into the spreadsheet.
There may be "no potential of exposure to contaminated soils" for a number of
reasons, including: (1) the soil is considered to be uncontaminated or (2) the
contaminated soil is completely covered by a building.
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5.1.2 Indoor Air
Indoor air exposures are evaluated based upon residential exposure assumptions
(described in Section 8.11) for those disposal sites which have been impacted by
volatile organic compound (VOC) contamination. These exposure assumptions are
embedded in the spreadsheet and cannot be modified by the risk assessor.
For those disposal sites which have no potential current or future indoor air
impacts, this exposure pathway may be eliminated from consideration. In this case
no indoor air concentrations would be entered into the spreadsheet.
5.2 Groundwater Use
As part of the Waste Site Cleanup program redesign/the
Department is developing guidance on determining the current and
foreseeable use of groundwater, and on the applicability of the
Department's groundwater standards. The Documentation for the
Residential ShortForm will be revised as this guidance is completed.
5.2.1 Groundwater As Drinking Water
If the current or foreseeable use of the groundwater is determined to be drinking
water, then the potential exposures associated with the use of that water are
evaluated. The exposure assumptions incorporated in the drinking water pathway
(described in Section 8.9) are consistent with the residential use of the site. These
assumptions are embedded in the spreadsheet and cannot be modified by the risk
assessor.
5.2.2 Groundwater Is NOT Used As Drinking Water
If the current and foreseeable future use of the groundwater is determined not to
be drinking water, then this exposure pathway may be eliminated from the
assessment. In this case no groundwater concentrations of OHM would be entered
into the spreadsheet.
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5.3 Universe Of Applicable Sites
As described above and in Section 2.0, the Residential ShortForm may be considered
applicable at a wide range of disposal sites which would fall under the general category of
"residential use". The following table (Table 5-1) describes nine (9) general residential
site types based upon their potential for exposure. Only the "multi-media" types would be
evaluated via the Residential ShortForm. Table 2-1 delineates the applicability of the
Residential ShortForm for various exposure scenarios.
Table 5-1
EXPOSURES FOR RESIDENTIAL LAND USE
GROUNDWATER USE
DRINKING WATER NOT DRINKING WATER
RESIDENTIAL
LAND
USE
drinking water
soil, direct contact soil, direct contact
soil, gardening soil, gardening
indoor air indoor air
1
drinking water
soil, direct contact soil, direct contact
soil, gardening soil, gardening *
drinking water
soil, direct contact soil, direct contact *
drinking water
indoor air indoor air *
drinking water *
These sites would not be evaluated using the "multi-media"
ShortForm, as they are "single-medium" (Method 3a) situations.
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6.0 HAZARD IDENTIFICATION
For any disposal site being evaluated with the Residential ShortForm, hazards associated
with OHM located at the disposal site and the surrounding environment must be
described as part of the risk assessment process. The Hazard Identification section
identifies the OHM present at the disposal site, summarizes the analytical data which has
been collected, and describes the potential health effects which may be associated with
exposure to these materials. The Residential ShortForm currently lists 49 chemicals for
which a quantitative risk assessment may be performed. These chemicals were selected
on the basis of their frequency of occurrence at C.21E sites, and it is expected that
additional chemicals will be added to the ShortForm as it is updated. Users of this tool
are encouraged to submit suggestions for chemicals to add. The current Residential
ShortForm chemicals are listed in Table 6-1.
Table 6-1
Residential ShortForm Chemicals
Metals & Inorganics VOCs & SVOCs PAHs
(10) (22) (17)
Arsenic Benzene Acenaphthene
Cadmium 8is(2-ethylhexyl) Acenaphthylene
Chromium Phthalate Anthracene
Lead Carbon Tetrachloride Benzo[a]anthracene
Mercury Chlorobenzene Benzo[a]pyrene
Nickel Chloroform Benzo[b]fluoranthene
Silver 1, 1-Dichloroethane Benzo[g,h,i]perylene
Thallium 1,2-Dichloroethane Benzo[k]Fluoranthene
Zinc 1, 1-Dichloroethylene Dibenzo[a,h]anthracene
1,2-Dichloroethylene Chrysene
Ethylbenzene Fluoranthene
Cyanide Ethylene Dibromide Fluorene
Methylene Chloride Indeno[ l,2,3-cd]pyrene
Methyl Ethyl Ketone 2-Methylnaphthalene
Methyl t-Butyl Ether Naphthalene
Phenol Phenanthrene
PCBs Pyrene
Tetrachloroethylene
Toluene
1, 1, 1-Trichloroethane
Trichloroethylene
Vinyl Chloride
Xylenes
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
21
6.1 Identification Of Extent Of Release Of OHM
The Phase II Comprehensive Site Investigation performed under the Massachusetts
Contingency Plan is designed to gather sufficient data to define the extent of
contamination at the disposal site. This data is collected in part to support the risk
characterization process which is also required in Phase II. (For a discussion of data
requirements for the development of Exposure Point Concentrations, see Section 8.6)
The data collected should be summarized in a manner which clearly indicates which oil or
hazardous materials have been identified in each medium at the disposal site and in the
surrounding environment. The most straightforward means of presenting such data is to
construct a table (or set of tables) for each environmental medium. These tables would
present summary statistics for each OHM, including the number of samples taken, the
number of samples with concentrations reported above the Method Detection Limit, the
arithmetic mean, standard deviation and the range of reported concentrations.
The raw data is often included as an appendix to the Phase II Report. The limit of
detection should be included for each analysis. The limit of detection is the smallest
concentration or amount of a substance that can be reliably detected by a given
measurement process and distinguished from background noise. If the laboratory uses a
different definition, that should also be reported. [Analytical results are often reported as
"not-detected". Section 8.6.2.2 discusses how these values should be incorporated into the
estimation of exposure point concentrations.]
Particular attention should be given to the adequacy of site sampling. Often times site
sampling does not produce the data necessary to characterize exposures at a disposal site.
The sampling plan should insure the collection of data which can adequately characterize
exposures and risks at the disposal site, and the plan should be developed with input
from the risk assessor. Exposure points and the activity patterns of potential receptors
should be considered before the sampling is performed. A description or illustration of
the sampling design (random, cluster, grid, stratified, etc.) should be included.
One of the most common shortcomings ofPhase II Reports submitted to the
Department is the inadequacy of the site data for use in the risk assessment
It is time- and cost-effective to consult with the risk assessor before the
sampling plan is finalized
The Department has issued a policy, Suggested Outline, Content and Format of Phase II
Human Health Risk Assessment Scope of Work, (MA DEP, 1991b) which can assist the
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site manager in identifying the data requirements of the risk assessment early in the site
nfifiPRRment nrocess.assessme p ss
6.2 Elimination Of OHM From The Risk Assessment
The Residential ShortForm lists 49 individual chemicals for which risk may be
characterized. The presence of a chemical on this list, however, does not imply that the
risks associated with that chemical must always be estimated at all disposal sites. There
are several reasons why an individual chemical may be dropped from the quantitative risk
characterization, including:
• Reported levels are consistent with "background" and there is no evidence that their presence is related
to the disposal at the location,
• Low frequency of detection and low concentration, and
• The rhamiffftla are laboratory contaminants.
The first of these items is automatically addressed in the Residential ShortForm. The
spreadsheet contains a screening mechanism which eliminates chemicals which are
present at levels consistent with background. This background screen is discussed in
more detail in Section 6.3, which follows.
If a chemical is reported in the analytic data at low frequency and low concentration,
there are several options to evaluate. The risk assessor may determine that the existing
data are insufficient and additional samples need to be taken to better describe the
extent of contamination for that chemical. (The information may indicate the presence of
a localized hot-spot.) If the data are considered to be sufficient to adequately characterize
the disposal site, then the low concentration and frequency of detection may justify
exclusion of the chemical from further quantitative risk assessment. In most such cases
it is sufficient to discuss these contaminants qualitatively. It is the risk assessor's option,
of course, to carry the chemical through the quantitative risk characterization, as this
does not require much additional time or cost using the ShortForm.
Unfortunately it is not uncommon for an environmental sample to become contaminated
with chemicals unrelated to the disposal site. Such contamination may occur in the field
during the sample collection process, while the samples are being transported to the
laboratory, or in the laboratory itself either during sample preparation or the actual
analysis. The sampling plan should detail proper sampling and handling techniques, and
include adequate blank samples to identify extraneous contamination should it occur.
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Data which are determined to result from laboratory contamination may be excluded from
the risk assessment.
The decision to eliminate chemicals from the quantitative risk assessment
based on frequency of detection or laboratory contamination must be
adequately justified with supporting data
6.3 Comparison To Background Levels
The Massachusetts Contingency Plan requires that the background levels of oil or
hazardous materials at the disposal site be identified (310 CMR 40.545(3)(e)).
"Background" in the MCP is considered to be those levels of OHM which would exist in
the absence of the disposal site. The identification of background levels, however, is
often problematic due to technical considerations (care must be taken in the selection of
Rumpling locations) and cost (each background sample translates into one less site
sample). Background sampling is perceived to be pointless and contribute little to overall
knowledge of the site. As a result, the temptation to use generic lists of background
levels is very strong. Background information serves several purposes in the MCP risk
management process, however, and the use of site-specific information may be very
important in the determination of need for remediation and in the selection of a remedial
alternative.
One use of the identified background levels is the selection of contaminants for exclusion
from further assessment. Chemicals may be eliminated from the quantitative risk
characterization if they are present at levels consistent with background. Local
background information can be used in conjunction with the ShortForm in this manner,
as described below.
For more generic application, the Residential ShortForm contains a background screening
mechanism which will automatically compare the Exposure Point Concentrations entered
by the risk assessor to a list of background concentrations contained in the spreadsheet
(listed in the Toxicity Information table). There are two possible results:
• If the Exposure Point Concentration is less than the background
concentration for that chemical, then the chemical is eliminated from
further quantitative assessment and the notation "< Background" is
inserted in the column for the Operational Exposure Point Concentration.
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• If the EPC is equal to or greater than the background concentration for
that chemical, then the Operational EPC is equal to the Exposure Point
Concentration entered by the risk assessor.
The screening mechanism may be manually disabled by the risk assessor through the
Options Menu in the ShortForm. Disabling the screen is useful when site-specific
background levels are known and the risk assessor performs the background comparison
manually. In this instance, the report generated would detail the identification of
background levels, the comparison of Exposure Point Concentrations to these background
levels, and any decisions to eliminate contaminants based upon the comparison. It may
also be useful to disable the background screening mechanism when developing target
cleanup levels and evaluating remedial alternatives.
There is not one concentration of a chemical, of course, which can correctly be labelled
the background level. Hundreds of years of human activities have only broadened the
naturally occurring range of concentrations reported as "background", and this range is
best thought of as a statistical distribution. For the purposes of many environmental
regulations, however, we often select point values from the range of representative
background levels, and consider these to be representative of background. The use of
such point-value "background" levels is essentially a short-cut method which allows
consideration of background when little analytical data is available. When sufficient
information has been collected (enough site-specific background and on-site samples to
establish and describe distributions for each), comparisons to background can be
accomplished through statistical tests of the sample populations. This is rarely the case,
however, and the Residential ShortForm has incorporated the short-cut method using a
point value for its background comparisons.
The point values selected for the ShortForm background comparisons have been chosen
so that the majority of chemicals which are present at concentrations consistent with
background would be dropped from further quantitative risk assessment. Given the wide
ranges seen in distributions of background concentrations it is clear that the choice of a
point value within that range balances the need to eliminate background chemicals with
the need to retain for evaluation those chemicals whose presence is related to the
disposal practices at the site but which are reported at relatively low to moderate
concentrations. [The terms "low" to "moderate" are used here in a subjective sense to
describe concentrations which may be in or slightly above the upper bounds of the
background range. The terms imply nothing about potential human health risks.] It is
inevitable that some chemicals which are unrelated to the site disposal but present at
concentrations at the high end of the background range will not be caught by the
ShortForm's background screen. Conversely, some chemicals which are related to the
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disposal practices at the site (and are not background) will be screened out of the risk
assessment by the ShortForm. The goal is to minimize both kinds of error.
The Residential ShortForm does not contain background concentrations for all chemicals
in all media, although the Department is continuing work in this area. Until such values
are identified, any reported concentration for a chemical lacking a background level is
assumed to be above background and the associated risks will be calculated.
Alternatively, the risk assessor may identify medium-specific background concentrations
for the chemical and perform the background screen manually. The documentation for
the identification of the background value and the manual background screen should be
included in the written report.
The following sections describe the background values identified for use in the
Residential ShortForm. The background concentrations were selected from several
different data sources as no one source was determined to be adequate. General factors
which influenced the selection of these values included the size of the data set from
which they were derived, their suitability for comparison to Massachussets environmental
media and their comparability to analytical data typically generated at 2IE disposal sites.
6.3.1 Background Levels In Soil
Soil background levels have been identified for 24 chemicals and a list of these
values is given in Table 6-2. These soil background levels are described in the
sections which follow, grouped according to the data sets from which they were
derived.
6.3.1.1 Chromium, Lead, Nickel and Zinc
The background soil concentrations for these four chemicals were estimated from
a data set published by Peter Veneman of the Department of Plant and Soil
Sciences at the University of Massachusetts at Amherst (Veneman, 1985). This
data set consists of individual data points for various locations throughout
Massachusetts. The Veneman data were preferred when available because it is a
large data set, it represents only Massachusetts conditions, and the sampling and
analysis were done in a manner that appeared to be both more consistent from
location to location and more comparable with methods used in site assessment.
The data selected consisted of 36 surficial (approximately 0-2 feet) soil samples.
Samples taken from current or former orchards were excised from the lead data
set, however, due to historic pesticide use. This left 28 data points for lead.
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For each of the four chemicals, cumulative frequency plots were generated for
each chemical (Figures 6-1 through 6-4) and the 95
th
Percentile value was
estimated graphically.
Table 6-2
SHORTFORM SOIL BACKGROUND CONCENTRATIONS
Background Background
Soil Cone. Soil Cone.
Chemical mg/kg Chemical mg/kg
Arsenic 32 Fluoranthene 0.5
Acenaphthene 0.5 Fluorene 0.5
Acenaphthylene 0.5 Indenof l,2,3-cd]pyrene 0.5
Anthracene 0.5 Lead 69
Benzo[a]anthracene 0.5 Mercury 0.5
Benzo[a]pyrene 0.5 2-Methylnaphthalene 0.5
Benzo[b]fluoranthene 0.5 Naphthalene 0.5
Benzo[g,h,i]perylene 0.5 Nickel 30
Benzo[k]fluoranthene 0.5 Phenanthrene 0.5
Chromium 105 Pyrene 0.5
Chrysene 0.5 Thallium 19
Dibenzo[a,h]anthracene 0.5 Zinc 110
6.3.1.2 Arsenic and Mercury
The background concentrations for these two chemicals are taken from the U.S.
Geological Services Professional Paper 1270 (Shacklette, 1984). This report
summarized data rather than list the individual data points. For each chemical,
the number of samples, range, geometric mean and deviation were given.
Assuming that each data set fit a lognormal distribution, the upper 95 Percent
,th
limit was estimated as described in Table 6-3. The 95 limit (corresponding
approximately to the 97.5
th
percentile value) was chosen as the concentration below
which background concentrations of arsenic and mercury are likely to fall at most
locations. Table 6-3 presents this information for these chemicals.
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TABLE 6-3
METALS CONCENTRATIONS IN EASTERN U.S. SOILS
from Shacklette, 1984)
GEOMETRIC GEOMETRIC UPPER 95%
MEAN DEVIATION RANGE LIMIT*
METAL RATIO' Uig/g) (Mgfe> <Mgfe> 0*gfe)
Arsenic 521/527 4.8 2.56 <0.1 - 73 32
Mercury 534/534 0M1 2^52 001 - 3.4 0£
Ratio = # detected/* Samples
95% of the samples in randomly selected soil should fall between the levels M x D and M/D , where M is the
geometric mean and D is the geometric deviation.
6.3.1.3 Polycyclic Aromatic Hydrocarbons (PAHs)
Polycyclic Aromatic Hydrocarbons (PAHs) are ubiquitous environmental
contaminants resulting from combustion. Known sources of PAHs include forest
fires, waste incineration, and the burning of fossil fuels in automobiles and
airplanes. PAHs are often reported at C.21E disposal sites, and "background*
values (listed in Table 6-2) are included in the Residential ShortForm to eliminate
from quantitative risk assessment those PAHs consistent with levels from the
general anthropogenic non-point sources. It is recognized, however, that these
values do not represent clear delineations ofwhat situations are and are not related
to discrete disposal sources.
A review of the literature (Edwards, 1983; Jones, 1989a and 1989b; Vogt, 1987;
Youngblood, 1975; and Wang, 1981) and MA DEP data (MA DEQE, 1989b; MA
DEP, 1990b) provided a range of Total PAH values from 0.073 ppm (mean) to 60.3
ppm (one sample) from areas considered to be background (in this case,
background is considered to be an area not associated with a known point-source.
It is not necessarily pristine.) Based on this information, a Total PAH level of 10
ppm has been identified as an upper percentile value "background" concentration.
This Total value has been apportioned among the 17 PAH compounds listed in the
Residential ShortForm, resulting in a value of approximately 0.5 ppm for each
compound.
The apportioned value of 0.5 ppm for each of the Residential ShortForm PAHs
may not be appropriate in situations where only one of two PAHs are present.
The user is reminded that site-specific information can be used to screen
contaminants of concern before Exposure Point Concentrations are entered into
the spreadsheet (Section 6.3). Alternatively, the concentration of Total PAHs may
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be manually compared to the 10 ppm Total PAH level discussed above. Exposure
Point Concentrations would not be entered into the ShortForm if the calculated
Total PAH concentration were less than the 10 ppm "background" level.
Documentation of such a comparison must be included in the report to justify the
elimination of PAH compounds from further quantitative assessment.
The Department is extremely wary of the publication of these
values, and the risk assessor is cautioned against using them in any
other context. Further research is necessary to better identify
"background* levels for each of the PAH compounds, and these
values are sure to be updated m later versions of the ShortForm,
6.3.2 Background Levels In Air
Indoor air background levels have been identified for 13 chemicals and a list of
these values is given in Table 6-4. These levels are described in the sections
which follow, grouped according to the source from which they were taken.
TABLE 6-4
SHORTFORM INDOOR AIR BACKGROUND CONCENTRATIONS
Chemical Background Background
Indoor Air Indoor Air
Cone Cone
M*/m3 Chemical M*/«»»3
Benzene 21 Naphthalene 5
Carbon Tetrachloride 1 Tetrachloroethylene 11
Chlorobenzene 10 Toluene 29
Chloroform 3 1, 1, 1-Trichloroethane 30
Ethylbenzene 10 Trichloroethylene 5
Methylene Chloride 600 Xylenes 40
Methyl Ethyl Ketone 42
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6.3.2.1 Benzene, Carbon Tetrachloride, Chloroform, Ethylbenzene,
Methyl Ethyl Ketone, Tetrachloroethylene, Toluene,
1,1,1-Trichloroethane, Trichloroethylene
The background concentrations in indoor air for these nine chemicals were taken
from an analysis of the National Ambient Volatile Organic Compounds Data Base
(Shah, 1988). The concentrations chosen from this database represent the Upper
Quartile (75%) values from each of the data sets. Table 6-5 presents these data.
This data base was chosen as the principal source for the indoor air background
concentrations, due primarily to the large number of samples, on the order of
approximately 2000 per chemical (Methyl Ethyl Ketone and Toluene being the
exceptions with 4 and 220 samples respectively).
The values were presented in the paper in parts-per-billion by volume, and were
converted to iig/m for use in the ShortForm: pg/m = (ppbv * MW) + 24.45
(@ 25° C), where MW is the compound's molecular weight.
TABLE 6-5
INDOOR AIR CONCENTRATIONS
(modified from Shah, 1988)
# of Data Upper
Points Average Median Quartile
Chemical M*/«n3 /**/n»
3
M*/n»3
Benzene 2128 16.5 10 21
Carbon Tetrachloride 2120 2.5 0.0 0.8
Chloroform 2120 4.0 0.51 3.4
Ethylbenzene 2278 12.5 4.8 9.6
Methyl Ethyl Ketone 4 27.2 21.1 42.2
Tetrachloroethylene 2195 20.7 5.0 11.0
Toluene 220 27.8 6.2 28.7
1, 1, 1 -Trichloroethane 2120 266 10 29.9
Trichloroethylene 2132 7.3 0.7 4.6
6.3.2.2 Chlorobenzene, Methylene Chloride, Xylenes, Naphthalene
The background concentrations in indoor air for these four chemicals were taken
from an analysis of VOCs in the residential environment (Stolwijk, 1990). This
paper presents the arithmetic mean and 10*, 50th
,
90
th
,
and 98th percentile values
for various organic compounds in indoor air, generated primarily from a German
survey of 500 homes, but considering additional studies yielding a total of 1160
homes sampled. The author notes that the figures presented have a range of
uncertainty of about 50%.
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Table 6-6 presents the indoor air concentrations for these four chemicals. The 90*
percentile value was chosen for use in the ShortForm for the background
comparison screen. The values were presented in /ig/m3 , and needed no further
conversion.
TABLE 6-6
INDOOR AIR CONCENTRATIONS
(from Stolwyk, 1990)
Arithmetic SO* 90*
Chemical Mean, Hg/m Percentile Percentile
Mg/m3 Mg/m3
Chlorobenzene 1 < 0.6 10
Methylene Chloride NCa < 10 600
Naphthalene NC 2 6
m,p-Xylenes 20 20 40b
o-Xylene 10 5 10
* NC - Not Calculated
The 90 percentile value for the m,p-Xylenes was chosen as
the background concentration for Total Xylenes in the
absence of such a value for Total.
6.3.3 Background Levels In Groundwater
Groundwater background levels have been identified for six metals and a list of
these values is given in Table 6-7. These concentrations were developed from a
data set collected by the Massachusetts DEP Division of Water Supply and
computerized by volunteers from the Streamlining Risk Assessment Workgroup.
The MA DEP Division of Water Supply (DWS) has been collecting routine drinking
water samples from public water supplies for over 15 years. Analytical results
from this sampling program have been kept according to town name in DWS files.
The analyses were carried out primarily by the MA DEP's Lawrence Experiment
Station. As the data included both surface and groundwater sources, only those
samples specifically described as coming from a well were selected. A total of 114
well samples were identified, although results were not reported for all chemicals
in all samples. Thus the number of samples (n) for any given chemical actually
varies from 49 to 73.
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Table 6-7
SHORTFORM GROUNDWATER
BACKGROUND CONCENTRATIONS
(from MA DEP DWS Data)
Background Background
Groundwater Groundwater
Conoentr. Conoentr.
Chemical M*/L Chemical MR/L
Arsenic 5.5 Lead 8.8
Cadmium 4.2 Mercury 0.95
Chromium 4.9 Silver 4.7
In the analysis of this data, results reported as being less than a detection limit
were automatically assigned a value equal to \ the limit of detection. It was not
uncommon to find variation up to an order of magnitude in the detection limits
for any given chemical.
Hi
Table 6-8 presents the number of samples, the arithmetic mean, 50 percentile
and 95th percentile values for each chemical listed in the ShortForm for which data
was found in the DWS files.
Table 6-8
METALS CONCENTRATIONS IN
MASSACHUSETTS GROUNDWATERS
(from MA DEP DWS Data)
CHEMICAL # of Data % of Arithmetic 60*' 95*
Points (n) Samples Mean Percentile Percentile
< DL m«/L M*/L M*/L
Arsenic 70 57 4.4 1.5 5.5
Cadmium 55 87 3.2 0.5 4.2
Chromium 73 66 2.1 1 4.9
Lead 64 48 4.8 2 8.8
Mercury 60 73 0.36 0.1 0.95
Silver 49 98 0.9 0.5 4.7
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6.4 Toxicity Profiles
Toxicity Profiles or Summaries are provided in Appendix B for each of the chemicals (or
groups of chemicals) included in the Residential ShortForm.
Toxicity Profiles serve several purposes. First, they are summaries of the potential
human health hazards posed by each OHM, and include references for the dose-response
relationships described in Section 7.0 of this document. The Toxicity Profiles included
with the ShortForm contain six sections:
General Background Information
Pharmacokinetics
Human Toxicological Profile
Mammalian Toxicological Profile
Genotoxicity
References
Information contained in the Toxicity Profiles may be used to group chemicals by health
endpoint and mechanism of toxicity in order to estimate more detailed Hazard Indices
(Sections 9.0 and 10.0).
The profiles also serve as accessible reference material for non-toxicologists affiliated with
the site, including site owners, site managers, DEP staff and the general public who are
concerned about the potential health impacts associated with the contaminants found at
the site. As part of the Hazard Identification component of the risk assessment, these
toxicity profiles should be copied and included in the Phase II Report.
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
37
THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
38
7.0 DOSE RESPONSE ASSESSMENT
7.1 Basic Assumptions
In general, the dose-response assessment describes the observed effects in humans and/or
laboratory animals associated with particular exposures (or doses) of the chemical of
concern. This information is obtained from published literature describing epidemiologic
or toxicologic studies involving the particular chemical.
The TOXICITY INFORMATION section of the ShortForm contains the dose-response
information for each of the OHM listed in the spreadsheet. This information is later
coupled with information on the nature and magnitude of the hypothetical residential
exposures in order to characterize risk.
The dose-response information contained in the ShortForm may be divided into three
major categories:
• Toxicity information associated with threshold (non-carcinogenic) health
effects.
• Toxicity information concerning carcinogenicity, either from human
epidemiologic data or from laboratory studies.
• The Relative Absorption Factors (RAFs) used to relate the toxicity values
from the literature to the exposure pathways of concern in this
spreadsheet.
All the chemicals listed in the Residential ShortForm are evaluated for potential non-
carcinogenic health effects. In addition, any substance considered to be a known,
probable, or possible human carcinogen is also evaluated for its potential carcinogenic
effect. The classification of a chemical as a carcinogen does not preclude an evaluation of
that same chemical for potential non-carcinogenic health risks.
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7.1.1 Threshold Effects
For non-carcinogenic health effects it is believed that a dose level exists at and
below which no adverse health effects would be expected. Such a level is referred
to as a threshold dose. While it is impossible to specify a theoretical threshold
dose for a given chemical, it is possible to estimate a human sub-threshold dose at
which no adverse health effects would be expected. Such a value is typically
derived from the No Observable Adverse Effects Level (NOAEL) of an animal
study by application of uncertainty factors (UF) to account for interspecies
variation, exposure duration and to protect sensitive populations. Important
factors to consider when identifying and using such a sub-threshold dose include:
• the route of administration of the dose (inhalation, oral, dermal
contact, etc..)
• the duration of exposure to that dose (lifetime, chronic, subchronic,
or acute exposure)
• the absorption efficiency (if any) used to calculate that dose
• the age of the person receiving the dose.
7.1.2 Carcinogenic Effects
Unlike the non-carcinogenic health effects, it is generally assumed that there is no
threshold dose for carcinogenicity, that there is no dose of a carcinogenic
substance (other than no exposure) which is associated with zero risk. The ability
of a chemical to increase the incidence of cancer in a target population is described
by one of two measures: the carcinogenic potency value or the unit risk. These
values are listed in the Residential ShortForm in the TOXICITY INFORMATION
section for any chemical considered to be carcinogenic.
7.1.2.1 Carcinogenic Potency Value (CPV)
The Carcinogenic Potency (or Slope) Value for a chemical is derived by the EPA's
Cancer Assessment Group (CAG). Using data derived from animal studies, the
Potency Value is an estimate of the upper 95% Confidence Limit of the slope of
the dose-response curve extrapolated to low doses. For some chemicals, human
epidemiologic data is the basis of an estimate of the carcinogenic potency, although
the most common basis of these values is an animal study.
The Potency value is given in units of (mg/kg/day)' 1 . It is based upon the concept
of a lifetime average daily dose. While both oral and inhalation potency values
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have been developed, the Residential ShortForm uses only the oral CPVs to
evaluate oral and dermal exposures.
7.1.2.2 Inhalation Unit Risk Values (URs)
The Inhalation Unit Risk is the upper 95% Confidence Limit of the mean
incremental lifetime cancer risk estimated to result from lifetime exposure to an
agent if it is in the air at a concentration of 1 ngfm or in the drinking water at a
concentration of 1 ngfL. These values are used in lieu of the chemical's Potency
Value when an estimate of a lifetime average concentration of the chemical is
available. The Residential ShortForm uses the unit risk in air to evaluate
inhalation exposures.
7.1.3 Relative Absorption Factors (RAFs)
The equations used in the Residential ShortForm incorporate Relative Absorption
Factors (RAFs) which have been determined or estimated for each chemical via
each route of exposure.
The RAF addresses two major issues:
the absorption efficiency for the chemical via the route and medium of
exposure being evaluated for the disposal site, and
the absorption efficiency for the route and medium of exposure in the
experimental study which is the basis of the Reference Dose or the Potency
Value for the chemical in question.
Thus the RAF adjusts the dose (or exposure) estimates based on these two
absorption efficiencies. MA DEQE (1989a) describes the development of RAFs in
its Appendix B. (The factors were called "Bioavailability Adjustment Factors", or
"BAFs" in that document.) US EPA (1989a), Appendix A also provides guidance for
the "Adjustments For Absorption Efficiency".
The risk assessor is reminded that an absorption efficiency (or absorption factor)
which doesn't consider derivation of the toxicity values (Reference Dose, Reference
Concentration, Potency Value or Unit Risk) is not an RAF.
The RAFs used in the Residential ShortForm calculations are listed in the
TOXICITY INFORMATION section of the spreadsheet, and the derivation of
individual RAF values is described in APPENDIX C.
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7.2 Sources of Dose-Response Information
7.2.1 Threshold Effects
Several types of "sub-threshold dose" values have been identified or developed for
use in ShortForm. The sources of these values are described in general below.
The TOXICITY INFORMATION section of the Residential ShortForm is
reproduced in Table 7-1. The source for a specific toxicity value may be found
using the references adjacent to each value in the table, and the list of references
at the end of Table 7-1.
7.2.1.1 Oral and Dermal Exposures
The U.S. EPA derived oral Reference Dose (RfD) is used in the Residential
ShortForm when one is available for the chemical of concern. Chronic RfDs are
available from the U.S. EPA's on-line database, the Integrated Risk Information
System (IRIS). Subchronic RfDs from the U.S. EPA's Health Effects Assessment
Summary Tables (HEAST) are used for the evaluation of subchronic exposures.
HEAST also serves as a source of US EPA derived chronic RfDs.
When a subchronic or chrome RfD is not available from IRIS or HEAST for a
chemical in the ShortForm, an analogous toxicity value has been identified or
developed by MA DEP Office of Research and Standards staff. The documentation
for these values is provided in APPENDIX D.
7.2.1.2 Inhalation Exposures
The U.S. EPA derived inhalation Reference Concentration (RfC) is used in the
Residential ShortForm when one is available for the chemical of concern. Chronic
RfCs are available from the U.S. EPA's IRIS (as the primary source) and HEAST.
Subchronic RfCs from HEAST are used for the evaluation of subchronic exposures.
In the absence of an EPA derived Reference Concentration, the "Allowable
Threshold Concentration" (MA DEQE, 1989a) is used. The Allowable Threshold
Concentration (ATC) is a value derived from the Threshold Effects Exposure Limit
(TEL) described in CHEM (MA DEP, 1990c). (The TEL value represents 20% of
an allowable concentration, or ATC. Thus the ATC is equal to five times the TEL.
The TEL was derived in a manner considering children to be the most sensitive
potential receptors.) The ATC is a concentration of the chemical in air which
would not be expected to result in adverse non-carcinogenic health effects. The
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ATC is derived considering acute and chronic threshold health endpoints,
including reproductive effects.
When neither an RfC nor ATC is available for a chemical listed in the ShortForm,
MA DEP Office of Research and Standards staff has identified or developed an
analogous toxicity value. The documentation for these values is provided in
APPENDIX D.
7.2.2 Carcinogenic Effects
7.2.2.1 Oral and Dermal Exposures
The U.S. EPA derived oral Carcinogenic Potency Value (CPV) is used to evaluate
both oral and dermal exposure to carcinogens. The U.S. EPA's IRIS database and
the Health Effects Assessment Summary Tables serve as the primary and secondary
sources of the potency values.
7.2.2.2 Inhalation Exposure
When available, the U.S. EPA derived Unit Risk (UR) is used to evaluate indoor
air exposures in the ShortForm. Again, IRIS and HEAST serve as the sources of
these unit risk values. CHEM (MA DEP, 1990c) is used as a secondary source for
these values.
7.2.3 Relative Absorption Factors
Currently there are no published lists of Relative Absorption Factors (RAFs)
derived in a manner consistent with Massachusetts or Federal guidance (MA
DEQE 1989a; US EPA 1989a). The RAFs listed in the TOXICITY INFORMATION
section of the spreadsheet were developed specifically for the ShortForm by MA
DEP Office of Research and Standards staff. The documentation for the
development of the RAFs is contained in APPENDIX C.
As new toxicity values are constantly being proposed and old values updated, it is
important that each toxicity value be adequately referenced and that the most recent
values be used. At a minimum, the Residential ShortForm will be updated annually (in
September) to insure that the toxicity values contained in the spreadsheet remain
current. More frequent updates may also occur as considered necessary, and the user is
urged to add their name and address to the Department's mailing list (see page ii) and to
constantly check the MA DEP/ORS computer bulletin board for relevant announcements.
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7.3 Toxicity Information Summary Tables
The following summary tables are extracted from the Residential ShortForm and
reproduced here to document the selection and development of individual toxicity values.
The numerical references contained in Table 7-1 are explained at the end of that table.
TABLE 7-1
SHORTFORM TOXICITY VALUES
(TABLES FROM THE SHORTFORM)
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TABLE 7-1 CONTINUED...
References for the
ShortForm Toxicity Values
Reference # Description
1. U.S. EPA Integrated Risk Information System (IRIS). On-line search: current as of
September 2, 1992.
La. The oral Carcinogenic Potency Value from IRIS is used as a dermal CPV.
I.e. The chronic inhalation RfC (from IRIS) has been used here as a subchronic inhalation RfC
equivalent.
l.d. This toxicity value for CHROMIUM is taken from the IRIS file for hexavalent chromium
(Cr VI).
I.e. The chronic oral RfD (from IRIS) has been used here as a subchronic oral RfD equivalent.
l.f. This oral Carcinogenic Potency Value equivalent for arsenic is back-calculated from a drinking
water Unit Risk value from IRIS.
l.g. This Carcinogenic Potency Value or Unit Risk for benzo[a]pyrene (from IRIS) has been applied
to the seven PAH compounds which are designated as category A, Bl, B2 or C carcinogens.
2. U.S. EPA Health Effects Assessment Summary Tables (HEAST), Annual FY-1992.
[OERR 9200.6-303 (92-1), NTIS No. PB92-921199] March, 1992.
2.a. The oral Carcinogenic Potency Value from HEAST is used as a dermal CPV.
2.b. This subchronic oral RfD (from HEAST) for naphthalene has been used as the subchronic oral
RfD equivalent for all PAH compounds for which subchronic oral RfDs are unavailable.
2.c. The chronic inhalation RfC (from HEAST) has been used here as a subchronic inhalation RfC
equivalent.
2d. The chronic oral RfD for food (from HEAST) has been used as the oral RfD for cadmium
2.e. The chronic oral RfD for cadmium (from HEAST) has been used here as a subchronic oral RfD
equivalent.
2.f. The chronic oral RfD for naphthalene (from HEAST) has been used as the chronic RfD
equivalent for all PAH compounds for which chronic oral RfDs are unavailable.
2.g. This toxicity value for CHROMIUM (taken from HEAST) is for hexavalent chromium (Cr VI).
2.h. This Carcinogenic Potency Value or Unit Risk was taken from a fact sheet distributed by the
U.S. EPA Superfund Health Risk Technical Support Center at ECAO-Cincinnati, current as of
September 2, 1992.
2.i. The oral Carcinogenic Potency Value (from the ECAO-Cincinnati fact sheet) is used here as a
dermal CPV.
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TABLE 7-1 CONTINUED...
References for the
ShortForm Toxicity Values
Referenoe # Description
3. Allowable Threshold Concentrations (ATCs) from MA DEQE (1989a), Guidance for Disposal Site
Risk Characterization and Related Phase U Activities - In Support of the Massachusetts
Contingency Plan, Appendix J.
3.a. The chronic inhalation ATC (from MA DEQE, 1989a) has been used here as a subchronic
inhalation ATC equivalent.
3.b. The ATC for 'total concentration of naphthalene and 2-methylnaphthalenen is used here as the
ATC for this chemical.
3.c. The chronic inhalation ATC for naphthalene has been used as the chronic inhalation RfC
equivalent for all PAH compounds for which chronic inhalation RfCs are unavailable.
3.d. The chronic inhalation ATC for naphthalene has been used as the subchronic inhalation RfC
equivalent for all PAH compounds for which subchronic RfCs are unavailable.
4. Developed for the Residential ShortForm by MA DEP staff. Documentation of this value may be
found in APPENDDC D.
NC Not Calculated
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8.0 EXPOSURE ASSESSMENT
8.1 Introduction
Exposure assessment is the link between hazard identification, dose-response assessment and
risk characterization. An exposure assessment concerns itselfwith identification ofreceptors,
exposure pathways, exposure points, exposure routes, and frequency, duration and magnitude
of exposures.
8.2 Basic Approach/Assumptions
The basic approach used in this exposure assessment is that the most useful assessment is
one which is realistic and health protective. This assessment is not a worst case exposure
assessment. Worst case assessments are useful screening tools which may demonstrate that
risks are clearly insignificant, but they are not useful in determining whether realistic risks
are actually significant (US EPA, 1988).
This assessment consciously uses some intake rates, contact rates and bodyweights which
represent mid-range estimates of the possible values for each of those parameters.
Arithmetic means of concentrations at exposure points are recommended for use in the risk
calculations. "Upper bound" (conservative, health protective) estimates of cancer potency
factors are used in the assessment. The Reference Doses, Inhalation Reference
Concentrations and Threshold Effects Exposure Limits used in the assessment are all
considered health protective and very conservative. The values used for frequency and
duration of exposure are intended to reflect realistic values for Massachusetts and the
climatic conditions in Massachusetts. This mix of mid-range, realistic exposure assumptions
and "upper bound" or conservative, health protective toxicity values is intended to produce
realistic risk estimates . These estimates are considered to be protective of public health in
that they are not likely to be underestimates of the "true risk". (See Section 10 -
Uncertainty Analysis.)
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8.3 Receptors
8.3.1 Maximally Exposed Individual
This residential scenario concerns itself with theoretical on-site residents and the
exposures they might experience.
The exposure parameters and assumptions are targeted to average exposures for the
maximally exposed individual in this receptor group. In this context, the maximally
exposed individual is that person whose activities realistically result in the exposure
via all of the realistic exposure pathways at that location. For example, at a residence
with soil and drinking water contamination, with vapor problems associated with
groundwater or subsurface soil contamination, and a garden, the individual who plays
or works in the yard regularly, drinks and showers with tap water, eats homegrown
fruits and vegetables, and breathes vapors in the home would be the maximally
exposed individual.
A Visitor/Trespasser Receptor is not explicitly evaluated in this assessment although
there is certainly opportunity for visitors or trespassers to be exposed at a
"residential" disposal site. Once a decision has been made that a location has a
current or foreseeable use which is "residential," then the visitor/trespasser would
have lower frequency and daily duration of soil exposures and indoor vapor inhalation
than the resident. The visitor would also experience lower (if any) drinking water
and fruits/vegetable intakes. The visitor/trespasser would only be important if
"residential" use did not become a reality and an on-site receptor is irrelevant. In
such a case, however, the use of the Residential ShortForm might not be appropriate
(it would overestimate risks).
The exposure assessment must characterize exposures in a way which is compatible with the
risk characterization approach. In this assessment, the risk characterization is conducted via
Method 3b of the Massachusetts Contingency Plan (310 CMR 40.545(3)(g)3.b.). Method 3b
requires the comparison of exposure point concentrations to promulgated public health
standards and it requires that Total Sites Risks be characterized for both cancer risk
(expressed as excess lifetime cancer risk [ELCR]) and non-cancer risk (expressed as a Hazard
Index [HI]). The risk characterization requirements of the MCP are discussed in more detail
in Section 9.0.
In this Residential Scenario, exposure point concentrations are directly employed to
characterize exposures for the purpose of (1) comparison to drinking water standards and (2)
for the calculation of HI and ELCR for volatile organic compound inhalation exposures
indoors. Average daily contaminant doses are employed to characterize exposures for the
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purpose of calculating HI and ELCR for soil ingestion, soil dermal contact, fruits and
vegetable, and drinking water exposures.
Although exposure is often defined as the amount of contaminant available at an exchange
boundary Gung, gastrointestinal tract), a broader definition of exposure assessment is used
here. The estimation of both exposure rates and dose rates are included in this exposure
assessment.
8.3.2 Age Groups
While the Residential ShortForm assessment is performed for the maximally exposed
receptor, identified as the resident who lives on or near the disposal site for up to 30
years, risk estimates are generated for different age periods in that receptor's
lifetime. This methodology has been adopted in the knowledge that exposure is not
constant over a receptor's lifetime, but in fact varies with age-related factors such as
body weight and patterns of activity. The variation in exposure rate over the course
of the receptor's lifetime is particularly relevant for the evaluation of threshold health
effects: it is important to identify the age group(s) which represent the highest
subchronic and chronic exposure periods. A risk analysis which focuses on these
identified age groups will be adequately protective of all stages of the receptor's life
and will substantially reduce the number of risk characterizations necessary to assess
the disposal site. It is unnecessary, for example, to calculate an Excess Lifetime
Cancer Risk for a childhood exposure if the calculation is also performed for the
receptor's duration of residence (30 years) and that period includes childhood.
The age groups which are the focus of this exposure assessment are:
• ages 1-2 years: for subchronic exposures and threshold effects;
• ages 1-8 years: for chronic exposures and threshold effects; and
• ages 0-30 years: for carcinogenic effects.
The selection of age groups for subchronic and chronic exposure evaluation is based
on the following definitions of the terms subchronic and chronic with respect to
human exposures: subchronic is an exposure greater than 30 days but less than 7
years; chronic is an exposure of 7 years or more. The age groups are selected as
follows.
For subchronic exposures, the age group evaluated has the highest total
exposure (all pathways) for any period greater than 30 days but less
than 7 years.
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For chronic exposures, the age group evaluated has the highest total
exposure (all pathways) for any period equal to or greater than 7 years.
Visual inspection of the graphs in Figures 8-1 through 8-3 indicates that exposure to
soil, drinking water, and fruits and vegetables is highest during the childhood years,
falls off, and then remains fairly constant as age increases. The exposure to indoor
air (Figure 8-4) appears marginally higher in the childhood years than in other
portions of the lifetime.
It is clear that the age 1-2 years is associated with the highest exposure for any
period less than seven years in duration and is therefore the age group which is
appropriate for subchronic exposure characterization. In a like manner it appears
that children aged 1-8 years experience the highest exposure rate (all pathways) of
any age group representing an exposure period of 7 or more years duration.
Therefore, the age group 1-8 years was chosen the appropriate exposure period for
the assessment of risks for chronic threshold effects.
NOTE: The graphs in Figures 8-1 through 8-4 depict medium specific exposure rates
(not contaminant exposure rates). The exposure rates for direct soil contact, drinking
water exposures, fruit and vegetable ingestion and inhalation of indoor air incorporate
the intake and contact rates as well as the frequencies and durations used in this
assessment. These graphs do not incorporate contaminant concentrations nor
Relative Absorption Factors (RAF). Of course, the contaminant concentrations may
vary greatly from site-to-site and from chemical-to-chemical at a given site. The RAFs
also vary by chemical and medium. The combination of contaminant concentration
and RAF in conjunction with the medium-specific exposure rates produce the
contaminant specific exposure rates. The contaminant exposure rates are therefore
not generalizable and the medium-specific exposure rates are used here only to select
age groups for subchronic and chronic exposures used in threshold effects risk
assessment.
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8.4 Potential Exposure Pathways
The following list of exposure pathways comprises the universe of pathways which are
potentially important and may require quantitative evaluation for a "residential" scenario.
Soil ingestion
Soil dermal contact
Fugitive dust inhalation
Fruits and vegetables ingestion
Drinking water ingestion
Drinking water dermal contact
Indoor Vapor inhalation related to showering
Indoor Vapor inhalation related to other domestic water use
Indoor Vapor inhalation related to subsurface soil or groundwater
NOTE: No surface water-related exposures are considered. If contaminated surface water
represents a potential exposure medium at a particular residential site, then a supplemental
human health risk assessment may be required, with the results then combined with those
produced by the Residential ShortForm. Alternatively, all the exposure pathways related to the
site could be evaluated without the aid of the ShortForm.
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8.5 Pathways Evaluated
An evaluation of these potential exposure pathways resulted in the following list of pathways
which are evaluated quantitatively. Note that version 1.6a of the Residential ShortForm
allows the quantitative evaluation of all of these pathways. Version 1.6b is identical to
version 1.6a with the exception that the ingestion of homegrown fruits and vegetables is not
considered.
soil: ingestion
dermal contact
Fruits and
Vegetables: ingestion (v. 1.6a only)
Drinking
water: ingestion
dermal contact
Indoor vapor: inhalation
(from showering)
Indoor vapor: inhalation
(from subsurface
soil or groundwater)
Inhalation of fugitive dust is not quantitatively evaluated in this assessment because the
magnitude of that exposure is insignificant for a residential scenario where soil ingestion and
soil dermal contact exposures are also occurring. The technical documentation which
supports this conclusion is found in Section 8.8.
Indoor vapor inhalation related to non-showering domestic use of tap water was not explicitly
evaluated here. However, the indoor vapor pathway (primarily related to subsurface soil or
groundwater) may account for the vapors generated by non-showering domestic tap water
use. It is strongly recommended that the indoor vapor pathway is evaluated using only in-
home vapor concentration measurements (not modelled concentrations). Measurement of
vapors indoors would quantify vapors in the home from any number of sources including fuel
storage, migration into the residence from subsurface soil and groundwater, release of
volatiles from domestic water use, and domestic use of solvent - containing products.
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The shower-related vapor inhalation exposure is evaluated separately in order to include the
short-duration, high intensity exposure in the shower which would not be adequately
characterized by typical indoor air monitoring programs designed to characterize "average"
subchronic or chronic exposures. In this assessment, the measured indoor vapor
concentrations used to evaluate non-showering related vapor problems are not based on any
bathroom air quality samples. The shower related vapor inhalation pathway evaluated here
is limited to bathroom exposures only.
No surface water-related exposures were considered here. Recreational dermal contact and
incidental ingestion of surface water and sediment and ingestion of locally caught fish were
not evaluated. At some later date, these pathways may be incorporated into the Risk
Assessment ShortForm.
Some exposure pathways are not evaluated via the use of measured concentrations of OHM
in the exposure medium. These pathways are (1) dermal absorption of OHM from water
during showering, (2) inhalation of OHM vapors generated during showering and
(3) ingestion ofOHM from fruits/vegetables grown in contaminated soil. Exposures for these
pathways are quantified by using models to generalize the magnitude of these exposures in
comparison to drinking water ingestion or by modeling exposure point concentrations.
Dermal absorption exposures of OHM during showering are assumed to be roughly
equivalent to ingestion exposures for volatiles and semi-volatiles, as described in Section 8.9.
[** This pathway is under review, and future versions of the Residential ShortForm may
adopt an alternative model.] Inhalation exposure to volatiles generated during showering is
assumed to be roughly equivalent to drinking water ingestion exposures, as described in
Section 8.9. [** This pathway is also under review, and future versions of the Residential
ShortForm may adopt an alternative model.] The model used to estimate exposures to OHM
from ingestion of fruits and vegetables is provided in Section 8.10. [** The homegrown fruits
and vegetables pathway is currently under review, and future versions of the Residential
ShortForm may adopt an alternative model.]
Optionally, when it is impossible or infeasible to measure exposure point concentrations
(when the exposure is not yet occurring or OHM has not yet reached the exposure point),
modeled exposure point concentrations are appropriate for all drinking water exposures,
including ingestion.
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8.6 Exposure Point Concentrations
This section identifies the approach and techniques used to identify exposure point
concentrations for use in the risk assessment.
8.6.1 Identification Of Exposure Points
Exposure points describe an area of a disposal site or surrounding environment, not
necessarily a single, discrete point. It is at the Exposure Point that the receptor is
assumed to be exposed to the oil or hazardous material, resulting in some increase
in risk of harm to the receptor's health.
It is not unlikely that a receptor is exposed to contamination related to a given
disposal site at multiple exposure points. For example, the resident receptor who is
the subject of the Residential ShortForm may be exposed to contaminants in drinking
water in the home while being exposed via direct contact with contaminated soil at
a local playground. In more complicated scenarios, the risk assessor may identify
multiple Exposure Points for the same route of exposure (direct contact with soil).
Before the Residential ShortForm is employed
the risk assessor must clearly identify all the
potential Exposure Points to be evaluated.
8.6.2 Identification/Estimation Of Exposure Point Concentrations
This section addresses the issues involved in identifying and estimating exposure
point concentrations. Guidance is given on how to estimate exposure point
concentrations that are representative of disposal site conditions. The selection of
analytical data that are representative of exposures and the manner in which these
data, including non-detects and trace values, are incorporated into the calculation of
average exposure point concentrations are discussed.
Though direct measurement ofexposure point concentrations is preferred, estimation
of exposure point concentrations may be acceptable. Measured concentrations may
serve as input to models which predict emissions, fate, transport or persistence.
Modeling methods should be fully referenced and described. Some general guidelines
and references for estimating exposure point concentrations are presented.
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8.6.2.1 Selection of Analytical Data for Estimation of Exposure Point
Concentrations
Analytical data will be generated during the MCP Phase II Comprehensive Site
Investigation in order to characterize the nature, concentration, and horizontal and
vertical distribution of the oil and hazardous materials at the disposal site. This data
collection phase also provides analytical data for use in the Phase II risk assessment,
and care must be given to insure that the resulting data meet the requirements of
the risk assessor. A sampling plan should be developed in consultation with the risk
assessor.
Analytical data for samples which are representative of actual or potential exposures
should be selected for use in estimating representative exposure point concentrations.
• If exposures are confined to a particular portion of the site only data taken from these areas should be
included in the estimation of representative exposure point concentrations.
• If exposures predominate in one area, data from these areas should be weighted and incorporated into the
calculation of exposure point concentrations accordingly
.
• In addition, samples taken in inaccessible locations should not be considered when evaluating exposures via
ingestion or dermal contact with surface soils. For example, use of data from samples taken under buildings
or at a depth of ten feet may be appropriate only when there is a foreseeable mechanism for bringing humans
into contact with the soil contaminants (e.g. excavation during construction, or a seasonal high water table
which brings subsurface contaminants to the surface).
8.6.2.2 Treatment of Non-Detects in the Estimation of Exposure Point
Concentrations
In estimating exposure point concentrations, it is not uncommon for the risk assessor
to be presented with analytic data for a chemical at the site which includes a number
of samples reported to be below the Method Detection Limit (MDL). Such results are
referred to as "Non-Detects".
Non-Detect results may be classified into two general situations. First, if a chemical
is truly not present at the disposal site (virtually all the samples are reported as Non-
Detect), and there is no history of a release of that chemical, then the risk assessor
may conclude that the chemical be dropped from the quantitative risk assessment.
Second, if the chemical is reported at the site at concentrations ranging from Non-
Detect to some site maximum, then the risk assessor may conclude that the reported
Non-Detects actually represent a distribution of concentrations between zero and the
MDL. These Non-Detect results contribute to the information known about the
disposal site and should be incorporated into the quantitative risk assessment in a
meaningful way. [There is a third possible situation, where the spatial pattern of
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positive and Non-Detect results indicate that contamination is localized to specific
areas. This would represent a combination of the previous two examples.]
There are several options for the treatment of "non-detects" described in the
literature (Travis, 1990; Helsel, 1990; Haas, 1990 Klassen, 1986). The methodologies
described include the use of log-probit analysis, maximum likelihood estimation and
probability plotting procedures. The level of effort and number of data points
required to effectively employ these methods vary, and the risk assessor is encouraged
to exercise professional judgement in the selection of a method to treat the Non-
Detect results.
It is the Department's recommendation, however, that for the majority of Chapter
2IE disposal sites a more straightforward approach is often appropriate:
When a contaminant is known to be present in the area under
investigation and the laboratory reports the concentration ofan OHM in
a sample taken from the area as "Non-Detect", the concentration of the
OHM in that sample should be assumed to be one-half of the Practical
Quantitation Limit (PQL) (or the Method Detection Limit, MDL).
This methodology (using 1/2 the MDL) for Non-Detect values suffers from the twin
sins of being easy to understand and facile to implement. These benefits must be
weighed against the bias which is introduced in the resulting EPC estimate. The ND
method selection should also consider, however, the often high level of uncertainty
which is inherent in environmental sampling and analysis procedures, resulting from
a failure to take an adequate number of samples, from mistakes on the part of the
sampler, from the heterogeneity of the matrix being sampled, and from intentional
bias in the sample collection. For relatively small disposal sites, these inherent
uncertainties may overwhelm the bias introduced by using 1/2 the MDL. A more
statistically oriented ND method may not, in such cases, significantly reduce the
uncertainty inherent in the resulting EPC. It is up to the risk assessor to judge the
level of sophistication appropriate to the data set.
As always, there may be exceptions to this guidance, particularly when detection limits
are unusually high, or when the site history and the NDs may indicate the absence of
an OHM at a site (or areas within site). In the latter case, the chemical may be
dropped from the quantitative risk assessment or the NDs may be factored into the
Exposure Point Concentration as a zero value with appropriate justification.
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8.6.2.3 Calculating Exposure Point Concentrations
The exposure point concentrations should be calculated in a way that is consistent
with its ultimate use or the standard to which it will be compared.
In comparing EPCs to applicable or suitably analogous standards, attention should be
given to whether the standards represent averages over time (e.g., the arithmetic
mean offour quarterly samples for the Massachusetts Maximum Contaminant Levels).
Generally the text of the regulations containing the standards will describe how to
develop concentrations which are comparable to the standards. Such guidance usually
includes sampling methodology as well as any averaging procedures.
For the purposes of quantitative risk assessment, the frequency and distribution of
both sampling data and exposures should be considered: sampling data should be
appropriately weighted to represent actual exposures. Guidance is provided below for
a variety of situations likely to be encountered.
As exposure to contaminants at a disposal site is a function ofboth time
and space, the most appropriate measure ofconcentration to use to derive
an EPC is the arithmetic mean.
Because sampling data and exposures are not necessarily distributed uniformly across
the site, consideration should be given to actual or potential exposure patterns as well
as the sampling frequency across the site. At any given site, the following scenarios
are possible:
• Frequency of sampling data may be unequally distributed across the site;
• Frequency of exposure may be unequally distributed across the site;
• Both frequency of sampling data and frequency of exposures may be unequally distributed across
the site (these distributions may or may not be coincident);
• Both frequency of sampling data and frequency of exposures may be equally distributed across the
site (these distributions may or may not be coincident).
The calculation of representative exposure point concentrations should take these
exposure patterns and sampling frequencies into account. At least two methods may
be used to account for unequal exposures or unequal sampling frequency. The first
method involves estimating a weighted average exposure point concentration. A
weighted average exposure point concentration is considered a representative
estimation of exposures at a given site. In this method, analytical data should be
weighted in a manner which reflects the exposure patterns and the sampling
frequency in the areas of actual or potential exposures.
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EXAMPLE: If 20 equidistant samples were taken in a portion of a site approximately 60 meters by 50 meters,
each sample can be said to represent 125 m
2 (2500 m2 / 20 samples). If three additional equidistant
samples were obtained from another portion of the site approximately 100 meters by 100 meters
(in order to verify the assumption that the area was free of contamination) each sample could be
said to represent 3333 m
2
. If exposures are equally likely throughout the entire site, the sample
values should be weighted according to the relative area each represents. If exposures are not
equally likely throughout the site, sample values should be weighted according to both the relative
area each sample value represents as well as the relative exposure likelihood in each area. Only
data which represent actual or potential areas of exposure should be incorporated. The weighted
average exposure point concentrations obtained from this exercise would be used as inputs to any
emission models, transport models, or persistence models which require an average concentration
for OHM present at the site.
The second method involves calculating separate risks using the Residential
ShortForm for each subarea of exposure and then weighting the resulting risks to
estimate a Total Site Risk which reflects exposure patterns at the entire site.
EXAMPLE: At a given site, 90 percent of the exposure time takes place on half of the site and 10 percent of
the exposure time takes place on the other half of the site. The average exposure point
concentration for the first half of the site should be calculated (sample frequency should be
considered when calculating this average value). The average exposure point concentration for the
remaining half of the site, upon which only 10 percent of total exposure time takes place, should
also be calculated. Total Site Risks dose for the entire site would weigh the separate Total Risks
from each area according to the relative time of exposure in each area.
8.6.2.4 Evaluation of Acute Exposures.
The Residential ShortForm does not evaluate potential risks associated with acute (up
to one month) exposures. It is left to the risk assessor to independently evaluate
such exposures at any time during the site assessment process to identify potential
Imminent Hazards. In cases when short term exposures may result in adverse health
effects, it would be important to consider the highest concentrations to which an
individual may be exposed during this short period of time. In the case of acute
exposure evaluations, a maximum reported value, or the arithmetic mean of data
points in a small area would be chosen to represent the exposure point concentration.
8.6.2.5 Modeling of Exposure Point Concentrations
Though direct measurement of contaminants is preferred for use in the Residential
ShortForm, there are times when it is necessary to estimate exposure point
concentrations through the use of mathematical models. Exposures may be expected
via air, groundwater, or soil, though analytical data may not be available for each
relevant medium. Mathematical models can be used to estimate emissions, fate and
transport, or persistence of contaminants in the environment and to estimate the
concentrations of OHM at exposure points when measured data are not available.
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Mathematical models refer to analytical solutions that can be performed using a hand
calculator, or analytical or numerical models implemented as programs to be run on
a computer.
In the absence of measured data, the need for mathematical modeling should be
based on an assessment of the potential mobility ofthe contaminant from the location
in which it was originally discovered to locations where exposure is likely to occur.
For example, if contamination was originally discovered in soil, important questions
to consider include the following:
• Is leaching of OHM possible?
• Is release to groundwater possible?
• Is volatilization release to air possible?
Models that predict either intramedia or intermedia transport should consider
site-specific as well as chemical-specific parameters. Potentially relevant site specific
parameters include meteorological data, soil type, bulk density and porosity, stream
velocity, and hydraulic conductivity. Potentially relevant chemical specific parameters
include the appropriate phase transfer coefficients, Henry's Law Constant, vapor
pressure and solubility.
Models must also be able to simulate the relevant physical processes occurring within
the specified environmental setting. These processes may include adsorption,
attenuation, diffusion, dispersion, volatilization, erosion or density effects related to
temperature and concentration.
The data selected as inputs to mathematical models should be selected carefully and
should be representative of the actual area where emissions contributing to exposures
are occurring. If an average contaminant concentration is required as input to the
model, the concentration would generally be the weighted arithmetic mean of all data
for the medium of concern in the appropriate area during a sampling event.
Techniques for modeling emissions, persistence and transport of OHM should be
generally accepted and well documented. If models are commercially available,
complete references including a brief discussion of the models input coefficients,
assumptions and uncertainties should be provided. If models are not commercially
available, source codes or other documentation which allows technical review of the
model and a more complete discussion of the models input coefficients, assumptions
and uncertainties should be provided.
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
65
8.7 Soil - Direct Contact
The soil exposure assessment described in this section is extracted from an ongoing project
within the Department to develop methodology for deriving soil advisory levels (MA DEP,
1991a).
8.7.1 Narrative Description
Incidental ingestion of and dermal contact with surface soils and dust have been
identified as potential exposures of concern for both children and adults in residential
settings.
In the scenario developed for the Residential ShortForm, the receptor's exposure to
contaminated soil and dust varies seasonally. Outdoor exposures are limited to 5 days
per week during the months of May through September (a period of 153 days).
During this time, it is assumed that the literature values for soil ingestion rates
(LaGoy, 1987) represent the sum of the outdoor soil exposures and indoor dust
exposures on days when exposure occurs. During the colder months (212 days), the
receptor is assumed to be exposed "indoors only" and the exposures are assumed to
occur primarily by hand contact with dust with subsequent mouthing behavior. This
"indoor only" exposure has been applied to children 1-6 years of age.
The exposure rate normalized to bodyweight is most often the expression of exposure
which is of most toxicological significance. This concept is particularly important in
the assessment of direct soil contact because the soil exposure rate normalized to
bodyweight is not constant over the lifetime (as demonstrated in Figure 8-1), but
rather is relatively high in young children and falls off to a lower, fairly constant level
in adults. Knowledge about the age dependent variability of the soil exposure rate
can be used to choose the appropriate age groups to consider for subchronic and
chronic exposures, and which 30-year period of the receptor's life to select for the
evaluation of cancer risk, as described in Section 8.3.2.
In this assessment, chemical exposures are a function of the concentration of an OHM
in soil and the average soil exposure rate normalized to bodyweight for various
exposure durations and age groups. The concentrations of OHM are assumed to
remain constant in soil over time, although a more sophisticated analysis could
conceivably include a decay function. As described below, the soil ingestion rates and
soil dermal contact rates used here incorporate the frequency and duration of
exposure and the appropriate averaging period.
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8.7.2 Equations
The equation used to evaluate potential non-carcinogenic effects associated with direct
contact with contaminated surface soil is given as:
[OHM]^ * ((NADSIR * RAF) + (NADSCR * RAF)) * C
11 = (1)
The equation used to evaluate potential carcinogenic effects associated with direct
contact exposure with contaminated surface soil is given as:
HHR = [OHM]^ • ((NLADSIR * RAF) + (NLADSCR * RAF)) * C * WW
(2)
where the exposure related terms (not shaded above) are:
[OHM]^, — The operational Exposure Point Concentrations (EPC) of the oil or hazardous material in surface
soil
. In units: nig/kg.
NADSIR = The formalized Average Daily Soil Ingestion Rate (normalized to bodyweight) for the exposure
period of concern. (Table 8-1) These values are rates of soil ingestion (not rates of OHM
ingestion). In units: mg
ao|/kg/day.
NADSCR = The Normalized Average Daily Soil Dermal Contact Rate (normalized to bodyweight) for the
exposure period of concern. (Table 8-1) These values are rates of soil contact (not contact with
OHM). In units: mg^kg/day.
RAF = The RelativeAbsorption Factors for soil ingestion or dermal contact and threshold or cancer health
effects (a chemical-, medium-, route-
,
and health endpoint-specific value). See Appendix C
Dimensionless.
C = Units Conversion Factor: 1 kg/10 mg
NLADSIR = Time-weighted Normalized Lifetime Average Daily Soil Ingestion Rate (normalized to bodyweight).
(Table 8-1) This value represents a 30 year exposure averaged over a lifetime, not a lifetime
exposure. In units: mgH|/kg/day.
NLADSCR = Time-weighted Normalized Lifetime Average Daily Soil Dermal Contact Rate (normalized to
bodyweight). (Table 8-1) This value represents a 30 year exposure averaged over a lifetime, not a
lifetime exposure. In units: mgM|/kg/day.
The Normalized Average Daily Soil Ingestion Rate, (NADSIR) and the Normalized
Average Daily Soil Contact Rate (NADSCR) for subchronic and chronic exposures
were used to calculate the subchronic and chronic direct contact Hazard Indices
respectively. The Normalized Lifetime Average Daily Soil Ingestion Rates (NLADSIR)
and the Normalized Lifetime Average Daily Soil Contact Rates (NLADSCR) are used
to calculate the direct contact Excess Lifetime Cancer Risks. The numerical value for
each of these soil exposure rates is shown in Table 8-1.
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Tables 8-2 through 8-10 document in a step-by-step approach the derivation of the
soil ingestion rates and the soil dermal contact rates summarized in Table 8-1. The
average exposure rates can be reproduced from the information in these tables and
the references cited. All of these exposure rates are based on a methodology
described in the DRAFT Development of Soil Advisory Levels. Technical
Support Document (MA DEP, 1991a).
TABLE 8-1
'—
SUMMARY OF SOIL INGESTION AND
DERMAL CONTACT RATES
THRESHOLD EFFECTS
Normalized (to BW) Normalized (to BW)
Average Daily Soil Ingestion Average Daily Soil/Skin
Bate Contact Bate
(NADSDl) (NADSCB)
Age
Exposure Type years mg^/kg/day mg^/kg/day
Subchronic 1-2
Chronic 1-8
4.5
3.1
30.6
28.5
NON-THRESHOLD (CARCINOGENIC) EFFECTS
Normalized (to BW) Normalized (to BW)
Lifetime Average Daily Soil Lifetime Average Daily
Ingestion Bate Soil/Skin Contact Bate
(NLADSnt) (NLADSCB)
Age
years mg^/kg/day mg^/kg/day
0-30 0.41 7.3
The derivation of these values is presented in the following tables.
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8.7.3 Soil Ingestion Intakes
This section will describe the development of the soil ingestion rates used in the
ShortForm formulae. These values are age specific and are normalized to body
weight. The exposure model used to quantify the soil ingestion pathway assumes that
some soil intake will occur in the home during winter months, but that the majority
of the exposure will be received from indoor and outdoor exposures during the
warmer time of the year. As a result of the detailed analysis, each age group
experiences a slightly different exposure, and annual average daily soil ingestion rates
calculated ranges between 20 to 60 mg of soil per day. The step-wise process followed
in the calculation of the exposure rates is summarized below.
STEP 1: Ingestion of indoor dust was considered for young children, aged 1 to
6 years. It is assumed that each exposure event consists of the
ingestion of the dust/soil covering the surface of one half of one finger.
Table 8-2 develops soil ingestion rates for these indoor exposures, and
this information is used in Step 2.
TABLE 8-2
INDOOR-ONLY SOIL INGESTION EXPOSURE
Skin Surface Dust Fraction of Frequency of Hours of Soil Ingested -
AGE Area: 1/2 of Adherence Dust from Finger Exposure per DNDOOR
One Finger Soil3 Mouthing
Events
day ONLY6
years cm /event mg/cm events/hour hrs/day mg soil/day
1 < 2 7.3 0.056 0.8 9 3
2
8.8
2 < 3 7.7 0.056 0.8 9 7 21.7
3 < 4 9.9 0.056 0.8 9 7 27.9
4 < 5 10.1 0.056 0.8 9 7 28.5
5 < 6 11.1 0.056 0.8 9 7 31.3
1 The surface area of 1/2 of one finger is assumed to be approximately equal to 1/40 the surface area of both
hands. The source of the Surface area information is described in more detail in Table 8-6. This value is
derived from that table: (Column 2 * Column 3 /100/40).
2 Hawley, 1985; average dust covering indoor surfaces assumed to be the average dust covering finger.
3 Hawley, 1985
4 MA DEQE, 1985
5 The mass of soil ingested as a result of finger mouthing activities. Example, age 1 < 2:
7.3 • 0.056 * 0.8 • 9 * 3 = 8.8 mg soil/day
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STEP 2: An annual average daily soil intake was developed for each age group,
as shown in Table 8-3. This value is weighted to reflect the relative
time spent outdoors where greater exposure to soil would be expected.
The resulting soil ingestion rates are then used in Step 3.
TABLE 8-3
CALCULATION OF AGE-SPECIFIC SOIL INGESTION RATES
ANNUAL
SOIL INGESTION RATES FREQUENCY OF EXPOSURE AVERAGE
** On days Exposed **
a
365 days
Indoors Indoors + DAILY SOIL
Indoor Indoor & Only3 Outdoors
4 INGESTION
Exposure Outdoor Oct. -> April May -> Sept. RATE
5
AGE Only1 Exposure2 of 212 days
days
of 153 days
years mgsoil/d mgsoil/d days mgsoil/d
< 1
1 < 2 8.8 100 212 44 + 109 - 153 47.0
2 < 3 21.7 100 212 44 + 109 - 153 54.5
3 < 4 27.9 100 212 44 + 109 = 153 58.1
4 < 5 28.5 100 212 44 + 109 = 153 58.5
5 < 6 31.3 100 212 44 + 109 = 153 60.1
6 < 7 50 44 + 109 = 153 21.0
7 < 8 50 44 + 109 = 153 21.0
8 < 9 50 44 + 109 = 153 21.0
9 < 10 50 44 + 109 = 153 21.0
10 < 11 50 44 + 109 = 153 21.0
11 < 12 50 44 + 109 = 153 21.0
12 < 13 50 44 + 109 = 153 21.0
13 < 14 50 44 + 109 = 153 21.0
14 < 15 50 44 + 109 = 153 21.0
15 < 16 50 44 + 109 » 153 21.0
16 < 17 50 44 + 109 = 153 21.0
17 < 18 50 44 + 109 = 153 21.0
18 < 25 50 44 + 109 = 153 21.0
25 < 30 50 44 + 109 = 153 21.0
1 - Indoor ONLY Exposures taken from Table 8-2.
2 - Soil Ingestion Rate on days when BOTH Indoor & Outdoor exposures may occur taken
from LaGoy (1987)
3 - 212 days is approximately 7 days/week from October through April. No outd x>r exposure is
assumed to occur during this period.
4 - 153 days approximates indoor exposures 2 days/week and outdoor exposures i > daya/week
during this period.
5 - The average daily soil ingestion rate for this age group, adjusted for the freqilency of
exposure. Example, age 1 < 2 years:
[(8.8 mg/d * 212 d) + (100 mg/d * 153 d)]/365 days = 47.0 mg soU/c lay
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STEP 3: The soil ingestion rates from Step 2 are normalized to the body weight
of each age group and weighted for the number of years in that age
group (This is important for ages 18<25 and 25<30). This calculation
is presented in Table 8-4.
TABLE 8-4
CALCULATION OF TIME-WEIGHTED AVERAGE DAILY
SOIL INGESTION EXPOSURES
NORMALIZED TO BODYWEIGHT
DADLY SOIL
AGE MEDIAN SOIL WEIGHTING DIGESTION RATE
BODY INGESTION FACTOR3 FOR THE TIME
yean WEIGHT1 RATE2
years
PERIOD4
kilograms mg soil/day (mg • yrs)/(kg * d)
< 1 8.5 1
1 < 2 10.5 47.0 1 4.5
2< 3 12.6 54.5 1 4.3
3< 4 14.6 58.1 1 4
4 < 5 16.4 58.5 1 3.6
5 < 6 18.8 60.1 1 3.2
6 < 7 21.0 21.0 1 1
7 < 8 23.5 21.0 1 0.89
8< 9 27.3 21.0 1 0.77
9< 10 29.6 21.0 1 0.71
10 < 11 34.3 21.0 1 0.61
11 < 12 40.0 21.0 1 0.53
12 < 13 45.2 21.0 1 0.46
13 < 14 48.6 21.0 1 0.43
14 < 15 52.8 21.0 1 0.40
15 < 16 53.9 21.0 1 0.39
16 < 17 55.3 21.0 1 0.38
17 < 18 58.3 21.0 1 036
18 < 25 57.1 21.0 7 2.6
25 < 30 59.9 21.0 5 1.8
1 - 50,h percentile body weights taken from U.S. EPA 1989b, pp . 5-43 & 5-45.
2 • Soil Ingestion Rate calculated in Table 8-3.
3 - Weighting Factor is equal to the number of years represented by each age group.
4 - The Soil Ingestion Rate Normalized to Body Weight for the s pecified time period.
Example Calculation, age 1 < 2:
[(47.0 mg soil/d) * 1 yrJ/10.5 kg = 4.5 (mg * yr)/(kg * d)
STEP 4: Finally, these age-specific values are combined to yield the time-
weighted, normalized values used in the ShortForm for the subchronic,
chronic and 30-year exposures. These values are developed in
Table 8-5, and the results summarized in Table 8-1.
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TABLE 8-5
CALCULATION OF THE
NORMALIZED DAILY SOIL INTAKE RATES
USED IN THE RESIDENTIAL SHORTFORM
SUBCHRONIC
EXPOSURE
AGE
yean
DAILY SOIL INGESTION
RATE FOR THE TIME
PERIOD
(mg * yrs)/(kg • d)
30 YEAR EXPOSURE
AGE
years
DAILY SOIL INGESTION
RATE FOR THE TIME
PERIOD
(mg * yrs)/(kg * d)
1 < 2
# Years 1
4.5
SUM: 4.5
Normalized Average Daily Soil Intake Rate:
4.5/1 = 4.5 mg soil/(kg*day)
CHRONIC EXPOSURE
AGE
years
DAILY SOIL INGESTION
RATE FOR THE TB£E
PERIOD
(mg * yrs)/(kg • d)
1 < 2
2 < 3
3 < 4
4 < 5
5 < 6
6 < 7
7< 8
4.5
4.3
4
3.6
3.2
1
0.89
# Years = 7 SUM: 21.5
Normalized Average Daily Soil Intake Rate:
21.5/7 = 3.1 mg soil/(kg*day)
< 1
1 < 2
2< 3
3<4
4 < 5
5 < 6
6< 7
7 < 8
8 < 9
9 < 10
10 < 11
11 < 12
12 < 13
13 < 14
14 < 15
15 < 16
16 < 17
17 < 18
18 < 25
25< 30
Exposure Period = 30 yr
AVERAGING PERIOD
75 Years
Normalized Lifetime Average Daily Soil Intake Rate:
31/75 0.41 mg soil/(kg * day)
4.5
4.3
4
3.6
3.2
1
0.89
0.77
0.71
0.61
0.53
0.46
0.43
0.40
0.39
0.38
0.36
2.6
1.8
SUM: 31
For the evaluation of non-cancer risk, the averaging
period is equal to the exposure period. For cancer risk,
the averaging period is a lifetime (75 years), independent
of the length of the exposure period (MA DEQE, 1989a).
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8.7.3 Dermal Contact Rates
This section will describe the development of the rates of contact between the soil
and the receptor's skin. Absorption through the skin is potentially an important
route of exposure which depends, in part, on the exposed skin surface area. Since
surface area varies by age, the soil/dermal contact rate would be expected to vary by
age as well. The rates developed in a step-wise fashion in the following tables are
embedded in the ShortForm formulae. The values are age-specific and are normalized
to body weight. The exposure model used to quantify the dermal contact exposure
pathway assumes that some contact will occur in the home during winter months, but
that the majority of the exposure will be received from indoor and outdoor exposures
during the warmer time of the year. As a result of the detailed analysis, each age
group experiences a slightly different exposure, and annual average daily contact rates
calculated range between 10 to 1200 mg of soil per day. The step-wise process
followed in the calculation of the exposure rates is summarized below and detailed in
Tables 8-6 through 8-10.
STEP 1: For exposures which occur indoors, the amount of soil which comes
into contact with the receptor's skin is calculated in Table 8-6. This
contact rate is for those days when exposure is thought to occur. The
indoor exposure is quantified for ages 0-6. During the colder months
only the hands are assumed to be regularly exposed to household dust,
and infants are assumed not to be exposed. During the warmer months
children are assumed to have a greater surface area exposed. The
amount of soil in contact with the skin is dependent upon the surface
area of the exposed body parts, the adherence of the dust to the skin,
and the fraction of the household dust derived from soil sources.
STEP 2: For the days when the receptor is exposed both indoors and outdoors,
the amount soil in contact is calculated in Table 8-7. This contact rate
is for those days when exposure is thought to occur. Exposure to
adults is quantified here as it is assumed that all ages have the
opportunity for contact with the soil through play or gardening.
STEP 3: The indoor and outdoor soil contact rates (the results of Tables 8-6 and
8-7, respectively) are then combined with exposure frequency
assumptions to yield an average daily soil contact rate for the year.
These rates are presented in Table 8-8, and range between 10 to 1200
mg soil per day, depending upon the age of the receptor.
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TABLE 8-6
INDOORS ONLY - DERMAL CONTACT
OCTOBER - APRIL
Exposed Soil In Contact
Body Parts and Total Body Adherence Fraction of Dust With Skin On
AGE % of Total Body
Surface Area
Surface Area Factor
3 Derived From
Soil
4
Days Exposed
INDOORS ONLY5
yean
2
cm mg/cm mg soil/day
< 1 none, • 4450
8 0.056 0.8 .
1 < 2 hands, 5.68% 5130
8 0.056 0.8 13.1
2 < 3 hands, 5.3% 5790 0.056 0.8 13.7
3< 4 hands, 6.1% 6490 0.056 0.8 17.7
4 < 5 hands, 5.7% 7060 0.056 0.8 18.0
5< 6 hands, 5.7% 7790 0.056 0.8 19.9
> 6 none, • - 0.056 0.8 y. .
MAY • SEPTEMBER
AGE Exposed Total Body Adherence Fraction of Dust Soil In Contact
Body Parts and Surface Area Factor Derived From With Skin On
years % of Total Body Soil4 Days Exposed
Surface Area
2
cm tnfnatn DTOOORS ONLY5
mg soil/day
< 1 Hands, Arms,
Legs, Feet, 46%
4450 0.056 0.8 91.7
1 <2 Hands, Arms,
Legs, Feet, 48%
5130 0.056 0.8 110.3
2< 3 Hands, Arms,
Legs, Feet, 47%
5790 0.056 0.8 12L9
3 < 4 Hands, Arms,
Legs, Feet, 54%
6490 0.056 0.8 157.0
4 < 5 Hands, Arms,
Legs, Feet, 55%
7060 0.056 0.8 174.0
5 < 6 Hands, Arms,
Legs, Feet, 52%7
7790 0.056 0.8 181.5
> 6 none, • - 0.056 0.8 -
1 - Percentage of total body surface area by body part taken from U.S. EPA 1989b, (mean values, p.4-12).
2 • 50
th
Percentile values for Total Body Surface Areas taken from U.S. EPA 1989b (p. 4-31), except as noted
below (6]I.
3 - Hawley, 1985
4 - Hawley, 1985
5 • The soil in contact with the skin (on days exposed) during this time period for the age group specified.
Example calculation, age < 1: 0.46 • 4450 * 0.056 * 0.8 91.7 mg soil
6 - The total body surface area for ages < 1 and 1<2 have been estimated using the equation SA = K*BW*/3
(U.S. EPA 1989b, p. 4-20), where SA = Surface Area, K is a constant (estimated from data available for ages
2<3) and BW is the receptor's body weight (Table 8-8).
7 - Data are unavailable for this age group. The Percentage of total body surface area used here is assumed to be
equal to that for the 6 > 7 year old.
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TABLE 8-7
INDOORS & OUTDOORS - DERMAL CONTACT
MAY - SEPTEMBER
Total
Body
Soil In Contact
With Skin On
Days Exposed
Both Indoors &
Surface Adherence Fraction Adhered Outdoors
AGE Exposed Body Parts and % of
Total Body Surface Area
Area Factor Material Derived
from Soil
mg soil/day
yean cm tng/cm
< 1 none, • 4450
s
0.51 0.8
1 < 2 Hands, Arms, Legs, Feet, 48% 51308 0.51 0.8 1005
2 < 3 Hands, Arms, Legs, Feet, 47% 5790 0.51 0.8 3110
3< 4 Hands, Arms, Legs, Feet, 54% 6490 0.51 0.8 1430
4 < 5 Hands, Arms, Legs, Feet, 55% 7060 0.51 0.8 1584
5 < 6 Hands, Arms, Legs, Feet, 52% 7790 0.51 0.8 1653
6 < 7 Hands, Arms, Legs, Feet, 52% 8430 0.51 0.8 1789
7 < 8 Hands, Arms, Legs, Feet, 54% 9170 0.51 0.8 2020
8 < 9 Hands, Arms, Legs, Feet, 54% 10000 0.51 0.8 2203
9 < 10 Hands, Arms, Legs, Feet, 54% 10600 0.51 0.8 2335
10 < 11 Hands, Arms, Legs, Feet, 57% 11700 0.51 0.8 2721
11 < 12 Hands, Arms, Legs, Feet, 57% 13000 0.51 0.8 3023
12 < 13 Hands, Arms, Legs, Feet, 57% 14000 0.51 0.8 3256
13 < 14 Hands, Arms, Legs, Feet, 57% 14800 0.51 0.8 3442
14 < 15 Hands, Arms, Legs, Feet, 59% 15500 0.51 0.8 3731
15 < 16 Hands, Arms, Legs, Feet, 59% 15700 0.51 0.8 3779
16 < 17 Hands, Arms, Legs, Feet, 59% 16000 0.51 0.8 3852
17 < 18 Hands, Arms, Legs, Feet, 61% 16300 0.51 0.8 4057
18 < 30 Hands, Forearms, Lower legs,
Feet, 30%
16900 0.51 0.8 2069
1 - Mean values for Percentage of total body surface area by body part taken from U.S. EPA 1989b (pp. 4-11
& 4-12), except as noted below (7).
2 - 50
th
Percentile Total Body Surface Areas taken from U.S. EPA 1989b (pp. 4-29 & 4-31), except as noted
below (6).
3 - Hawley, 1985
4 . Hawley, 1985
5 - The soil in contact with the skin (on days exposed) during this time period for the age group specified.
Example calculation, age 1 < 2:
0.48 * 5130 • 0.51 * 0.8 s 1005 mg soil/day
6 • The total body surface area for ages < 1 and 1 < 2 have been estimated using the equation SA = K'BW273
(U.S. EPA 1989b, p. 4-20), where SA = Surface Area, K is a constant (estimated from data available for
ages 2<3) and BW is the receptor's body weight (Table 8-8).
7 - Data are unavailable for this age group. The Percentage of total body surface area used here is taken
from the next oldest age group for which data is available (i.e., the % for the 6<7 yr old a used for the
5<6 age group).
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TABLE 8-8
CALCULATION OF AGE-SPECIFIC SOIL DERMAL CONTACT RATES
ANNUAL
SOIL DERMAL CONTACT RATES FREQUENCY OF EXPOSURE AVERAGE
*• On days exposed 'I* 365 days
Indoor & Indoor Only Indoor Only Indoor & DAILY
Indoor Only Indoor Only Outdoor Oct -> May -> Outdoor son.
Oct-> May -> May -> April Sept.
8 May -> DERMAL
AGE April Sept.2 Sept.3 of 212 days of 153 days Sept.
6
of 153 days
CONTACT
RATE7
yean mg soil/day mg soil/day mg soil/day days days days mg soil/d
< 1 91.7 44 11.1
1 < 2 13.1 110.3 1005 212 44 109 321
2 < 3 13.7 121.9 1110 212 44 109 354
3< 4 17.7 157.0 1430 212 44 109 456
4 < 5 18.0 174.0 1584 212 44 109 504
5 < 6 19.9 181.5 1653 212 44 109 527
6 < 7 1789 109 534
7 < 8 2020 109 603
8 < 9 2203 109 658
9 < 10 2335 109 697
10 < 11 2721 109 813
11 < 12 3023 109 903
12 < 13 3256 109 972
13 < 14 3442 109 1028
14 < 15 3731 109 1114
15 < 16 3779 109 1129
16 < 17 3852 109 1150
17 < 18 4057 109 1212
18 < 30 2069 109 618
1 - Indoor Only Contact Rates for October through April taken from Table 8-6.
2 - Indoor Only Contact Rates for May through September taken from Table 8-6.
3 • Contact Rates on days when both indoor and outdoor exposure is thought to occur taken from Table 8-7.
4 - 212 days is approximately 7 days/week from October through April.
5 - 44 days is approximately 2 days/week from May through September.
6 - 109 days is approximately 5 days/week from May through September
7 • The average daily <sxposure to soil in dermal contact with the skin for this age group, adjusted for the frequency
of exposure. Exampie calculation, agti 2<3 years:
((13.7 * 212) + (121.9 • 44) + (UK * 109))/365 = 354 mg soil/day
STEP 4: The annual average contact rates derived in Table 8-8 are then
normalized to the body weight of each age group and weighted by the
number of years in that age group. This calculation is presented in
Table 8-9.
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TABLE 8-9
CALCULATION OF TIME-WEIGHTED AVERAGE DAILY
SOIL DERMAL CONTACT EXPOSURES
NORMALIZED TO BODYWEIGHT
DAILY SODL
AGE MEDIAN SOIL DERMAL WEIGHTING DERMAL CONTACT
BODY CONTACT FACTOR3 RATE FOR THE
years WEIGHT1 RATE2 TIME PERIOD4
kilograms
years
mg soil/day (mg • yrs)/(kg * d)
< 1 8.5 11.1 L 1.3
1 < 2 10.5 321 I 30.6
2< 3 12.6 354 I 28.1
3 < 4 14.6 456 L 31.2
4 < 5 16.4 504 L 30.7
5 < 6 18.8 527 I 28.0
6 < 7 21.0 534 L 25.4
7< 8 23.5 603 L 25.7
8 < 9 27.3 658 ]L 24.1
9 < 10 29.6 697 ]L 23.5
10 < 11 34.3 813 ]I 23,7
11 < 12 40.0 903 ]L 22.6
12 < 13 45.2 972 ]L 21.5
13 < 14 48.6 1028 )I 21.2
14 < 15 52.8 1114 ]L 21.1
15 < 16 53.9 1129 1L 20.9
16 < 17 55.3 1150 :L 20.8
17 < 18 58.3 1212 :L 20.8
18 < 25 57.1 618 ',r 75.8
25 < 30 59.9 618 I> 51.6
1 - 50 percentile body weights taken from U.S. EPA
2 - Soil Dermal Contact calculated in Table 8-8.
, 1989b, pp. 5-43 & 5-45.
3 • Weighting Factor is equal to the number of years
4 • The Soil Dermal Contact Rate Normalized to Bod,
period. Example Calculation, age 1 < 2:
[(321 mg soil/d) * 1 yr]/10.5 kg = 30.6 (it
represented by each age group.
y Weight for the specified time
« * yr)/(kg * d)
STEP 5: Finally, these age-specific values are combined to yield the time-
weighted, normalized exposure rates used in the ShortForm for the
subchronic, chronic and 30-year exposures. These values are developed
in Table 8-10 and the results summarized in Table 8-1.
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TABLE 8-10
CALCULATION OF THE
NORMALIZED DAILY SOIL DERMAL CONTACT RATES
USED IN THE RESIDENTIAL SHORTFORM
SUBCHRONIC
EXPOSURE
AGE
yean
DAILY SOIL DERMAL
CONTACT RATE FOR
THE TEME PERIOD
(mg • yn)/(kg • d)
30 YEAR EXPOSURE
AGE
yean
DADLY SOIL DERMAL
CONTACT RATE FOR
THE TBIE PERIOD
(mg * yn)/(kg * d)
1 < 2
#Yean = 1
30.6
SUM: 30.6
Normalized Average Daily Soil Dermal Contact Rate:
30.6/1 = 30.6 mg soil/(kg*day)
CHRONIC EXPOSURE
AGE
yean
DAH.Y SOn. DERMAL
CONTACT RATE FOR
THE TIME PERIOD
(mg * yn)/(kg * d)
< 1
1 < 2
2< 3
3< 4
4 < 5
5 < 6
6< 7
7 < 8
8 < 9
9 < 10
10 < 11
11 < 12
12 < 13
13 < 14
14 < 15
15 < 16
16 < 17
17 < 18
18 < 25
25< 30
1.3
30.6
28.1
31.2
30.7
28.0
25.4
25.7
24.1
23.5
23.7
22.6
21.5
21.2
21.1
20.9
20.8
20.8
75.8
51.6
SUM: 548.6
1 < 2
2 < 3
3< 4
4 < 5
5 < 6
6 < 7
7 < 8
30.6
28.1
31.2
30.7
28.0
25.4
25.7
# Yean = 7 SUM: 199.7
Normalized Average Daily Soil Dermal Contact Rate:
199.7/7 = 28.5 mg soil/(kg*day)
Exposure Period = 30 yr
AVERAGDfG PERIOD
75 Yean
Normalized Lifetime Average Daily Soil Dermal
Contact Rate:
648.6/75 = 7.3 mg soil/(kg * day)
For the evaluation of non-cancer risk, the averaging
period is equal to the exposure period. For cancer risk,
the averaging period is a lifetime (75 yean), independent
of the length of the exposure period (MA DEQE, 1989a).
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1 6 a & b - 10/92
78
8.8 Soil Particulates - Inhalation
The Risk Assessment ShortForm - Residential Scenario does not include a quantification of
potential risks associated with the inhalation of fugitive dust at or from a disposal site.
8.8.1 Discussion Of Pathway
The inhalation of fugitive dust (airborne soil particulates) is a potential exposure
pathway which is frequently included for disposal sites where surficial soil
contamination is present.
Typically, neither the analysis of fugitive dust for oil or hazardous materials (OHM)
nor monitoring of suspended particulate levels are performed during the site
investigation and the risk assessor is left to construct a hypothetical model to quantify
potential risks. Pathway-specific assumptions are made about: (1) the level of
particulates in the air, (2) the concentration of OHM in the fugitive dust, (3) the
percentage of dust in the ambient air derived from the site soil, (4) the volume of
dust-laden soil inhaled by a receptor and (5) the amount of OHM which may
dissociate from the soil particles and be absorbed by the human body.
The Residential ShortForm acknowledges that the residential receptors may be
exposed to oil or hazardous materials via direct contact with contaminated surficial
soils (see Section 8.7) and via the inhalation of soil-derived suspended particulates in
air.
However, for residential (non-construction) exposure scenarios,
the exposure to OHM via the fugitive dust pathway is
insignificant relative to the direct contact exposures. For this
reason the fugitive dust pathway is not quantified in the
Residential ShortForm.
A demonstration of the insignificance of this pathway for a residential exposure
scenario is presented in the following sections. Overall, a receptor's lifetime exposure
to fugitive dust may represent only one one-hundredth of 1 percent (0.01 %) of the
exposure received via incidental ingestion and dermal contact.
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This pathway may be of greater importance (and should be quantified) at disposal
sites where:
there are large areas of exposed (i.e. no vegetative ground cover) contaminated surficial soil,
the current or foreseeable future use of the property includes excavation/construction activities,
there are demonstrably high levels of fugitive dust in the air,
inhalation of fugitive dust is the only potential exposure pathway for the soil, or
the chemicals of concern are known to be relatively more toxic (by two+ orders of magnitude) via
inhalation than by ingestion or dermal absorption.
8.8.2 Demonstration Of Insignificance
The following tables were generated based upon information from the soil exposure
summary spreadsheets prepared by the MA DEP Office of Research and Standards
(MA DEP, 1991a). The average daily intake rates which appear in the tables are
time-weighted averages which are normalized to body weight (^gwn/kgbody¥W)flh,/day).
The calculations for soil ingestion and dermal contact exposure estimates are in more
detail in Section 8.7. The equation for the calculation of potential exposure via the
inhalation of particulates is given in the next section. The (conservative) assumption
was made that the concentration of soil respirable particulates is the same indoors
and outdoors.
Table 8-11 compares the age specific receptor exposure via the inhalation of
particulates to the receptors concurrent exposure via incidental ingestion. For those
receptors with a higher tendency to ingest soil (young children aged 1-6 years) the
inhalation/(inhalation + ingestion) ratio ranges as low as 0.0008 (0.08 %, age 2-3
years). The highest ratio (0.006, 0.6%) for ages greater than 18 years old) indicates
that the particulate contribution to exposure is still just a fraction ( < 1%) of the
exposure attributable to incidental soil ingestion.
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TABLE 8-11
COMPARISON OF INHALATION OF PARTICULATES TO
SOIL INGESTION PATHWAY
% of Combined
Average Daily Soil Exposure
Particulate Daily Soil (Tnh. & Ing.)
Age Inhalation Rate 1 Ingestion Rate2 Attributable to
Inhaled
years mgtoI/kg/day mg.a/kg/day Particulates
3
1-2 0.0041 4.5 0.09%
2-3 0.0035 4.3 0.08%
3-4 0.0038 4 0.09%
4-6 0.004 3.6 0.1 %
5-6 0.0035 3.2 0.1%
6-7 0.0023 1 0.2%
7-8 0.0029 0.89 0.3%
8-9 0.0025 0.77 0.3%
9- 10 0.0023 0.71 0.3%
10-11 0.002 0.61 0.3%
11-12 0.0017 0.53 0.3%
12-13 0.0024 0.46 0.5%
13-14 0.0023 0.43 0.5%
14-15 0.0021 0.40 0.5%
15-16 0.002 0.39 0.5%
16-17 0.002 0.38 0.5%
17-18 0.0019 0.36 0.5%
18-25 0.0026 2.6/7 = 0.4 0.6%
25-30
MEAN age 1-2:
0.0024
0.0041 mg ./kg/d
1.8/5 = 0.4
4.5 mg -/kg/d
0.6%
0.09%
MEAN ages 1-8: 0.0034 mg -/kg/d 3.1 mg^/kg/d 0.1%
MEAN ages 1-30: 0.0026 mg^J/kg/d 1.1 mg^kg/d 0.2%
1 • Average Daily Soil Particulate Inhalation Rate calculated from equation in Section 8.8.3.
2 • Daily Soil Ingestion Rate from Table 8-4.
3 - (Column 2/(Column 2 + Column 3)) * 100. Example Calculation, ages 25-30:
(0.0024/(0.0024 + 0.4)) * 100 = 0.6 %
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Table 8-12 presents a similar analysis, comparing the particulate inhalation exposures
to those received via dermal contact with the contaminated soils. Once again the
exposure attributable to the inhalation of particulates is relatively insignificant,
perhaps as high as 0.02 % of the dermal exposure for some age groups.
TABLE 8-12
COMPARISON OF INHALATION OF PARTICULATES TO
SOIL DERMAL CONTACT PATHWAY
% of Combined
Average Daily Soil Exposure
Particulate Daily Soil Dermal (Inh. & Derm.)
Age Inhalation Rate Contact Rate
2
Attributable to
Inhaled
years mg^/kg/day mg^/kg/day Particulates3
1-2 0.0041 30.6 0.01%
2-3 0.0035 28.1 0.01%
3-4 0.0038 31.2 0.01%
4-5 0.004 30.7 0.01%
5-6 0.0035 28.0 0.01%
6-7 0.0023 25.4 0.01%
7-8 0.0029 25.7 0.01%
8-9 0.0025 24.1 0.01%
9- 10 0.0023 23.5 0.01%
10-11 0.002 23.7 0.01%
11-12 0.0017 22.6 0.01%
12-13 0.0024 21.5 0.01%
13-14 0.0023 21.2 0.01%
14-15 0.0021 21.1 0.01 %
15-16 0.002 20.9 0.01 %
16-17 0.002 20.8 0.01%
17-18 0.0019 20.8 0.01%
18-25 0.0026 75.8/7 = 10.8 0.02%
25-30
MEAN age 1-2:
0.0024 51.6/5 = 10.3 0.02%
0.0041 mg _/kg/d 30.6 mg ./kg/d 0.01 %
MEAN ages 1-8: 0.0034 mg^/kg/d 28.6 mg^kg/d 0.01 %
MEAN ages 1-30: 0.0026 mg^/kg/d 18.9 mg^kg/d 0.01%
1 • Average Daily Soil Particulate Inhalation Rate calculated from equation in Section 8.8.3.
2 - Daily Soil Dermal Contact Rate from Table 8-9.
3 - (Column 2/(Column 2 + Column 3)) * 100. Example Calculation, ages 25-30:
(0.0024/(0.0024 + 10.3)) * 100 = 0.02 %
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Table 8-13 summarizes the relationship between the estimated exposure from the
inhalation of fugitive dust and the exposure received from direct contact (incidental
ingestion and dermal contact combined) with the contaminated surficial soil.
TABLE 8-13
INHALATION PATHWAY EXPOSURE
AS A PERCENTAGE OF TOTAL
(INGESTION & DERMAL) SOIL EXPOSURE
Receptor
(age in years)
Ratio of Inhaled Particulate Exposure to Total
(Ingestion + Dermal + Inhalation) Exposure
%
MEAN, 1 - 2 years 0.01%
MEAN, 1 - 8 years 0.01%
MEAN, 1 - 30 years 0.01%
NOTE: This demonstration of the relative insignificance of exposure via the
inhalation of particulates does not consider the absorption efficiencies
of specific chemicals, nor the relative importance of chemicals exhibit
toxic effects at the portal of entry. Chemical-specific information can
and should be used to evaluate specific circumstances. The conclusions
drawn here should be interpreted as a gross generalization.
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8.8.3 Equations
The equation used to evaluate potential exposure associated with inhalation of
contaminated airborne particulates is given as:
ADE.*.
1 y— = E«tnt.c + E.pring4WI + E•uiraw (3)
and
E.
[RPL, *P*VR # F*D1*D2*C*DE
BW * AP
(4)
Where:
CADEW i
E =
P -
VR =
F =
Dl =
C =
D2 =
DE «
BW =
AP =
The Average Daily Exposure to airborne soil particulates in air (calculated for 1 year:
winter, spring & fall, and summer). In units: mg/kg/day.
Seasonal exposures (winter, spring & fall, and summer), each averaged over the year. In
units: mg/kg/day.
The Proportion (fraction) of the respirable particulate assumed to be derived from the
contaminated on-site soils. Dimensionlesa.
The concentration of Respirable Particulates (PM10) in air. In units: (ig/m .
Respiratory rate for the receptor of concern. In units: m /hour.
The Frequency (F) of exposure. In units: events/day.
The Duration (Dl) of each exposure event. In units: hours/event.
Units Conversion factor 10 tng/^g.
The Duration (D2) of the exposure period. In units: days.
Deposition Efficiency of PM10 in lung. In units:
percent
The receptor's Body Weight. In units: kg.
The Averaging Period (AP). In units: days.
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TABLE 8-14
INHALATION OF PARTICULATES - EXPOSURE ASSUMPTIONS
Parameter
Value or
Range of
Values Discussion
Respirable
Particulate
Concentration,
[RPL
44 f£<r/m3 The niflximmn annual mean recorded PM10 level in Massachusetts in6/
1986 (MA DEQE, 1987)
Proportion, P 0.4 or 0.5 In the winter, 40% (0.4) of the fugitive dust in the air is assumed to
come from the local (contaminated) area. In the spring, summer and
fall 50% (0.5) of the respirable particulates are assumed to have the
contaminated area as their source.
Respiratory 0.17 - 1.04 Hourly intake for the receptor of concern: age specific.
Volume, VR m3/hr (U.S. EPA, 1989b)
Frequency of
Exposure, F
Duration of
Exposure
Event, Dl
Duration of
Exposure
Period, D2
1 event/day r^ie receptors are assumed to spend at least part of every day in the
home, and thus exposed to the contaminated fugitive dust.
24 hr/event ' Children 0-6 years are assumed to spend 24 hr/day at home, as are
1 2 rir /«»v«»Tit- c*u^ ren 6**2 years during the summer.
'
• Children 6-18 years are assumed to spend 12 hr/day at home during
lb nr/event the fall, winter and spring months, as are children 12-18 yrs during
the summer.
• Female adults are assumed to spend 16 hr/day at home.
92 122 or WINTER: 151 days, Nov. -> March
1 kt A* SPRING & FALL: 122 days, April, May, September & OctoberlOl aaVS SUMMER: 92 days, June, July & August
Averaging 365 days 365 days per year of exposure for the indicated receptor
Period, AP
Body Weight,
BW
Deposition
Efficiency
10.8 to
59.9 kg
50%
Age-specific values, ranging from 8.5 kg for a child < 1 yr to 59.9 kg
for a 3- year old female (US EPA 1989b)
,th
50 percentile female (MA DEP, 1991a; US EPA 1989b)
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8.9 Drinking Water -
Inhalation, Dermal Contact, and Ingestion
8.9.1 Narrative Description
The Residential ShortForm evaluation of drinking water includes consideration of
three potential exposure routes which may result from the use of contaminated water:
(1) inhalation of substances volatilized from the water; (2) dermal absorption of
chemicals during skin contact with the water; and (3) ingestion of the contaminated
drinking water. Inhalation and dermal exposures would typically occur during
showering, bathing, washing dishes, cooking, and other household activities.
The residential receptor is not assumed to be exposed to all chemicals via all three
exposure routes. Those substances which are considered to be volatile organic
compounds (or VOCs) are evaluated for all three exposure routes. Semi-volatile
organic compounds (or SVOCs) are evaluated for dermal and ingestion exposures.
Metals are evaluated for ingestion exposures only.
For volatile organic compounds, it is assumed that inhalation exposures resulting from
the use of contaminated drinking water may result in absorbed doses and risks equal
to or greater than the ingestion doses and risks associated with drinking the water
(Andelman, 1985; Foster and Chrostowski, 1987; McKone, 1987; McKone, 1991a). For
dermally absorbed compounds (VOCs and SVOCs), it has also been suggested that
doses received via dermal contact during bathing or showering may be equal to or
greater than the doses associated with ingestion exposures (Brown, 1984). This
analysis thus assumes that exposures associated with inhalation and dermal contact
are each equal to those estimated from drinking the contaminated water. [These
assumptions are being re-evaluated by the Department, and future versions of the
Residential ShortForm may use a different model.]
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For VOCs, the total dose and total risk associated with exposure
to contaminated drinking water is three times the dose and risk
associated with drinking the water only.
For SVOCs, the total dose and risk associated with exposure to
contaminated drinking water is twice the dose and risk
associated with drinking the water only.
For metals, the total dose associated with exposure to
contaminated drinking water is equal to the dose associated with
drinking the water only.
The Residential ShortForm estimates exposures associated with subchronic, chronic
and 30 year (adult) exposures. Note that the 30 year exposure is assumed to occur
entirely during adulthood to be consistent with standard US EPA and MA DEP
practices for evaluating drinking water exposures. A lifetime average body weight
(62 kg) is used with an adult drinking water intake (2 liters/day), rather than
weighted averages over the 0-30 year age period. This simplification is considered
justified since water intake increases with age, and the dose remains relatively
constant over a lifetime. This trend is shown in Figure 8-2, where the intake
normalized to bodyweight for ages to 18, while variable, averages to approximately
the adult exposure.
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8.9.2 Equations
The equation used to evaluate potential non-carcinogenic effects associated with
exposure to contaminated drinking water is given as:
HI =
[OHM]^ • VI • RAF * F * Dl * D2 * MULT
* BW * AP • C
(5)
The equation used to evaluate potential carcinogenic effects associated with exposure
to contaminated drinking water is given as:
ELCE =
[OHM]^ * VI * RAF * F * Dl * D2 * MULT * %gg^
BW * AP * C
(6)
Where the exposure related terms (not shaded above) are:
[OHM]^ =
VI
RAF
FandDl =
D2 and AP =
MULT =
BW
C
The Operational Exposure Point Concentration (EPC) of the oil or hazardous material in drinking
water. In units: fig/liter.
Daily volume of drinking water ingested by the receptor of concern. In units: liters/day.
The Relative Absorption Factor for drinking water ingestion and threshold effects (A chemical- and
route- specific value). Dimensionless.
The Frequency (F) of exposure and the Duration (Dl) of each exposure event. The receptors are
assumed to be exposed to the drinking water each and every day, and that exposure occurs over the
course of the day.
F = 1 event/day and Dl = 1 day/event
The product of these terms is equal to 1, and it is dimensionless. They have thus been eliminated
from the actual formulae contained in the spreadsheet.
The Duration (D2) of the exposure period and the Averaging Period (AP). For the purposes of
these evaluations, the drinking water exposures are assumed to occur over the relevant age of the
receptor
Subohronio:
Chronic:
Lifetime:
D2 = 1 year
D2 = 7 years
D2 = 30 years
AP = 1 year
AP = 7 years
AP = 75 years
The quotient of these two terms is dimensionless.
The Multiplier for non-ingestion in-home uses of the water. Dimensionless.
The receptor's Body Weight, age specific. In units: kg.
Units Conversion Factor: 10 fig/mg
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8.9.3 Summary of Drinking Water Exposure Parameters
TABLE 8-15
DRINKING WATER - EXPOSURE ASSUMPTIONS
Parameter for Subchronic HI
Calculations
for Chronic HI
Calculations
for ELCR
Calculations
Water Volume
Ingested, VI
1 liter/day
Discussion follows
1 liter/day
Discussion follows
2 liters/day
Discussion follows
Relative
Absorption
0.006 - 1.3
Discussion follows
0.006 - 1.3
Discussion follows
0.006 - 1.3
Discussion follows
Factor, RAF
Multiplier, MULT 1, 2, or 3
Discussion follows
1, 2, or 3
Discussion follows
1, 2, or 3
Discussion follows
Body Weight, BW 10.5 kg
Discussion follows
16.8 kg
Discussion follows
62 kg
Discussion follows
Frequency of
Exposure, F
1 event/day
Each day is considered an
exposure "event"
1 event/day
Each day is considered an
exposure "event"
1 event/day
Each day is considered an
exposure "event"
Duration of
Exposure Event,
Dl
1 day/event
The consumption of water is
assumed to take place over
the course of the day
1 day/event
The consumption of water is
assumed to take place over
the course of the day
1 day/event
The consumption of water is
assumed to take place over
the course of the day
Duration of
Exposure Period,
D2
1 year
The drinking water is
assumed to remain
contaminated over the course
of the 1 year subchronic
exposure
7 years
The drinking water is
assumed to remain
contaminated over the course
of the 7 year chronic
exposure
30 years
The drinking water is
assumed to remain
contaminated over the
duration of the residential
period
Averaging Period,
AP
1 year
For the evaluation of
noncarcinogenic effects,
AP = D2
7 years
For the evaluation of
noncarcinogenic effects,
AP = D2
75 years
For the evaluation of
carcinogenic effects, the AP
is equal to a lifetime
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8.9.4 Exposure Parameters
There are four exposure parameters in the equations which evaluate drinking water
related exposures. The input value for each parameter may vary according to the
type of risk being evaluated (carcinogenic or non-carcinogenic) and the chemical of
concern. Each of the parameters are discussed in more detail below.
8.9.4.1 Water Volume Ingested, VI
The drinking water consumption rates of 2 liters/day for adult (lifetime) exposures
and 1 liter/day for infant's (subchronic) and childhood (chronic) exposures are
standard assumptions described by the U.S. Environmental Protection Agency (U.S.
EPA 1989b & 1991). An individual's water intake may vary by age, sex, geography or
level of activity. Estimates ofmean tap water consumption rates for adults (ofvarious
ages) fall in the range of approximately 0.6 to 1.6 liters/day. Estimates of mean
intakes for young children fall in the range of approximately 0.2 to 0.5 liters/day
(Ershow and Cantor, 1989).
8.9.4.2 Body Weight, BW I
For each receptor evaluated, the values chosen represents the 50
th
percentile of the
female body weight for the age group under consideration (US EPA, 1989b).
Female, age 1-2 years, BW = 10.5 kg
Female, age 1-8 years, BW = 16.8 kg
Female, adult lifetime, BW 62 kg
These values are embedded in the formulae contained in the spreadsheet.
8.9.4.3 Relative Absorption Factor, RAF
The methodology for deriving these chemical- and route-specific factors has been
described by both the MA DEP and the U.S. EPA (MA DEQE, 1989a; US EPA,
1989a). The derivation of the input values used in this spreadsheet may be found in
Appendix C. It should be remembered that an RAF is not simply an absorption
factor.
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8.9.4.4 Multiplier, MULT
Multipliers are used to evaluate potential exposures to a residential receptor from
dermal contact with contaminated drinking water and the inhalation of material
volatilized from the water. Various papers (Andelman, 1985; Brown, 1984) have
indicated that the exposures received via each of these pathways may be roughly
approximate to the dose from ingesting the water. A Multiplier of three (3) is used
for chemicals which may be dermally absorbed, inhaled and ingested. A multiplier
of two (2) is used for chemicals which may be dermally absorbed and ingested. A
Multiplier of one (1) is used for chemicals which are not volatile nor easily absorbed
through the skin.
The assumption of equivalency between exposure pathways related to drinking water
is being examined by the Department, and alternative models may be incorporated
into future versions of the ShortForm.
TABLE 8-16
CHEMICALS AND THEIR
ASSIGNED DRINKING WATER USAGE
MULTIPLIERS
1 2 3
Arsenic Bis(2-ethylhexyl)phthalate Benzene
Cadmium Carbon Tetrachloride
Chromium Cyanide Chlorobenzene
Lead Mercury Chloroform
Nickel PAHs 1, 1-Dichloroethane
Silver PCBs 1, 1-Dichloroethylene
Thallium Phenol 1,2-Dichloroethane
Zinc 1,2-Dichloroethylene
Ethylbenzene
Ethylene Dibromide
Methylene Chloride
MEK
MTBE
2-Methylnaphthalene
Naphthalene
Tetrachloroethylene
Toluene
1, 1, 1-Trichloroethane
Trichloroethylene
Vinyl Chloride
Xylenes
These multipliers are embedded in the formulae contained in the spreadsheet.
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8.10 HOME GROWN FRUITS AND VEGETABLES
Reminder The consumption of homegrown fruits and vegetables is
evaluated in version 1.6a of the Residential ShortForm. This
pathway is not considered in version 1.6b.
8.10.1 NARRATIVE DESCRIPTION
The Food Chain Exposure Assessment was developed to support the Residential
ShortForm, although its use can be generalized to the analysis of any situation where
the consumption of fruit and vegetables grown in contaminated soil may be of
concern. This analysis evaluates typical exposures to a gardener who ingests home
grown produce. It does this in two parts: (1) estimating the contaminant
concentration in the produce as a function of the contaminant's soil concentration,
and (2) estimating the amount of home grown produce a typical receptor consumes.
This exposure pathway model is under review, and future versions of the ShortForm
may incorporate a new or modified model.
The evaluation of the food chain exposure pathway, while commonly overlooked in
disposal site risk characterizations, is potentially significant. The National Gardening
Association (as reported in US EPA, 1989b) estimates that approximately 1.9 million
households in New England (37%) maintain vegetable gardens, and that, nationwide,
vegetable gardens are just slightly less common in urban households (26%) than in
suburbia (33%).
8.10.1.1 Contaminants of Concern
The Residential ShortForm contains 49 chemicals commonly reported at M.G.L. C.21E
disposal sites. These chemicals include metals, volatile organic compounds (VOCs)
and semi-volatile organic compounds (SVOCs). Of these 49 compounds, the volatile
organic compounds were not evaluated in the food chain assessment. It is believed
that significant levels of these chemicals can not accumulate in a plant due to their
volatile characteristic. In addition, cyanide, phenol, and Bis(2-ethylhexyl)phthalate
were not evaluated in the food chain assessment due to insufficient evidence that
these chemicals accumulate in plant tissue.
Table 8-17 lists the chemicals which were included in the food chain analysis. Note
that the term PAHs includes seventeen of the forty-nine distinct Residential
ShortForm chemicals.
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TABLE 8-17
FOOD CHAIN ANALYSIS
CONTAMINANTS OF CONCERN
arsenic
cadmium
chromium
lead
mercury
nickel
silver
thallium
zinc
PAHs
PCBs
8.10.1.2 Food Intake
There is, perhaps, no exposure factor in risk assessment which is as difficult to
characterize as the American diet. Food consumption varies by both composition and
mass: what you eat and how much of it you eat. Factors which affect a person's food
intake include age, sex, health status, place of residence, season, religion and
philosophical beliefs.
For this food chain analysis a typical market basket of fresh garden fruits and
vegetables was created following the three steps described below. This simplified
approach does contain many uncertainties due both to insufficient data and wide
variations in food intake.
The market basket is based on information gathered by the U.S. Department of
Agriculture in the 1977-78 USDA Nationwide Food Consumption Survey (USDA,
1983) and on data used by the U.S. EPA for assessing the land application of
municipal sludge (US EPA, 1989d). Nineteen garden fruits and vegetables (listed in
the first column of Table 8-18) are included in the market-basket and the average
daily consumption rates for the homegrown fruits or vegetables were calculated for
different age groups as described below.
STEP 1: The relationship between the amount of homegrown produce and total
ingested produce was described. This was done by subtracting the amount (lbs/week)
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of produce purchased from the total amount of produce eaten (E). The difference (D)
is assumed to be homegrown. The ratio D/E give the proportion of the total intake
which is considered to be homegrown for this evaluation. This information is specific
to households in the New England states (US DA, 1983). The population considered
was made up of families in all types of urbanization (central city, suburban and non-
metropolitan). The intakes were averaged over the entire year.
TABLE 8-18
PROPORTION OF FRESH PRODUCE THAT IS HOMEGROWN1
** for the General Population **
(Northeastern U.S.)
Amount Amount Difference Proportion
Eaten Bought (D)
(E) D/E
PRODUCE (lbs/wk) (lbs/wk) (lbs/wk)
White Potato 2.94 2.77 0.17 0.0578
Lettuce 1.27 1.22 0.05 0.0394
Spinach 0.08 0.07 0.01 0.1250
Cabbage 0.54 0.48 0.06 0.1111
Broccoli 0.23 0.22 0.01 0.0435
Cauliflower 0.09 0.08 0.01 0.1111
Peppers 0.26 0.22 0.04 0.1538
Beans (wax) 0.28 0.16 0.12 04286
Peas 0.04 0.02 0.02 0.5000
Beets
Carrots
Onions
Corn
Cucumbers
Pumpkin, Squash
Strawberries
Tomatoes
Cantaloupe
Other Berries
0.06
0.46
0.60
0.56
0.50
0.21
0.11
1.14
0.59
0.06
0.01
0.41
0.55
0.40
0.38
0.10
0.09
0.66
0.54
0.03
0.05
0.05
0.05
0.16
0.12
0.11
0.02
0.48
0.05
0.03
0.8333
0.1087
0.0833
0.2857
0.2400
0.5238
0.1818
0.4211
0.0847
0.5000
1- Taken from US DA (1983), Tables 12, 13, and 14. The amount eaten (E) is based on
the average family size of 3.06 members/household in this survey.
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STEP 2: The total produce intakes (purchased + homegrown) were identified (US
EPA, 1989d) for four age groups: 0.5 to 1 year old, 2 years old, 14 to 16 years old,
and 26 to 30 years old. These produce-specific intakes are given in dry weight, and
are listed in Table 8-19.
TABLE 8-19
AVERAGE DAILY INTAKE OF PRODUCE
(Dry Weight)
** General Population **
Total Intake Total Intake Total Intake Total Intake
0.5 < 1 yr 2 year old 14 < 16 yr 26 < 30 yr
g/day g/day (g/day) (g/day)
Produce
White Potato 0.8390 2.4001 3.8646 4.2338
(136, 137, 139, 143)
Lettuce (109, 147) 0.0053 0.1071 0.5466 0.9468
Spinach (107) 0.0160 0.0470 0.0470 0.2000
Cabbage (110, 111) 0.0143 0.0539 0.1900 0.2700
Broccoli (113) 0.0300 0.1100 0.1400 0.3600
Cauliflower (116) 0.0271 0.0283 0.0582
Peppers (125) 0.0005 0.0046 0.0200 0.0700
Beans (wax) (121) 0.0278 0.0724 . 0.0967 0.1878
Peas (046) 0.1700 0.1200 0.1600 0.3000
Beets (131) 0.0021 0.0371 0.0806 0.0976
Carrots (127, 143) 0.2016 0.3993 0.3340 0.6109
Onions (128, 139, 142, 148) 0.0206 0.0606 0.3391 0.3065
Corn (054) 0.1000 1.04 2.0900 1.5300
Cucumbers (123) 0.0070 0.0380 0.0870 0.1700
Pumpkin, Squash (126, 124) 0.1264 0.0590 0.1153 0.2773
Strawberries (086) 0.0500 0.1200 0.1600 0.1900
Tomatoes (117, 142, 151, 120) 0.0627 0.3462 0.6887 1.1263
Cantaloupe (089) 0.0561 0.0631 0.3010 0.2824
Other Berries (065) 0.0005 0.0082 0.0110 0.0114
Dry weight of food taken from U.S. EPA (1989d), Table Al-3. The numbers in
parentheses by the food name refers to the lines in that Table which were used.
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STEP 3: The average daily intake of homegrown produce was estimated for each
fruit and vegetable by multiplying the proportion of homegrown to total (calculated
in Table 8-18) by the total intake (Table 8-19) of each plant. The results are shown
in Table 8-20.
TABLE 8-20
AVERAGE DAILY INTAKE OF HOMEGROWN PRODUCE
(Dry Weight)
General Population ****
Produce
Homegrown
Intake
0.5 < 1 yr
g/day
Homegrown
Intake
2 year old
g/day
Homegrown
Intake
14 < 16 yr
(g/day)
Homegrown
Intake
26 < 30 yr
(g/day)
White Potato
Lettuce
Spinach
Cabbage
Broccoli
Cauliflower
Peppers
Beans (wax)
Peas
Beets
Carrots
Onions
Corn
Cucumbers
Pumpkin, Squash
Strawberries
Tomatoes
Cantaloupe
Other Berries
0.0485 0.1387 0.2234 0.2447
0.0002 0.0042 0.0213 0.0369
0.0020 0.0059 0.0059 0.0250
0.0016 0.0060 0.0211 0.0300
0.0013 0.0047 0.0060 0.0155
0.0030 0.0031 0.0065
0.0001 0.0007 0.0031 0.0108
0.0119 0.0311 0.0415 0.0806
0.0850 0.0600 0.0800 0.1500
0.0017 0.0309 0.0671 0.0813
0.0220 0.0435 0.0364 0.0666
0.0017 0.0050 0.0281 0.0254
0.0286 1.2974 0.5977 0.4376
0.0017 0.0091 0.0209 0.0408
0.0662 0.0309 0.0604 0.1453
0.0091 0.0218 0.0291 0.0346
0.0264 0.1458 0.2899 0.4742
0.0048 0.0054 0.0256 0.0240
0.0003 0.0041 0.0055 0.0057
Dry weight of homegrown produce is the product of the proportion of
produce eaten which is homegrown (D/E) and the Total Intake (TI) of
produce for each age group. These factors are shown in Tables 8*18
and 8-19, respectively.
D/E * Tl = Homegrown Intake
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The use of this hypothetical market basket indicates that the "average" adult receptor
(25 to 30 years of age) ingests approximately 11.2 grams (a0.4 ounces, dry weight) of
fresh vegetables and garden fruits per day and that approximately 17% of that total
is home grown. (0.4 ounces, dry weight is approximately equal to 4 ounces wet
weight.) In this analysis, "fresh" includes all the fresh produce used by the families
surveyed in the US Department of Agriculture study, including that eaten fresh,
cooked or preserved for later use.
Note that the produce consumption information is available for four age periods
which do not correspond with the receptors of interest to this evaluation. Some
modification of these values is thus necessary, and the resulting intake values are
presented in Table 8-21.
SUBCHRONIC EXPOSURES: The homegrown garden produce intake of the 1 to 2
year old child who is the receptor of concern for the ShortForm evaluation of
subchronic exposures is assumed to be equal to the Total Intake of the 2 year old
given in Table 8-20 (column 3). The assumed daily intake rates of homegrown fruits
and vegetables are listed in Table 8-21 for the 1 to 2 year old receptor.
CHRONIC EXPOSURES: The receptor of concern for the ShortForm evaluation of
chronic exposures is a child 1 to 8 years old, a period of seven years. The intakes for
the 2 year old (Table 8-20, column 3) is assumed to be equal to the intakes for the
first 4 years of the chronic exposure (ages 1-5 years) and the intake of the 14 to
16 year old (Table 8-20, column 4) is assumed to be equal to the intakes for the last
3 years of the chronic exposure (ages 5-8 years). Thus the homegrown produce
intake used in the estimates for chronic exposure are weighted averages of the values
presented in Table 8-19:
Intake^
v
= [(4 * Intake2yr) + (3 * Intake 14.16yt,)l h- 7
The resulting intake rates ofhomegrown fruits and vegetables are listed in Table 8-21
for the 1 to 8 year old receptor.
30 YEAR EXPOSURE: The receptor of concern for the cancer risk evaluations in the
ShortForm is exposed for 30 years from birth to age 30. As with the chronic exposure
detailed above, the intake of homegrown fruits and vegetables used for this pathway
evaluation is a weighted average of the four time periods for which consumption
information is available (Table 8-19).
Intake,^ = [(Intake<1 ) + (4 * Intake2yr) + (13 * Intake 14.16yr) + (12 * Intake^ J] h- 30
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The resulting intake rates ofhomegrown fruits and vegetables are listed in Table 8-21
for the to 30 year old receptor.
TABLE 8-21
AVERAGE DAILY INTAKE OF HOMEGROWN PRODUCE
(Dry Weight)
General Population ****
Produce
White Potato
Lettuce
Spinach
Cabbage
Broccoli
Cauliflower
Peppers
Beans (wax)
Peas
Beets
Carrots
Onions
Corn
Cucumbers
Pumpkin, Squash
Strawberries
Tomatoes
Cantaloupe
Other Berries
Homegrown Homegrown Homegrown
Intake Intake Intake
1 < 2yiV 1 < 8yrs2 < 30 yrs3
g/day g/day g/day
0.139 0.175
0.297
0.009
0.031
0.022
0.146
0.005
0.004
0.426
0.014
0.044
0.025
0.208
0.014
0.005
0.215
0.004 0.012 0.025
0.006 0.006 0.013
0.006 0.012 0.022
0.005 0.005 0.01
0.003 0.003 0.004
0.001 0.002 0.006
0.031 0.035 0.055
0.060 0.069 0.106
0.031 0.046 0.066
0.043 0.04 0.049
0.005 0.015 0.023
0.474
0.027
0.091
0.03
0.336
0.021
0.005
1 - The 1 < 2 year old is assumed to have the same intake of homegrown fruits and
vegetables as the 2 year old in Table 8-20.
2 - The average daily 1 < 8 year old intake rate is a weighted combination of the intake
rates of the 2 year old (weight = 4) and the 14< 16 year old (weight = 3) in Table 8-20:
Intake,^ = [(4 * Intake2) + (3
* Intake14<16 )] -s- 7
3 - The average daily < 30 year old intake is a weighted combination of the four age
groups for which intakes are presented in Table 8-20:
Intake^ = [(Intake^) + (4 • Intake2) + (13 * Intake14<16) + (12 * Intake2e<30)] -s- 30
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8.10.1.3 Plant Uptake
As described by Chaney (1984), plant absorption of chemicals from soil is related to:
(1) chemical properties; (2) soil properties (pH, chemical concentration in the soil,
organic matter, cation exchange capacity, and the level of other chemicals in the soil),
and (3) plant properties (plant age, species, and the type of edible portion of the crop
[leafy or root vegetable, or garden fruit]). This food chain analysis simplifies the
complicated issues surrounding the plant uptake coefficients by focussing on chemical
concentration in soil and the species of plant.
The accumulation of different chemicals has been reviewed extensively in studies of
potential effects of sewage sludge application on cropland. Many of the uptake factors
used in this analysis were found in such reviews. Table 8-22 lists the plant uptake
factors used in this evaluation and gives the references for the specific values.
8.10.1.4 Output
The Food Chain Exposure Assessment does not calculate risk estimates directly,
unlike the other exposure pathways in the ShortForm. For each chemical, three
distinct risk Multipliers are derived through this analysis and these are used in
conjunction with chemical specific factors (such as soil concentration and toxicity) in
the Residential ShortForm to estimate risk. The Multipliers are listed in Table 8-23,
and are contained in the TOXICITY INFORMATION section of the ShortForm.
These multipliers incorporate plant uptake factors, produce-specific intake rates,
home grown fraction, bodyweight and units conversion factors. The multiplier is a
fruit and vegetables pathway exposure factor, similar to that described by McKone
(1989), which represents vegetable contaminant intake normalized to body weight and
expressed in soil equivalents. The numerical value of the multiplier represents the
mass of soil which contains the mass of contaminant in the daily homegrown intake
of all of the fruits or vegetables, divided by the body weight of the receptor.
There are three multipliers for each chemical evaluated in this pathway, the
Subchronic Hazard Index Multiplier, the Chronic Hazard Index Multiplier and the
Cancer Risk Multiplier.
Each Multiplier is specific to a chemical, type of exposure and age group (chronic,
subchronic) and health endpoint (threshold, carcinogenic). All Multipliers are
expressed in units of Kg^^AKg^ * day), which is sometimes simplified to 1/day.
The specific equations which use these Multipliers in risk characterization are
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described in more detail in Section 9.0. The three risk multipliers derived for each
chemical evaluated are:
The Subchronic Hazard Index Multiplier, SHIM, is used in the evaluation of the
potential risks ofthreshold (i.e., noncarcinogenic) health effects following a short term
exposure. The receptor of concern is the 1-2 year old infant who ingests
approximately 0.03 ounces (dry weight) of home grown fruits and vegetables per day.
The Chronic Hazard Index Multiplier, CHIM, is used in the evaluation of the
potential risks ofthreshold (i.e., noncarcinogenic) health effects following an extended
exposure (seven years or more). The receptor of concern is the 1-8 year old child who
ingests approximately 0.04 ounces (dry weight) of home grown fruits and vegetables
per day.
The Cancer Risk Multiplier, CRM, is used in the estimation of a receptor's Excess
Lifetime Cancer Risk resulting from an exposure of any specified duration. The
receptor of concern in this evaluation experiences an exposure of a typical residential
duration (30 years), eating approximately 0.05 ounces (dry weight) of home grown
fruits and vegetables per day.
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TABLE 8-22
PLANT UPTAKE FACTORS
KSPpM/aol = (mgo^yKg^Vtmg^Kg^)
(References)
Produce ARSENIC CADMIUM CHROMIUM LEAD MERCURY NICKEL
White Potato 0.0006 0.03 0.11 (1) 0.0008 0.0033 0.125
Lettuce 0.04 0.43 0.0075 (2) 0.008 0.007 0.09
Spinach 0.04 0.43 0.0075 (3) 0.008 0.007 0.09
Cabbage 0.04 0.43 0.0075 (2) 0.008 0.007 0.09
Broccoli 0.04 0.43 0.0075 (2) 0.008 0.007 0.09
Cauliflower 0.04 0.43 0.0075 (2) 0.008 0.007 0.09
Peppers 0,002 0.05 0.01 (2,4) 0.002 0.0033 0.04
Beans (wax) 0.0002 0.01 0.81 (1) 0.001 0.001 0.13
Peas 0.0002 0.01 0.81 (1) 0.001 0.001 0.13
Beets 0.02 0.22 0.0125 (5) 0.003 0.017 0.52
Carrots 0.02 0.22 0.0125 (5) 0.003 0.017 0.52
Onions 0.02 0.22 0.0125 (5) 0.003 0.017 0.52
Corn 0.0001 0.03 0.0125 (5) 0.01 0.0033 0.13
Cucumbers 0.002 0.05 0.0125 (5) 0.002 0.0033 0.04
Pumpkin, Squash 0.002 0.05 0.0125 (5) 0.002 0.0033 0.04
Strawberries 0.002 0.05 0.0125 (5) 0.002 0.0033 0.04
Tomatoes 0.002 0.05 0.0125 (5) 0.002 0.0033 0.04
Cantaloupe 0.002 0.05 0.0125 (5) 0.002 0.0033 0.04
Other Berries 0.002 0.05 0.0125 (5) 0.002 0.0033 0.04
All uptake factors 1taken from U.S. EPA (1989d) unless otherwise noted:
(D- Grant, 1977
(2)- Baes, 1984
(3)- Walsh, 1977
(4)- Cary, 1990
(5)- Rinne, 1986
continued..
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TABLE 8-22, continued..
PLANT UPTAKE FACTORS, continued...
(References)
Produce SILVER THALLIUM ZINC PAHs PCBs
White Potato 0.8 (5) 0.0004 (2) 0.02 0.42 0.02
Lettuce 0.8 (5) 0.0004 (2) 0.8 0.29 0.38
Spinach 0.8 (5) 0.0004 (2) 0.8 0.29 0.38
Cabbage 0.8 (5) 0.0004 (2) 0.8 0.29 0.38
Broccoli 0.8 (5) 0.0004 (2) 0.8 0.29 0.38
Cauliflower 0.8 (5) 0.0004 (2) 0.8 0.29 0.38
Peppers 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
Beans (wax) 0.8 (5) 0.0004 (2) 0.04 0.42 0.002
Peas 0.8 (5) 0.0004 (2) 0.04 0.42 0.002
Beets 0.8 (5) 0.0004 (2) 0.05 0.61 0.36
Carrots 0.8 (5) 0.0004 (2) 0.05 0.61 0.36
Onions 0.8 (5) 0.0004 (2) 0.05 0.61 0.36
Corn 0.8 (5) 0.0004 (2) 0.04 0.42
Cucumbers 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
Pumpkin, Squash 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
Strawberries 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
Tomatoes 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
Cantaloupe 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
Other Berries 0.8 (5) 0.0004 (2) 0.04 0.42 0.02
All uptake factors taken from U.S. EPA ( 1989d) unless otherwise noted:
(2) • Baes, 1984
(5) • Rinne, 1986
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8.10.2 Equations
The general equation (modified from McKone, 1989) used to calculate the Multipliers
for a given chemical (i) is given as:
M, = SjEHGFI, * Ksp, D2 C t BWt AP] (7)
Where:
M,
HGFIj =
Rsp,,
D2&AP =
BW
C
The Multiplier for chemical (i): Either the Cancer Risk Multiplier (CRM), the Chronic
Hazard Index Multiplier (CHEM), or the Subchronic Hazard index Multiplier (SHIM). In
unit*: Kg«| /(K^b. * «i»y)
The Home Grown Food Intake (dry weight) of the fresh produce (j) consumed
(Table 8-21). In units: gramsVday
The steady state partition coefficient (Uptake Factor) for chemical (i) between the dry
mass of vegetable (j) and the soil (Table 8-22). In units: (mg
(
/Kgj)/(aig/Kg
ao-
)
The Duration ofthe exposure period and the Averaging Period. For the purposes of these
evaluations, the food chain exposures are assumed to occur over the relevant age of the
receptor
Subchronic:
Chronic:
Lifetime:
D2 s 1 year
D2 = 7 years
D2 = 30 years
AP = 1 year
AP = 7 yean
AP = 75 years
The receptor's average Body Weight over the exposure period. In units: Kg
fa
Conversion factor 10 Kg^/g,
The type of Multiplier derived (SHIM, CHIM, or CRM) is determined by the exposure
scenario chosen and the corresponding input values. The Multipliers used in the
Residential ShortForm are given in Table 8-23.
The equation used to evaluate potential non-carcinogenic effects associated with the
consumption of homegrown fruits and vegetables is given as:
HIM * [OHM]w * RAF
(8)
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The equation used to evaluate potential carcinogenic effects associated with the
consumption of homegrown fruits and vegetables is given as:
HIE = CRM * [OHMU * RAF • §§1 (9)
Where the exposure related terms (not shaded above) are:
HIM = The Hazard Index Multiplier for the chemical: Either the Chronic Hazard Index
Multiplier (CHIM, in the TOXICITY INFORMATION section of the ShortForm), or the
Subchronic Hazard Index Multiplier (SHIM, in the TOXICITY INFORMATION section
of the ShortForm). In units: Kg^ /(Kg^ * day)
CRM - The Cancer Risk Multiplier (CRM, in the TOXICITY INFORMATION section of the
ShortForm). In units: Kg^,, /(Kg*, * day)
[OHM]^ = The Operational Exposure Point Concentration (EPC) of the oil or hazardous material
in the soil.
RAF = The Relative Absorption Factor for food intake. RAFs are specific to the chemical, route
of exposure and toxicity information. RAFs are presented for the evaluation of non-
carcinogenic effects and for carcinogenic effects. Appendix C. Dimensionless.
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TABLE 8-23
FOOD CHAIN MULTIPLIERS
(from the Residential ShortForm)
Oil or
Hazardous
Material
CANCER SUBCHRONIC CHRONIC
RISK HAZARD INDEX HAZARD INDEX
MULTD7LD2R MULTD7UER MULTIPUER
1/day 1/day 1/day
ARSENIC
CADMIUM
CHROMIUM
LEAD
MERCURY
7.1E-08 3.0E-07 2.6E-07
NC 5.0E-06 4.4E-06
NC 9.2E-06 6.8E-06
NC 3.8E-07 3.4E-07
NC 5.0E-07 4.5E-07
NC 1.1E-05 9.5E-06
NC 6.5E-05 5.5E-05
NC 3.2E-08 2.8E-08
NC 4.8E-06 4.3E-06
9.4E-07 4.3E-06 3.6E-06
6.9E-06 3.5E-05 3.0E-05
NC 3.5E-05 3.0E-05
NICKEL
SDLVER
THALLIUM
ZINC
PCBs
CARCINOGENIC
PAHs
NON-
CARCmOGENIC
PAHs
1/day is simplified from Kg^/Gtg^ * day)
NC - Not Calculated (The chemical is assumed not to be
carcinogenic via the oral route, or no carcinogenic
potency value is available.
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8.10.3 SUMMARY OF FOOD INTAKE PARAMETER VALUES
TABLE 8-24
INGESTION OF FOOD - EXPOSURE ASSUMPTIONS
Subchronic Hazard Chronic Hazard Cancer Risk
Index Multiplier Index Multiplier Multiplier (CRM)
Parameter (SHIM) (CHIM)
Body Weight, 10.5 kg 16.8 kg 42.3 kg
BW
Homegrown 0.85 g/day 1.16 g/day 1.6 g/day
Food Intake, dry weight dry weight dry weight
HGFI, (0.03 oz/d) (0.04 oz/d) (0.06 oz/d)
Plant Uptake 0.0001 - 0.81 0.0001 - 0.81 0.0001 - 0.81
Coefficient, Ksp
u
Relative 0.006 -> 1.3 0.006 -> 1.3 0.006 -> 1.3
Absorption
Factor, RAF
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8.11 VAPORS - INDOOR AIR
8.11.1 NARRATIVE DESCRIPTION
The Residential ShortForm includes an evaluation of exposures which may result
from the presence of chemicals in indoor air. Of particular concern are those
groundwater contaminants which may volatilize and infiltrate a residence, although
any situation in which the indoor air is impacted by oil or hazardous material from
a disposal site must be evaluated. Only those chemicals considered to be volatile are
included in the indoor air pathway, and these chemicals are listed in Table 8-25.
TABLE 8-25
CHEMICALS INCLUDED IN THE INDOOR
AIR EXPOSURE PATHWAY
Benzene Carbon Tetrachloride
Chlorobenzene Chloroform
1,1-Dichloroethane 1,2-Dichloroethane
1,2-Dichloroethylene Ethylbenzene
Ethylene Dibromide Mercury
Methylene Chloride Methyl Ethyl Ketone
Methyl t-Butyl Ether Phenol
Tetraehloroethylene Toluene
1, 1,1•Trichloroethane Trichloroethylene
Vinyl Chloride Xylenes
In the evaluation of subchronic exposures, the 1-2 year old receptor is assumed to
be continuously exposed (24 hours/day) for a period of one month. (Exposures of
duration less than one month would be considered acute, and are not evaluated in the
Residential ShortForm.)
For chronic exposures and lifetime exposures, receptors are assumed to spend an
average of 16 hours per day in the home.
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8.11.2 EQUATIONS
The equation used to evaluate potential non-carcinogenic effects associated with
inhalation of contaminated indoor air is given as:
[OHMl^ * F * Dl * D2
00)
AP
The equation used to evaluate potential carcinogenic effects associated with inhalation
of contaminated indoor air is given as:
[OHM].,, * F * Dl * D2 * By
AP
(11)
Where the exposure related terms (not shaded above) are:
[OHM],,, =
F&D1 =
The Operational Exposure Point Concentration (EPC) of the oil or hazardous material in indoor
air
. In units: fig/m .
The Frequency (F) of exposure and the juration (Dl) of each exposure event. The receptors are
assumed to be continuously exposed to the contaminated indoor air while they are in the home.
For subohronio exposure:
F = 1 event/24 hr and Dl = 24 hr/event
The product of these terms is equal to 1, and it is dimensionless. They have
thus been eliminated from the actual formulae contained in the spreadsheet.
For chronic and lifetime exposures:
F s 1 event/24 hr and Dl = 16 hr/event
D2 and AP = The Duration (D2) of the exposure period and the Averaging Period (AP). For the purposes of
these evaluations, the indoor air exposures are assumed be of durations:
Subehronie:
Chronic:
Lifetime:
D2 = 1 month
D2 = 7 years
D2 = 30 years
AP = 1 month
AP = 7 years
AP = 75 years
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3. SUMMARY OF INDOOR AIR EXPOSURE PARAMETERS
TABLE 8-26
INHALATION OF INDOOR AIR EXPOSURE ASSUMPTIONS
Parameter for Subchronic HI for Chronic HI for ELCR
Calculations Calculations Calculations
1 event/24 hr
Frequency of 1 event/24 hr 1 event/24 hr
Exposure, F
Duration of 24 hr/event 16 hr/event 16 hr/event
Exposure Event,
Dl
Duration of 1 month 7 years 30 years
Exposure Period,
D2
Averaging Period, 1 month 7 years 75 years
AP
8.11.4 EXPOSURE PARAMETERS
The methodology for evaluating indoor air differs from that used for other exposure
pathways in that Reference Concentrations and Unit Risks are used in lieu of
Reference Doses and Carcinogenic Potency Values. Since concentration and not dose
is the basis of these toxicity values, body weight, respiration rate and RAFs are not
incorporated in the formulae.
In general, the exposure period (D2) may be thought of as the span of the receptor's
lifetime during which the exposures occur at some intermittent rate. How often the
receptor is exposed during that time is the Frequency (F) and the duration of each
individual exposure event is Dl.
By definition, the Excess Lifetime Cancer Risk is estimated from a lifetime average
daily exposure, and the averaging period for these calculations is the length of a
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lifetime (75 years) no matter how long the exposure duration may be. In other words,
even if a receptor were exposed a single time (D2 = 1 day), the exposure would be
averaged over a lifetime (AP = 75 years * 365 days/year). In the calculation of a
Hazard Index, however, the exposure of interest is that which the receptor
experiences during the exposure period, and so the averaging period is set equal to
that exposure period (AP = D2).
8.11.4.1 Frequency of Exposure, F
For each of the exposures evaluated (subchronic, chronic and lifetime), the receptor
is assumed to be exposed to the volatilized OHM in the indoor air of the home each
and every day. Thus each day is considered to include an exposure "event", and this
is mathematically represented as "1 event/24 hours".
8.11.4.2 Duration of the Exposure Event, Dl
While all the receptors are considered to be exposed each and every day, the
evaluation assumes that the older receptors do not spend all of their time indoors.
The time spent out of the home (in school, at play or at work) is reflected in the
duration of the exposure event. On average these receptors are assumed to spend 8
hours/day away from home, and Dl is thus 24 - 8 = 16 hours/event. The receptor
for the subchronic exposure (the 1-2 year old child) is assumed to remain in the home
virtually 24 hours/day during the exposure period.
8.11.4.3 Duration of the Exposure Period, D2
For a residential indoor air exposure, the exposure period depends on how long the
receptor lives in the affected house. The Residential ShortForm assumes that the
receptor may live in the same house for up to 30 years, representing the 95th
percentile of a typical duration of residence (U.S. EPA, 1989b), and thus D2 is
contingent on the definitions of subchronic, chronic and residency exposures. Since
a subchronic exposure may range from 1 month to 7 years, D2tubehronte = 1 month;
chronic exposure may range from seven years to a lifetime, and 1)2^^ = 7 years;
for the cancer risk calculations, the duration of the exposure period is equal to the
expected residence time in the affected home, and 02,^,,^ = 30 years.
8.11.4.4 Averaging Period, AP
For subchronic and chronic Hazard Index calculations, the averaging period is equal
to the duration of exposure (D2). For the evaluation of Excess Lifetime Cancer Risk,
the Averaging Period is equal to 75 years.
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9.0 RISK CHARACTERIZATION
9.1 Purpose
The purpose of the MCP Phase II Health Risk Characterization is to provide the
necessary information which will allow a site manager to answer the question, "Based
upon the risk of harm to public health, is remediation necessary at this disposal site?".
(See Section 10.0 - Conclusions.)
As described in Section 4.2, the Massachusetts Contingency Plan details very specific risk
management criteria to be used in the determination of the need for remediation. These
criteria include public health standards and the Total Site Risk Limits contained in
310 CMR 40.545(3)(g)3b. These criteria are also employed in the evaluation of remedial
alternatives which is part of the MCP Phase HI.
The Risk Characterization portion of the risk assessment combines the results of the
Hazard Identification, Dose-Response Assessment and the Exposure Assessment to yield
quantitative measures of risk (the Hazard Index and Excess Lifetime Cancer Risk) for
each chemical in each exposure medium. These chemical-specific values are then
combined to yield Total Site Cancer and Noncancer Risk estimates for the residential
receptor who is the focus of Residential ShortForm. In addition, the Risk
Characterization compares the calculated Exposure Point Concentrations to the applicable
or suitably analogous public health standards identified for each exposure medium.
In order for the comparison to the MCP risk management criteria to be valid, it is
important that the Exposure Point Concentrations (EPCs) and Total Site Risks be
calculated in a manner consistent with Departmental guidance. Deviations from
acceptable risk assessment methodology may result in the development of Exposure Point
Concentrations and Total Site Risks which are not comparable to the risk management
criteria and which could not be used to determine the need for remediation.
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
111
9.2 Comparison of EPC To Standards
The Massachusetts Contingency Plan requires that the characterization of risk of harm to
human health include a comparison of current and reasonably foreseeable exposure point
concentrations to applicable or suitably analogous public health standards (310 CMR
40.545(3)(g)).
9.2.1 Soil Standards
There are currently no applicable or suitably analogous public health standards for
soil.
9.2.2 Drinking Water Standards
The Risk Assessment ShortForm - Residential Scenario automatically compares the
site-specific Drinking Water Exposure Point Concentrations (typed into the DATA
ENTRY section of the ShortForm by the risk assessor) to the Massachusetts
Maximum Contaminant Levels (MMCLs).
The Massachusetts MCLs are contained in regulations promulgated by the
Massachusetts Department of Environmental Protection, Division of Water Supply.
These regulations are frequently updated, and revised copies of the Massachusetts
Drinking Water Regulations (310 CMR 22.00) are available at the State Bookstore
in Boston at (617) 727-8234 or Springfield (413) 784-1376. The Residential
ShortForm will be updated annually to insure that the comparison to drinking
water standards remains current.
The Massachusetts Drinking Water Standards are listed in the COMPARISON TO
DRINKING WATER STANDARDS SUMMARY TABLE. The standards are given
in units of /Kg/liter, and thus are directly comparable to the Exposure Point
Concentrations entered by the user.
If the Exposure Point Concentration entered in the DATA ENTRY section of the
ShortForm is greater than the listed drinking water standard for that chemical, a
"1" is placed in the columns headed "EXCEEDS DW STD" (of the COMPARISON
OF EPC TO DRINKING WATER STANDARDS SUMMARY TABLE). The number
of exceedances summed and the total given at the bottom of the COMPARISON
TO DRINKING WATER STANDARDS SUMMARY TABLE.
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9.2.3 Fruit And Vegetables Standards
There are currently no applicable or suitably analogous public health standards for
contaminants in food.
9.2.4 Vapors - Indoor Air
There are currently six (6) ambient air quality standards which are considered
applicable or suitable analogous under the Massachusetts Contingency Plan. The
Massachusetts Ambient Air Quality Standards (310 CMR 6.00) contain numerical
criteria for sulfur oxides, PM10, Carbon Monoxide, Ozone, Nitrogen Dioxide
and Lead.
The indoor air exposure pathway developed for the Residential ShortForm
(described in Section 8.4 and 8.5) is concerned with the infiltration of volatile
organic compounds (VOCs) into a building from contaminated groundwater. There
are no air standards for any of the VOCs of concern in this scenario, and thus no
comparison of Exposure Point Concentration to standards can be made.
For sites where there is evidence of indoor air contamination not consistent with
the infiltration model used in this spreadsheet, the Residential ShortForm may
not provide a complete characterization of the potential human health risks.
9.3 Hazard Index
9.3.1 Narrative Description
The potential for non-carcinogenic (or threshold) health effects is characterized in
the Residential ShortForm by the use of the Hazard Index.
For a given chemical, the Hazard Index is the ratio of a receptor's quantified
exposure and the "acceptable" (or "allowable") exposure level. A Hazard Index of
1.0 would indicate that the receptor's exposure is equal to the "acceptable"
exposure level, and it is considered unlikely that adverse health effects would
occur. A Hazard Index greater than 1 does not imply that health impacts would
necessarily be expected: the interpretation of the Hazard Index must consider the
appropriateness of the exposure assumptions and the basis of the toxicity values
used in the calculations. For the Residential ShortForm, the toxicity values are
described in Section 7.0 - Dose Response Assessment, and the exposure
assumptions for each receptor are described in Section 8.0 - Exposure Assessment.
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In its most general form, the Hazard Index associated with a chemical via a route
of exposure is calculated:
HI = ADD/RfD (1)
HI = [OBM]JBIC (2
or
Where:
'
HI = The Hazard Index associated with exposure to the chemical via the specified route of exposure.
Dimensionless.
ADD = The estimated Average Daily Pose of the chemical via the specified exposure route. In units:
mg/kg/day.
RfD = The oral Ae/erence Dose or substitute toxicity value identified for the chemical of concern and
appropriate to the specific exposure pathway. The selection of these toxicity values is described
in Section 7.0. In units: mg/kg/day.
[OHM]^ = The Exposure Point Concentration of the oil or hazardous material in mr. In units: ng/tn .
RfC = The Reference Concentration or substitute toxicity value identified for the chemical of concern.
The selection of the toxicity values is described in Section 7.0. In units: fig/m .
The Average Daily Dose in equation (1) above represents the "exposure related
terms" which were described in Section 8.0. Factors such as the Exposure Point
Concentration, Frequency of exposure and Body Weight are included in the ADD.
Note that the Residential ShortForm does not calculate an average daily dose as a
separate step: the actual equations contained in the spreadsheet combine the
exposure and risk calculations.
Separate calculations are performed for the characterization of risk for the
subchronic (1 year) and chronic (7 year) exposures for the residential receptors.
9.3.2 Equations
The following sections present the pathway-specific equations which are used to
estimate the Subchronic and Chronic Hazard Indices. The actual equations
contained in the Residential ShortForm combine the steps of calculating average
daily dose and quantifying risk. The equations which follow are repeated from
Section 8.0 and the portions of the equation specific to the quantification of dose
are shaded here to highlight the risk related portion of each equation. [In Section
8.0, these risk terms were shaded.]
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9.3.2.1 Soil
The equation (repeated from Section 8.7.2) used to evaluate potential non-
carcinogenic effects associated with direct contact with contaminated surface soil is
given as:
$OH»BU C<NADSIR * RAF) + (NADSCR * EAF» * C
HI = _____ (3)
RFD
where the risk-related terms (not shaded above) are:
HI = Either the Subchronic Hazard Index or the Chronic Hazard Index. These values represent the
Hazard Index associated with exposure to the individual chemical through direct contact with
the contaminated soils. Dimensionless.
R£D = The oral Reference Dose or substitute toxicity value identified for the particular chemical of
concern. Either the Subchronic Oral RfD or the Chronic Oral R£D. In units of: mg/kg/day
9.3.2.2 Drinking Water
The equation (repeated from Section 8.9.2) used to evaluate potential non-
carcinogenic effects associated with exposure to contaminated drinking water is
given as:
[OB3M0U* VI* KAF | F* Dl * D2 MULT
HI = (4)
RfD *iiii|iiiiii
Where the risk-related (not shaded) portion of the equation is:
HI = Either the Subchronic Hazard Index or the Chronic Hazard Index. These values represent the
Hazard Index associated with exposure to the individual chemical through the use of the
contaminated drinking water. In units of: Dimensionless.
RfD = The oral Reference Dose or substitute toxicity value identified for the particular chemical of
concern. Either the Subchronic Oral RfD or the Chronic Oral RfD. In units of: mg/kg/day.
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9.3.2.3 Fruits and Vegetables
Reminder: The consumption of homegrown fruits and vegetables is evaluated in
version 1.6a of the Residential ShortForm. This pathway is not
considered in version 1.6b.
The equation (repeated from Section 8.10.2) used to evaluate potential non-
carcinogenic effects associated with exposure to homegrown fruits and vegetables
is given as:
HI = (5)
RfD
Where the risk-related (not shaded) portion of the equation is:
HI = Either the Subchronic Hazard Index or the Chronic Hazard Index. These values represent the
Hazard Index associated with exposure to the individual chemical through the consumption of
garden fruits and vegetables grown in the contaminated soil. In units of: Dimensionless.
RfD = The oral Reference Dose or substitute toxicity value identified for the particular chemical of
concern. Either the Subchronic Oral RfD or the Chronic Oral RfD. In units of: mg/kg/day.
9.3.2.4 Vapors - Indoor Air
The equation (repeated from Section 8.11.2) used to evaluate potential non-
carcinogenic effects associated with exposure to vapors in indoor air is given as:
HI= (6)
Where the risk-related (not shaded) portion of the equation is:
HI = Either the Subchronic Hazard Index or the Chronic Hazard Index. These values represent the
Hazard Index associated with exposure to the individual chemical through the inhalation of
vapors in indoor air. In units of: Dimensionless.
RfC = The Reference Concentration or substitute toxicity value identified for the particular chemical of
concern. Either the Subchronic RfC or the Chronic RfC. In units of: /ig/tn .
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9.4 Excess Lifetime Cancer Risk
9.4.1 Narrative Description
The potential for carcinogenic (i.e. non-threshold) health effects is characterized in
the Residential ShortForm in the calculation of Excess Lifetime Cancer Risk
(ELCR) for the residential receptor.
The Residential ShortForm calculates an excess lifetime cancer risk based upon a
30-year exposure. The 30 year period was chosen as it represents the 95th
percentile of the typical duration of residence in a house (US EPA, 1989b). The
cancer risks associated with shorter exposure periods (i.e. the 1-year subchronic
exposure or the 7-year chronic exposure) are not calculated. ELCR estimates for
such exposures would be duplicative given the assumption of potential exposure
during the entire 30 year residence time.
The 30-year exposure is averaged over a lifetime to yield the Lifetime Average
Daily Dose necessary for the cancer risk calculations. Use of the Lifetime Average
Daily Dose should not be interpreted to mean that the ShortForm assumed a
lifetime exposure, however.
For a given chemical, the estimated ELCR is the product of the receptor's
quantified exposure and a measure of carcinogenic potency. The resulting risk
estimate is considered to be an upper-bound probability of the likelihood of
developing cancer as a result of that exposure. As described in Section 7.12, the
measures of carcinogenic potency employed in the ShortForm are the
Carcinogenic Potency Value (CPV) and the Unit Risk (UR). The assumptions
used to quantify exposure are detailed in Section 8.0 - Exposure Assessment.
In its most general form, the Excess Lifetime Cancer Risk associated with
exposure to a chemical via a particular pathway is estimated:
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or
ELCR = LADD • CPV (7)
ELCR = [OHM]^ * UR (8)
Where:
ELCR « The Excess Lifetime Cancer Bisk associated with exposure to the chemical via the specified
route of exposure. Dimensionless.
LADD - The estimated Lifetime Average Daily Dose of the chemical via the specified exposure route. In
units: mg/kg/day.
CPV = The Carcinogenic Potency Value identified for the chemical of concern and appropriate to the
specific exposure pathway. The identification and selection of the CPVs is described in Section
7.0. In units: (mg/kg/day)" .
[OHM] . = The Exposure Point Concentration of the oil or hazardous material in air. In units: fig/m .
UR m The Unit Risk for the particular rh*m\™* of concern. The identification and selection of the
URs is described in Section 7.0. In units: fig/m .
The Lifetime Average Daily Dose in equation (7) above represents the "exposure
related terms" which were previously described in detail (Section 8.0). Factors
such as the Exposure Point Concentration, Frequency of exposure and Body
Weight are included in the LADD. Note that the Residential ShortForm does not
calculate a lifetime average daily dose as a separate step: the actual equations
contained in the spreadsheet combine the exposure and risk calculations.
9.4.2 Equations
The following subsections present the pathway-specific equations which are used
to estimate the Excess Lifetime Cancer Risks (ELCR). The actual equations
contained in the Residential ShortForm combine the steps of quantifying exposure
and estimating risk. The equations which follow are repeated from Section 8.0
and the portions of the equation specific to the quantification of exposure is
shaded here to highlight the risk-related terms. [In Section 8.0, the risk portion
of each equation was shaded.]
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9.4.2.1 Soil
The equation (copied from Section 8.7.2) used to evaluate potential carcinogenic
effects associated with direct contact exposure with contaminated surface soil is
given as:
elcr = prawiStCPLAism; *;:p*W3^^ * cpv (9)
Where the risk-related terms (not shaded above) are:
CPVo = The oral Carcinogenic Potency Value for the particular chemical of concern. In units of:
(mg7kg/day).l
ELCR = The Excess Lifetime Cancer Risk associated with exposure to the individual chemical through
direct contact with the contaminated soils. Dimensionless.
9.4.2.2 Drinking Water
The equation (repeated from Section 8.9.2) used to evaluate potential carcinogenic
effects associated with exposure to contaminated drinking water is given as:
JOBMW* VI * BAF * F •m * 1)2 * MlJItf * CPV
ELCR = (10)
Where the risk-related terms (not shaded above) are:
CPVo = The oral Carcinogenic Potency Value for the particular chemical of concern. In units
of: (mg/kg/day)-l
ELCR — The Excess Lifetime Cancer Risk associated with exposure to the individual chemical
through the use of the contaminated drinking water. Dimensionless.
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9.4.2.3 Fruits and Vegetables
Reminder The consumption of homegrown fruits and vegetables is evaluated in
version 1.6a of the Residential ShortForm. This pathway is not
considered in version 1.6b.
The equation (repeated from Section 8.10.2) used to evaluate potential
carcinogenic effects associated with exposure to homegrown fruits and vegetables
is given as:
elcr = wmm:i®BB&ymjs^cpv. ou
Where the risk-related terms (not shaded above) are:
ELCR =
CPV
The Excess Lifetime Cancer R isk associated with exposure to the individual chondral
through the consumption of homegrown fruits and vegetables. Dimensionless.
The oral Carcinogenic Potency Value for the particular chemical of concern. In units
of: (mg/kg/day)'
9.4.2.4 Vapors - Indoor Air
The equations used to evaluate potential carcinogenic effects associated with
inhalation of vapors in indoor air is given as:
;
* iiiiiiii * ur^
ELCR = (12)
Where the risk-related terms (not shaded above) are:
ELCR =
U*inh
The Excess Lifetime Cancer i? isk associated with exposure to the individual chemical
through the inhalation of vapors present in indoor air. Dimensionless.
The inhalation Unit Risk for the particular chemical of concern.
In units of: (fig/tar)
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9.5 Total Site Risks
The Residential ShortForm estimates Total Site Risks for a residential receptor for both
carcinogenic and noncarcinogenic health effects. These risks are then available to the
site manager for decision making purposes under the MCP. Rather than simply
providing a single, final "Total Risk" value, however, the ShortForm also details the
chemical- and medium-specific risks which contribute to the Total Site Risks. The
accessibility of these intermediate values provides additional information to the site
manager which can be used in the development of remedial alternatives and target
cleanup levels.
9.5.1 Noncarcinogenic Risk
The Residential ShortForm calculates several types of Hazard Indices for the
evaluation of noncarcinogenic risk: chemical-specific, route-specific, and a
Total Hazard Index.
HI^^p^ = S HIc^^^c (13)
m^.^ Sm,
„„,
(14)
The chemical-specific hazard indices (both subchronic and chronic) are
presented in each of the exposure pathway SUMMARY TABLES respectively) of
the ShortForm. These values are the hazard indices associated with each chemical
for a given pathway. The chemical-specific His answer very pointed questions,
such as: "What is the non-carcinogenic risk associated with exposure to toluene in
the indoor air?".
The route-specific hazard indices (both subchronic and chronic) are presented
in each of the exposure pathway SUMMARY TABLES of the ShortForm (the
Totals at the bottom of each table), and in the OVERALL HEALTH RISKS
SUMMARY TABLE. These values represent the hazard indices associated with
each exposure pathway. The route-specific His answer more general questions,
such as: "What is the non-carcinogenic risk associated with drinking the
contaminated water at this site?"
The Total Hazard Indices (both subchronic and chronic) are presented in the
OVERALL HEALTH RISKS SUMMARY TABLE of the ShortForm. These values
represent the hazard index associated with cumulative exposure experienced by
the receptor. The Total Hazard Indices answer the most general question, "What
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is the cumulative (non-carcinogenic) impact that this site might have on a
residential receptor?" The Total Hazard Indices also answer the specific MCP
question, "Is remediation required at this disposal site to eliminate a significant
risk of harm to human health?"
The Total Hazard Index and the Route-Specific Hazard Indices calculated in the
Residential ShortForm are actually screening Hazard Indices which sum the
chemical-specific His of all the OHM in the relevant exposure pathways regardless
of each chemical's health endpoint, mechanism of action or target organ.
Section 10.0 discusses the interpretation of the Hazard Index results within the
context of the Massachusetts Contingency Plan and the use of these estimates as a
risk management tool.
9.5.2 Carcinogenic Risk
The Residential ShortForm calculates several types of Excess Lifetime Cancer
Risks: chemical specific, route-specific, and Total Site Cancer Risk.
ELCR _ = 21 ELCRdie(nfcll^fc (15)
ELCR^ = X ELCRroi-Mp^nc (1 6)
The chemical-specific ELCRs are presented in each of the exposure pathway
SUMMARY TABLES of the ShortForm. These values are the cancer risks
associated with each chemical for a given pathway. The chemical-specific ELCRs
answer very pointed questions, such as: "What is the carcinogenic risk associated
with exposure to benzene in the indoor air?".
The route-specific ELCRs are presented in each of the exposure pathway
SUMMARY TABLES (the Totals at the bottom of each table), and in the
OVERALL HEALTH RISKS SUMMARY TABLE. These values represent the
excess lifetime cancer risks hazard associated with each exposure pathway. The
route-specific ELCRs answer more general questions, such as: "What is the
carcinogenic risk associated with drinking the contaminated water at this site?"
The Total Site Cancer Risk is presented in the OVERALL HEALTH RISKS
SUMMARY TABLE of the ShortForm. This value represents the total excess
lifetime cancer risk associated with the cumulative exposure experienced by the
residential receptor. The Total Site Cancer Risk answers the most general
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question, "What is the cumulative (carcinogenic) impact that this site might have on
a residential receptor?" The Total Site Cancer Risk also answers the specific MCP
question, "Is remediation required at this disposal site to eliminate a significant
risk of harm to human health?"
The calculation of excess lifetime cancer risk is performed for those chemicals
identified at the disposal site which are considered to be known, probable or
possible human carcinogens (EPA Class A, B or C) and for which adequate toxicity
information is available.
Section 10.0 discusses the interpretation of the Excess Lifetime Cancer Risk
results within the context of the Massachusetts Contingency Plan and the use of
this estimate as a risk management tool.
9.6 Results - SUMMARY TABLES
The Residential ShortForm contains six summary tables (five in version 1.6b) which
present the results of the risk characterization for this residential exposure scenario.
The printed summary tables provide the basis of the Phase II Risk Characterization
Report required under the Massachusetts Contingency Plan, and should be submitted as
part of any Report completed with the aid of the ShortForm.
9.6.1 Exposure Route Summary Tables
The four route-specific summary tables (#1-4: soils, drinking water, homegrown
vegetables and indoor air) consist of six columns of information:
the name of the Oil or Hazardous Material (OHM),
the Exposure Point Concentration (EPC),
the Operational Exposure Point Concentration (OEPC),
the Subchronic Hazard Index (SHI),
the Chronic Hazard Index (CHI), and
the Excess Lifetime Cancer Risk (ELCR).
Reminder: Version 1.6b of the Residential ShortForm does not consider the
homegrown fruits and vegetables pathway. Thus, version 1.6b has three route-
specific summary tables.
The names of the 49 Oil or Hazardous Material (OHM) included in the
ShortForm are repeated at the left of each of these summary tables. This list is
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identical to that contained in the DATA ENTRY section of the ShortForm, and will
be updated as more chemicals are added to the spreadsheet.
The Exposure Point Concentration (EPC, mg/kg) listed in the Summary
Tables is the value entered by the risk assessor in the DATA ENTRY section of
the ShortForm. If no value was entered for a given chemical this column will
remain blank.
The Operational Exposure Point Concentration (OEPC, mg/kg) listed in the
Summary Tables is the value used within the spreadsheet to estimate the
potential risks of harm to human health. The OEPC is determined by comparing
the Exposure Point Concentration entered by the risk assessor to a standard
"background- level contained in the TOXICITY INFORMATION section of the
ShortForm.
If the EPC for a given OHM is less than the
"background" level listed for that chemical, then the
OEPC is set to zero and the OHM is not carried
through quantitative the estimation of risk.
If the EPC for a given OHM is equal to or greater than the
"background" level listed for that chemical, then the OEPC is
set equal to the EPC and the chemical is carried through the
quantitative risk characterization.
Note that the Residential ShortForm does not subtract out "background". This
operation is included in the ShortForm in order to screen out of the quantitative
risk assessment those chemicals present at levels consistent with "background".
For a complete discussion of issues relating to the elimination of OHM from the
quantitative risk assessment see Section 6.2.
The Subchronic Hazard Index listed in the Summary Tables is the
quantification of the potential non-carcinogenic risk of harm to health associated
with a short-term (one year or less) residential exposure. The equations contained
in this column are described in detail in Section 9.3. The chemical-specific results
in the body of the Summary Table are summed at the bottom of the column to
yield a route-specific Subchronic Hazard Index.
The Chronic Hazard Index listed in the Summary Tables is the
quantification of the potential non-carcinogenic risk of harm to health associated
with a longer-term (one to seven years) residential exposure. The equations
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contained in this column are described in detail in Section 9.3. The chemical-
specific results in the body of the Summary Table are summed at the bottom of
the column to yield a route-specific Chronic Hazard Index.
The Excess Lifetime Cancer Risk (ELCR) listed in the Summary Tables is
the quantification of the potential carcinogenic risk of harm to health associated
with a 30-year residential exposure. The equations contained in this column are
described in detail in Section 9.4. The chemical-specific results in the body of the
Summary Table are summed at the bottom of the column to yield a route-specific
Excess Lifetime Cancer Risk.
9.6.2 Comparison Of EPCs To Standards Summary Table
Summary Table 5 (Table 4 in version 1.6b) presents the comparison of Exposure
Point Concentrations to Drinking Water Standards. This table consists of four
columns:
• the name of the Oil or Hazardous Material (OHM),
• The Exposure Point Concentration (EPC),
• Any Drinking Water Standard for that chemical, and
• A notation if the EPC exceeds the standard.
The first two columns are described above. The drinking water standards
are taken from the applicable Massachusetts Drinking Water Regulations (310
CMR 22.00) as described in Section 9.2.
.
The last column contains a notation (the character "1") if the exposure
point concentration entered by the risk assessor exceeds the drinking water
standard for that chemical. The number of exceedances is summed at the bottom
of the column.
9.6.3 Overall Health Risk Summary
Summary Table 6 (table 5 in version 1.6b) presents a summary of the cumulative
risks calculated for the residential exposure scenario. The table includes the
route-specific risks estimated for direct contact with soil, for drinking water, for
eating homegrown produce (excluded in version 1.6b) and for inhaling indoor air.
Total Site Risks are summarized at the bottom of the table for the Subchronic
Hazard Index, Chronic Hazard Index and the Excess Lifetime Cancer Risk.
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10.0 CONCLUSIONS
As described previously (Sections 1.0 and 2.0), the Residential ShortForm has been
developed primarily to streamline the baseline risk characterization process required as
part of the Massachusetts Contingency Plan's Phase II investigation. The conclusions
which may be drawn from the results of a ShortForm risk assessment are based on the
risk management criteria (Section 4.0) which are contained in the MCP.
Alternative uses of this ShortForm beyond the C.21E/MCP universe may require the
application of different sets of risk management criteria. It is important to identify in
advance the decision-making criteria which would be employed in such cases, and to
have the concurrence of the appropriate regulatory authority.
The MCP Phase II health risk characterization is designed to answer the question, "is
remediation required at this disposal site?". The health risk characterization is performed
after the Comprehensive Site Assessment is completed: this insures that sufficient data
has been collected to adequately characterize the extent of contamination and potential
human exposures. Inadequate site information introduces an additional level of
uncertainty which may undermine the conclusions of the risk characterization.
The conclusions of the ShortForm multi-media health risk characterization follow directly
from the Massachusetts Contingency Plan.
The Department's Waste Site Cleanup is currently being redesigned in a
manner which will result in significant changes in the Massachusetts
Contingency Plan. As these changes are^implemented, the TJesicfenria/
ShortForm and its Documentation... will be revised to reflect the new program.
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10.1 When No Further Remedial Response Action Is Necessary
The risk assessor may conclude that no further remedial response action is necessary,
based on human health considerations, if the disposal site will not pose a significant risk
of harm to health during any foreseeable period of time. The risk assessor is referred to
the specific regulations which concern this decision, contained in 310 CMR 40.545(3)(i).
The criteria used to conclude that no further action is necessary are:
• The current and all reasonably foreseeable exposure point
concentrations are less than or equal to any applicable or suitably
analogous public health standards. The Residential ShortForm
automatically compares the groundwater exposure point concentrations
entered by the risk assessor to the Massachusetts drinking water standards.
Summary Table 5 (table 4 in version 1.6b) contains this comparison.
• The current and reasonably foreseeable total site cancer risk is
equal to or less than the total site cancer risk limit of one in one
hundred thousand (1 x 10*5) AND the total site non-cancer risk is
equal to or less than the total site non-cancer risk limit which is a
Hazard Index equal to 0.2. The Residential ShortForm automatically
calculates the total site cancer and non-cancer risks. These values are
presented in Summary Table 4 - Overall Health Risk Summary (Table 3 in
version 1.6b).
1 0.2 When A Remedial Response Action Is Necessary
Somewhat oddly, the Massachusetts Contingency Plan defines the need for remediation
based upon the absence of significant risk, as described above. Remedial response actions
are thus required when the site does not meet the conditions for No Further Remedial
Response Action. 310 CMR 40.545(3)(j) provides the regulatory language for this
determination. However it may be helpful to state, in english, the conditions when a
remedial response action is required, based upon human health considerations.
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A remedial response action is necessary, if:
• The current and all reasonably foreseeable exposure point
concentrations are greater than any applicable or suitably
analogous public health standards. The Residential ShortForm
automatically compares the groundwater exposure point concentrations
entered by the risk assessor to the Massachusetts drinking water standards.
Summary Table 5 (Table 4 in version 1.6b) contains this comparison.
• The current and reasonably foreseeable total site cancer risk is
greater than the total site cancer risk limit of one in one hundred
thousand (1 x 10*) OR the total site non-cancer risk is greater than
the total site non-cancer risk limit which is a Hazard Index equal to
0.2. The Residential ShortForm automatically calculates the total site
cancer and non-cancer risks. These values are presented in Summary
Table 4 - Overall Health Risk Summary (Table 3 in version 1.6b).
10.3 Phase II Health Risk Characterization Conclusion
The Phase II Report must contain conclusions based upon the characterization of risk of
harm to human health (310 CMR 40.545(4)(j)).
The conclusions may be either that:
No Further Remedial Response Action is Necessary (based on human health
considerations) if the human health risk characterization demonstrates that the
disposal site meets the requirements set forth in 310 CMR 40.545(3)(i) and
described above (Section 10.1), or
A Remedial Response Action Is Necessary (based on human health considerations)
if the human health risk characterization demonstrates that a No Further Action
(NFA) determination is not justified, as set forth in 310 CMR 40.545(3)(j) and
described above (Section 10.1).
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10.4 Safety, Public Welfare And The Environment
The Residential ShortForm addresses the characterization of risk of harm to human
health. Use of the ShortForm does NOT absolve the risk assessor from the
Massachusetts Contingency Plan requirement to characterize the risk of harm to safety,
public welfare and the environment. The reader is referred to the MCP requirements set
forth in 310 CMR 40.545(3)(h), 545(3)(i), 545(3)0') and 545(4), which deal with the
characterization of these risks and the determination of need for response actions.
Remediation may be required, based upon the risk of harm to safety,
public welfare or the environment, even if no further remedial
response action is necessary based upon human health considerations.
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1 1 .0 Uncertainty Analysis
11.1 Narrative Discussion
The key to understanding how risk assessment can be appropriately used in the site
remediation process lies in understanding the strengths, limitations and uncertainties
inherent in the characterization of risk. While risk assessment is an analytic process that
is firmly based on scientific considerations, it also requires judgments to be made when
available data and information is incomplete. These judgments or "assumptions"
inevitably draw on both scientific and policy considerations which result in the
introduction of uncertainty.
The risk estimates generated for the characterization of Chapter 2IE disposal sites are
usually not fully probabilistic estimates of risk but rather conditional point estimates.
These estimates are prone to scientific uncertainty resulting from limitations in available
data and the assumptions made in the absence of data. The risk estimates generated in
many risk assessments (the Residential ShortForm being a typical example) are not
measures of actual or absolute risks, but are generally intended to represent upper-bound
(or high) estimates which are unlikely to underestimate the actual risk. The actual risk
to a hypothetical receptor may be as high as the risk estimate, but is likely to be much
lower. Thus, it is important to fully discuss the assumptions and uncertainties in any
risk assessment to place risk estimates in perspective and aid in risk management
decisions. Another use of an uncertainty analysis is to identify areas where a moderate
amount of additional data collection might significantly improve the risk assessment
process and thus improve the basis for selecting remedial alternatives.
The purpose of the uncertainty analysis is to document major assumptions and
limitations and, if possible, provide an indication of whether they have resulted in an
over- or under-estimation of risk. The uncertainty analysis may be qualitative,
quantitative or both. Types of uncertainty analyses and the information they provide is
discussed below.
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1 1 .2 Sources Of Uncertainty
According to the National Research Council (NRC, 1983), the uncertainties inherent in
risk assessment can be grouped in two general categories: (1) missing or ambiguous
information on a particular substance, and (2) gaps in current scientific theory. These
uncertainties will exist in each step of the risk assessment process. In terms of site risk
assessments, the sources of uncertainty can be broken into a number of components:
• uncertainty in the «»hami<»al monitoring data used to characterize exposure point concentrations;
• uncertainty in the environmental parameter measurements;
• uncertainty in the models used to evaluate contaminant transport and fate and to estimate exposure point
concentrations in the absence of monitoring data;
• uncertainty associated with the exposure assessment including estimating frequency, duration and
magnitude of exposure and with assigning exposure parameters to a non heterogenous population;
• uncertainty in the risk characterization process which reflects errors or uncertainties introduced through
combination of the above sources of uncertainly.
Finally, additional uncertainties are incorporated in the risk assessment when exposure to
multiple substances across multiple pathways are summed. A more complete discussion
of these sources of uncertainty appears below.
Uncertainty in site characterization and site sampling data can stem from the error
inherent in the sampling and analysis procedures, from a failure to take an adequate
number of samples to arrive at sufficient characterization of the type and quantity of
OHM released at or from the site, from mistakes on the part of the sampler, from the
heterogeneity of the matrix being sampled, or from intentional bias in sample collection.
Environmental parameter measurements primarily contribute to uncertainty due to their
absence. Lack of site-specific measurements dictates that estimates must be made based
on literature values, regression equations, extrapolations, and best professional judgment.
In the absence of site specific sampling or environmental parameter measurements
models are often used to predict exposure point concentrations and exposure doses.
Modeling error arises primarily from the use of an inappropriate model or the use of an
appropriate model but with inappropriate boundary conditions. A further limitation in
modeling is that a model can only approximate reality. Other model errors can stem
from a lack of validation or verification of the models.
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The dose-response assessment is often one of the largest sources of uncertainty in any
risk assessment. As noted by EPA in its Risk Assessment Guidance Document for
Superfund Sites (U.S. EPA, 1989a):
Toxicity information for many of the chemicals found at disposal sites if often limited. Consequently,
there are varying degrees of uncertainty associated with the toxicity values calculated. Sources of
uncertainty include:
• using dose-response information from effects observed at high doses to
predict the adverse health effects that may occur following exposure to the
low levels expected from human contact with the agent in the environment;
• using dose-response information from short-term exposure studies to predict
the effects of long-term exposures, and vice-versa;
• using dose-response information from animal studies to predict effects in
humans; and
• using dose-response information from homogeneous animal populations or
healthy human populations to predict the effects likely to be observed in the
general population consisting of individuals with a wide range of sensitivities.
In addition to the uncertainties in dose-response values (such as the Reference Dose or
Carcinogenic Potency Value), the Relative Absorption Values (RAFs) may also be a source
of uncertainty.
The exposure assessment also introduces a number of uncertainties into the risk
assessment process, particularly in the development of exposure point concentrations and
the quantification of exposure parameters, many of which are not directly observable (e.g.,
frequency and duration of exposure). Exposure is in part based on the behavior patterns
and personal habits of the exposed populations. Variations in human behavior thus
represent a major source of uncertainty. There is also uncertainty associated with
assigning point-estimates to exposure parameters such as body weight, ventilation rates
and surface areas which are best described as distributions.
By definition, risk is a function of both exposure and toxicity. Thus, if either or both
exposure or toxicity information are not accurate, risk estimates may not accurately
reflect the potential risk.
In addition to the uncertainty that exists in evaluating the risk from single chemicals,
further uncertainty is introduced in evaluating exposure and risk to multiple chemicals or
mixtures. At most disposal sites, a mixture of chemicals is present in each media. To
assess the overall effects of multiple chemicals, EPA developed "Guidelines for the Health
Risk Assessment of Chemical Mixtures" (U.S. EPA, 1986). This guidance states that if
sufficient data are not available on the effects of the chemical mixture of concern, or a
reasonably similar mixture, the proposed approach is to assume additivity. This
assumption, according to EPA, is expected to yield generally neutral risk estimates (i.e.,
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neither conservative nor lenient). More recent guidance (U.S. EPA, 1989a) also
references the "Guidelines for the Health Risk Assessment of Chemical Mixtures", but
further states that the assumption of additivity assumes independence of action and that
if this assumption is incorrect, over- or under-estimation of the actual multiple substance
risk could result.
The impact of uncertainty on risk estimates and methods for evaluating uncertainty are
discussed below.
11.3 Impacts Of Uncertainty On Risk Estimates
Historically, most disposal site risk assessments only provided a qualitative discussion of
uncertainty. Usually, the discussion focused on a general discussion of the various
sources of uncertainty discussed in Section 11.2, but provided very little information as to
the relative impact of the various sources of uncertainty on the resultant site specific risk
estimates.
It is well accepted in the field of environmental risk assessment that uncertainty about
numerical risk estimates is generally large (i.e., an order of magnitude or greater). Given
this level of uncertainty, it is important to focus on identifying the key site-related
variables and assumptions that contribute most to uncertainty. To account for
uncertainty and determine which factors most affect risk estimates, several approaches
have been applied.
Rather than present a single point estimate representative of either an "average" or
"maximum" exposure, risk assessments often present more than one risk estimate, each
reflecting a combination of input values taken from the theoretical range of values for
each parameter. The risk assessment results then include a range of risk estimates
thought to place bounds on the risk.
The benefit of this approach is that while no one value may be thought to reflect actual
exposure or risk, there is confidence that the "real risks" lay somewhere within the
bounds of the risks presented. In some instances, the use of a range of risk estimates
representing average and "worst case" exposure may be further evaluated by performing a
sensitivity analysis. In a sensitivity analysis, the range of parameters suspected of driving
the risks are varied and the corresponding degree to which changes in risk estimates
occur can be described.
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Even when a range of point estimates is presented, it is important to recognize that most
risk assessments currently do not quantitatively deal with uncertainty. Because the risk
assessment is based on a combination of uncertain point estimates for input values, the
uncertainty in the final risk estimates reflects the accumulation of uncertainty in the
assessment process.
For many of the factors which go into characterizing risks, point estimates may not be
realistic, depending on the input values that are used. To account for this uncertainty,
an alternate approach is to look at the distribution of many of these factors rather than
rely on point estimates. The use of such probability distributions may provide a more
realistic prediction of site risk.
Recently, methodologies for performing quantitative uncertainty analyses in public
health risk assessments using Monte Carlo techniques have been developed. These
approaches utilize distributions of values for key input parameters such as exposure point
concentrations or exposure parameters while identifying distributions of risk values.
Overall, the technique provides a quantitative means for estimating the probability
distributions for health risks given the available information. These techniques can be
used to "replace" the traditional point estimate risk assessment approach, or as an
uncertainty analysis technique to evaluate point estimates.
In Monte Carlo type analyses, a range of risk is presented in terms of probability
distributions. Using appropriate statistical summaries of the results, one can identify
"mean" risk values, "median" risk values, and risk values at various percentiles of the
distribution. This type of analysis enables risk managers to evaluate the risk assessment
tool and its point estimates in terms of the risk management philosophy desired. This
type of analysis has shown that typical health risk assessment methods produce very
conservative point estimates (Burmaster, 1991; Finkel, 1990; Hawkins, 1991; McKone,
1991b; Roseberry, in press).
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
135
11.4 Just How Conservative Are We?
To be protective of human health and the environment, most risk assessments make
assumptions that are very conservative and sometimes "worst case". The effect of
combining multiple conservative input values in exposure and risk calculations is the
development of very conservative "point estimates" of risk. In many cases, these very
conservative "point estimates" overestimate the risks for a large majority of the
population evaluated. In some cases, these point estimates may be overestimates for
virtually the entire population (more than 99.99 % of the population. Such extremely
conservative risk estimates may result in unnecessary public concern or unnecessarily
expensive mitigation.
Work is currently underway to quantitatively assess the uncertainty in the Residential
ShortForm process. In particular, an attempt will be made to put the ShortForm point
estimates in perspective in order to evaluate the appropriateness of the standardized
exposure and toxicity input values given the Bureau of Waste Site Cleanup's risk
management philosophy.
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APPENDIX A
GLOSSARY OF
TERMS AND ACRONYMS
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GLOSSORY OF
TERMS & ACRONYMS
ADD
ADE
ADSCR
ADSIR
AF
AIC
AIS
AP
ATC
Background
BAF
BW
wg
c
C.21E
CAG
Cancer Risk Multiplier
Carcinogenic Potency Value
CHIM
Average Daily Dose of a contaminant received by a receptor
of concern (units of mg/kg/day)
Average Daily Exposure
Average Daily Soil Contact Rate (mg^/kg/day)
Average Daily Soil Intake Rate (mg^/kg/day)
Fraction ofOHM in soil absorbed through the skin (unitless)
Allowable Intake, Chronic
Allowable Intake, Subchronic
Averaging Period (units: days)
Allowable Threshold Concentration (in air)
The level of oil or hazardous material in the environment
which would exist in the absence of the disposal site
Bioavailability Adjustment Factor (unitless), now called a
Relative Absorption Factor
Average Body Weight of the receptor of concern during the
period of exposure (units: mass)
Appropriate units conversion factor
Massachusetts Law Chapter 2IE, The Massachusetts Oil and
Hazardous Material Release Prevention and Response Act.
U.S. EPA's Carcinogen Assessment Group
A factor which combines food consumption parameters and
plant uptake factors.
Upper 95% Confidence Limit of the slope of the dose-
response curve extrapolated to low doses.
Chronic Hazard Index Multiplier
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Chronic Hazard Index
Multiplier
CPV
CRM
DAQC
DEP
DEQE
Disposal Site
A factor which combines food consumption parameters and
plant uptake factors for the evaluation of non-cancer health
impacts from chronic exposures.
Carcinogenic Potency Value
Cancer Risk Multiplier
Average duration of each exposure event
(units: hours/event)
Duration of the exposure period
(units: days)
The Massachusetts DEP Division of Air Quality Control:
(617) 292-5630.
The Massachusetts Department ofEnvironmental Protection
The Massachusetts Department of Environmental Quality
Engineering (former name of the MA DEP)
Any structure, well, pit, pond, lagoon,
impoundment, ditch, landfill or other place or area,
excluding ambient air or surface water, where uncontrolled
oil or hazardous material has come to be located as a result
of any spilling, leaking, pouring, abandoning, emitting,
emptying, discharging, injecting, escaping, leaching,
dumping, discarding, or otherwise disposing of such oil or
hazardous material. The term shall not include any site
containing only oil or hazardous materials which: are
lead-based paint residues emanating from a point of original
application of such paint; resulted From emissions from the
exhaust of an engine; are building materials still serving
their original intended use or emanating from such use; or
resulted from release of source, by-product or special nuclear
material from a nuclear incident, as those terms are defined
in 42 U.S.C.s.2014, if such release was subject to
requirements with respect to financial protection established
by the Nuclear Regulatory Commission under 42
U.S.C.s.2210. A Disposal Site requires a Remedial Response
Action.
Dose The amount of a substance, expressed in mg/kg body
weight/day, which is absorbed into the body as a result of
exposure(s).
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DWPC
DWS
ELCR
Environment
EP
EPA
EPC
Excess Lifetime Cancer Risk
Exposure
Exposure Point
Exposure
Concentration
Point
FI
Hazard Index
The Massachusetts DEP Division ofWater Pollution Control:
(617) 292-5673.
The Massachusetts DEP Division of Water Supply: (617)
292-5770.
Excess Lifetime Cancer Risk
Waters, land, surface or subsurface strata, or ambient air of
the Commonwealth
Exposure Point
The United States Environmental Protection Agency
Exposure Point Concentration
The estimated probability that an individual's exposure,
during a lifetime, to an oil or hazardous material would
result in cancer.
Any contact with or ingestion, inhalation, or assimilation of
oil or hazardous materials, including irradiation. Also, the
amount of material contacted and available for absorption.
The place at which a human or environmental receptor is
exposed to an oil or hazardous material
The concentration of an oil or hazardous material in a
specific medium at an exposure point.
Average number of events/day during the period of exposure
(units: events/day)
Daily intake of contaminated food on days exposed during
the exposure period (units: mass/event)
A calculation of the possibility of non-cancer health effects
as the result of exposure to one or more oil or hazardous
materials with similar modes of toxic action. The Hazard
Index (HI) is defined as HI = D
1
/AD
l
+ D2/AD2 + ... D./AD,
where D is the daily dose for a particular oil or hazardous
material, and AD is the allowable daily dose for a particular
oil or hazardous material. The allowable daily dose is the
Reference Dose or other allowable daily dose specified by the
Department.
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Hazardous Material
HI
I
IARC
IM
Imminent Hazard
Interim Measure
mis
LADD
LADSCR
LADSIR
Limit of Detection
LOD
MADEP
Material including, but not limited to, any material in
whatever form which, because of its quantity, concentration,
chemical, corrosive, flammable, reactive, toxic, infectious or
radioactive characteristics, either separately or in
combination with any substance or substances, constitutes a
present or potential threat to human health, safety, welfare,
or to the environment, when improperly stored, treated,
transported, disposed of, used, or otherwise managed. The
term shall not include oil, but shall include waste oil and all
those substances which are included under 42
U.S.C.S.960K14), but it is not limited to those substances.
The term shall include but should not be limited to, all
materials regulated as hazardous waste or regulated
recyclable materials pursuant to 310 CMR 30.000.
Hazard Index
Daily soil ingestion rate on days exposed during the
exposure period (units: mass/day)
The International Agency for Research on Cancer
Interim Measure
A hazard which would pose a significant or otherwise
unacceptable risk ofharm to health, safety, public welfare or
the environment if it were present for even a short period
of time.
A category of actions which may be implemented at M.G.L.
C.21E disposal sites according to the MA DEP Bureau of
Waste Site Cleanup policy # WSC-131-90.
The US EPA's Integrated Risk Information System
Lifetime Average Daily Dose
Lifetime Average Daily Soil Contact Rate normalized to
bodyweight (mg^/kg/day)
Lifetime Average Daily Soil Intake Rate normalized to
bodyweight (mg^/kg/day)
Generally, the smallest concentration ofa substance that can
be reliably distinguished from background noise. Typically,
the signal to noise ration is 3.
Limit of Detection
The Massachusetts Department ofEnvironmental Protection
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Massachusetts Contingency
Plan
MCP
MDL
Media
Method 3a
Method 3b
Method Detection Limit
Migration Pathway
MS
Multi-media
MW
ND
NFA
NOAEL
NRC
OHM
Oil
310 CMR 40.000
The Massachusetts Contingency Plan
Method Detection Limit
Air, soil, or water
A single-medium risk characterization conducted under the
MCP pursuant to 40.545(3)(g)3.a.
A multi-media risk characterization conducted under the
MCP pursuant to 40.545(3)(g)3.b.
Generally, the level which can be measured with 99%
accuracy using EPA Standard Methods.
A pathway by which an oil or hazardous material is
transported at or from a disposal site.
Mass of soil in contact with unit surface area of skin (units:
mass/area)
The most common contamination scenario. A disposal site
where exposure is thought to occur via more than one
exposure medium.
Molecular Weight
Not Detected
No Further Action
The No Observable Adverse Effects Level
National Research Council
Oil or Hazardous Material
Insoluble or partially soluble oils of any kind or origin or in
any form, including, without limitation, crude or fuel oils,
lube oil or sludge, asphalt, insoluble or partially insoluble
derivatives of mineral, animal or vegetable oils. The term
shall not include waste oil, and shall not include those
substances which are included in 42 U.S.C.s. 9601(14).
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Permanent Solution
Phase H
Phase m
Potency Value
Potentially Responsible
Party
ppb
ppm
PQL
Practical Quantitation Limit
PRP
RAF
Receptors
Reference Concentration
Reference Dose
A measure or combination of measures which will, when
implemented, ensure attainment of a level of control of each
identified substance of concern at a disposal site or in the
surrounding environment such that no substance of concern
will present a significant or otherwise unacceptable risk of
damage to health, safety, public welfare, or the environment
during any foreseeable period of time.
The Comprehensive Site Assessment phase of the
Massachusetts Contingency Plan
The Evaluation of Remedial Response Alternatives and the
Final Remedial Response Plan pnase of the Massachusetts
Contingency Plan.
US EPA's Cancer Assessment Group's published cancer slope
value
Any person who is potentially liable pursuant to MGL c. 2IE
(PRP)
Parts Per Billion
Parts Per Million
Practical Quantitation Limit
Generally, the smallest concentration of a substance for
which quantitative results may be obtained with a specified
degree of confidence.
A Potentially Responsible Party
U.S. EPA's Cancer Assessment Group's published cancer
slope value
Relative Absorption Factor
Individual or environmental population exposed to oil or
hazardous materials.
The concentration in air of an oil or hazardous material
which would not be expected to result in any adverse non-
cancer health effects as published by the U.S. EPA.
The daily dose of an oil or hazardous material which would
not be expected to result in any adverse non-cancer health
effects as published by the U.S. EPA.
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Relative Absorption Factor
Release
Remedial Response Action
Residential
RfC
RfD
Route of Exposure
RP
SA
SHIM
ShortForm
Short Term Measure
A factor which adjusts the dose estimate in consideration of
the absorption efficiencies of the study which is the basis of
the toxicity information and the absorption efficiency of the
route of exposure of concern. It is not itself an absorption
efficiency. This term was formerly called a "Bioavailability
Adjustment Factor" by the Department.
Includes any spilling, leaking, pumping, pouring, emitting,
emptying, discharging, injecting, escaping, leaching, dumping
or disposing into the environment, but excludes: (1)
emissions from the exhaust of an engine; (2) release of
source, by-product, or special nuclear material from a
nuclear incident, as those terms are defined in 42
U.S.C.s.2014, if such release is subject to requirements with
respect to financial protection established by the Nuclear
Regulatory Commission under 42 U.S.C.s 2210; (3) the
normal application of fertilizer, and (4) the application of
pesticides m a manner consistent with their labeling.
A response action at a Location To Be Investigated (LTBI) or
a disposal site that is taken pursuant tothe Massachusetts
Contingency Plan
Those disposal sites for which the current or reasonably
foreseeable use has been determined to be residential, or
those sites which are evaluated with the assumption that the
use could be residential, or sites "surrounded" by residential
properties.
Reference Concentration
The U.S. EPA's published Reference Dose
A mechanism, including, but not limited to ingestion,
inhalation, dermal absorption, and transpiration by Wnich an
oil or hazardous material comes into contact with a human
or environmental receptor.
Respirable Particulates (units: mass)
Skin surface area in contact with the contaminated soil on
days exposed (units: area/day)
Subchronic Hazard Index Multiplier
The Risk Assessment ShortForm, the spreadsheet risk
assessment tool.
A measure or combination of measures that is taken
pursuant to 310 CMR 40.542. See MA DEP Bureau ofWaste
Site Cleanup policy # WSC-130-90.
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Single-Medium
Site
STM
Subchronic Hazard Index
Multiplier
Substantial Hazard
SVOC
TEL
Temporary Solution
Total Site Cancer Risk
Total Site Noncancer Risk
UF
Unit Risk
Disposal sites where exposure is thought to occur via a
single exposure medium, or where the nature of combined
exposures indicates that a single medium-specific program
within the MA DEP (DAQC, DWS) would normally address
the problem.
Any building, structure, installation, equipment, pipe or
pipeline including any pipe discharging into a sewer or
publicly-owned treatment works, well, pit, pond, lagoon,
impoundment, ditch, landfill, storage container, motor
vehicle, rolling stock, or aircraft, or any other place or area
where oil or hazardous material has been deposited, stored,
disposed of or placed, or otherwise come to be located. The
term shall not include any consumer product in consumer
use or any vessel.
Short Term Measure
A factor combining food intake parameters and plant uptake
factors for subchronic exposures.
A hazard which would pose a significant or otherwise
unacceptable risk of harm to health, safety, public welfare,
or the environment if it continued to be present for several
years.
Semi-Volatile Organic Compound
Threshold Effects Level (from CHEM, MA DEP 1990c)
A measure or combination of measures which will, when
implemented, eliminate any substantial hazards posed by a
priority disposal site until a permanent solution can be
implemented.
The sum of the estimated excess lifetime
cancer risks associated with exposure to all oil and hazardous
materials at or from a disposal site at all exposure points for
a given receptor.
A calculation of the possibility of non-cancer health effects
associated with exposure to all oil and hazardous materials
at or from a disposal site at all exposure points for a given
receptor. The Hazard Index is a measure of the Total Site
Non-Cancer Risk.
Uncertainty Factor
The Upper 95% Confidence Limit of the lifetime cancer risk
estimated to result from lifetime exposure to a unit
concentration of an agent.
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UR Unit Risk Value
VI Daily volume of drinking water ingested by the receptor of
concern at the exposure point during the exposure period
(units: volume/day)
VM Daily volume of mother's milk ingested by the infant during
the exposure period (units: volume/day)
VOC Volatile Organic Compound
VR Daily respiratory volume for the receptor of concern during
the period of exposure (units: volume/day)
[ X ] Concentration of substance "X" in medium "y"
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TOXICITY PROFILES
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APPENDIX B - TOXICITY PROFILES
This appendix contains a Toxicity Profile (or Summary) for each of the substances contained
in the Residential ShortForm.
The MCP Phase II Risk Characterization Report should contain a Toxicity Profile for each
of the chemicals reported at the disposal site. As described in Section 4.4, these Profiles
serve several purposes, including educating the public about potential hazards associated with
the chemicals and serving as a basis for the quantitative risk characterization.
The Toxicity Profiles contained in this Appendix may be copied and submitted as part of the
Phase II Report. These Profiles will be periodically updated, and the risk assessor should
insure that the most current version is used.
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ACENAPHTHENE
GENERAL BACKGROUND INFORMATION
Acenaphthene is a member of the polycyclic aromatic hydrocarbons (PAH). PAHs are a class
of non-polar compounds that contain two or more aromatic rings. They are ubiquitous in
nature and are both naturally occurring and man-made. The database for acenaphthene is
very limited.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of acenaphthene.
HUMAN TOXICOLOGICAL PROFILE
No data were found regarding the human toxicology of acenaphthene.
MAMMALIAN TOXICOLOGICAL PROFILE
Adverse effects on the lungs, glands, and blood were observed in rats following aerosol
administration of 12 mg/m3 acenaphthene for 5 months (U.S. EPA, 1981).
GENOTOXICITY
Mutagenicity tests for acenaphthene were negative (U.S. EPA, 1981). Carcinogenicity tests
were negative (IARC, 1983).
REFERENCES
International Agency for Research on Cancer (IARC) (1983) Monograph on the evaluation of carcinogenic risk of
chemicals to man: polynuclear aromatic hydrocarbons. 32:33-43.
U.S. Environmental Protection Agency (U.S. EPA) (1981) An exposure and risk assessment for acenaphthalene . U.S.
EPA Contract No. 68-01-6017. Office of Water Regulations and Standards, Washington, D.C
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ACENAPHTHYLENE
GENERAL BACKGROUND INFORMATION
Acenaphthylene is a member of the polycyclic aromatic hydrocarbons (PAH). PAHs are a
class of non-polar compounds that contain two or more aromatic rings. They are ubiquitous
in nature and are both naturally occurring and man-made. The data on acenaphthylene are
limited.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of acenaphthylene.
HUMAN TOXICOLOGICAL PROFILE
No data were found regarding the human toxicity of acenaphthylene.
MAMMALIAN TOXICOLOGICAL PROFILE
No data were found regarding the mammalian toxicity of acenaphthylene.
GENOTOXICITY
Data from a single mutagenicity assay using acenaphthylene were positive (U.S. EPA, 1982).
REFERENCES
U.S. Environmental Protection Agency (U.S. EPA) (1982) An exposure and risk assessment for polvnuclear aromatic
hydrocarbons (acenaphthylene) . U.S. EPA Contract 68-01-6017. Office of Water Regulations and Standards.
Washington, D.C.
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ANTHRACENE
GENERAL BACKGROUND INFORMATION
Anthracene is a polycyclic aromatic hydrocarbon (PAH). PAHs are a class of compounds
which are non-polar and contain two or more aromatic rings. They are ubiquitous in nature
and are both naturally occurring and man-made. As a PAH, anthracene is found in tobacco
smoke, certain foods, and the emissions from industrial or natural burning.
PHARMACOKINETICS
Little data were found regarding the pharmacokinetics of anthracene. The intestinal
absorption of anthracene is less dependent on the presence of bile in the stomach than is
the absorption of larger PAHs such as benzo(a)pyrene (Rahman et al, 1986).
HUMAN TOXICOLOGICAL PROFILE
Anthracene is a skin irritant and allergen (Sax, 1984). Humans exposed to anthracene in an
occupational setting may demonstrate skin disorders (Clement, 1985). Anthracene has been
associated with gastrointestinal tract toxicity in humans (Badiali et al, 1985). However, the
usefulness of this study is limited due to confounding factors. Hematopoietic toxicity has
also been observed in cancer patients who have been treated with anthracene-containing
chemotherapeutics (Falkson et al, 1985). No control groups and concomitant exposure to
other ingredients in the therapeutic agents prevents any definitive conclusions.
MAMMALIAN TOXICOLOGICAL PROFILE
A subchronic study where anthracene was administered to mice by gavage for at least 90
days found no treatment-related effects at doses up to 1000 mg/kg-day (USEPA, 1989).
The data on the carcinogenicity of anthracene are considered inadequate by EPA
(IRIS, 1991).
GENOTOXICITY
Tests for DNA damage, mutation, chromosome effects and cell transformation in a variety
of eukaryotic cell preparations have shown negative results. The majority of tests using
anthracene in prokaryotes are negative, but positive results are reported in one or two tests
(ATSDR, 1990; IRIS, 1991).
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REFERENCES
Agency for Toxic Substances and Disease Registry (ATSDR) (1990) Toxicological summary for polycvclic aromatic
hydrocarbons . U.S. Public Health Service.
Badiali, D. et al. (1985) Melanosis of the rectum in patients with constant constipation. Dis Colon Rectum 28:241-245.
Clement (1985) Chemical physical and biological properties of compounds present at hazardous waste sites .
Falkson, G. Klein, B., Falkson, H. (1985) Hematological toxicity: experience with antracyclines adn anthracenes. Exp.
Hematol 13:64-71.
Integrated Risk Information System (IRIS) (1991) U.S. Environmental Protection Agency
International Agency for Research on Cancer (IARC) (1983) Monograph on the evaluation of carcinogenic risk of
chemicals to man, anthracene. 32:433-440.
Sax, NX (1984) Dangerous Properties of Industrial Materials . 6th edition. Van Nostrand Reinhold Company, N.Y.
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ARSENIC
GENERAL BACKGROUND INFORMATION
The toxicity of arsenic depends upon its chemical form along with the route, dose, and
duration of exposure. In general, arsenites (As
+3
) are potentially more toxic than arsenates,
soluble arsenic compounds are potentially more toxic than insoluble compounds, and
inorganic arsenic compounds are potentially more toxic than organic derivatives (U.S. EPA,
1985).
PHARMACOKINETICS
Absorption from the gastrointestinal tract is dependent upon the solubility of the specific
arsenic compound and the dose. Absorption from the respiratory tract is also dependent
upon the specific arsenic compound, along with particle size (see section on Relative
Absorption Factors).
HUMAN TOXICOLOGICAL PROFILE
Depending upon dose and exposure route, arsenic is an irritant of the skin, mucous
membranes, and the gastrointestinal tract. Acute toxicity from the ingestion of higher doses
of arsenic may result in vomiting, diarrhea, convulsions, a severe drop in blood pressure, and
cardiovascular effects. The lethal dose for humans is reported to be 1.0 to 2.6 mg/kg-bw
(Vallee et al., 1960). Acute toxicity from inhalation exposure to arsenic adsorbed to
particulate matter may result in conjunctivitis and pharyngitis. Subchronic effects included
hyperpigmentation (melanosis), multiple arsenical keratoses, sensory-motor polyneuropathy,
persistent chronic headache, lethargy, gastroenteritis, and mild iron deficiency anemia.
Inhaled arsenic compounds have been reported to be associated with skin lesions,
cardiovascular and respiratory effects, and peripheral neuropathy (Stokinger, 1981;
IARC, 1980). Chronic oral exposure of humans to inorganic arsenic compounds has been
reported to cause skin lesions, peripheral vascular disease, and peripheral neuropathy (Silver
and Wainman, 1952). The incidence of blackfoot disease, a peripheral circulatory disease
characterized by gangrene of the extremities, has reportedly been related to the presence
of arsenic in the drinking water of residents of the southwest of Taiwan (Tseng, 1977). The
symptoms of chrome inhalation exposure to arsenic compounds are similar to those
associated with chrome oral toxicity.
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MAMMALIAN TOXICOLOGICAL PROFILE
Oral LDgo values for trivalent arsenic vary from 15 to 293 mg/kg in rats and from
10-150 mg/kg in other test species (U.S. EPA, 1984). Chronic toxicity data from arsenic
exposure to rats cannot be extrapolated to man as the rat is able to store this compound
bound to hemoglobin in red blood cells (Lanz et al., 1950). This binding results in extremely
slow excretion by rats compared to other species (Mealey et al., 1959). For this reason, dogs
have been used to obtain experimental toxicity information. Studies of the subchronic oral
toxicity of diets containing sodium arsenite or sodium arsenate in dogs report that arsenite
is potentially more toxic than arsenate. The NOEL (no observed effect level) was reported
to be 50 mg/kg-diet for both substances (Byron et al., 1967). Schroeder and Balassa (1967)
studied the chronic oral toxicity of arsenic on growth and survival in mice. Ingestion of
water containing As
+3
at 5 mg/L over two years is reported to have resulted in decreased
survival and reduced median life span in male and female mice. No information regarding
chronic inhalation exposure of experimental animals to arsenic could be located in the
available literature. Animal studies to test the teratogenic potential of arsenic have been
performed. Matsumoto et al. (1973) reported decreased fetal weight in oral doses of up to
40 mg-arsenate/kg-bw/day administered to pregnant mice for three consecutive days. Diets
containing up to 100 mg-arsenite/kg-diet, however, were reported to have had no effect on
offspring (Kojima, 1974). No data regarding the teratogenicity of inhaled arsenic could be
found in the literature.
GENOTOXICITY
Nearly all results of gene mutation studies for arsenic (III) and arsenic (V) compounds have
been negative. Arsenite and arsenate also have been inactive in gene-specific mutation
assays in yeast and in cultured mammalian cells. In contrast, arsenic (HI), arsenic (V),
arsenite and arsenate have been found to result in chromosome aberrations and sister
chromatid exchanges in cultured animal and human cells tested in vitro (ATSDR, 1987).
There is limited evidence that occupational exposure to arsenic may cause chromosome
changes in humans (Beckman et al., 1977). Beckman et al. (1977) reported an increase in
gaps, chromatid aberrations and chromosome aberrations from mine workers at a smelter in
northern Sweden.
The majority of tests in which experimental animals were exposed orally to a variety of
arsenic compounds produced negative results regarding carcinogenicity (Hueper and Payne,
1962; Byron et al., 1967). A few studies have, however, reported tumorigenic effects of
arsenic treatment (Schrauzer et al., 1978). Mixed results were reported in arsenic inhalation
studies (Ishinishi et al., 1977; Ivankovic et al., 1979). Epidemiological studies conducted in
the U.S. have failed to correlate the incidence of skin cancer with arsenic in drinking water
(Morton et al., 1976; Goldsmith et al., 1972). A dose-response relationship between the
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occurrence of skin cancer and arsenic consumption in the drinking water of Taiwanese,
however, was reported by Tseng et al. (1977). Arsenic exposure at certain doses may produce
a pattern of skin disorders, hyperpigmentation, and keratosis that may develop into basal or
squamous cell carcinoma (U.S. EPA, 1985). Several epidemiological studies of workers
occupationally exposed to arsenic have reported a correlation between this exposure and
mortality due to respiratory cancer (Higgins et al., 1982; Enterline and Marsh, 1982; Brown
and Chu, 1983). Based upon epidemiological data, the EPA has classified arsenic as Group
A -Human Carcinogen.
REFERENCES
Agency for Toxic Substances and Disease Registry (ATSDR) (1987) Toxicological profile for arsenic . U.S. Public Health
Service.
Beckman, G. et aL, (1977) Chromosome aberrations in workers exposed to arsenic. Environ. Health Perspeot 19:145.
Brown, C.C. and Chu, K.C. ( 1983). Implications ofthe multistage theory ofcarcinogenesis applied to occupational arsenic
exposure. J. NatL Cancer Inst 70:455-463.
Byron, WJL, Bierbower, G.W., Brouwer, J.B. and Hansen, W.H. (1967) Pathological changes in rats and dogs from two-
year feeding of sodium arsenite or sodium arsenate. ToxicoL AppL Pharmacol. 10:132-147.
Enterline, P.E. and Marsh, G.M. ( 1982) Mortality among workers exposed to arsenic and other substances in a copper
smelter. Am. J. Epidemiol 116:895-910.
Goldsmith, J.R. et al. ( 1972) Evaluation ofhealth implications ofelevated arsenic in well water. Water Res. 6: 1 133- 1 136.
Higgins, I., Welch, K. and Burchnel, C. (1982) Mortality of Anaconda smelter workers in relation to arsenic and other
exposures . Dept. of Epidemiology, Univ. of Michigan, Ann Arbor, MI.
Hueper, W.C. and Payne, W.W. (1962) Experimental studies in metal carcinogenesis. Chromium, nickel, iron, arsenic.
Arch. Environ. Health 5:445.
IARC (International Agency for Research on Cancer). (1980) Arsenic and arsenic compounds . IARC Monographs on the
Evaluation of Carcinogenic Risk of Chemicals to Humans. WHO, Lyon, France. 23:39-142.
Ishinishi, N., et al. (1977). Preliminary experimental study on carcinogenicity of arsenic trioxide in rat lung. Environ.
Health Perspect 19:191-196.
Ivankovic, S., Eisenbrand, G. and Pressman, R. (1979) Lung carcinoma induction in BD rats after single intratracheal
instillation of an arsenic containing pesticide mixture formerly used in vineyards. Int J. Cancer 24:786-788.
Kojima, H. (1974) Studies on developmental pharmacology of arsenite. U. Effect ofarsenite on pregnancy, nutrition, and
hard tissue. FoL Pharmacol. Japon. 70:149-163.
Lantz, H., Wallace, P.W. and Hamilton, J.G. ( 1950) 77ie metabolism ofarsenic in laboratory animals using As— as trace.
Univ. Calif. Pub. Pharmacol. 2:263-282.
Mealey, J., BronweU, G.L. and Sweet, W.H. (1959) Radioarsenic in plasma, urine, normal tissues, and intracranial
neoplasms. Arch. NeuroL Psychiatry 81:310-320.
Morton, W., Starr, G., Pohl, D., Stoner, J., Wagner, S. and Weswig, P. (1976) Skin cancer and water arsenic in Lane
County, Oregon. Cancer 37:2523-2532.
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administration of arsenite and selenite on the genesis of mammary adenocarcinoma in inbred female C3H/ST mice.
Bioorg. Khim. 9:245-253.
Schroeder, HA. and Balassa, JJ. (1967) Arsenic, germanium, tin, and vanadium in mice: Effects on growth, survival
and tissue levels. J. Nutr. 92:245-252.
Silver, AS. and Weinman, PX. (1952) Chronic arsenic poisoning following use of an asthma remedy. JAMA 150:584.
Stokinger, H.E. (1981) The Metals: Arsenic. In: Patty's Industrial Hygiene and Toxicology. Vol. II, 3rd ed., CD. Clayton
and FJE. Clayton, Ed.; John Wiley and Sons, Inc., NY. pp. 1517-1531.
Tseng, WP. (1977) Effects and dose-response relationships ofskin cancer and Blackfoot Disease with arsenic. Environ.
Health Perspeet 19:109-119.
U.S. Environmental Protection Agency (EPA) (1985) Health advisories for 52 chemicals which have been detected in
drinkjng_water. Office of Drinking Water. NTIS PB860118338.
U.S. Environmental Protection Agency (EPA) (1984) Health effects assessment for arsenic . ECAO-HO20. Prepared
for the Office of Emergency and Remedial Response by the Environmental Criteria and Assessment Office.
Vallee, B.L., Ulmer, D.D. and Wacker, W.E.C. (1960) Arsenic toxicology and chemistry. Arch. Ind. Health 21:132-151.
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BENZENE
GENERAL BACKGROUND INFORMATION
Benzene is a clear, volatile, highly flammable, aromatic hydrocarbon which exists naturally
and is produced by volcanoes and forest fires. Benzene is also a very common industrial
solvent, produced from petroleum. It is used as a solvent for fats, inks, paints, plastics,
rubber, in the extraction of oils from seeds and nuts, in photogravure printing, as a chemical
intermediate and in the manufacture of detergents, explosives, pharmaceuticals and
dyestuffs. It is also a component of gasoline and other petroleum-based fuels. Exposure to
benzene can occur via inhalation, ingestion, especially of contaminated drinking water, and
dermal contact (as in contact with liquid benzene found in gasoline.) (Sittig, 1981;
ATSDR, 1989)
PHARMACOKINETICS
Benzene is readily absorbed through ingestion, moderately absorbed through inhalation and
poorly absorbed through intact skin (see section on Relative Absorption Factors). Once in
the bloodstream, benzene is distributed throughout the body, with the concentration in any
one compartment dependent on the degree of perfusion of tissues by blood. Since benzene
is lipid-soluble, it accumulates in fat, but the rate of accumulation is slow since fat is poorly
perfused. The metabolites of benzene are responsible for its toxic effects. These include
phenol (which is either formed via an unstable benzene oxide precursor or directly from
benzene), catechol, hydroquinone and conjugated phenolic compounds. The primary site of
benzene metabolism is the liver via the cytochrome P450 mixed function oxidase system.
Some benzene metabolism may also occurs in the bone marrow via the same enzyme system.
Benzene is excreted either unchanged from the lungs or as metabolites in the urine
(ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Benzene targets its effects on the hemopoietic, immune and nervous systems (ATSDR, 1989).
Exposure to benzene has produced irritation of the skin, eyes and upper respiratory tract.
Acute exposure has produced central nervous system depression, headache, dizziness, nausea,
convulsions, coma and death at extremely high concentrations (Sittig, 1981). Health effects
in humans have been reported starting as low as 50 ppm via inhalation. Twenty-five ppm
for 6 hrs had no obvious effects though benzene was detected in blood (Sandmeyer, 1981).
Early autopsy reports found benzene-induced hemorrhages of the brain, pericardium, urinary
tract, mucous membranes and skin (Sittig, 1981). Chronic exposure to benzene produces
blood changes involving an initial increase in levels of erythrocytes, leukocytes and
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thrombocytes, followed by aplastic anemia indicated by anemia, leukopenia and
thrombocytopenia (Sittig, 1981).
MAMMALIAN TOXICOLOGICAL PROFILE
The following effects have been produced experimentally in laboratory animals, following
exposure to benzene: decreased leukocyte and/or erythrocyte counts, reduction in cellular
immunity and bone marrow depression (reduced number of granulopoietic stem cells).
Animal studies do not indicate that benzene is teratogenic, but the following fetotoxic effects
have been found: reduced fetal weight, altered fetal hematopoiesis, fetal skeletal variations
and increased resorptions in pregnant exposed animals. In addition, benzene has produced
histopathologic^ changes in ovaries and testes of test animals (ATSDR, 1989).
GENOTOXICITY
Benzene and its metabolites have been shown to be mutagenic in a number of in vitro and
in vivo studies. Genotoxic effects produced experimentally include structural and numerical
chromosome aberrations in humans, animals and cell cultures, and sister chromatid
exchanges and micronuclei in in vivo animal studies. Benzene exposure has been found to
produce an increase in the number of chromosome aberrations associated with myelotoxicity
(Sittig, 1981). In addition, sperm head abnormalities, inhibition ofDNA and RNA synthesis,
DNA binding and interference with cell cycle progression have been shown in in vitro studies
(ATSDR, 1989). The epidemiologic data indicate that benzene is leukemogenic. The
evidence is most convincing for acute myelogenous and acute erythroleukemia, although a
correlation has also been found with chronic leukemia. Benzene has been designated a group
A human carcinogen Geukemogen) by inhalation. Although data are insufficient to validate
the carcinogenicity of benzene via ingestion, it would not be unreasonable that benzene is
carcinogenic via this route as well if present in sufficient quantities. The carcinogenicity of
benzene via dermal exposure is considered to be lower since benzene is absorbed poorly
through the skin (ATSDR, 1989).
REFERENCES
Agency for Toxic Substances and Disease Registry (ATSDR) ( 1989) Toxicological profile for benzene . U.S. Public Health
Service.
Sandmeyer, E.E. (1981) Aromatic hydrocarbons. In: Patty's Industrial Hygiene and Toxicology. Vol. 2, 3rd ed., Clayton
GJX, Clayton F.E., eds. New York. Interscience Publishers, pp. 3253-3283.
Sittig, M. (1981) Handbook of Toxic and Hazardous Chemicals . Noyes Publications.
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BENZO[a]ANTHRACENE
GENERAL BACKGROUND INFORMATION
Benzo[a]anthracene (BaA) is a member of the polycyclic aromatic hydrocarbons (PAH). PAHs
are a class of non-polar compounds that contain two or more aromatic rings. They are
ubiquitous in nature and are both naturally occurring and man-made. The overall database
for benzo[a]anthracene is limited. Human exposures to BaA can come from the oral,
inhalation or dermal routes. BaA is produced when gasoline or other organic material is
burned. It is also found in cigarette smoke and cooked food. People most at risk from
exposure to BaA are those in the coal tar and asphalt production industries, cooking plants,
coal gasification plants, smoke houses and industrial plants that burn wood, trash, coal or oil.
PHARMACOKINETICS
BaA is absorbed by the dermal and oral routes. There is no information on absorption by
inhalation. Biotransformation to reactive intermediates is necessary for toxicity (ATSDR,
1990). BaA accumulates in adipose tissue. The metabolism of BaA is similar to the
metabolism of benzo[a]pyrene (Cooper et al., 1983). In brief, the aromatic ring is oxidized
by arene oxides to form reactive intermediates. The reactive intermediates are subsequently
hydrolyzed to diols (Sims and Grover, 1974). The diols are conjugated with glutathione and
excreted.
HUMAN TOXICOLOGICAL PROFILE
There are no reports directly correlating human exposure to BaA with the development of
excess tumors.
MAMMALIAN TOXICOLOGICAL PROFILE
The only toxicity endpoint that has been adequately studied for BaA is dermal
carcinogenicity. There is some evidence that benz[a]anthracene is carcinogenic in laboratory
animals by the oral route (Klein, 1963; Bock and King, 1959) and also by subcutaneous
injection (IARC, 1973). BaA has been shown to cause skin tumors after dermal application
(Bingham and Falk, 1969). Tumorigemcity of the diol epoxide metabolite has been shown
(Levin et al., 1978) as well as the mutagenicity of the diol epoxide (Wood et al., 1977).
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GENOTOXICITY
The metabolism of BaA is an essential event in producing genotoxic effects in both in vitro
and in vivo biological test systems (ATSDR, 1990). The intermediates formed by BaA
metabolism are reactive electrophiles which are capable of interacting with DNA.
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BENZO[a]PYRENE
GENERAL BACKGROUND INFORMATION
Benzo[a]pyrene (BaP) is a member of the class of compounds generally referred to as
polyaromatic hydrocarbons (PAH).
PAHs contain two or more aromatic rings. They are ubiquitous in nature and are both
naturally occurring and man-made. BaP is a component of fossil fuels and is produced from
the incomplete combustion of organic compounds. BaP and other PAHs are found in coal
tar, creosote oils and pitches formed from the distillation of coal tars (ATSDR, 1990).
PHARMACOKINETICS
BaP is readily absorbed by dermal, inhalation and oral routes (see section on Relative
Absorption Factors). Distribution ofBaP is rapid among several tissues. Following inhalation
exposure to °H labeled BaP, maximum levels of radioactivity were found in the liver,
esophagus, small intestine and blood after 30 minutes. After 12 hours, maximum levels were
found in the cecum, stomach and large intestine (Sun et al., 1982). This and other studies
provide evidence for the enterohepatic circulation of BaP metabolites.
Mammalian metabolism of BaP follows the mechanism established for smaller aromatic
compounds (Williams, 1959). There is an initial oxidation of a double bond on one of the
rings to an arene oxide. The oxide is then hydrolyzed to the diol. Oxidations may occur at
multiple sites on the BaP molecule. Phase II metabolism is considered the detoxication
pathway and involves the conjugation of the activated Phase I metabolites with easily
eliminated substrates such as glutathione, glucuronide or sulfate (Cooper et al., 1983). In
addition to being conjugated, the diol intermediate can undergo (1) further oxidation to
several uncharacterized metabolites via the P-450 monooxygenase system, (2) spontaneous
rearrangement to the phenol or (3) hydration to the trans-diols through a reaction catalyzed
by epoxide hydrolase (Cooper et al., 1983). BaP 7,8-diol-9,10-epoxide has been established
as an ultimate carcinogen (ATSDR, 1990). The primary route of excretion of BaP is through
the feces. BaP undergoes first-pass metabolism and is reabsorbed via enterohepatic
circulation (Chipman et al., 1982). Rats exposed by gavage to 14C labeled BaP in peanut oil
excreted up to 85% in the feces. Excretion in the urine was 1 to 3% of the administered
dose (Hecht et al., 1979).
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HUMAN TOXICOLOGICAL PROFILE
The database for the toxicological effects of BaP on humans, separate from PAHs, is limited.
Toxic effects attributable to mixtures of PAHs include a variety of skin lesions and non-
cancer lung diseases such as bronchitis (IARC, 1973).
MAMMALIAN TOXICOLOGICAL PROFILE
BaP is a moderately potent experimental carcinogen in numerous species by many routes of
exposure (IARC, 1983). Mice exposed to doses of BaP ranging from 1.5 to 400 mg/kg/d
developed benign and malignant tumors of the forestomach (Hartwell, 1951; Thompson,
1971). Acute intragastric doses of 50 to 67 mg/kg of BaP have been shown to elicit
pulmonary adenomas and forestomach papillomas in mice (Sparnins et al., 1986; Wattenberg
and Beuding, 1986). Intermittent gavage exposure of mice to 50 to 67 mg/kg BaP resulted
in 100% forestomach and pulmonary tumor incidences at 30 weeks of age (Sparnins et al.,
1986; Wattenberg and Leong, 1970). Mice fed BaP at concentrations equivalent to
33.3 mg/kg/d exhibited gastric neoplasms following two or more days of consumption.
However, lower concentrations of BaP (equivalent to 13.3 mg/kg/d) administered for up to
7 days did not produce any forestomach tumors (Neal and Rigdon, 1967). Hamsters have
developed papillomas and carcinomas of the alimentary tract following gavage or dietary
exposure to BaP (Chu and Malmgrem, 1965). A single oral dose of 100 mg BaP (200mg/kg)
produced mammary tumors in 88% offemale Sprague-Dawley rats (Huggins and Yang, 1962).
A 77% mammary tumor incidence was observed 90 weeks after a single oral dose of BaP of
50 mg (lOOmg/kg) was administered to rats (McCormick, 1981).
GENOTOXICITY
There are no studies relating exposure to BaP in humans to genotoxicity. In short-term in
vitro and in vivo genetic toxicology tests, BaP has been shown to be a potent genotoxic agent
when metabolically activated. In mice, oral exposure to 10 mg/kg BaP produced gene
mutations in the mouse coat color spot test (Davidson and Dawson, 1976,1977). BaP shows
positive mutagenic activity, in vitro, in several strains of Salmonella typhimurium in the
presence of either rodent microsomes or hepatocytes for exogenous metabolic activation
(ATSDR, 1990). Epidemiological studies have shown increased incidences of lung cancer in
humans exposed via inhalation to mixtures of PAHs which include BaP (ATSDR, 1990).
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BENZO[b]FLUORANTHENE
GENERAL BACKGROUND INFORMATION
Benzo[b]fluoranthene (BbF) is a member of the class of compounds referred to as polycyclic
aromatic hydrocarbons (PAHs). PAHs contain two or more aromatic rings. PAHs are
ubiquitous in nature and are both naturally occurring and man-made. Exposure to BbF can
come from air, water, or soil. As a PAH, BbF is present in the emissions from industrial
plants that produce coal tar, cooking plants, asphalt production plants, and home heating
with wood and coal. BbF is also present in charcoal-broiled foods and cigarette smoke
(ATSDR, 1990).
PHARMACOKINETICS
No data on the absorption, distribution or excretion of BbF were identified. BbF is
metabolized under in vitro incubation conditions to phenol and dihydrodiol metabolites
(Amin et al., 1982). The general metabolic pathways elucidated for benzo(a)pyrene are also
active on BbF (Cooper et al., 1983; Levin et al., 1982; Grover et al., 1986). The reactive
metabolites associated with the tumorigemc effects of BbF may not be the diol epoxides
(Amin et al., 1982; Amin et al., 1985). As for the other PAHs, the material excreted is
expected to consist primarily of dihydrodiol and phenol conjugates (Grover et al., 1986).
HUMAN TOXICOLOGICAL PROFILE
The database for human toxicity is very limited. There are no studies correlating exposure
to BbF and cancer or systemic toxicity. The only data implicating BbF as a carcinogen come
from carcinogenicity studies using a mixture of PAHs.
MAMMALIAN TOXICOLOGICAL PROFILE
The database on the toxicity of BbF is limited. Intratracheal administration of BbF to rats
resulted in an increase in respiratory tract tumors (Deutsch-Wenzel et al., 1983). BbF has
caused skin tumors in mice following dermal application (Wynder and Hoffman, 1959). The
skin tumor initiating ability of BbF has been demonstrated in mice using a standard
initiation/promotion protocol with either croton oil or phorbol myristate acetate as a tumor
promotor (Amin et al., 1985; LaVoie et al., 1979, 1982).
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GENOTOXICITY
The genotoxicity of BbF has been shown equivocally in three in vitro studies. BbF has been
shown to be mutagenic in Salmonella typhimurium in the presence of an exogenous rat-liver
preparation (LaVoie et al., 1979). Mutagenic activity has been reported in another similar
study (Hermann, 1981). Negative results were reported by Mossanda (1979). The results
cannot support an unequivocal determination regarding the genotoxicity ofBbF at this time.
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BENZOI&MPERYLENE
GENERAL BACKGROUND INFORMATION
Benzo[g,h,i]perylene is a member of the polyaromatic hydrocarbons (PAH). PAHs constitute
a class of non-polar compounds that contain two or more aromatic rings. They are
ubiquitous in nature and are both naturally occurring and man-made. The data regarding
benzo[g,h,i]perylene are limited. As a PAH, it is found in food (charcoal broiled meats),
vegetables, tobacco smoke and soot (U.S. EPA, 1980). Exposure occurs by inhalation,
ingestion and by dermal contact.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of benzo[g,h,ilperylene.
HUMAN TOXICOLOGICAL PROFILE
No data were found regarding the human toxicology of benzo[g,h,i]perylene.
MAMMALIAN TOXICOLOGICAL PROFILE
No data were found regarding the mammalian toxicity of benzo[g,h,i]perylene.
GENOTOXICITY
No data were found regarding the genotoxicity of benzo[g,h,i]perylene.
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BENZO[k]FLUORANTHENE
GENERAL BACKGROUND INFORMATION
Benzo[k]fluoranthene (BkF) is a member of the class of compounds referred to as polycyclic
aromatic hydrocarbons (PAHs). PAHs contain two or more aromatic rings. PAHs are
ubiquitous in nature and are both naturally occurring and man-made. Exposure to BkF can
come from air, water, or soil. As a PAH, BkF is present in the emissions from industrial
plants that produce coal tar, cooking plants, asphalt production plants, and home heating
with wood and coal. BkF is also present in charcoal-broiled foods and cigarette smoke
(ATSDR, 1990).
PHARMACOKINETICS
No data on the absorption, distribution or excretion of BkF were identified. BkF is believed
to be metabolized to phenol and dihydrodiol metabolites (ATSDR, 1990). The general
metabolic pathways elucidated for benzo[a]pyrene are believed to be active on BkF. As for
the other PAHs, the material excreted is expected to consist primarily of dihydrodiol and
phenol conjugates (Levin et al., 1982; Cooper et al., 1983; Grover et al., 1986).
HUMAN TOXICOLOGICAL PROFILE
The database for human toxicity is very limited. There are no studies correlating exposure
to BkF and cancer or systemic toxicity. The only data implicating BkF as a carcinogen come
from carcinogenicity studies using a mixture of PAHs.
MAMMALIAN TOXICOLOGICAL PROFILE
The database on the toxicity of BkF is limited. The skin tumor initiating ability of BkF has
been demonstrated in mice using a standard initiation/promotion protocol with either croton
resin or phorbol myristate acetate as tumor promotors (Van Duuren et al., 1966; LaVoie et
al., 1982). Chronic dermal application of benzo[k]fluoranthene to mice resulted in no skin
tumors, suggesting that BkF alone is not a complete carcinogen (Wynder and Hoffman, 1959).
GENOTOXICITY
The genotoxicity of BkF has not been documented in in vitro studies. In vivo, a single
topical application of BkF was reported to bind to DNA in CD-I mouse skin (Weyland et al.,
1987). Covalent binding of chemicals to DNA can result in strand breaks and DNA damage,
ultimately leading to mutations (ATSDR, 1990).
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BIS(2-ETHYLHEXYL)PHTHAIATE
GENERAL BACKGROUND INFORMATION
Bis(2-ethylhexyl)phthalate, often referred to as Di(2-ethylhexyl)phthalate (DEHP), exists as
a colorless, oily liquid at room temperature. It is used industrially as a plasticizer for resins,
to make plastic materials more flexible. DEHP is contained in many plastic products such
as imitation leather, rainwear, footwear and toys. It is used in the manufacture of tubing
and containers used for blood transfusions and kidney dialysis. DEHP is also used in the
manufacture of organic pump fluids in electrical capacitors. DEHP may migrate into the
environment under improper use/disposal conditions. As a result, exposure could occur via
air, water and food. Patients receiving blood transfusions or kidney dialysis can also be
exposed to DEHP (ATSDR, 1989; Sittig, 1981).
PHARMACOKINETICS
DEHP is readily absorbed through ingestion and inhalation and poorly absorbed through the
skin (see section on Relative Absorption Factors). DEHP is largely metabolized prior to
intestinal absorption, via hydrolysis, to its corresponding monoester metabolite (MEHP), with
the release of 2-ethylhexanol. Once absorbed, DEHP and its metabolites are distributed
throughout the body, with most of the compounds initially going to the liver. In general,
DEHP and its metabolites are converted to more polar derivatives and are then excreted.
DEHP is rapidly cleared from the body, with little potential for accumulation. There are
differences in the way DEHP is metabolized among species. Although phase I reactions are
essentially the same across species except for quantitative differences, phase II reactions
differ among species as to the ability to glucuronidate DEHP and its metabolites. The
relationship between pharmacokinetics and toxicity is not known due to gaps in knowledge
regarding mechanisms of toxic action (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Acute toxicity from DEHP is relatively low by both inhalation and ingestion. A 1-hr
exposure to 23,670 mg/m3 DEHP did not result in any deaths. The oral LD50 for DEHP
ranges from 26,000 to 49,000 mg/kg (ATSDR, 1989). Exposure to DEHP has produced
irritation of the eyes, and mucous membranes, nausea and diarrhea (Sittig, 1981). Liver
biopsies from dialysis patients showed liver abnormalities (peroxisome proliferation) (ATSDR,
1989). Most of the toxicity data for DEHP originate from animal studies.
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MAMMALIAN TOXICOLOGICAL PROFILE
Laboratory studies indicate that DEHP targets the liver and the testes. DEHP, administered
at high levels, has induced morphological and biochemical liver changes in a number of
rodent studies. Both DEHP and MEHP, its metabolite, have also been shown to produce
reduced organ weight and damage to the seminiferous tubules of the testes. DEHP has also
produced developmental and reproductive effects in laboratory rodents. Developmental effects
include exencephaly and spina bifida. Reproductive effects include reduced fertility and fewer
and smaller Utters (ATSDR, 1989).
GENOTOXICITY
There is a large database on the mutagenicity of DEHP involving a large number of tests
conducted in bacterial systems as well as in in vivo and in vitro mammalian test systems.
In addition, a less extensive database is available on the mutagenicity of the metabolites,
MEHP and 2-ethylhexanol. The overall weight of evidence indicates that DEHP is not
mutagenic (ATSDR, 1989). A carcinogenic feeding bioassay conducted by the National
Toxicology Program (NTP) in B6C3F1 mice and F344 rats found an increased incidence of
hepatocellular tumors which increased with increasing dose (NTP, 1982). EPA has
designated DEHP as a B2, Probable Human Carcinogen.
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CADMIUM
GENERAL BACKGROUND INFORMATION
Cadmium typically exists in the environment as a salt of the +2 valence state or as a metal.
It forms no stable organic compounds. Cadmium releases are generally associated with
mining, smelting, manufacturing operations, and from the disposal of alkaline batteries
containing cadmium (Doull, 1980; U.S. EPA, 1981).
PHARMACOKINETICS
Cadmium is absorbed by all routes of exposure (see section on Relative Absorption Factors).
Absorption through the gastrointestinal tract is low, respiratory absorption more efficient and
dermal absorption relatively insignificant (ATSDR, 1989). Absorbed cadmium is widely
distributed throughout the body, with the major portion of the body burden located in liver
and kidney (Sumino et al., 1975). The distribution of cadmium is linked to the distribution
ofmetallothionein, a low-moleculer-weight protein, rich in cadmium-binding sites. Cadmium
is not known to undergo any direct metabolic conversions in vivo. The principle excretory
route for absorbed cadmium is urinary. Excretion is slow, accounting for the long half-life
of cadmium in the body (17-38 years) (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Cadmium is a local respiratory tract irritant. Systemic symptoms occur in a few hours after
an acute exposure to cadmium dust or fumes. Upper respiratory tract irritation is followed
by coughing, chest pain, sweating, and chills. These symptoms resemble nonspecific upper
respiratory infection (Sittig, 1985). Within 24 hours severe pulmonary irritation may
develop, with progressively increasing pain in the chest, dyspnea, pulmonary edema, cough,
and generalized weakness. Chronic exposure to cadmium fumes may result in emphysema-
like lung damage (Sittig, 1984). Renal dysfunction may ensue (Friberg, 1950). Bernard and
Lauwerys (1984) observed that the gastrointestinal tract is adversely affected by acute oral
exposure with such symptoms as nausea, vomiting, salivation, abdominal pain, cramps, and
diarrhea. The principal effects of chronic cadmium exposure are osteomalacia and
osteoporosis (Itai Itai disease) secondary to glomerular and tubular necrosis in the kidney.
The Itai Itai ("ouch-ouch") disease is endemic areas in Japan, which have been contaminated
with mining wastes containing cadmium. Victims display the osteomalacia and osteoporosis
as primary symptoms, as well as protein, sugar and amino acids not normally found in the
urine. Other chronic effects include immunosuppression and decreases in measures of
respiratory fitness (ventilation capacity, vital capacity, forced expiratory volume, etc.) (U.S.
EPA, 1981).
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MAMMALIAN TOXICOLOGICAL PROFILE
Several subchronic and chronic oral toxicity studies have been conducted in animals. Roller
et al. (1975) and Fitzhugh and Meiller (1941) conducted feeding studies using mice and rats,
respectively. The first group of researchers reported immunological impact manifested by
a decrease in the number of lymphocytes secreting antibodies (to sheep red blood cells) as
well as some renal effects. The second set of authors observed hematological symptoms
expressed as marked anemia. Yuhas et al. (1979) conducted a drinking water study using
Sprague-Dawley male rats. Decreased weight gain was observed at the highest dose level.
In addition, the authors identified increases in cadmium content and decreases in the zinc
content of the bone. Renal dysfunction or otherwise generalized adverse effects on the
kidney have been reported in a number of long-term cadmium ingestion studies (Friberg et
al., 1974; Kijikawa et al., 1981; Schroeder et al., 1964; Kanisawa and Schroder, 1969). In
addition, the latter two research groups have observed renal and cardiac arteriosclerosis.
GENOTOXICITY
Results of mutagenicity tests in bacteria and yeasts have been inconclusive. Positive results
have been obtained in mutation assays in Chinese hamster cells and in mouse lymphoma
cells. Conflicting results have been obtained in assays of chromosomal aberrations in human
lymphocytes treated in vitro or obtained from exposed workers. Cadmium treatment in vitro
or in vivo appears to result in aneuploidy in germ cells of mice or hamsters (ATSDR, 1989).
Reports of elevated prostate cancer in cadmium workers have been evaluated as insufficient
evidence of the carcinogenic action of the compound (U.S. EPA, 1985), but the elevated risk
of lung cancer observed by Thun et al. (1985) is more convincing. Thus, the carcinogenic
potential of inhaled cadmium should be viewed as limited, but suggestive. Although
ingestion of cadmium may result in kidney effects, no carcinogenic response has been
demonstrated for this route.
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CARBON TETRACHLORIDE
GENERAL BACKGROUND INFORMATION
Carbon Tetrachloride is a clear, heavy aromatic liquid with a sweet odor. Although this
compound does not occur naturally, it is distributed extensively in the earth's atmosphere
due to its extensive anthropogenic production and use. Carbon tetrachloride is currently
widely used as a refrigerant and a propellant. Carbon tetrachloride is also used a solvent for
oil, fats, lacquers, varnishes, rubber, waxes and resins. Until the mid-1960s, carbon
tetrachloride was used as an industrial degreaser, as a household spot remover, and as a fire-
extinguishing agent. Until 1986, carbon tetrachloride was used to fumigate grain. Carbon
tetrachloride is very stable in the atmosphere, with a half-life in air of about 30-100 years.
Thus, it persists in the environment for many years (Sittig, 1981; ATSDR, 1989).
PHARMACOKINETICS
Carbon tetrachloride is readily absorbed through ingestion and inhalation and poorly
absorbed through the skin (see section on Relative Absorption Factors). The metabolism of
carbon tetrachloride occurs primarily in the liver, where a specific form of hepatic
cytochrome P-450 initiates a reductive dehalogenation yielding a trichloromethyl free radical
and a chloride ion. The trichloromethyl radical is then further reacted upon either
anaerobically or aerobically. Anaerobically, either CHCL,, CI3CCCI3 or CO +/HCOO' can be
produced depending on which of several anaerobic reactions take place. Aerobically, the
precursor, CLjC04 could be produced, leading to formation of phosgene (COCy. Hydrolytic
cleavage ofCOC^ leads to formation of HC1. Although it is known that metabolism of carbon
terachloride plays an important role in its toxicity, the specific mechanism relating the
metabolites to toxicity has not yet been determined. Excretion of carbon tetrachloride from
the body has been found to occur largely in the form of the parent compound. Exposure
studies in animals have shown that about 30-40% of an inhaled dose of carbon tetrachloride
is recovered in expired air and about 50-60% is recovered in feces. Via oral exposure, one
rat study indicated that about 70-90% of an administered oral dose was recovered in expired
air and lower amounts were recovered as C02 or CHCI3 or as nonvolatile metabolites in feces
or urine. Via dermal exposure, carbon tetrachloride excretion has also been found to occur
rapidly through expired air, but this was not quantified (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Most of the human health data for carbon tetrachloride come from acute exposure case
studies in individuals who have been exposed to large doses for short periods of time. Health
effects of carbon tetrachloride include defatting of skin leading to a dry, fissured dermatitis
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and transient eye irritation. Acute exposure is associated with central nervous system
depression, gastrointestinal effects, and liver and kidney damage. Specific symptoms include
headache, dizziness, nausea, vomiting and in severe cases, stupor or coma, with the potential
for permanent damage to nerve cells. Liver damage can be manifested with nausea,
vomiting, abdominal pain, diarrhea, enlarged and tender liver, jaundice and fatty liver
(symptoms of toxic hepatitis) (ATSDR, 1989; Sittig, 1989). Kidney damage can result in a
more slowly accumulating, lower urinary volume, the presence of red and white blood cells
in urine, albumuria, coma and death (Sittig, 1981). Kidney failure, resulting in the
accumulation of waste products in the blood and accumulation of water in the body,
especially the lungs, is a major cause of death from carbon tetrachloride. Effects to the liver
and kidney are reversible after exposure ends, if damage is not too severe (ATSDR, 1989;
Sittig, 1981).
MAMMALIAN TOXICOLOGICAL PROFILE
Acute oral toxicity in animals was found to occur at 4,000 mg/kg, producing respiratory
edema, atelectasis and hemorrhage (Gould and Smuckler, 1971). The effects of carbon
tetrachloride have been widely studied in animals. A range of adverse liver effects have been
found including destruction of the endoplasmic reticulum and associated enzyme activities,
inhibition of protein synthesis, impaired secretion of triglycerides with resultant fat
accumulation and centrilobular necrosis (ATSDR, 1989). The kidney has also been found to
be a target organ for carbon tetrachloride in animal studies, although in animals, carbon
tetrachloride is more toxic to the liver than to the kidney (ATSDR, 1989). In animals
administered oral doses of 1,400 mg/kg/day during gestation, maternal toxicity and total
resorption of fetuses occurred in some animals but no teratogenic or other apparent effects
were evident in offspring (Wilson, 1954). In rats exposed to carbon tetrachloride in food for
five generations, no reproductive toxicitywas noted ofparameters investigated (% conception,
% with litters, mean Utter size, mean body weight of offspring at birth and at weaning). An
increase in neonatal mortality was found in the low dose (6 mg/kg/day) group but not at the
higher dose (15 mg/kg/day).
GENOTOXICITY
There is no available information on the mutagenic effects of carbon tetrachloride in
humans. Very little information was found for carbon tetrachloride in animals. In one study
in which rats were exposed orally to carbon tetrachloride, an increase in DNA synthesis
associated with tissue regeneration was found, but no increase in unscheduled DNA
synthesis. One study in yeast found suggestive evidence of mutagenicity but this test was
conducted using concentrations of carbon tetrachloride significantly above the solubility of
carbon tetrachloride in water (Callen, et al., 1980). EPA has designated carbon tetrachloride
as a group B2 (Probable Human Carcinogen) based on conclusions by both EPA and the
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International Agency for Research on Cancer (IARC) that sufficient evidence exists to
designate this compound carcinogenic in experimental animals (ATSDR, 1989).
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CHLOROBENZENE
GENERAL BACKGROUND INFORMATION
Chlorobenzene is a clear liquid with an almond-like odor. Although chlorobenzene does not
occur naturally in the environment, it is used in industry as a solvent, in the manufacture
of aniline, phenol and chloronitrobenzene, and as an intermediate in the manufacture of
dyestuffs and pesticides (ATSDR, 1990; Sittig, 1981).
PHARMACOKINETICS
Chlorobenzene is assumed to be readily absorbed via ingestion, moderately absorbed through
inhalation and poorly absorbed through the skin, based on its structural similarity to benzene
(see section on Relative Absorption Factors). The major metabolites of chlorobenzene are
p-chlorophenylmercapturic acid and 4-chlorocatechol. Excretion of chlorobenzene occurs via
urine in the form of its two metabolites, with the excretion of p-chlorophenylmercapturic
acid reported to be much lower than of 4-chlorocatechol. A portion of an absorbed dose is
excreted as unchanged chlorobenzene through the lungs (ATSDR, 1990).
HUMAN TOXICOLOGICAL PROFILE
Acute exposure to chlorobenzene has produced the following health effects in workers
exposed to high levels: irritation of the eyes and nose, skin irritation, central nervous system
depression with symptoms such as drowsiness, incoherence, numbness, nausea and vomiting.
However, these workers were simultaneously exposed to other solvents so it is not clear
whether chlorobenzene is responsible for these effects (ATSDR, 1990; Sittig, 1989).
MAMMALIAN TOXICOLOGICAL PROFILE
Acute lethality via both inhalation and ingestion is relatively low in animals. One study
produced 100% mortality in mice after 2 hrs of exposure to 4,300 ppm. In rats exposed to
a single dose of 4000 mg/kg and mice exposed to a single dose of 1000 mg/kg via corn oil
by gavage, death occurred in 2-3 days (ATSDR, 1990). Animal studies indicate that exposure
to chlorobenzene via either inhalation or ingestion can produce severe kidney and liver
damage. Typical signs of liver damage reported include increased serum enzymes, changes
in liver weights, degeneration, necrosis and interference with porphyrin metabolism. Signs
of kidney damage include degeneration or focal necrosis of proximal tubules and increased
kidney weights. Animal evidence also exists that chlorobenzene is immunotoxic via ingestion
with the potential of producing thymic necrosis and lymphoid or myeloid depletion of bone
marrow, spleen or thymus. Neurological effects, manifested by miscellaneous spasms and
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narcosis, have been shown in animals acutely exposed via inhalation to chlorobenzene. There
are very few animal data on the developmental and reproductive effects of chlorobenzene.
The available data do not indicate that chlorobenzene produces developmental or
reproductive effects via either inhalation or ingestion.
GENOTOXICITY
There were no data located regarding the mutagenicity of chlorobenzene in either animals
or humans following oral exposure. Limited in vitro mutagenicity testing in bacterial and
mammalian test systems suggest that chlorobenzene may not be genotoxic in humans
(ATSDR, 1990). In a National Toxicology Program (NTP) chrome, oral carcinogenic bioassay
conducted in both sexes of mice and rats, the only significant finding was an increase in the
incidence of neoplastic nodules of the liver of male rats in the higher dose group but not at
the lower dose. On the basis of these data, EPA has classified chlorobenzene as a Class D
carcinogen (inadequate evidence of carcinogenicity in both humans and animals) (ATSDR,
1990; NTP, 1985).
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CHLOROFORM
GENERAL BACKGROUND INFORMATION
Chloroform is a clear, colorless, liquid with a characteristic odor, which exists both naturally
and as a man-made compound. Chloroform was one of the earliest general anaesthetics but
was later banned because of toxic effects. Chloroform is largely used in the production of
fluorocarbon 22 (used as a coolant in air conditioners and to make fluoropolymers)
(ATSDR, 1989). In addition, chloroform is used as a solvent, in the extraction and
purification of pharmaceuticals, in the manufacture of pesticides and dyes and in various
products including fire extinguishers, dry cleaning agents, artificial silk, plastics and floor
polishes. Chloroform is also widely found in drinking water supplies as a byproduct of
chlorination (ATSDR, 1989; Sittig, 1981).
PHARMACOKINETICS
Chloroform is readily absorbed via inhalation and ingestion and poorly absorbed through the
skin, unless the dose is occluded, in which case it is very well absorbed (see section on
Relative Absorption Factors). Chloroform is lipid-soluble and passes through cell membranes
easily. Thus it will reach the central nervous system and cross the placental barrier. It has
been found in fresh cow's milk and is thus expected to reach human milk too. Chloroform
is metabolized via cytochrome P450 by oxidative dechlorination to form phosgene. The
phosgene either reacts with glutathione to form diglutathionyl dithiocarbonate or causes
cytotoxicity directly by reacting with other cellular constituents. Inorganic chloride ion and
carbon monoxide are minor metabolites of chloroform metabolism. Although there are
species differences as to relative amounts metabolized, chloroform is largely excreted
unchanged through the lungs. Carbon dioxide is also a major endproduct of chloroform
metabolism, most of which is excreted via the lungs but some of which is also incorporated
into endogenous metabolites and excreted as bicarbonate, urea, methionine and other amino
acids. Carbon monoxide is a minor metabolite also excreted through the lungs. In addition,
inorganic chloride ions are excreted via the urine (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Skin contact with chloroform can produce burns. Chloroform is a central nervous system
depressant and was used in the past as an anaesthetic until it was determined that it caused
liver and kidney toxicity. Specific central nervous system symptoms resulting from acute
exposure include fatigue, dizziness, headache, digestive disturbance and mental dullness, as
well as
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coma at high levels. Chronic exposure has produced liver and kidney enlargement and
jaundice (Sittig, 1981; ATSDR, 1989).
MAMMALIAN TOXICOLOGICAL PROFILE
Chloroform is acutely toxic via inhalation, with an LC50 of 10,000 ppm for 4 hours in rats
(Lundberg et al., 1986). A concentration of 1025 ppm for 1-3 hours was lethal to mice
(Derringer et al., 1958). The lowest oral LD50 value reported for rats is 444 mg/kg (Kimura
et al., 1971). In a 90 day study, rats exposed to chloroform via the oral route had an
increased mortality at 350 mg/kg/day (Chu et al., 1982). Chloroform has been found to
target the liver, kidney and central nervous system in animal studies, after inhalation or oral
exposure. Central nervous system effects found in animals via inhalation exposure include
disturbed equilibrium (cats) at 7,200 ppm, deep narcosis (mice) at 4,000 ppm and slight
narcosis (mice) at 2,500 ppm. Liver effects found in lab animals include fatty infiltration,
focal necrosis, lobular granular degeneration and increased enzyme levels (SGOT, SGPT).
Kidney effects include cloudy swelling, increased weight, tubular necrosis and tubular
regeneration. Developmental effects observed after inhalation exposure include increased
incidence of missing ribs, imperforate anus, subcutaneous edema and delayed and abnormal
ossifications. In a questionable study, pregnant rats treated during gestation via gavage with
126 mg/kg/day were found to produce fetuses with reduced body weight. Reproductive
effects found in lab animals include a significant increase in percentage abnormal sperm and
gonadal atrophy (ATSDR, 1989).
GENOTOXICITY
The genetic toxicology database for chloroform indicates mixed results in mutagenicity tests.
Negative results were obtained in bacteria and gene mutations, as well as chromosome
aberrations in mammalian cells. Mixed results were obtained in yeasts. In vivo test results
include negative results in Drosophila and DNA damage in rats and mice, whereas tests for
chromosome aberrations and sperm abnormalities were mixed. Although the available data
on genotoxicity suggests that chloroform may be mutagenic, the overall evidence is currently
inconclusive (ATSDR, 1989). Carcinogenicity data via the inhalation route are currently not
available for chloroform. A number of animal studies have indicated that chloroform is
carcinogenic by the oral route. A 1976 NCI gavage study found a dose-related increased
incidence of hepatocellular carcinoma in mice (NCI, 1976). A number of studies have found
an increased incidence in kidney tumors (Roe et al., 1979; Jorgensen et al., 1985). Based on
the above data, the Environmental Protection Agency (EPA) has designated chloroform a B2
carcinogen.
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CHROMIUM
GENERAL BACKGROUND INFORMATION
Chromium is used in plating for corrosion resistance and decorative purposes (appliances,
tools, automobiles, etc.), in the manufacture of alloys (including stainless steel and heat
resistant alloys), and in printing, dyeing, photography, tanning, and numerous other
industrial applications (ATSDR, 1989).
PHARMACOKINETICS
Absorption studies of chromium compounds indicate that it is absorbed by all routes of
exposure (see section on Relative Absorption Factors) with chromium (VI) compounds being
more readily absorbed than chromium (HI) compounds. Once absorbed, chromium is rapidly
distributed to all organs, including the developing fetus. Chromium VI is readily reduced
to Cr HI in vivo. Excretion occurs primarily through the kidneys via urine (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
In humans, the respiratory tract is the primary system of concern for chromium toxicity.
Renal damage has also been observed. Hexavalent chromium has been shown to be highly
toxic, causing ulceration of nasal mucosa and carcinoma of the lung following long-term
occupational exposure. Cases of acute poisoning in man have been reported from the
medical use of chromic acid.
Chrome exposures of workers in chromium-related industries have been observed to result
in skin and nasopharyngeal irritations. Both Cr(III) an Cr(VI) can cause allergic contact
dermatitis and irritation (Samitz and Shrager, 1966). Chromium was shown to be an allergen
in recurrent contact dermatitis of the feet (Correia and Brandao, 1986). Hexavalent forms
are responsible for effects on the upper respiratory system, including ulceration and
perforation of the nasal septum, chrome rhinitis, and pharyngitis. Lindberg and
Hedenstierna (1983) reported that subjective and objective evidence of adverse nasal effects
were found at exposure levels of 2 to 20 ug Cr(VI)/m
3
but not at less than 1 ug/m3 . They
also reported that workers exposed to 2 to 20 ug Cr(VI)/m
3 had slight transient decreases
in measures of pulmonary mechanics (e.g., forced vital capacity, FVC) with recovery (no
changes) seen by two (non-exposed) days later.
MAMMALIAN TOXICOLOGICAL PROFILE
In laboratory animals, Cr compounds are of low oral acute toxicity. Hexavalent chromium
is more acutely toxic than Cr(HI), with kidney failure being the primary symptom. The LC 50
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in rats for inhalation of sodium chromate(VI) was reported as 33 mg Cr/m3/4H, and the
LDgo's for oral and dermal exposures were given as 16.7 mg Cr/kg and 514 mg Cr/kg,
respectively (Gad et al., 1986). Chromium was found to localize in the proximal renal tubules
when intraperitoneal doses of potassium dichromate were administered to rats 5 times
weekly for 8 months (Berry et al., 1978). Low level hexavalent chromium exposure increases
respiratory defense mechanisms while they are inhibited by long-term, high level exposure
(Glaser et al., 1985). Chromium salts have been shown to be teratogenic and embryotoxic
in mice and hamsters following intravenous or intraperitoneal injection. However, these are
unnatural routes of administration for assessing effects of environmental exposures, and
further research is needed (U.S. EPA, 1984).
GENOTOXICITY
Both Cr(IQ) and Cr(VI) have been shown to interact with DNA in bacterial systems. Cr(III)
is generally considered to be a relatively inactive genotoxic agent since it is unable to cross
cell membranes. It was recently shown, however, to cause chromosomal aberrations in
human lymphocytes (Friedman et al., 1987). Hexavalent chromium has consistently caused
transformations and mutations in a wide variety of in vitro assays (Bianchi and Lewis, 1985).
Chromosomal damage has been observed in lymphocytes cultured from workers exposed to
chromium. The epidemiologic studies of respiratory cancer in chromate production workers
provide the bulk of the evidence for chromium carcinogenicity. Studies of chromate
production faculties in the United States, Great Britain, and Japan have all found an
association between occupational exposure to chromium and lung cancer (U.S. EPA, 1984).
Workers were exposed to both Cr(VI) and Cr(m), and it is unclear whether Cr(VI) alone is
the etiologic agent or whether CrdQ) is implicated as well. The U.S. EPA (1984) concluded
that in rats, only calcium chromate had consistently produced lung tumors by several routes
of administration, and that other Cr(VI) compounds produced local sarcomas or lung tumors
in rats at the site of administration (subcutaneous, intraperitoneal, intermuscular,
intrabroncheal, and intratracheal). Trivalent chromium compounds have not been found to
be carcinogenic by any route of administration, but these compounds have not been studied
as extensively.
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CHRYSENE
GENERAL BACKGROUND INFORMATION
Chrysene is one of the polycyclic aromatic hydrocarbon (PAH) compounds which are formed
during the combustion of organic material. Chrysene often exists in particulate form,
adsorbing to existing particulate material in air. Human exposure can occur in the workplace
(coal and asphalt production plants, cooking plants, smoke houses) or in the environment due
to chrysene contamination of air, food, soil and water (ATSDR, 1990).
PHARMACOKINETICS
Chrysene can be absorbed by all routes of exposure (see section on Relative Absorption
Factors). Its absorption is believed to be qualitatively similar to benzo[a]pyrene (ATSDR,
1990). Following absorption, chrysene distributes to all organs, reaching the highest
concentration in tissues with large fat content (adipose tissue, mammary tissue, brain)
(Modica et al., 1983). Chrysene undergoes metabolic biotransformation mediated by the
mixed function oxidase enzyme system to form reactive intermediates hypothesized to be
responsible for its toxicity. The major metabolites include trans-dihydrodiols, phenols, diol
epoxides and triol epoxides (Thakker et al., 1985). The reactive metabolites are conjugated
and excreted primarily in feces (Schlede et al., 1970).
HUMAN TOXICOLOGICAL PROFILE
There is no information available on threshold toxic effects of chrysene in humans. Since
it is structurally similar to benzo[a]pyrene, it would be expected to produce effects similar
to B[a]P following acute or chronic exposure (see Toxicity Profile on Benzofalpyrene).
MAMMALIAN TOXICOLOGICAL PROFILE
There is no information available on threshold toxic effects of chrysene in animals. Since
it is structurally similar to benzo[a]pyrene, it would be expected to produce effects similar
to B[a]P following acute or chronic exposure (see Toxicity Profile for Benzo[a]pyrene).
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GENOTOXICITY
The genotoxicity of chrysene has been evaluated in in vivo and in vitro cytogenetic tests.
Chrysene produced weak positive results in bacterial mutation assays, human epithelial
mutation studies, cell transformation assays and in vivo cytogenetic studies (Waters et al.,
1987). Metabolism of chrysene is essential to produce the observed positive responses.
Chrysene is not genotoxic in all test systems, however, it is believed to be a weak mutagen
(ATSDR, 1990). The carcinogenicity of chrysene has not been adequately studied. There
are no reports directly correlating human chrysene exposure and tumor development. There
is limited evidence that chryesene is a skin carcinogen in animals following long-term dermal
application (Wynder and Hoffmann, 1959; Hecht et al., 1974).
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CYANIDE
GENERAL BACKGROUND INFORMATION
Both cyanide gases and salts are used in industrial processes. Minor uses of HCN include
insecticides and rodenticides for fumigating enclosed spaces (e.g., grain storage area).
Cyanide salts are used mainly in the electroplating and metal-finishing industries. Minor
applications of the salts include the manufacture of dyes and pigments, as well as use as
insecticides and rodenticides (ATSDR, 1989)
PHARMACOKINETICS
Cyanide is readily absorbed following inhalation and oral exposure (see section on Relative
Absorption Factors). Human and animal studies indicate cyanide is rapidly distributed by
the blood following exposure (ATSDR, 1989). Metabolism involves (1) the conversion of
cyanide to thiocyanate, (2) conversion to 2-aminothiazoline-4-carboxylic acid, (3) incorporation
into a 1-carbon metabolic pool or (4) combining with hydroxycobalamin to form
cyanocobalamin (ATSDR, 1989). Cyanide metabolites are excreted primarily in urine with
small amounts eliminated through the lungs (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
The fatal effects of exposure to high doses of cyanide over short periods of time are well
known. Inhalation of 100 ppm HCN for 0.5 to 1 hour has been fatal to humans. Exposure
to HCN vapors resulted in palpitations, shortness of breath, pain over the heart, vertigo, and
involuntary eye movements (Carmelo, 1955), cyanosis, headache, altered EEG, and left-sided
blindness (Sandberg, 1967). The cardiovascular effects are believed to be secondary to the
CNS effects (ATSDR, 1989). HCN fumigators also exposed by inhalation and dermal contact
developed palpitations, shortness of breath, pain over the heart, vertigo, and involuntary eye
movements (Carmelo, 1955). The LDgo in humans for ingestion exposure has been reported
to be 1.5 mg/kg/day of CN-. A lower fatal dose in humans has been reported at 0.6
mg/kg/day CN- (ATSDR, 1989). Brief exposure to lower levels of cyanide has resulted in
rapid, deep breathing, shortness of breath, convulsions, and loss of consciousness. Because
cyanide is not sequestered in the body, these effects are reversible over time. However,
longer-term exposure to these low levels has resulted in CNS, thyroid gland, and
cardiovascular effects. Several occupational studies of workers exposed to HCN produced
thyroid abnormalities. In a case-control study of electroplating workers exposed to 6.4 to
10.4 ppm HCN for 5 to 15 years, 56 percent of the exposed group had enlarged thyroid
glands and significantly elevated hemoglobin levels and lymphocyte counts. It should be
noted that these workers were also exposed to volatiles, there were varying exposure levels,
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and unmatched controls (El Ghawabi et al., 1975). Workers in a silver-reclaiming factory
exposed an average of 10.5 months to a TWA of 16.6 mg/m3 HCN developed headache,
dizziness, and mild thyroid abnormalities (Blanc et al., 1985). No studies of developmental
effects in humans resulting from inhalation of cyanide are available.
MAMMALIAN TOXICOLOGICAL PROFILE
When monkeys were exposed to 87 to 196 ppm HCN, severe disruptive changes in
respiration and unconsciousness were noted (Purser et al., 1984). Tremors, convulsions, loss
of equilibrium, dyspnea, nausea, exaggerated intestinal peristalsis, and diarrhea were noted
in dogs exposed to 45 ppm HCN for varying durations (Valade, 1952). When rats were
exposed to inhalation of HCN at low concentrations, cardiac enzyme changes resulted
(OTlaherty and Thomas, 1982). The previously cited Purser study of monkeys exposed to
87 to 196 ppm HCN from pyrolyzed polyacrylonitrile also found cardiovascular effects,
including rapid induction of a semiconscious state and severe disruptive changes in
respiration.
Male rats were fed 30 mg/kg/day cyanide for 11.5 months and developed vacuolization and
myelin degeneration of the spinal cord (Philbrick et al., 1979). No CNS effects were reported
by Howard and Hanzell (1955) for rats fed up to 10.8 mg/kg/day of CN-in HCN-fumigated
feed for two years. Dogs fed 0.27 and 0.53 mg/kg/day cyanide in capsules for 16 weeks
developed degenerative changes in the CNS ganglion cells, reduced ribonucleic acid (RNA)
content, and inflammation (Hertting et al., 1960). Numerous studies of orally exposed
pregnant animals have found maternal toxicities and developmental abnormalities in the
offspring. Pregnant hamsters exposed to cyanide as D,L-amygdalin (a component of laetrile)
exhibited maternal toxicity at 250 mg/kg and greater. Fetuses were examined at 15-days
gestation, and dose-related abnormalities were observed in this group (Willhite, 1982).
Female rats were fed a basal cassava diet containing 12 mg/kg HCN and a basal diet with
1.25 gm KCN per kg diet prior to mating, during gestation, and through lactation. The
weanlings were subsequently fed these same diets. Those weanlings exposed to higher levels
of cyanide in utero and during the post-weaning period had significantly decreased protein-
efficiency ratios. Both the dams and weanlings fed the potassium cyanide enhanced diet had
significantly increased serum thiocyanate levels (Tewe and Maner, 1981).
GENOTOXICITY
Cyanides have tested negative for mutagenicity and effects on DNA synthesis except for a
study by Kushi et al. (1983) in which a marginally mutagenic response for HCN was
reported. There are no data available indicating that cyanide has any carcinogenic effects
(ATSDR, 1989).
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DIBENZO[a,h]ANTHRACENE
GENERAL BACKGROUND INFORMATION
Dibenzo[a,h]anthracene is a member of the polycyclic aromatic hydrocarbons (PAH). PAHs
are a class of compounds which are non-polar and contain two or more aromatic rings. They
are ubiquitous in nature and are both naturally occurring and man-made. The data
regarding dibenzo[a,h]anthracene are very limited. As a PAH, it is found in tobacco smoke,
food, and the emissions from industrial or natural burning.
PHARMACOKINETICS
Dibenzo[a,h]anthracene is metabolized similarly to benzo(a)pyrene (ATSDR, 1990). However,
while the metabolic profiles of these two compounds (and other alternant PAHs) are
qualitatively similar, there are differences in the levels and rates of formation of specific
metabolites among tissues and cell preparations used. Sanders et al (1986) applied "C -
dibenzo[a,h]anthracene to the shaved backs of mice. After 24 hours, the majority of activity
was recovered from the application site, with the remainder from body tissues and excreta.
In comparison, benzo(a)pyrene similarly applied was found predominantly in the excreta and
body tissues, with the remainder at the application site.
HUMAN TOXICOLOGICAL PROFILE
The database for the toxicological effects of dibenzo[a,hlanthracene on humans, separate
from other PAHs, is limited. Toxic effects attributable to mixtures ofPAHs include a variety
of skin lesions and non-cancer lung diseases such as bronchitis (IARC, 1973).
MAMMALIAN TOXICOLOGICAL PROFILE
Dibenzo[a,h]anthracene has been shown to induce skin tumors in lab animals (i.e. it is a
complete carcinogen) following dermal exposure (Wyndner and Hoffman, 1959; Van Duuren
et al, 1967; and Lijinsky et al, 1965). Dibenzo[a,hlanthracene ahs also demonstrated tumor
initiation activity (Slaga et al. 1980).
Carcinogenic PAHs as a group has immunosupprssive effects, with the degree of
immunosuppression correlated with carcinogenic potency (ATSDR, 1990).
Dibenzo[a,h]anthracene was also tested for developmental effects via parenteral routes and
was found to produce fetolethal effects in rats (Wolfe and Bryan, 1939).
MA DEP, ORS & BWSC
Documntation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b • 10/92
B-53
GENOTOXICITY
Dibenzo[a,h]anthracene is mutagenic (Barfknecht et al, 1982; Rocchi et al, 1980) and
produces DNA damage (Martin et al, 1978) in cultured human cells. Test results in
nonhuman systems were also positve (ATSDR, 1990).
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1,1-DICHLOROETHANE
GENERAL BACKGROUND INFORMATION
1,1-Dichloroethane (1,1-DCA) is a colorless, oily, lipophilic liquid which evaporates quickly
at room temperature and has an ether-like odor. Its liquid and vapor forms ignite easily and
may pose a fire hazard when handled improperly. It does not dissolve easily in water. 1,1-
DCA is used primarily as an industrial solvent and as a dissolving agent for paint, varnish,
finish removers and grease (ATSDR, 1990).
PHARMACOKINETICS
Little information exists quantitating the absorption of 1,1-DCA. However, based on its
chemical and physical properties, it would be predicted to be readily absorbed via any route
of exposure (ATSDR, 1990). Once absorbed, it should be readily distributed to bodily tissues,
with highest concentrations achieved in tissues of greatest lipid content (Sato and Nakajima,
1987). A large percentage of an administered dose is exhaled unchanged (Mitoma et al.,
1985). The remainded undergoes biotranformation mediated by the microsomal mixed
function oxidase enzyme system to yield reactive acylchloride metabolite(s) which covalently
bind to cellular macromolecules (Colacci et al., 1985). An alternative MFO-mediated pathway
yields 2,2-dichloroethanol which undergoes subsequent oxidation to dichloroacetaldehyde and
dichloroacetic acid (McCall et al., 1983). These metabolites are excreted through urine or
further metabolized to C02 (Sato and Nakajima, 1987).
HUMAN TOXICOLOGICAL PROFILE
Relatively little information is available on the health effects of 1,1-dichloroethane in
humans. It induces central nervous system depression and anesthesia upon inhalation. In
fact, it was used as an inhalation anesthetic in the past. The use of 1,1-DCA as an inhalation
anesthetic was discontinued when it was discovered that this compound induced cardiac
arrhythmias in humans at anesthetic doses ((Reinhardt et al., 1971). No studies were located
concerning threshold effects of exposure on any other organ system.
MAMMALIAN TOXICOLOGICAL PROFILE
Limited data indicate that 1,1-dichloroethane is less toxic than its isomer, 1,2-dichloroethane
and most other chlorinated aliphatic solvents (Parker et al., 1979). Exposure of animals to
1,1-DCA results in central nervous system depression which may be fatal if exposure levels
are high (Plaa and Larson, 1965). Nephrotoxicity has been observed in cats and mice
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following subchronic exposure. One study (Schwetz et al., 1974) suggests that exposure in
utero results in retarded fetal development.
GENOTOXICITY
Results from in vitro genotoxicity test are conflicting. 1,1-DCA tested negative in the Ames
assay (Nohmi et al., 1985) and in yeast cells (Bronzetti et al., 1987). However, it did increase
the transformation frequency in hamster embryo cells (Hatch et al., 1983). In vivo studies
suggest that 1,1-DCA may be genotoxic since it was found to covalently bind to DNA (Colacci
et al., 1985). This chemical has been classified as a possible human (C) carcinogen by EPA
This classification is based on conflicting chronic bioassay results in mice (NCI, 1977; Klaunig
et al., 1986).
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1,2-DICHLOROETHANE
GENERAL BACKGROUND INFORMATION
1,2-Dichloroethane (1,2-DCA or ethylene dichloride) is a clear, colorless, volatile liquid with
a pleasant odor. Approximately 80% of 1,2-dichloroethane is used to produce vinyl chloride.
It is also used to produce vinylidene chloride, 1,1,1- trichloroethane, TCE, PCE, aziridines
and ethylene diamines. Minor applications include various solvent functions, use as a
fumigant for grains, upholstery and carpets and as a lead-scavenging agent in gasoline (IRP,
1985).
PHARMACOKINETICS
1,2-DCA is readily absorbed through the lungs following inhalation exposure in both humans
and animals (ATSDR, 1989). Absorption from the gastrointestinal tract is rapid and
complete. Excretion of unmetabolized 1,2-DCA is almost exclusively via the lungs.
However, metabolism and excretion of metabolites by other routes is extensive and dose
related. Tissue distribution of 1,2-DCA is consistent with its lipophilic nature. It crosses the
blood-brain and placental barriers and distributes into breast milk (U.S. EPA, 1985).
HUMAN TOXICOLOGICAL PROFILE
Short-term ingestion or inhalation of 1,2-DCA results in symptoms of CNS depression,
gastrointestinal upset and systemic injury to the liver, kidneys and lungs (Clayton and
Clayton, 1981). Long term exposure ofworkers to 1,2-DCA in an occupational environmment
have been associated with loss of appetite, nausea, vomiting, epigastric pain, irritation of the
mucous membrane, neurologic changes and liver and kidney impairment (IRP, 1985).
MAMMALIAN TOXICOLOGICAL PROFILE
Acute inhalation exposure of a number of animal species to 1,2-DCA resulted in death in rats
and guinea pigs at 400 ppm and in mice, rabbits and dogs at 1500 ppm (Heppel et al., 1945,
1946; Spencer et al., 1951). Liver and kidney effects were noted, as well as associated
adverse effects to the respiratory and cardiovascular systems. A 15 percent increase in fat
accumulation and an increase in liver triglycerides were observed in rats fed 80 mg/kg/day
in the diet for 5 to 7 weeks (Alumot et al., 1976). No changes in liver weight was reported
at this dose level. No hepatic effects were noted in the same study at 30 mg/kg/day. No
hepatotoxicity was noted in mice administered up to 189 mg/kg/day in drinking water for
90 days (Munson et al., 1982). Chronic exposure of rats to 25 mg/kg/day in food for two
years did not result in abnormalities in liver function as measured by transaminases and
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cholesterol values (Alumot et al., 1976). No dose-related reproductive effects were seen in
mice fed 5-50 mg/kg/day in drinking water (Lane et al., 1982) or rats fed diets containing
12.5 or 25 mg/kg/day (Alumot et al., 1976). Intermittent exposure (7 hr/day) of female rats
to 4.69 +/- 7 ppm of 1,2-DCA for 4 months prior to the mating period followed by inhalation
exposure during pregnancy resulted in a statistically significant increase in embryo mortality
(Vozavaya, 1977).
GENOTOXICITY
In-vivo exposure of mice to 1000 ppm of 1,2-DCA vapors for 4 hours or to a single nontoxic
oral dose of 100 mg/kg resulted in irreversible DNA damage as revealed by single-stranded
breaks in the hepatocytes of mice (Storer et al., 1984). 1,2-DCA has been found to be
carcinogenic in rats and mice following oral gavage exposure (NCI, 1978). A dose of 47
mg/kg/day administered to rats produced tumors at locations remote from the site of
administration. Statistically significant increases in multiple tumor types (malignant and
nonmalignant) were noted in treated animals of both species. An increased incidence of
fibroma s of the subcutaneous tissue and hemangiosarcomas of the spleen, liver, pancreas and
adrenal gland was observed in male rats exposed to 47 or 95 mg/kg/day. Male rats exposed
to 95 mg/kg/day were observed to have an increase in squamous-cell carcinomas of the
forestomach, and female rats at this dosage had increased adenocarcinomas and
fibroadenomas of the mammary gland.
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1,1 -DICHLOROETHYLENE
GENERAL BACKGROUND INFORMATION
1,1-Dichloroethylene (1,1-DCE or vinylidene chloride) is a synthetic chemical used to make
certain plastic products and flame retardant fabrics. It is released into the environment
primarily as a result of air and water emissions coming from factories where 1,1-DCE is
manufactured, hazardous waste sites where 1,1-DCE has been improperly disposed of, or as
a result of accidental spills. 1,1-DCE is also found as a breakdown product of other chemicals
present in the environment. Although high percentages of 1,1-DCE in soil and water quickly
escape to the air, small concentrations remain and undergo biodegradation into other
compounds. Once in the air, the compound rapidly decomposes through a variety of
processes. It is estimated that 1,1-DCE released into the atmosphere persists for only about
two days (ATSDR, 1988).
PHARMACOKINETICS
1,1-DCE is rapidly absorbed by the oral and inhalation routes. In animal studies, it was
found to accumulate preferentially in the kidney, liver, and lung. 1,1-DCE undergoes
complex biotransformation processes and numerous metabolites have been identified. The
initial metabolic step is possibly the formation of an unstable reactive epoxide intermediate.
Metabolites are ultimately conjugated with glutathione and excreted in urine (ATSDR, 1988).
HUMAN TOXICOLOGICAL PROFILE
Humans exposed to high concentrations of 1,1-DCE (approximately 4,000 ppm) show central
nervous system depression which sometimes progresses to convulsions, spasm, and
unconsciousness (Tierney et al., 1979). Repeated exposure to 1,1-DCE causes hepatotoxicity.
Preliminary clinical findings on workers exposed to 1,1-DCE for up to 6 years in a
polymerization plant in New Jersey revealed a high incidence of hepatotoxicity (U.S. EPA,
1985).
MAMMALIAN TOXICOLOGICAL PROFILE
Signs of central nervous system toxicity are the predominant effects observed in animals
acutely exposed to high concentrations of 1,1-DCE via the inhalation route. The toxic signs
consist primarily of central nervous system depression, lacrimation, dyspnea, tremor,
convulsions, and narcosis, finally resulting in death (Klimisch and Freisberg, 1979a,b; Zeller
et al., 1979). Rodents acutely exposed to high levels of 1,1-DCE (500 - 15,000 ppm) via
inhalation show irritation of the mucous membranes and pulmonary edema, congestion and
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hyperemia (Zeller et al., 1979). Acute inhalation exposure to 1,1-DCE produces
cardiovascular effects, such as contraction of the main vessels, dilation of the right side, and
hyperemia (Klimisch and Freisberg, 1979; Zeller et al., 1979). The liver is a major target
organ for 1,1-DCE toxicity. Four-hour inhalation exposure to 200-250 ppm of 1,1-DCE
resulted in increased liver weight, hepatic enzyme induction and massive histologic injury
(Jackson and Conolly, 1985; Jaeger, 1977). Glutathione appears to play an important role
in reducing the toxic effects of 1,1-DCE. For example, fasted rats which have depleted
glutathione levels, display much greater 1,1-DCE induced toxicity (Reynolds et al., 1980).
Acute exposure to 1,1-DCE also results in renal damage, with the severity of the kidney
lesions increasing with increasing dose and duration of exposure (Reitz et al., 1980).
Long-term inhalation exposure to 1,1-DCE is associated with adverse respiratory effects as
evidenced by irritation of the upper respiratory tract. Nasal irritation was observed in rats
exposed to 200 ppm for 4 weeks (Gage, 1970). Other pulmonary effects seen in rats, guinea
pigs, and dogs exposed to similar concentrations of 1,1-DCE for 90 days include discoloration
and morphologic changes in the lungs (Prendergast et al., 1967). Quast et al. (1986) reported
hepatotoxic effects in rats exposed to 21 ppm 1,1-DCE 6 hours/day, 5 days/week for six
months. Studies by Short et al. (1977) demonstrated that inhalation exposure of pregnant
rats to 1,1-DCE produced a statistically significant increase in early embryo resorptions in
rats at 57 and 449 ppm, and in mice exposed at 57 ppm. Maternal lethality was also
increased. 1,1-DCE induced weak teratogenic effects in laboratory animals. Prenatal
exposure caused tissue anomalies in rats and skeletal defects in rats, mice and rabbits.
GENOTOXICITY
1,1-DCE is mutagenic in a number of test systems. In in vitro test systems, 1,1-DCE
required metabolic activation before demonstrating mutagenicity. 1,1-DCE was mutagenic
in Salmonella after metabolic activation with an exogenous activation system derived from
human liver samples (Jones and Hathway, 1978), showing that human liver is capable of
activating 1,1-DCE into mutagenic metabolites. In in vivo mutagenicity studies, 1,1-DCE did
not produce mutations (Anderson et al., 1977). Inhalation of 1,1-DCE was associated with
low rates of DNA alkylation in the livers and kidneys of mice and rats (Reitz et al., 1980).
Out of several carcinogenicity studies conducted with 1,1-DCE, only one inhalation study
provides evidence of a positive carcinogenic effect (Maltoni et al., 1985). In this study,
increases in renal adenocarcinomas were noted in male Swiss mice exposed by inhalation to
25 ppm 1,1-DCE.
Van Duuren et al., (1979) evaluated the carcinogenicity of 1,1-DCE in mice treated by dermal
application amd by subcutaneous injection. 1,1-DCE was inactive as a complete carcinogen
when applied repeatedly for a lifetime to mouse skin, and did not induce sarcomas after
subcutaneous injection. However, a dermal initiation-promotion study indicated 1,1-DCE was
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active as a tumor-initiating agent (Van Duuren et al., 1979). U.S. EPA has classified 1,1-DCE
as a Group C agent (possible human carcinogen) for which there is limited evidence of
carcinogenicity in animals.
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1,2-DICHLOROETHYLENE
GENERAL BACKGROUND INFORMATION
There are two isomers of 1,2-dichloroethene (1,2-DCE), cis and trans. Neither of these
isomers has developed wide industrial usage in the United States partly due to their
flammability. The trans isomer is more widely used in industry than either the cis isomer
or the 60:40 cis/trans mixture. It is used as either a low-temperature extraction solvent or
as a direct solvent in materials such as dyes, perfume oils, waxes, resins and thermoplastics.
It is also used as a chemical intermediate in the synthesis of polymers. 1,2-DCE is highly
volatile, weakly adsorbed by soil and has no significant potential for bioaccumulation. It may
volatilize from soil surfaces, but that portion not subject to volatilization is likely to be
mobile in groundwater (IRP, 1985).
PHARMACOKINETICS
1,2-DCE is absorbed by all routes of exposure (see section on Relative Absorption Factors)
(ATSDR, 1989). Distribution is expected to be rapid. Due to the lipophilic nature of 1,2-
DCE, tissues of high lipid content would be expected to attain the highest levels. 1,2-DCE
is metabolised via the mixed function oxidase enzyme system to chloroethylene epoxides
which undergo rearrangement to dichloroacetaldehyde or chloroacetic acids (Henschler, 1977;
Liebman and Ortiz, 1977). Excretion of 1,2-DCE and its metabolites has been largely
uncharacterized (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
1,2-DCE was once used as a general inhalation anesthetic in humans (Proctor and Hughes,
1978). Exposure to the trans isomer at a level of 2000 ppm causes burning of the eyes,
vertigo and nausea (Proctor and Hughes, 1978). Within the limited industrial usage, only
one toxic effect in humans was reported - a fatality due to very high vapor inhalation in a
small enclosure (Rosenthal-Deussen, 1931). 1,2-DCE causes eye and skin irritation upon
contact (Grant, 1974). There are no reports of long-term human exposure to 1,2-DCE
isomers.
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MAMMALIAN TOXICOLOGICAL PROFILE
Toxicological data for 1,2-DCE are limited, since it is not widely used. The only available
data are old, and the purity of the samples could not be verified. According to Smyth (1956),
the cis isomer did not kill or anesthetize rats in 4 hours at 8000 ppm. At 16,000 ppm, rats
became anesthetized in 8 minutes and died in 4 hours. Smyth also stated that he found the
trans isomer to be twice as toxic as the cis isomer. A 6-hour LC^ value of 22,000 ppm was
reported for mice exposed to the trans isomer (Mathies, 1970). Adverse lung effects were
reported in rats receiving a single 8-hour exposure to 200 ppm of the trans isomer (Freundt,
1977). Dogs repeatedly exposed to dichloroethylene vapor developed superficial corneal
clouding which was reversible within 24 to 48 hours (Grant, 1974). There are conflicting
data about the chronic toxicity of 1,2-DCE. Torkelson reported no adverse effects in rats,
rabbits, guinea pigs and dogs exposed to either 500 or 1000 ppm of 1,2-DCE 7 hours daily,
5 days per week for 6 months. The sample consisted of 60% cis- and 40% trans-1,2-DCE
(ACGIH, 1980). Similarly, no effects were seen in rats dosed subcutaneously, percutaneously
or by ingestion (ACGIH, 1980). In contrast, Freundt et al. (1977) reported marked effects
in rats exposed 8 hours daily, 5 days per week for 16 weeks to vapor levels of 200 ppm of the
trans isomer. Liver and lungs were affected and leukocyte counts were decreased. No data
on reproductive toxicity are available on the 1,2-DCE isomers (IRP, 1985).
GENOTOXICnY
Both isomers of 1,2-DCE were tested in Salmonella with and without activation in vitro and
in vivo host-mediated assays. Both isomers were toxic but did not induce any genetic effects
(Bronzetti et al., 1982). No carcinogenicity data are available for either the cis- or trans-
isomers of 1,2-DCE. Neither IARC nor the NTP have evaluated 1,2-DCE (IRP, 1985).
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ETHYLBENZENE
GENERAL BACKGROUND INFORMATION
Ethylbenzene is a colorless liquid that smells like gasoline. It is volatile and flammable.
Ethylbenzene occurs naturally in coal tar and petroleum, and is also manufactured for
commercial uses in paints, inks, and insecticides (ATSDR, 1990). The two major uses of
ethylbenzene are in the plastic and rubber industry, where it is used in the synthesis of
styrene (U.S. EPA, 1980). Gasoline contains about 2% (by weight) ethylbenzene (ATSDR,
1990). Ethylbenzene has a wide environmental distribution due to its widespread use.
PHARMACOKINETICS
Ethylbenzene has been shown to be readily absorbed via inhalation, ingestion, and dermal
exposure in humans as well as in laboratory animals (see section on Relative Absorption
Factors). Following exposure, ethylbenzene is distributed throughout the body, with the
highest levels detected in the kidney, lung, adipose tissue, digestive tract, and liver (Chin et
al., 1980). There appears to be quantitative differences in metabolism of the chemical in
humans and laboratory animals. However, in all species, ethylbenzene undergoes a variety
of microsomally-mediated side-chain hydroxylations to yield the major metabolites, mandelic
acid and phenylglyoxylic acid (Engstrom et al., 1984). The oxidation products are conjugated
followed by urinary excretion which appears to be complete within 2 days of exposure
(ATSDR, 1990).
HUMAN TOXICOLOGICAL PROFILE
Humans exposed to low levels of ethylbenzene in air for short periods of time experience eye
and throat irritation. Exposure to higher levels may cause more severe effects such as
central nervous system depression, decreased movement and dizziness, and more severe
mucous membrane irritation. No studies have reported death in humans following exposure
to ethylbenzene. No information was located to indicate that ethylbenzene produces toxicity
in other organ systems upon short-term or prolonged exposure (ATSDR, 1990).
MAMMALIAN TOXICOLOGICAL PROFILE
Animal studies indicate that the primary symptoms resulting from acute exposure to
ethylbenzene are manifested as neurological and respiratory depression. Other studies
suggest that the liver, kidney and hematopoietic system may also be targets of ethylbenzene
toxicity (ATSDR, 1990). Studies indicate that ethylbenzene exposure of pregnant rats can
produce fetotoxic effects at doses that also induce maternal toxicity (Andrew et al., 1981).
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Additionally, oral administration resulted in blockage of the estrus cycle in female rats
(Ungvary, 1986).
GENOTOXICITY
Results of in vitro genotoxicity test generally indicate that ethylbenzene is not mutagenic
in the presence or absence of metabolic activation (ATSDR, 1990). In one in vivo study,
there was no dose-dependent increase in the frequency of micronucleated polychromic
erythrocytes (Mohtashamipur et al., 1985). Ethylbenzene did cause a mutagenic effect in
mouse lymphoma cells and has been shown to induce a marginal yet significant increase in
SCE in human lymphocytes. Therefore, ethylbenzene may cause an increased potential for
genotoxicity in humans (ATSDR, 1990). No association between increased cancer incidence
in humans and exposure to ethylbenzene has been reported. In animal studies, the only
chronic bioassay produced inconclusive results of the tumorigenicity of oral ethylbenzene
(Maltoni et al., 1985). Ethylbenzene is classified as a Group D agent (not classified as to
carcinogenicity) by the EPA.
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ETHYLENE DIBROMIDE
GENERAL BACKGROUND INFORMATION
Ethylene dibromide (also known as EDB or 1,2-dibromoethane) is a colorless liquid with a
mild, sweet odor, high volatility, and high water solubility. EDB is relatively persistent in
groundwater and soil, but breaks down easily in air. The chemical is mostly man-made, and
has been used as a pesticide and gasoline additive. EPA stopped most of its pesticide uses
in 1984. EDB is added to leaded gasoline to produce better fuel efficiency, but because use
of leaded gasoline has fallen, less EDB is made for this use. EDB may also occur naturally
in the ocean in very small amounts (ATSDR, 1991).
PHARMACOKINETICS
EDB is readily absorbed by all routes of exposure (see section on Relative Absorption
Factors). It is rapidly absorbed in the bloodstream and distributed but retained to a limited
extent mainly in the kidneys, liver, and stomach (ATSDR, 1991). EDB is metabolized to
active forms capable of inducing toxic effects by either oxidation or conjugation processes
(ATSDR, 1991). Oral administration of EDB to rats primarily results in mercapturic acid
derivatives excreted in the urine (74% of administered dose). Unmetabolized EDB may be
excreted in the lungs, and a small amount (3%) may be excreted in feces (Plotnick et al,
1979).
HUMAN TOXICOLOGICAL PROFILE
Clinical signs in humans related to acute toxic exposure to EDB are depression and collapse,
indicative of neurologic effects, and erythema and necrosis of tissue at the point of contact
(oral and pharyngeal ulcers for ingestion, skin blisters and sloughing for dermal exposure).
Acute deaths following toxic doses are related to cardiopulmonary arrest or, if affected
individuals survive for a period of time, to hepatic and renal failure. Except for spermicidal
effects in men after occupational exposures, chronic effects of EDB exposure have not been
demonstrated in humans (ATSDR, 1991).
MAMMALIAN TOXICOLOGICAL PROFILE
Animals exposed to acute toxic doses ofEDB experience similar clinical signs as noted above.
Animal studies have also identified adverse ocular effects such as irritation and corneal
damage after exposure to high concentrations of EDB (NTP, 1982). Neurologic signs were
not reported in animals exposed by various routes over intermediate and chronic durations.
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Developmental effects have been observed at doses that produced maternal toxicity.
Antispermatogenic effects have been documented in animal studies ATSDR, 1991).
GENOTOXICITY
EDB is a potent mutagen, producing a broad spectrum of mutations in various test systems.
There is sufficient evidence to indicate that EDB presents potential genotoxic risks for
humans. There are no reports of cancer in humans associated with occupational exposure
to EDB. However, EDB has been shown to be a potent carcinogen in rats and mice, causing
malignant and benign neoplasms in multiple organ systems when administered by oral,
inhalation, or dermal routes (ATSDR, 1991). EPA has classified EDB in the Carcinogen
Assessment Group's Group B2: the evidence for carcinogenicity is adequate in animals but
inadequate in humans (U.S. EPA, 1987).
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FLUORANTHENE
GENERAL BACKGROUND INFORMATION
Fluoranthene is a member of the polyaromatic hydrocarbons (PAH). PAHs constitute a class
of non-polar compounds that contain two or more aromatic rings. They are ubiquitous in
nature and are both naturally occurring and man-made. Fluoranthene has been detected in
food, cigarette smoke, and smoke from industrial and natural burning.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of fluoranthene.
HUMAN TOXICOLOGICAL PROFILE
The database for the toxicological effects of fluoranthene on humans, separate from other
PAHs, is limited. Toxic effects attributable to mixtures of PAHs include a variety of skin
lesions and non-cancer lung diseases such as bronchitis (IARC, 1973).
MAMMALIAN TOXICOLOGICAL PROFILE
The database on the toxicity of fluoranthene is limited. A 13 week subchronic study where
CD-I mice were gavaged with up to 500 mg/kg-day of fluoranthene indicated nephropathy,
increased liver weights, hematological alterations and clinical effects (EPA, 1988). A
developmental study in which fluoranthene was administered once via intraperitoneal
injection to pregnant mice reported only an increased rate of embryo resorption (Irvin and
Martin, 1987).
Chronic dermal application of up to 1 percent fluoranthene to the backs of mice did not
induce skin tumors following lifetime application (Hoffman et al, 1972; Horton and Christian,
1974; and Wydner and Hoffman, 1959a). Fluoranthene is not a complete carcinogen (ATSDR,
1990) and does not exhibit iniation activity (Hoffman et al, 1972).
GENOTOXICITY
There is some evidence that fluoranthene is genotoxic (ATSDR, 1990). Genotoxic effects
have been reported in human cells with exogenous metabolic activation, but negative results
were recorded without metabolic activation.
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FLUORENE
GENERAL BACKGROUND INFORMATION
Fluorene is a member of the polyaromatic hydrocarbons (PAH). PAHs constitute a class of
non-polar compounds that contain two or more aromatic rings. They are ubiquitous in nature
and are both naturally occurring and man-made. The data on fluorene are very limited. Low
levels of (5 to 67 ug/kg) have been detected in smoked meats (U.S. EPA, 1982).
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of fluorene.
HUMAN TOXICOLOGICAL PROFILE
The database for the toxicological effects of fluoranthene on humans, separate from other
PAHs, is limited. Toxic effects attributable to mixtures of PAHs include a variety of skin
lesions and non-cancer lung diseases such as bronchitis (IARC, 1973).
MAMMALIAN TOXICOLOGICAL PROFILE
Limited information is available on the threshold effects of fluorene. An EPA study
(EPA,1989) indicated that CD-I mice exposed by gavage to up to 500 mg/kg-day of fluorene
showed hypoactivity as well as a decrease in red blood cell count and packed cell volume and
hemoglobin. Increases in absolute and relative liver, spleen and kidney weights was also
observed. Gershbein (1975) reported that partially hepatectomized rats fed a diet of 180
mg/kg-day of fluorene for 10 days showed a statistically significant increase in liver
regeneration, which is indicative of the ability to induce a proliferative response.
Fluorene is not reported to be a complete skin carcinogen (ATSDR, 1990). It was inactive
as a tumor initiator when an estimated total dose of 1.0 mg was applied prior to the
application of tetradecanoyl phorbol acetate (LaVoie et al, 1980).
GENOTOXICITY
There is no evidence that fluorene is genotoxic, but genotoxicity has been studied only in
a few in vitro assays (ATSDR, 1990).
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INDENO [1 ,2,3-cd]PYRENE
GENERAL BACKGROUND INFORMATION
Indeno[l,2,3,-cd]pyrene is a member of the polyaromatic hydrocarbons (PAH). PAHs
constitute a class of non-polar compounds that contain two or more aromatic rings. They are
ubiquitous in nature and are both naturally occurring and man-made. Indeno[l,2,3-cd]pyrene
is present in cigarette smoke (IARC, 1983) as well as emissions from industrial stacks.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of indeno[l,2,3-cd]pyrene. However, its
metabolism should be similar to another non-alternant PAH, benzo(b)fluoranthene (ATSDR,
1990).
HUMAN TOXICOLOGICAL PROFILE
The database for the toxicological effects ofindeno[l,2,3-cd]pyrene on humans, separate from
other PAHs, is limited. Toxic effects attributable to mixtures of PAHs include a variety of
skin lesions and non-cancer lung diseases such as bronchitis (IARC, 1973).
MAMMALIAN TOXICOLOGICAL PROFILE
Studies on laboratoyr animals have demonstrated that indeno[l,2,3-cdlpyrene can induce skin
tumors (i.e. it is a complete carcinogen) following dermal exposure (ATSDR, 1990).
It has tumor initiating activity, but is not as potent as benzo(b)fluoranthene (Rice et al,
1985).
Carcinogenic PAHs as a group are immunosuppressant, with the degree of suppression
correlated with the degree of potency (ATSDR, 1990)
GENOTOXICITY
In test systems using non-human cells, indeno[l,2,3-cd]pyrene was found to be genotoxic
(ATSDR, 1990).
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LEAD
GENERAL BACKGROUND INFORMATION
Lead is used extensively in the manufacture of storage batteries and was used in gasoline
and paint. Lead is also a natural constituent of many soils, for which concentrations
normally range from 10 to 30 mg lead per kilogram of soil (U.S. EPA, 1980).
PHARMACOKINETICS
Lead can be absorbed by the oral, inhalation or dermal exposure routes (see section on
Relative Absorption Factors). Gastrointestinal absorption of lead varies considerably
depending upon chemical form, dietary intake, and age (Forbes and Reina, 1974; Barltrop and
Meek, 1975). The deposition and absorption of inhaled lead depends upon particle size,
chemical form and the rate and depth of breathing (Randall et al., 1975; Nozaki, 1966;
Chamberlain et al., 1975). Once absorbed, lead is distributed to the various organs of the
body, with most distribution occurring into mineralized tissues (ATSDR, 1990). Placental
transfer to the developing fetus is possible (Bellinger et al., 1987). Inorganic lead is not
known to be biotransformed within the body. Absorbed lead is excreted via the urinary or
fecal routes (ATSDR, 1990)
HUMAN TOXICOLOGICAL PROFILE
Cases of acute lead poisoning in humans are not common and have not been studied in
experimental animals as thoroughly as chronic lead poisoning. Symptoms of acute lead
poisoning from deliberate ingestion by humans may include vomiting, abdominal pain,
hemolysis, liver damage, and reversible tubular necrosis (U.S. EPA, 1984). Subacute
exposures in humans reportedly may produce a variety of neurological effects including
dullness, restlessness, irritability, poor attention span, headaches, muscular tremor,
hallucinations, and loss of memory. Nortier et al., (1980) report encephalopathy and renal
damage to be the most serious complications of chronic toxicity in man and the
hematopoietic system to be the most sensitive. For this reason, most data on the effects of
lead exposure in humans are based upon blood lead levels. The effects of lead on the
formation of hemoglobin and other hemoproteins, causing decreased levels, are reportedly
detectable at lower levels of lead exposure than in any other organ system (Betts et al.,
1973). Peripheral nerve dysfunction is observed in adults at levels of 30 to 50 Mg/dL-blood.
Children's nervous systems are reported to be affected at levels of 15 /ig/dL-blood and higher
(Benignus et al., 1981). In high doses, lead compounds may potentially cause abortions,
premature delivery, and early membrane rupture (Rom, 1976).
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MAMMALIAN TOXICOLOGICAL PROFILE
Acute oral lethal doses of lead in animals depend upon chemical form, but generally range
from 500 to 30,000 mg/kg. Several reproduction studies on the effects of subchronic oral
exposure to lead in rats have been conducted (Kimmel et al., 1976; Grant et al., 1980; Fowler
et al., 1980). These studies report that lead acetate administered in drinking water at
various concentrations caused depressed body weights at 50 and 250 mg-Pb/L water,
histological changes in the kidneys of offspring, cytokaryomegaly of the tubular epithelial
cells of the inner cortex at concentrations greater than or equal to 25 mg/L and postnatal
developmental delays at 50 to 250 mg/L. Higher oral doses of lead may result in decreased
fertility and fetotoxic effects in a variety of species (Hilderbrand et al., 1973). A reduction
in the number of offspring of rats and mice exposed to 25 mg Pb/L drinking water with a
chromium deficient diet was reported by Schroeder et al. (1970). Chronic oral exposure of
female Long-Evans rats to lead (5 mg/PB/L-water) reportedly resulted in slight effects on
tissue excitability, systolic blood pressure, and cardiac ATP concentrations (Kopp et al.,
1980a,b).
GENOTOXICITY
Results of in vitro studies with human lymphocyte cultures using lead acetate were nearly
equally positive and negative. Results of in vivo tests are also contradictory but suggest that
lead may have an effect on chromosomes (sister chromatid exchange).
Results for gene mutations, DNA modification, and recombinations in various microorganisms
using lead acetate, lead nitrate and lead chloride were consistently negative with or without
metabolic activation. Lead chloride has been reported to inhibit both DNA and RNA
synthesis. In in vitro mammalian test systems, lead acetate gave conflicting results.
No epidemiological data regarding the oral carcinogenic potential of lead could be located in
the available literature, Chronic inhalation may result in a statistically significant increase
in deaths due to tumors in the digestive organs and respiratory systems in lead smelter
workers and battery plant workers (Kang et al., 1980). Several studies have reported tumor
formation in experimental animals orally administered specific lead salts, not normally
ingested by humans (Zawirska and Medras, 1972; Boyland et al., 1962; Ito, 1973). The
carcinogenicity of inhaled lead in experimental animals could not be located in the available
literature. The U.S. EPA has classified lead and lead compounds as Group B2 - Probable
Human Carcinogens.
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MERCURY
GENERAL BACKGROUND INFORMATION
Mercury has been used in the past for medicinal purposes (Gosselin et al., 1984). There are
a number of occupations associated with mercury exposure, particularly through inhalation.
These include mining, smelting, chloralkali production, and the manufacture of mercury-
containing products such as batteries, measuring devices (thermometers) and paints.
Mercury has also been used agriculturally as a seed and cereal protectant and as a fungicide.
PHARMACOKINETICS
The pharmacokinetics and pharmacodynamics of mercury depend largely on its chemical
form, organic, inorganic or elemental. Absorption efficiencies vary depending on route of
exposure and chemical form (see section on Relative Absorption Factors). Distribution,
metabolism and excretion depend largely on the lipid solubility, ionization state and
molecular size of the specific chemical form (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Exposure to most forms of mercury is associated with a high degree of toxicity. Elemental
(metallic) mercury causes behavioral effects and other nervous system damage. Inorganic
mercury salts do not generally reach the brain, but will produce kidney damage. Divalent
(mercuric) mercury is substantially more toxic in this regard than the monovalent
(mercurous) form. Organic mercury compounds are also toxic. Symptoms of chronic
mercury poisoning can be both neurological and psychological in nature as the central
nervous system is the primary target organ. Hand and finger tremors, slurred or scanning
speech patterns, and drunken, stupor-like (ataxic) gait are some motor-control impairments
that have been observed in chronic mercurial toxicity. Visual disturbances may also occur,
and the peripheral nervous system may be affected. A psychological syndrome known as
erethism is know to occur. It is characterized by changes in behavior and personality
including depression, fearfulness, restlessness, irritability, irascibility, timidity, indecision, and
early embarrassment. Advanced cases may also experience memory loss, hallucination, and
mental deterioration.
MAMMALIAN TOXICOLOGICAL PROFILE
In a study by Mitsumori et al. (1981), male and female mice were fed methyl mercury
chloride in their diet for up to 78 weeks. Most of the high dose group died from
neurotoxicity before the 26th week. Renal tumors developed in 13 of 16 males in the
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intermediate dosage group by 53 weeks while only 1 male in the control group developed
tumors. No renal tumors occurred in exposed or control females. Studies on rats have
reported similar effects such as damage to kidneys and the peripheral nervous system (U.S.
EPA, 1980). Mice treated with alkyl mercury phosphate were reported to have an increased
frequency of offspring with cleft palates (Oharazawa, 1968) while mice treated with
methylmercury had offspring with significantly lowered birth weights and possible
neurological damage (Fujita, 1969). No adequate epidemiological studies exist on the
teratogenic effects of methylmercury on humans (U.S. EPA, 1980).
GENOTOXICITY
Skerfving et al. (1974) reported a statistical relationship between chromosome breaks and
concentrations of methyl mercury in the blood of Swedish subjects on fish diets.
Concentrations were reported to be from 14-116 ng Hg/ml in the blood of exposed subjects
and from 3-18 ng/ml in nonexposed subjects.
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METHYLENE CHLORIDE
GENERAL BACKGROUND INFORMATION
Methylene chloride (also known as DCM or dichloromethane) is a colorless volatile liquid,
has a mild sweet odor, and evaporates very quickly. DCM is widely used as an industrial
solvent and paint stripper. It is also a component in certain pesticide and aerosol products.
DCM is used in photographic film manufacturing. It has a high lipid solubility and modest
solubility in water (ATSDR, 1989).
PHARMACOKINETICS
DCM is absorbed by all routes of exposure (see section on Relative Absorption Factors).
Once DCM enters the body, absorption is through body membranes into the systemic
circulation. In vivo studies have demonstrated two metabolic pathways: 1) an oxidative
pathway mediated by the P-450 mixed function oxidase system yielding CO and C02, and
2) a glutathione-dependent (GST) pathway that yields C02. The GST pathway shows no
indication of saturation at inhaled concentrations of up to 10,000 ppm (ATSDR, 1989). DCM
is primarily eliminated in expired air as parent compound and the major metabolites CO and
C02. A small amount of absorbed DCM has been detected in urine and feces (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Levels of >500 ppm of DCM in air can irritate the eyes, nose, and throat. If DCM is
topically applied, it may cause only mild skin irritation because it evaporates quickly. CNS
effects include lethargy, irritability, nausea, lightheadedness, and headaches. Symptoms
usually dissipate quickly after exposure ends. Smokers may experience CNS effects at lower
levels of DCM than non-smokers since smoking increases the CO content in blood.
Hepatotoxicity is not evident in epidemiological studies. Adverse renal effects such as
congestion and tubular changes show that DCM may be contributory, but not significant.
Individuals with pre-existing cardiac disease maybe more susceptible to DCM levels mediated
by CO via CO-Hb (carboxyhemoglobin), depending on the inhaled concentration of DCM
(ATSDR, 1989).
MAMMALIAN TOXICOLOGICAL PROFILE
Methylene chloride may cause acute lethality when animals are administered large doses by
any route of exposure (ATSDR, 1989). The liver and the central nervous system are the
primary targets following DCM exposure. CNS effects include narcosis, reduced REM during
sleep and other behavioral manifestations. Liver toxicity, evidenced as histomorphological
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alterations and alterations in liver cytochromes, was noted in a NCA drinking water bioassay
(NCA, 1982) in rats. Limited data show that high concentrations of DCM can cause upper
respiratory tract irritation and produce cardiovascular, ocular and renal effects (ATSDR,
1989).
GENOTOXICITY
Methylene chloride reportedly produced a dose related increase in chromosomal aberrations
in peripheral lymphocytes of animals. Chromosome damage occurred at all dose levels and
the extent of damage was greater in the presence of metabolic activation (Thilagar, 1983).
No evidence of abnormalities in bone marrow cells in rats was reported (Burek, 1980). DCM
was not found to be mutagenic in bacteria and yeast. Given evidence of in vitro DNA
binding studies, the U.S. EPA (1987) concluded that DCM may be a weak mutagen in
irmmmfllian systems. Results were generally negative in vivo. Overall, DCM is considered
to be a weak mutagen in lower species (ATSDR, 1989). In the NTP (1986) bioassay,
significant increases with dose were reported in the incidence of neoplastic mammary tumors
in male and female rats and for lung and liver tumors. A U.S. EPA assessment of the data
produced by a NCA (1983) study concluded that significant increases in the incidence of
hepatocellular adenomas/carcinomas were associated with the ingestion by mice ofDCM in
drinking water (EPA, 1985a). The U.S. EPA has classified DCM as a Group B2 - Probable
Human Carcinogen (U.S. EPA, 1985b).
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METHYL ETHYL KETONE
GENERAL BACKGROUND INFORMATION
Methyl ethyl ketone (also known as MEK or 2-butanone) is a colorless liquid with an
acetone-like odor, moderate water solubility and high volatility. The major uses ofMEK are
as a solvent for coatings, adhesives and printing inks, as a cleaning/degreasing agent and as
a chemical intermediate in the production of synthetic leathers, transparent paper and
aluminum foil. MEK is a highly flammable substance and may pose a fire hazard if handled
improperly (ATSDR, 1990).
PHARMACOKINETICS
MEK is readily absorbed by all routes of exposure (see section on Relative Absorption
Factors). It is readily soluble in blood and appears to distribute uniformly to all organs
(Perbellini et al., 1984). MEK is metabolized by both oxidative and reductive pathways
(DiVincenzo et al., 1976). It undergoes reduction to 2-butanol and oxidation to 3-hydroxy-2-
butanone, which is further reduced to 2,3-butanediol. Small amounts ofunmetabolized MEK
can be excreted in urine or exhaled air. All metabolites are excreted in the urine as
glucuronides or sulfate conjugates.
HUMAN TOXICOLOGICAL PROFILE
MEK can produce irritation to the eyes, respiratory tract and skin following high level
exposure. Central nervous system effects have been reported, including headache, dizziness,
nausea and fatigue (ATSDR, 1990). No studies were located regarding the possible
consequences of exposure on the liver, kidney, reproductive organs or developing fetus. This
ketone has been demonstrated to be very hazardous in combination with other solvents by
potentiating the neurotoxicity of n-hexane, methyl-n-butyl ketone and ethyl-n-butyl ketone
(Altenkirch et al., 1979).
MAMMALIAN TOXICOLOGICAL PROFILE
High level inhalation exposure to MEK results in upper respiratory tract and ocular
irritation. Exposure to high level MEK by the inhalation or oral route resulted in liver
congestion, increase liver weight and renal tubular necrosis (Patty, 1935; Cavender et al.,
1983). Narcosis and incoordination, indicators of central nervous system effects, were also
observed, with no signs of periphereal neuropathy. Inhalation exposure during gestation
resulted in fetotoxic effects such as reduced fetal weight, skeletal variations and delayed
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ossification (Deacon et al., 1981; Mast et al., 1989; Schwetz et al., 1974). No studies were
located regarding the possible consequences of exposure on the reproductive systems.
GENOTOXICITY
No in vivo studies were located regarding the genotoxicity of MEK. Results of in vitro tests
indicate that MEK is nongenotoxic following in vitro exposure (Thorpe, 1982; O'Donoghue
et al., 1988).
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2-METHYLNAPHTHALENE
GENERAL BACKGROUND INFORMATION
2-Methylnaphthalene is a member of the polycyclic aromatic hydrocarbons (PAH). PAHs are
a class of non-polar compounds that contain two or more aromatic rings. They are
ubiquitous in nature and are both naturally occurring and man-made. This compound is
used in the synthesis of organic chemicals and pesticides. The database for toxicological
information is very limited.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of 2-methylnaphthalene.
HUMAN TOXICOLOGICAL PROFILE
No data were found regarding the human toxicity of 2-methylnaphthalene.
MAMMALIAN TOXICOLOGICAL PROFILE
No data were found regarding the mammalian toxicology of 2-methylnaphthalene.
GENOTOXICITY
No data were found regarding the genotoxicity of 2-methylnaphthalene.
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METHYL TERT BUTYL ETHER
GENERAL BACKGROUND INFORMATION
Methyl tert butyl ether (MTBE) is an volatile organic ether with extensive water solubility
and lipophilicity. It is used clinically in the nonsurgical treatment of gallstones (Hofmann,
1990), as an industrial solvent and as a gasoline oxygenated octane enhancer. At normal
temperature and pressure, it exists as a clear liquid with a disagreeable odor. MTBE is
highly flammable and may pose a fire hazard if improperly handled (U.S. EPA, 1987).
PHARMACOKINETICS
Due to its lipophilicity, MTBE is well absorbed by all routes of exposure. It is readily soluble
in blood and rapidly distributes to all organ systems, including fetal tissue, with highest
concentrations occuring in organs with high lipid content such as adipose tissue and brain
(U.S. EPA, 1987). Most of an administered dose is excreted unchanged in expired air
(Biodynamics, 1984). The remainder undergoes oxidative metabolism mediated by the P-450
mixed function oxidase enzyme system to yield either tertiary butanol or formaldehyde
which are ultimately eliminated from the body as either exhaled C02 or formic acid in urine
and feces (Brady et al., 1990; Savolainen et al., 1985).
HUMAN TOXICOLOGICAL PROFILE
The only information concerning the human toxicity of MTBE involves its use as a
therapeutic agent to dissolve gallstones. The procedure entails catheterization of the
gallbladder through the abdominal cavity and subsequent perfusion with MTBE until the
stones are dissolved. More than 400 patients have been treated worldwide with a high
degree of success and few complications reported (Hofmann, 1990). Nausea, vomiting,
sedation, local pain and mild hemolysis are possible side effects. The only major complication
induced by MTBE has been a case of reversible renal failure in a patient during treatment
(Ponchon, 1988).
MAMMALIAN TOXICOLOGICAL PROFILE
MTBE is considered to have a relatively low order of acute toxicity, evident from reported
LDso values of 2962-3866 mg/kg and LC^ values of 33,427-39,461 ppm (U.S. EPA, 1987).
MTBE, in air, produces local irritation of the upper respiratory tract and mucous membranes.
By all routes of exposure, it produces central nervous system depression evidenced as
sedation, slowed reflexes, tremors, incoordination and altered behavior. Mild changes in
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hematological parameters, neurobehavioral indices and organ weights were evident upon
prolonged exposure (API, 1985).
Inhalation teratology and reproduction studies have failed to show any treatment related
effects (Biodynamics, 1984).
GENOTOXICITY
Limited in vivo and in vitro cytogenetic results are available. In vivo, clastogenic effects were
not observed in rats following subchronic exposure to MTBE (Bushy Run, 1989). In vitro
tests similarly failed to show any correlation between MTBE exposure and cytogenetic
abnormalities. MTBE did yield a dose-related positive response when tested in the mouse
lymphoma forward mutation assay in the presence of metabolic activation. Negative results
were obtained in the absence of metabolic activation (ARCO, 1987). No information on the
carcinogenicity of MTBE was located. However, structure-activity analysis predicts MTBE
to be neither a genotoxicant nor a carcinogen (Rosenkranz and Klopman, 1991).
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NAPHTHALENE
GENERAL BACKGROUND INFORMATION
Naphthalene is a white solid substance at room temperature. It has a distinct odor of
mothballs or tar. Humidity and sunshine cause evaporation into the air within a few hours.
When placed in water or soil, bacteria will destroy naphthalene, or will render it airborne
within a few hours (ATSDR, 1990). Tobacco smoke is known to release 3 ug of naphthalene
per cigarette (U.S. EPA, 1982). The compound is used in the production of dyes, solvents,
lubricants, motor fuels (U.S. EPA, 1980) and is a major component of many moth ball
preparations.
PHARMACOKINETICS
Humans can absorb naphthalene by dermal, inhalation and oral routes (see section on
Relative Absorption Factors). Metabolism occurs via the P450 mixed function oxidase
enzyme system to yield multiple intermediates which are then conjugated. Key metabolites
are responsible for each toxicity endpoint following intraperitoneal administration: 2-
naphthoquinones — > hemolysis; 1,2-naphthoquinones — > cataracts; 3-GSH adducts ->
pulmonary toxicity (Buckpitt et al., 1984). Excretion of metabolites occurs via urine and
feces (ATSDR, 1990).
HUMAN TOXICOLOGICAL PROFILE
Adults and children exposed to airborne naphthalene experience vomiting, abdominal pain
and anemia (ATSDR, 1990). Most of the data is for inhalation of naphthalene from
mothballs. The primary site of toxicity is the erythrocyte resulting in hemolytic crisis
(hemolytic anemia). Jaundice is seen upon dermal, inhalation, and oral exposures, as are
kidney effects (ATSDR, 1990). Near-blindness resulted in male and female subjects with 5
gram ingestion (ATSDR, 1990).
MAMMALIAN TOXICOLOGY PROFILE
Oral doses in rats have hepatic effects. Dogs (1800 mg/kg) for 5 days of exposure showed
signs of lethargy and ataxia, and decreased hemoglobin levels (ATSDR, 1990)
GENOTOXICITY
No studies of genotoxic effects in humans or laboratory animals were located. No human
epidemiological evidence for cancer.
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Inconclusive evidence for cancer in rats and mice were found (ATSDR, 1990).
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NICKEL
GENERAL BACKGROUND INFORMATION
Nickel in the ambient atmosphere typically exists as a constituent of suspended particulate
matter (U.S. EPA, 1985). The greatest volume of nickel emitted into the atmosphere is the
result of fossil fuel combustion. Other sources of nickel emissions are primary production,
incinerators, metallurgy, chemical manufacturing, cement manufacturing, coke ovens, nickel
recovery, asbestos mining/milling and cooling towers.
PHARMACOKINETICS
Studies of nickel absorption have shown that it is absorbed by all routes of exposure to
varying degrees, primarily dependent on the chemical form (see section on Relative
Absorption Factors). Absorbed nickel is bound to serum components and distributed to body
organs, reaching highest concentrations in kidney and lung tissue (Whanger, 1973). Nickel
is not known to be biotransformed. Excretion of absorbed nickel is primarily through urine,
with minor excretory routes through hair and sweat (ATSDR, 1988).
HUMAN TOXICOLOGICAL PROFILE
Nickel carbonyl Ni(CO)4 is a particularly toxic form of nickel upon inhalation and causes
chest pain, dry coughing, hyperpnea, cyanosis, occasional gastrointestinal symptoms, sweating,
visual disturbances and severe weakness. This is often followed by pulmonary hemorrhage,
edema and cellular derangement. Survivors may be left with pulmonary fibrosis. In the
workplace, nickel dermatitis may result at high nickel concentrations. At lower
concentrations some susceptible individuals develop eczema-like lesions. The threshold for
these health effects is much greater than exposures which occur in the ambient
environment. The major adverse effects of nickel in man are dermatitis, chemical
pneumonitis, and lung and nasal cancers.
MAMMALIAN TOXICOLOGICAL PROFILE
Deaths occurred in rats and mice at concentrations greater than 3.3 and 1.7 mg/m3 nickel,
respectively, upon extended inhalation exposure to NiS04 (Dunnick et al., 1987). Mice
exposed to NijS2 died due to necrotizing pneumonia at 7.3 mg/m
3
nickel (Benson et al.,
1987). Prolonged exposure of hamsters to nickel oxide at 41.7 mg/m3 resulted in decreased
survival due to emphysema (Wehner et al., 1975). Oral LD^s in rats vary depending upon
the nickel-containing compound to which the rats were exposed. These range from 355 mg
compound/kg (118 mg Ni/kg) for nickel acetate (Haro, 1968) to greater than 5000 mg
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compound/kg for nickel oxide, nickel sulfide, and nickel subsulfide (Mastromatteo, 1986).
Rats fed diets containing nickel sulfate hexahydrate at 0, 250, 500 and 1000 ppm nickel
showed no adverse effects over three generations in fertility, gestation, viability or lactation.
GENOTOXICITY
Weak evidence exists for the mutagenicity of nickel in bacterial and mammalian cells. Nickel
appears to induce chromosomal aberrations in cultured mammalian cells (Larramendy et al,
1981), but not in vivo (Waksvik and Boysen, 1982). Occupational studies ofhuman exposure
indicate that certain nickel compounds appear to be carcinogenic via inhalation. However,
there is no evidence of carcinogenicity in mammals through ingestion or dermal exposure
(U.S. EPA, 1985). Nickel subsulfide has been found to be carcinogenic via the inhalation
route in rats (Ottolenghi et al., 1974). Studies on nickel exposure via the oral route are
inadequate to reach conclusions on carcinogenicity (ATSDR, 1988).
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PHENANTHRENE
GENERAL BACKGROUND INFORMATION
Phenanthrene is a member ofthe polyaromatic hydrocarbons (PAH). PAHs constitute a class
of non-polar compounds that contain two or more aromatic rings. They are ubiquitous in
nature and are both naturally occurring and man-made. The database on the potential
health effects of phenanthrene is limited.
PHARMACOKINETICS
Little data are available regarding the pharmacokinetics of phenanthrene. The intestinal
absorption of phenanthrene is less dependent on the presence of bile in the stomach than
is the absorption of the larger PAHs (such as benzo(a)pyrene) (Rahman et al, 1986).
HUMAN TOXICOLOGICAL PROFILE
Phenanthrene has been shown to be a skin photosensitizer in humans (Sax, 1984).
MAMMALIAN TOXICOLOGICAL PROFILE
Phenanthrene has a reported LD 50 of 700 mg/kg in mice (Simmon et al., 1979). Rats
injected intraperitoneally evidenced liver effects (Yoshikawa et al, 1987).
There is equivocal evidence for cancer from dermal application of phenanthrene in rats
(IARC, 1983). Phenanthrene is not a complete skin carcinogen (ATSDR, 1990). It is neither
an initiator (LaVoie et al, 1981; Roe, 1962) nor a promoter (Roe and Grant, 1964). Higgins
and Yang (1962) reported no tumor production within two months after the ingestion of
200 mg of phenanthrene by rats.
GENOTOXICITY
There are limited data that suggest that phenanthrene is mutagenic (Wood et al., 1979).
However, the majority of tests are negative (ATSDR, 1990).
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PHENOL
GENERAL BACKGROUND INFORMATION
Phenol is a colorless to white solid when pure, but the commercial product is a liquid. It has
a sickeningly sweet and acrid odor, moderate solubility in water, low volatility, and has
flammable characteristics. Phenol is mainly a man-made chemical, although it is found in
nature in animal wastes and decomposing organic material (ATSDR, 1989). It is used in the
production of a large variety of aromatic compounds, including explosives, fertilizers, coke,
illuminating gas, lampblack, paints, paint removers, rubber, wood preservatives, synthetic
resins, textiles, drugs, disinfectants, perfumes, and plastic. It is also used in the petroleum,
leather, paper, soap, toy, tanning, dye, and agricultural industries (Clayton and Clayton,
1981).
PHARMACOKINETICS
Phenol is readily and rapidly absorbed by all routes and can produce symptoms within
minutes of exposure to acutely toxic doses. In animals, phenol is rapidly distributed to the
liver, heart, kidneys, lungs, blood, and muscle (ATSDR, 1989). Phenol then becomes fairly
uniformly distributed before it is metabolized and excreted (U.S. EPA, 1980). After exposure,
most of phenol is oxidized and conjugated with sulfuric, glucuronic, and other acids. It is
excreted in the urine as "free" and as "conjugated" phenol. Only traces of "free" phenol are
eliminated with the feces and expired air (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Acute poisoning by all routes of exposure may affect the central nervous system, leading to
sudden collapse and unconsciousness. It may be lethal within minutes in humans due to
respiratory failure. Swallowing phenol causes intense burning of the mouth and throat and
abdominal pain (Clayton and Clayton, 1981). Ingestion of phenol in drinking water (daily
doses of 10-240 mg) caused symptoms of diarrhea, mouth sores, and burning mouth (Baker
et al., 1978). Repeated exposures to phenol at high concentrations have resulted in chronic
liver damage (Merliss, 1972).
MAMMALIAN TOXICOLOGICAL PROFILE
The signs and/or symptoms of acute toxicity in humans and experimental animals are
similar. The central nervous system effects observed in humans exposed to acute toxic doses
are preceded in some animals by muscular twitchings and severe convulsions. In a severe
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intoxication, there may be damage to the lungs, myocardial degeneration and necrosis, and
liver damage (ATSDR, 1989).
GENOTOXICnY
No studies were located regarding genotoxic or carcinogenic effects in humans. The existing
information on the mutagenicity of phenol is equivocal and needs to be re-examined to
determine the mutagenicity of phenol. Cancer studies are inconclusive in animals (ATSDR,
1989). Phenol may have tumor promoting activity in certain strains of mice when repeatedly
applied to shaved skin after initiation with known carcinogens (U.S. EPA, 1980).
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POLYCHLORINATED BIPHENYLS (PCBs)
GENERAL BACKGROUND INFORMATION
The thermal stability, nonflammability, and dielectric capability ofPCBs resulted in their use
in electrical capacitors and transformers (NIOSH, 1986). The manufacturing, processing,
distribution in commerce, and use of PCBs after January 1, 1978 was prohibited under
Section 6(e) of the Toxic Substances Control Act. PCBs can be released to the environment
during fires involving electrical equipment containing these compounds. PCBs are strongly
adsorbed on solid surfaces, including glass and metal surfaces in laboratory apparatus, and
onto soils, sediments, and particulates in the environment.
PHARMACOKINETICS
Gastrointestinal absorption of most PCB isomers is large. PCBs can also be absorbed by the
inhalation and dermal routes but limited data are available (see section on Relative
Absorption Factors). Distribution of PCBs follows a biphasic pattern. Initially, PCBs
distribute to liver and muscle tissue. They are then redistributed to the fat, skin, and other
fat-containing organs (ATSDR, 1989). PCBs are poorly metabolized in humans with major
metabolites being 3- or 4-hydroxy compounds. Metabolism may proceed through formation
of arene oxide intermediates (U.S. EPA, 1988). The slow metabolism of PCB congeners to
more polar compounds is responsible for long biological half-lives of PCBs. Excretion occurs
primarily through the feces (Goto et al., 1974).
HUMAN TOXICOLOGICAL PROFILE
Dermatologic signs are the most persistent indicator of PCB toxicity. Skin manifestations
have been observed also in newborn infants of mothers exposed to high levels of PCBs and
related compounds. Cases of severe chloracne were reported in a work environment in which
PCB air levels were found to be between 5.2 and 6.8 mg/m3. The workers developing
chloracne had been exposed for 2 to 4 years. Other analyses revealed worker complaints of
dry sore throat, skin rash, gastrointestinal disturbances, eye irritation, and headache at work
area concentrations of 0.013 to 0.15 mg PCB/m3. Higher blood PCB levels are associated
with higher serum triglyceride and/or cholesterol levels, as well as high blood pressure. Air
PCB concentrations as low as 0.1 mg/m3 can produce toxic effects, and exposure to levels
producing no overt toxicity can affect liver function. Recovery after termination of exposure
occurs but is slow and depends upon the amount of PCBs stored in adipose tissue (Clayton
and Clayton, 1981). Human exposures to PCBs resulting in toxic effects have almost all
resulted from the ingestion of rice oil contaminated with "Kanechlor 400" in Japan (resulting
in Yusho or rice oil disease) or from industrial exposure. Clinical symptoms of poisoning
MA DEP, ORS & BWSC
Documntation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
B- 105
included acne-like skin eruptions (chloracne), eyelid edema, conjunctival discharge, skin and
nail pigmentation, and hyperkeratosis. Yusho patients are estimated to have ingested
approximately 0.07 mg/kg/day for at least 50 days. The rice oil was found to be
contaminated with polychlorinated dibenzofuran, which is believed to have played a
significant role in the observed toxicity (Bandiera et al., 1984; Kashimoto et al., 1981). As
suggested by laboratory experiments with Rhesus monkeys, fetal and newborn primates,
including humans, may be particularly susceptible to PCBs. Fein et al. (1984) studied the
effects of low-level chronic exposure to PCBs in pregnant women and their newborn offspring
from consumption of Lake Michigan fish. Low levels of PCBs were reported to cause
decreases in birth weight, head circumference, and gestational age of the newborn. PCBs
were apparently transmitted to the fetus across the placenta and to the newborn through
breast milk. Behavioral deficiencies, including immaturity of reflexes and depressed
responsiveness, were reportedly observed in infants exposed to PCBs. Jacobson et al. (1984)
correlated maternal consumption of PCB-contaminated fish with behavioral abnormalities in
newborns, including autonomic immaturity and depressed responsiveness. The authors
likened these responses to similar effects in laboratory animals.
MAMMALIAN TOXICOLOGICAL PROFILE
PCBs are only slightly toxic in acute exposures to laboratory animals. LD^ values for rats,
rabbits, and mice are generally in the range of 1 to 10 g/kg body weight (U.S. EPA, 1980).
Nonhuman primates seem to be particularly sensitive to PCB-induced reproductive effects
(U.S. EPA, 1980). Dietary exposures of cynomolgus and Rhesus monkeys to 200 ug of
Aroclor 1254/kg-day, 5 days per week for 28 months, resulted in symptoms of enlarged tarsal
glands, conjunctivitis, loss of eyelashes, progressive detachment of fingernails, exuberant nail
beds, hyperplasia of biliary ducts, hepatocellular enlargement and necrosis, and normocytic
anemia (Tryphonos et al., 1986a; Tryphonos et al., 1986b). Effects were less pronounced in
cynomolgus monkeys.
Monkeys that were fed diets containing 1.0 ppm ofAroclor 1016 for approximately 7 months
prior to mating and during pregnancy delivered infants with reduced birth weights (Barsotti
and Van Miller, 1984). Fetal mortality occurred at >2.5 ppm (0.1 mg/kg/day) of Aroclor
1248 in the diet in other studies with monkeys (Allen and Barsotti, 1976; Barsotti et al.,
1976; Allen et al., 1980). In rats, a dose of 269 ppm of Aroclor 1254 given continuously in
the food over the duration of pregnancy caused a decrease in the number of impregnated
rats that delivered Utters. Pups that were born were underweight, and most died within
7 days of birth. Two lower doses (26 and 2.5 ppm) caused altered neurobehavioral and
somatic ontogeny (Overmann et al., 1987). PCBs have been shown to be teratogenic in mice.
Cleft palate, dilated kidney pelvis, and thymus hypoplasia were observed. The ED50
(effective dose for 50% of the animals) for formation of cleft palate was a single 100 mg/kg
dose, with peak sensitivity occurring on the twelfth day of gestation (d'Argy et al., 1987).
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Immunological effects (decreased IgM, IgG induction) were noted in monkeys following a 27
month exposure at a dose of 0.005 mg/kg/day (Tryphonos et alM 1989).
GENOTOXICITY
Most genotoxicity assays of PCBs have been negative. The majority of microbial assays of
PCB mixtures and various congeners show no evidence of mutagenic effects (U.S. EPA,
1980). The carcinogenic effects of PCBs have been studied in rats and mice. In a study
conducted by Kimbrough et al. (1975) rats were exposed via the diet to 100 ppm Aroclor 1260
for 21 months. Hepatocellular carcinomas were observed in 26 of the 184 treated rats but
only in one of the 173 controls. Neoplastic nodules were not found in controls but occurred
in 144/184 of treated rats. The National Cancer Institute (NCI, 1978) reported a high
incidence of hepatocellular proliferative lesions in male and female Fischer 344 rats fed three
dose levels of Aroclor 1254 for 104-105 weeks, but, in part due to the small number of
animals tested, carcinogenicity was not statistically demonstrable. Norback and Weltman
(1985) fed a diet containing relatively high concentrations Aroclor 1260 (100 ppm for
16 months followed by 50 ppm for an additional 8 months) to Sprague-Dawley rats. In the
PCB-exposed group, neoplastic nodules were observed at 12 months followed by trabecular
carcinoma at 15 months and adenocarcinoma at 24 months (52/93). In the control rats, the
incidence of hepatocellular neoplasms was low (1/81). Metastases to distant organs was not
observed and mortality in the PCB exposed animals was not increased. The incidence of
these slow-growing hepatocellular neoplasms was strikingly higher in female rats than in
male rats.
PCBs (Clophen C) have also been shown to be cocarcinogenic. When PCBs were mixed with
diethylnitrosamine (DENA), twice as many tumors were observed as were observed in
animals treated with DENA alone (Brunn, 1987).
Based on the positive evidence for carcinogenicity of Aroclor 1254, Aroclor 1260, Kaneclor
500, and Clophen A-30 and A-60 in animals, along with adequate evidence in humans, the
U.S. EPA has placed these PCBs in categroy B2 - probable human carcinogen (U.S. EPA,
1988).
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PYRENE
GENERAL BACKGROUND INFORMATION
Pyrene is a member of the polyaromatic hydrocarbons (PAH). PAHs constitute a class of
non-polar compounds that contain two or more aromatic rings. They are ubiquitous in
nature and are both naturally occurring and man-made. As with many of the other PAHs,
pyrene has been detected in charbroiled meats and shellfish (U.S. EPA, 1982). It is found
in tobacco smoke, industrial stack smoke, and smoke from forest fires.
PHARMACOKINETICS
No data were found regarding the pharmacokinetics of pyrene.
HUMAN TOXICOLOGICAL PROFILE
Pyrene is reported to be a skin irritant (Sax, 1984).
MAMMALIAN TOXICOLOGICAL PROFILE
Rats given 150 mg/kg of pyrene had changes in blood chemistry, liver and kidney damage
(USEPA, 1982). A 1989 EPA study (EPA, 1989) reported nephropathy and decreased kidney
weights in mice exposed to 125 mg/kg-day of pyrene by gavage for 13 weeks.
Mouse skin painting assays indicate that pyrene is neither a complete skin carcinogen, nor
an initiating agent (ATSDR, 1990, IRIS, 1991).
GENOTOXICITY
The majority of genotoxic tests of pyrene are negative.
Positive results have been recorded in Salmonella typhimurium mutagenicity tests and in
in vitro mammalian cell systems (ATSDR, 1990).
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SILVER
GENERAL BACKGROUND INFORMATION
Silver is used in photographic materials, batteries, paints and jewelry. Silver is used
medically in dental amalgam and in medical supplies for burn treatment. Photographic
materials are the major source of silver that is released into the environment. Trace
amounts of silver are found in water from natural sources and industrial waste.
PHARMACOKINETICS
Studies in humans and animals indicate that silver compounds are absorbed readily by the
inhalation and oral routes. Individuals and individual organs absorb silver selectively. The
greatest concentrations are found in the reticuloendothelial organs. Silver undergoes
oxidation and reduction reactions within the body and is excreted primarily via the fecal
route (ATSDR, 1990).
HUMAN TOXICOLOGICAL PROFILE
Blue-gray discoloration of the skin has been observed in many individuals who have ingested
metallic silver and silver compounds over periods of months to years. This condition is
termed argyria. The pigmentation of the skin is primarily in sun-exposed areas. Silver-
containing granules are also observed in the dermis. Gradual accumulation of 1 to 5 grams
of silver will lead to generalized argyria. The discoloration is not known to be diagnostic of
any other toxic effect (ATSDR, 1990). Occupational exposure to silver dusts can lead to
respiratory and gastrointestinal irritation. The average air level was estimated to range from
0.039 to 0.378 mg/m3. Duration of employment ranged from less than one year to greater
than ten years. Symptoms included abdominal pain, sneezing, stuffiness, and sore throat.
Granular deposits were also observed in the conjunctiva and corneas of the eyes (Rosenman
et al., 1979; 1987). Medical case histories indicate that dermal exposure to silver and silver
compounds for extended periods of time can lead to local skin discoloration similar in nature
to the generalized pigmentation seen after repeated oral exposure. The amount of silver and
the duration of exposure necessary to produce this effect have not been established
(McMahon and Bergfeld, 1983).
MAMMALIAN TOXICOLOGICAL PROFILE
Oral doses of 1,680 mg/kg silver colloid resulted in the deaths of rats after four days
(Dequidt et al., 1974). Ingestion of silver nitrate and silver chloride will also cause deposition
of silver granules in the skin of animals (Walker, 1971). Granules were observed in the eyes
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of rats exposed to silver nitrate in drinking water at doses of 222 mg/kg/day over 37 weeks.
These doses also cause general deposition in other tissues (Matuk et al., 1981). Mice given
oral doses of 18.1 mg/kg/day silver nitrate for 125 days were observed to have silver deposits
in their nervous systems. These animals were less active than unexposed controls (Rungby
and Danscher, 1984). Silver has been found in the brains of neonatal rats whose mothers
received silver lactate on days 18 and 19 of gestation (Rungby and Danscher, 1984). No
studies were located that examine the reproductive effects of silver in animals or humans.
GENOTOXICITY
Silver is not mutagenic in bacteria but it has been found to cause DNA damage in
mammalian cell culture (Robinson et al., 1982). No studies were located regarding cancer
in humans or animals following oral, inhalation or dermal exposure to silver or silver
compounds (ATSDR, 1990).
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TETRACHLOROETHYLENE
GENERAL BACKGROUND INFORMATION
The major use for tetrachloroethylene (perchloroethylene, PCE) is in the dry-cleaning
industry. Its popularity in this area is due to its nonilammability, ease of recovery for reuse
and its compatibility with various fabrics. It is also used in cold cleaning and vapor
degreasing of metals. Its remaining uses are as a chemical intermediate in the synthesis of
fluorocarbons, various manufacturing and industrial processes as well as medicinal uses
(IRP, 1985).
PHARMACOKINETICS
PCE is readily absorbed by humans through the lungs into the blood. Pulmonary uptake is
proportional to ventilation rate, duration of exposure and (at lower concentrations of PCE)
to the concentration of PCE in the inspired air (Hake and Stewart, 1977). PCE is also
rapidly aborbed following oral administration, but is poorly absorbed following dermal
exposure (see section on Relative Absorption Factors). Distribution occurs rapidly with the
highest concentrations of PCE achieved in tissues of high fat content (ATSDR, 1990).
Metabolism of PCE is believed to be mediated by the microsomal mixed function oxidase
enzyme system involving the formation of an epoxide intermediate. Major metabolites of
PCE are trichloroacetic acid and trichloroethanol. Unmetabolized PCE is excreted largely
by exhalation with urinary excretion of metabolites representing a small percentage
(ATSDR, 1990).
HUMAN TOXICOLOGICAL PROFILE
Stewart et al. (1977) found that exposure of 11 subjects to a mean PCE concentration of
101 ppm for 7 hours produced symptoms of headache, dizziness, difficulty in speaking, and
sleepiness. Long-term exposed subjects are also reported to experience effects such as short-
term memory defects, ataxia, irritability, disorientation, and sleep disturbances (USEPA,
1985). PCE causes hepatotoxicity in humans. A number of reports of liver damage after
inhalation ofPCE in acute or chronic exposure situations have been documented (Hake and
Stewart, 1977). PCE ingestion in humans results in symptoms indicative of liver damage,
including elevated SGOT and SGPT levels, hepatomegaly, and fatty degeneration of the liver
cells (Koppel et al., 1985).
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MAMMALIAN TOXICOLOGICAL PROFILE
Male and female rats treated via stomach tube showed symptoms of tremors, ataxia, CNS
depression, and finally, death (Hayes et al., 1986). Moderate fatty degeneration of the liver
was observed in mice 1 day after a single 4-hour exposure to 200 ppm PCE, but not 3 days
after exposure (Kylin et al., 1963). Chronic exposure in animals has been found to damage
the CNS, producing symptoms such as hypertrophy and proliferation of astroglial cells in the
brain (Rosengren et al., 1986). In this study, there was a decreased DNA content observed
in the brain of gerbils exposed continuously to PCE concentrations as low as 60 ppm. It was
suggested that this may represent the development of brain atrophy. Rowe et al. (1952)
exposed rats, rabbits, guinea pigs, and monkeys to PCE vapors at levels of 100 to 400 ppm,
7 hour/day, 5 days/week for 6 months. Only guinea pigs showed adverse effects due to
exposure. These effects included increased liver weights with some fatty degeneration, a
slight increase in hepatic lipid content, and the presence of several small hepatic fat
vacuoles. PCE also causes renal effects in rodents. Groups of rats and mice of each sex were
exposed to PCE in corn oil by gavage 5 days/week for 78 weeks (NCI, 1977). Toxic
nephropathy occurred at all dose levels in both sexes of rats and mice. PCE has been found
to be fetotoxic, but not teratogenic at concentrations that are also maternally toxic (Schwetz,
1975). Fetotoxicity was usually expressed by decreased fetal weight and delayed skeletal
ossification. There is some evidence that PCE causes adverse effects on reproductive
systems. The finding of abnormal sperm in mice exposed to 500 ppm PCE is an indication
of chemical effects on the sperm. However, definitive evidence that PCE or its metabolites
reached germinal tissue and damaged DNA is not provided (U.S. EPA, 1985).
GENOTOXICITY
In vitro studies of PCE genotoxicity have been performed in prokaryotic, eukaryotic and
mammalian cells. The results using prokaryotic systems were all negative, whereas in
studies using yeast or mammalian cells, the results were mixed (Bronzetti et al., 1983; Price
et al., 1978). NTP (1985) conducted inhalation carcinogenicity studies in F344/N rats and
B6C3F1 mice of each sex for 6 hours/day, 5 days/week for 103 weeks. There were increases
in mononuclear cell leukemia in rats and hepatocellular adenomas and carcinomas in mice.
In chronic oral studies (NCI, 1977), PCE produced hepatocellular carcinomas in mice, but not
in rats.
Epidemiological studies of dry-cleaning and laundry workers have determined significant
excesses in mortality due to cancers of the lung, cervix, kidney, skin and colon (Blair et al.,
1979; Kaplan, 1980). Although these studies suggest an association between chronic
occupational exposure to PCE and increased cancer risk, the evidence is inconclusive, because
workers were exposed to other solvents as well. Considering the inconclusive evidence for
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carcinogenicity in humans, the U.S. EPA places PCE in Group B2, meaning that is
considered a probable human carcinogen.
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THALLIUM
GENERAL BACKGROUND INFORMATION
Pure thallium is a soft bluish-white metal that is widely distributed in trace amount in the
earth's crust. It is used in the manufacture of electronic devices, switches, and closures. It
is also used to a limited extent in the manufacture of special glasses and for medical
procedures that evaluate heart disease. Up until 1972, thallium was also used as a rat poison
(ATSDR, 1991).
PHARMACOKINETICS
Thallium appears to be nearly completely absorbed from the gastrointestinal tract. No
information was located on absorption following inhalation or dermal exposure. However,
flTiimal studies following intratracheal administration suggested that uptake through
respiratory epithelium was rapid and complete. There is little information on the
distribution of thallium in humans. Analysis of human tissues indicates that thallium is
distributed throughout the body. The highest levels were found in the scalp hair, kidney,
heart, bone, and spleen. In animals, the highest levels are found in the kidneys and liver.
Excretion of thallium occurs by both the urinary and fecal routes (ATSDR, 1991).
HUMAN TOXICOLOGICAL PROFILE
Thallium is acutely lethal to humans following oral exposure at doses of 54-110 mg
thaUium/kg ofbody weight as thallium sulfate (Davis et al., 1981). The estimated lethal dose
is approximately 14-15 mg/kg (Gosselin et al., 1984). Thallium compounds can affect the
respiratory, cardiovascular, and gastrointestinal systems, the liver, kidneys and the male
reproductive system. Alopecia (hair loss) and changes in the nervous system are
characteristic of thallium exposure. A retrospective study was conducted which compared
the incidence of congenital abnormalities in children born to mothers who had been exposed
to thallium during pregnancy (Dolgner et al., 1983). The number of anomalies in the
exposed group did not exceed the number of expected birth defects in the general
population.
MAMMALIAN TOXICOLOGICAL PROFILE
In animals, the lowest doses showing lethality for a brief exposure period ranged from 5 to
30 mg/kg body weight for several species (Downs et al., 1960). Exposure to low doses
(1.4 mg thallium as thallium sulfate/kg body weight/day) for longer durations (40-240 days)
also cause death (Manzo et al., 1983). Electromyographic abnormalities without changes in
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the myocardium are seem following a single oral dose (56 mg thallium/kg as thallium sulfate)
in rabbits (Grunfeld et al., 1963). Parenteral injection in animals has been observed to cause
liver effects. Thallium did not cause renal effects in rats following oral exposure, but
parenteral exposure studies demonstrated that thallium affects the kidneys following
subcutaneous administration. Rats exposed prenatally to 0.08 mg thallium/kg/day or greater
during gestation evidenced impairment of learning. These effects occurred at dose levels
below those at which other neurological effects (e.g structural and functional alterations of
peripheral nerves) have been observed. Cultured rat embryos exposed to thallium at
concentrations of 10, 30, or 100 ug/ml showed dose-related growth retardation at all levels
showing embyrotoxic effects (Anschutz et al., 1981). Administration by intraperitoneal
injection to pregnant rats at a dose of 2.0 mg thallium/kg/day (as thallium sulfate) during
gestation days 8-10 resulted in reduced fetal body weights, hydronephrosis, and the absence
of vertebral bodies (Gibson and Becker, 1970).
GENOTOXICITY
Animal and bacterial assays suggest than thallium is genotoxic. Thallium-induced dominant
lethal mutations in male rats in vivo. The overall embryonic mortality increased at doses of
0.04 ug thallium/kg day or greater as thallium carbonate. In vitro DNA damage tests
employing rat embryo cells were positive (Zasukhina et al., 1983). Thallium enhanced viral-
induced transformations in Syrian hamster embryo cells (Casto et al., 1979) and was positive
in bacterial assays (Kanematsu et al., 1980). No studies are available on the carcinogenic
effects of inhalation, oral or dermal exposure to thallium.
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TOLUENE
GENERAL BACKGROUND INFORMATION
Toluene is a clear, colorless organic liquid with a sweet smell and a high degree of lipid
solubility. It is used as an industrial solvent/degreaser, as an intermediate in the
manufacture of chemicals and pharmaceuticals, and is present as a component of gasoline
and other fuels, paints, lacquers, adhesives, rubber and printing ink. Toluene is a volatile
molecule with relatively low water solubility. It is flammable and may pose a fire hazard if
handled improperly (ATSDR, 1989).
PHARMACOKINETICS
Toluene is readily absorbed by all routes of exposure (see section on Relative Absorption
Factors). Once absorbed, it is rapidly distributed to all organ systems, including fetal tissue,
with highest concentrations occuring in organs with high lipid content such as adipose tissue,
brain and bone marrow. Toluene undergoes primarily oxidative metabolism to benzyl alcohol
mediated by the mixed function oxidase enzyme system. Benzyl alcohol is further oxidized
by alcohol and aldehyde dehydrogenase to produce benzoic acid which is primarily conjugated
with glycine or glucuronic acid and excreted in urine as hippuric acids or benzoyl
glucuronide. Toluene may also be excreted unchanged in exhaled air. Metabolism and
excretion occurs rapidly, with the major portion occurring within 12 hours of exposure
(Fishbein, 1985).
HUMAN TOXICOLOGICAL PROFILE
In humans, the most profound effects of toluene are on the central nervous system. Acute
exposure results in reversible depression of the central nervous system, neurological
dysfunction, impaired performance and narcosis. Chronic exposure has been reported to
result in permanent central nervous system effects such as ataxia, tremors and impaired
speech, hearing and vision (ATSDR, 1989). Toluene vapors cause irritation of the upper
respiratory tract, mucous membranes and eyes, and may produce cardiac arrhythmias upon
chronic exposure (Anderson et al., 1982). Reports of effects on the hematological system,
liver, kidney, immune system, reproductive organs and the developing fetus are confounded
by exposure to multiple solvents (ATSDR, 1989).
MAMMALIAN TOXICOLOGICAL PROFILE
Toluene has been demonstrated to produce similar effects in human s and animals. The
major target organ following acute or chronic exposure is the central nervous system. Signs
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of central nervous system damage include impaired motor abilities, narcosis, tremors,
alterations in EEG activity, changes in the levels of brain neurotransmitters and
morphological effects (ATSDR, 1989). High level inhalation exposure resulted in respiratory
irritation and inflammation and pulmonary lesions (NTP, 1989). Toluene does not appear
to be directly toxic to the cardiovascular system (Bruckner and Peterson, 1981). Decreased
leukocyte counts were observed in dogs following exposure to toluene (Hobara et al., 1984).
In addition, exposed mice exhibited increased susceptibility to respiratory infection (Aranyi
et al., 1985). Hepatic effects appear to be relatively mild with reported increases in liver
weight and minor ultrastructural changes (Ungvary et al., 1982). Renal toxicity has not been
observed (NTP, 1989; Bruckner and Peterson, 1981). Studies with animals provide evidence
that toluene may be a developmental toxicant. Exposure in utero resulted in skeletal
anomalies, retarded skeletal growth and low fetal weights (Ungvary, 1985). No reproductive
effects have been reported (API, 1985; NTP, 1989).
GENOTOXICITY
Available in vitro studies suggest that toluene is nongenotoxic (ATSDR, 1989). In vivo
studies in animals provide additional supportive evidence (API, 1981). A small number of
human studies have reported an increased incidence in chromosomal abnormalities, however,
these studies are confounded by possible co-exposure to other chemicals (Schmid et al., 1985;
Bauchinger et al., 1982). Other human studies have found no correlation between exposure
to toluene and increased frequencies of chromosomal abnormalities (Haglund et al., 1980;
Maki-Paakkanen et al., 1980).
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1,1,1 -TRICHLOROETHANE
GENERAL BACKGROUND INFORMATION
1,1,1-Trichloroethane (also known as 1,1,1-TCA) is a colorless man-made chemical. It can be
found in a liquid state, vapor, or dissolved in water or other chemicals. When found as a
liquid, it evaporates rapidly and becomes a vapor in the air. 1,1,1-TCA has a sweet, sharp
odor (ATSDR, 1990). 1,1,1-Trichloroethane is often used as a solvent to dissolve other
substances such as glue or paint. Industrially, it is used to remove oil or grease from
manufactured metal parts. Residentially, it is used for spot removal cleaners, aerosol sprays
and glues. 1,1,1-Trichloroethane can be found in hazardous waste sites in the soil, water and
in the air (ATSDR, 1990). It can be found in rivers, lakes, soil, drinking water, and drinking
water from underground wells.
PHARMACOKINETICS
1,1,1-Trichloroethane is rapidly and completely absorbed by ingestion and inhalation (U.S.
EPA, 1984). It distributes throughout the body and crosses the blood-brain barrier (U.S.
EPA, 1984). If spilled topically, absorption via the skin would occur in small amounts
because of quick evaporation into the air (U.S. EPA, 1984; ATSDR, 1990). Regardless ofhow
1,1,1-trichloroethane enters the body, most will quickly leave as exhalation occurs (ATSDR,
1990). What does not exit from expiration (metabolites) will be excreted through the urine
and breath in a few days.
HUMAN TOXICOLOGICAL PROFILE
The toxic effects of 1,1,1-TCA are generally seen at concentrations well above those likely
in an ambient environment. The most notable toxic effects of 1,1,1-TCA in humans are
central nervous system depression, including anesthesia at very high concentrations, and
impairment of coordination, equilibrium, and judgement at lower concentrations. Exposure
to high concentrations may also result in cardiovascular effects, including premature
ventricular contractions, decreased blood pressure and sensitization of the heart to
epinephrine-induced arrhythmias, leading possibly to cardiac arrest (U.S. EPA, 1985; ATSDR,
1990). Acute exposure to minimal concentrations of 1,1,1-trichloroethane did not produce
respiratory or lung volume effects (Dornette, 1960; Torkelson et al., 1958).
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MAMMALIAN TOXICOLOGICAL PROFILE
Similar effects as noted above are observed in animals exposed to 1,1,1-TCA In addition,
animal experiments investigating the influence of 1,1,1-TCA on liver and kidney function
yield conflicting results highly dependent on species, doses, and treatment schedules. Fatty
changes in rodent livers following exposure by inhalation have been reported (U.S. EPA,
1985).
GENOTOXICITY
No studies were located regarding genotoxic effects in humans or animals following exposure
to 1,1,1-trichloroethane (ATSDR, 1990). Evidence for or against an association between
exposure to 1,1,1-TCA and cancer in humans has not been reported. Animal studies fail to
provide any definitive link between exposure and carcinogenicity (ATSDR, 1990).
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TRICHLOROETHYLENE
GENERAL BACKGROUND INFORMATION
Trichloroethylene (TCE) is widely used as an industrial solvent, particularly in metal
degreasing, which consumes about 90% of TCE produced annually in the U.S. TCE is also
used for dry-cleaning, as a low-temperature heat exchange fluid, as a fumigant, as a diluent
in paints and adhesives, in aerospace operations, and in textile processing. Previously, TCE
was used as an extractant in food-processing. These uses were discontinued in 1975 due to
evidence of possible carcinogenic activity. Its earlier use in anesthetics was also discontinued
(IRP, 1985).
PHARMACOKINETICS
Absorption of TCE from the gastrointestinal and respiratory tracts is extensive. TCE is
extensively metabolized in humans to trichloroethanol, trichloroethanol glucuronide, and
trichloroacetic acid. Although the liver is the primary site of TCE metabolism, there is
evidence for extrahepatic metabolism in the lungs and kidneys (ATSDR, 1988).
HUMAN TOXICOLOGICAL PROFILE
TCE is assumed to be responsible for the deaths of four men employed at degreasing
operations using TCE as the solvent (Kleinfeld and Tabershaw, 1954). Toxicological analysis
revealed TCE in varying concentrations in various tissues. Kleinfeld and Tabershaw (1954)
reported that, despite treatment, a man died 11 days after he accidentally drank an unknown
quantity of TCE. TCE has been shown to affect the central nervous system. Short-term
exposure to high concentrations ofTCE caused dizziness, headache, nausea, confusion, facial
numbness, blurred vision, and, at very high levels, unconsciousness. Longer exposures cause
ataxia, decreased appetite, sleep disturbances, and trigeminal neuropathy (U.S. EPA, 1985).
Information regarding hepatotoxicity in humans is limited and derived from acute
overexposures. U.S. EPA (1985) has concluded that it is unlikely that chronic exposure to
trichloroethylene at concentrations found or expected in ambient air would result in liver
damage.
MAMMALIAN TOXICOLOGICAL PROFILE
In laboratory animals, the acute toxicity of trichloroethylene is low. Oral LD^ values of 4920
mg/kg in the rat, 3200 mg/kg in the mouse and 2800 mg/kg in the dog have been reported.
In a study by Baker (1958), several dogs died within 20 minutes of being exposed to TCE at
30,000 ppm. Rats exposed to 20,000 ppm for 5 hours died (Adams, 1951). A 2-year study
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in rats conducted by the NTP (1986a) showed decreased survival due to TCE treatment.
Deaths were attributed to toxic nephrosis. Behavioral changes were observed in rats at TCE
vapor concentrations as low as 100 ppm (Silverman and Williams, 1975). Liver enlargement
is the most commonly observed hepatic effect seen in TCE-exposed animals (Kjellstrand et
al., 1983). Mice, especially males, appear to be particularly sensitive to the hepatotoxic
effects of TCE. The only reproductive effects observed were reduced testis and epididymis
weights in rats exposed to dietary TCE (NTP, 1986b). There were no effects of reproductive
system histology, fertility, or other reproductive performance parameters in treated males
or females in these studies.
GENOTOXICITY
Perocco and Prodi (1981) found positive results for unscheduled DNA synthesis both with
and without metabolic activation in human lymphocytes in vivo. Another study reported a
significant increase in sister chromatid exchange in six workers exposed to TCE (Gu et al.,
1981). In vitro mutagenicity tests in bacteria, yeasts, and molds demonstrated weak positive
responses. Most of these tests required metabolic activation of the compound (Crebelli et
al., 1985). TCE has been shown to be carcinogenic in animals. Inhalation and oral exposure
produced liver and lung tumors in mice and kidney adenocarcinomas, testicular Leydig cell
tumors, and possibly leukemia in rats. These studies are deemed sufficient to place TCE in
CAG classification B2, probable human carcinogen (U.S. EPA, 1987). Further support that
TCE is a probable human carcinogen comes from studies that indicate that metabolism is
qualitatively similar in humans and test animals (U.S. EPA, 1987). The available
carcinogenicity studies indicate that mice are more susceptible to TCE carcinogenicity than
the rat. Factors contributing to this difference may be an increased rate of metabolic
conversion to trichloracetic acid in mice, and the more pronounced trichloroacetic acid-
mediated peroxisomal proliferation and cell proliferation in mice (Elcombe et al., 1985). The
peroxisomal proliferation may lead to an increase in the reactive oxygen species and DNA
damage, which may lead to hepatocellular carcinoma.
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VINYL CHLORIDE
GENERAL BACKGROUND INFORMATION
About 90% of the vinyl chloride produced in the U.S. is used to manufacture polyvinyl
chloride (PVC) and other vinyl polymers. The remainder is used to synthesize
1,1,1-trichloroethane. The major uses ofPVC are in the building and construction industries,
in consumer goods, packaging and electrical wire insulation. PVC is also used in packaging,
such as plasticized film, bottles and bottle-cap liners and gaskets (IRP, 1985).
PHARMACOKINETICS
Respiratory and gastrointestinal absorption of vinyl chloride is rapid and nearly complete.
Distribution may be widespread with the highest concentration of the parent compound
located in the fat. Metabolism and excretion occur rapidly. The highest levels of excretory
products are located in the liver and kidney (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Several epidemiologic studies have associated occupational exposure with impaired liver
function and biochemical or histological evidence of liver damage (U.S. EPA, 1985a,b).
Symptoms and signs of liver disease associated with occupational exposure to vinyl chloride
include pain or discomfort, hepatomegaly, portal hypertension, thrombocytopenia, esophageal
varices (Lee et al., 1977). Acute toxicity at high levels has resulted in lethality among
occupationally exposed workers. Death appeared to be due to narcosis (U.S. EPA, 1985a).
Acute inhalation exposure to high levels of vinyl chloride leads to CNS effects. Exposures
to 8,000 to 20,000 ppm have been associated with dizziness, giddiness, euphoria, ataxia,
headache, and narcosis (Nicholson et al., 1975; Lester et al., 1963). Dinceva et al. (1985)
reported electroencephalogram changes that they thought were indicative of early evidence
of neurotoxicity in workers exposed to vinyl chloride along with other organic solvents. Vinyl
chloride disease is the name given to the total clinical syndrome associated with occupational
exposure. It includes a syndrome known as acroosteolysis or dissolution of the ends of the
distal phalanges of the hands, circulatory disturbance in the extremities, Raynaud syndrome,
scleroderma, hematologic effects, and lung and liver effects (ATSDR, 1989).
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MAMMALIAN TOXICOLOGICAL PROFILE
Patty et al. (1930) reported that narcosis and death occurred within 30 to 60 min in guinea
pigs exposed to 10% vinyl chloride. U.S. EPA (1985a) reviewed a number of acute studies
in animals and reported 2 hour LC^ values ranging from 117 to 500 ppm for mice to 230 to
800 ppm for rabbits. Liver injury is observed in chronically-exposed animals. A study by the
Dow Chemical Company (1984) in rats chronically-exposed to vinyl chloride through
inhalation established 0.13 mg/kg/day as NOAEL, and 1.3 mg/kg/day as a LOAEL for
hepatotoxicity. Animals exposed orally or by inhalation manifest noncancerous liver effects
similar to those seen in humans; but other effects seen in humans, such as acroosteolysis,
Raynaud syndrome, and scleroderma, have not been reproduced in animals (ATSDR, 1989).
GENOTOXICITY
Vinyl chloride is mutagenic in S. typhimurium in numerous studies (ATSDR, 1989). Vinyl
chloride was positive for recessive lethal effects but negative for dominant lethal effects,
chromosomal translocation, and sex chromosome loss in D. melanogaster (Verburgt and
Vogel, 1977). Positive results were obtained in mutation and cell transformation tests and
in chromosomal aberration tests in vivo and in vitro mammalian systems (Styles, 1977; Laib
et al., 1985; Anderson and Richardson, 1981). Genotoxicity studies of vinyl chloride in
humans include a large number of chromosomal aberration tests in the peripheral
lymphocytes of occupationally exposed workers. These tests have all been positive (ATSDR,
1989). Anderson et al. (1980) observed an increase in lymphocytes with chromosomal
aberrations at exposure levels estimated at 50 ppm.
Maltoni and associates (1981) conducted vinyl chloride carcinogenicity studies in animals.
They exposed rats, mice and hamsters for 4 hours/day, 5 days/week for one year to vapor
concentrations of 1 ppm to 30,000 ppm or to 0.03 to 50 mg\kg bw vinyl chloride in olive oil
by ingestion, 5 days/week for one year. Liver angiosarcomas were observed in all the animals
tested. Bi et al. (1985) exposed adult male Wistar rats to 0, 10, 100, or 3000 ppm,
6 hours/day, 6 days/week for up to 12 months to evaluate effects on the testes. Relative
testicular weight was significantly reduced at 100 or 3000 ppm. Vinyl chloride workers are
at increased risk for developing cancer. Liver angiosarcomas, brain, skin and lung tumors,
and tumors of the lymphatic and blood-forming systems are some of the cancers seen in
exposed workers (Tamburro, 1984). Individuals residing near PVC processing plants may also
be at risk. Five cases of angiosarcoma of the liver were diagnosed in persons living in the
vicinity of vinyl chloride fabrication and polymerization plants for 8 to 62 years prior to the
diagnosis of the disease (U.S. EPA, 1980).
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XYLENES
GENERAL BACKGROUND INFORMATION
Xylenes are colorless liquid organic molecules with a sweet odor and a high degree of lipid
solubility. There are three isomers of xylene: meta- ortho- and para-xylene (m-, o- and
p-xylene, respectively). The term "total xylenes" is used to designate a mixture of the three
possible isomers, in any proportions. They are commonly used as industrial solvents, as
components of paints, varnishes, cleaners, degreasers and gasoline and as chemical
intermediates in the manufacture of other chemicals, plastics and synthetic fibers. Xylenes
are volatile molecules and therefore, evaporate quickly. They are also flammable and may
pose a fire hazard if handled improperly (ATSDR, 1990).
PHARMACOKINETICS
Xylenes are readily absorbed by all routes of exposure (see section on Relative Absorption
Factors). Xylenes are very soluble in blood and therefore are absorbed easily into the
systemic circulation during exposure (Astrand, 1982). Following absorption, distribution
occurs rapidly to all organs, including fetal tissue, with greatest distribution occuring to
organs having a high lipid content, such as adipose tissue, bone marrow and brain (Astrand,
1982; Engstron and Bjurstrom, 1978; Riihimaki et al., 1979). In humans, xylenes are
primarily metabolized by the mixed function oxidase enzyme system to methylbenzyl alcohols
which are further oxidized by alcohol and aldehyde dehydrogenase to yield methyl benzoic
acids. The acids are readily conjugated and excreted in urine (Fishbein, 1985). In addition,
a small percentage (3-6%) is exhaled unchanged due to the volatile nature of these
compounds.
HUMAN TOXICOLOGICAL PROFILE
Human data suggests that the three xylene isomers all produce qualitatively similar effects,
although the individual isomers are not necessarily equal in potency with regard to a given
effect (ATSDR, 1990). Exposure, by any route, results in primarily central nervous system
effects that may include headaches, nausea, mental confusion, narcosis, impaired learning
and memory, dizziness, tremors, unconscienceness and coma, depending on dose and length
of exposure. High doses may result in death. The respiratory system may also be a target
of xylene toxicity in humans, producing respiratory tract irritation, pulmonary edema and
inflammation after inhalation. Ocular irritation may result following exposure to xylene
vapors. Skin irritation, dryness and scaling may result following dermal exposure. Limited
data are available concerning effects of exposure on the hepatic, renal, cardiovascular,
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musculoskeletal or hematological system. Insufficient information is available regarding the
developmental and reproductive toxicity of xylenes in humans.
MAMMALIAN TOXICOLOGICAL PROFILE
Exposure to xylenes produces similar effects in humans and laboratory animals. The central
nervous system is the primary target for both short-term and long-term exposures.
Respiratory effects are observed following inhalation exposure. Data from animal studies
provide limited evidence that xylene may produce cardiovascular effects (arrhythmias, atrial
fibrillation and alterations in blood vessels and blood flow) (Morvai et al., 1976, 1987), hepatic
effects (enzyme induction, increased liver weight, ultrastructural alterations) (Condie et al.,
1988; Elovaara et al., 1980; Elovaara, 1982) and renal effects (enzyme induction, renal
atrophy, tubular alterations) (Condie et al., 1988; Elovaara, 1982; Toflgard and Nilsen, 1982).
These results suggest that humans might be at increased risk of developing such effects
following exposure. Findings in animal studies suggest that xylenes may produce
developmental defects including increased fetal death, decreased fetal weight, delayed
skeletal development and gross anomalies (Marks et al., 1982; Ungvary et al., 1980). No
animal data exists suggesting effects on reproductive organs, the musculoskeletal system or
hematological system.
GENOTOXICITY
Xylenes have been tested for genotoxicity in a variety of in vitro and in vivo assays. Results
of the various assays indicate that xylenes are nongenotoxic following in vitro and in vivo
exposure (ATSDR, 1990). No evidence of carcinogenicity exists in humans or laboratory
animals (ATSDR, 1990).
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ZINC
GENERAL BACKGROUND INFORMATION
Zinc is used most commonly as a protective coating for other metals and in alloys such as
bronze and brass. Zinc is emitted to the atmosphere during mining and refining,
manufacturing processes, and combustion of zinc-containing materials. Zinc is an essential
trace element in nutrition and is found in many foods (ATSDR, 1989).
PHARMACOKINETICS
It has been reported that about 20 to 30 percent of ingested zinc is absorbed and the
mechanism may be homeostatically controlled and carrier-mediated. When zinc levels in the
body are sufficient to sustain normal physiological functions, zinc absorption decreases.
Absorption occurs by the inhalation and dermal routes as well. Once absorbed, zinc is
distributed throughout the body where it is used as an essential cofactor in many enzyme
systems. Excretion occurs primarily through the feces (ATSDR, 1989).
HUMAN TOXICOLOGICAL PROFILE
Zinc compounds are of relatively low toxicity by ingestion. In humans, exposure to 2 g or
more of zinc produces symptoms of fever, nausea, vomiting, stomach cramps, and diarrhea
3-12 hours after ingestion. Zinc chloride is a primary component of smoke bombs, and
pathologic changes in humans due to acute inhalation exposure to ZnCl include laryngeal,
tracheal, and bronchial mucosal edema and ulceration, interstitial edema, interstitial fibrosis,
alveolar obliteration and bronchiolitis obliterans. Severe acute injury is associated with a
high mortality (Matarese and Matthews, 1986). Metal fume fever results from occupational
inhalation of freshly formed fumes of zinc oxides. It is characterized by transient chills and
fever, profuse sweating, and weakness some hours after exposure. The fumes usually consist
of extremely fine particles containing other metals in addition to zinc. The very small size
(submicronic) of the fume particles with their potential for alveolar deposition is thought to
be an important aspect of this phenomenon. It has generally been estimated that fume fever
does not occur at zinc oxide levels less than 15 mg/m3 although some occurrence of fume
fever has been reported at levels as low as 5 mg/m3 . This occupational hazard is not
considered to be a general public health problem (U.S. EPA, 1987a; U.S. EPA, 1987b).
Poorly ionized zinc compounds have low dermal toxicity and have been used therapeutically
and cosmetically for many years as mild astringents, antiseptics and perspirants (Gilman et
al., 1985).
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MAMMALIAN TOXICOLOGICAL PROFILE
The highly ionizable zinc salts such as zinc chloride can be acutely toxic. Acute toxicity in
laboratory animals was reported to be 250 mg/kg (LDL0) for the guinea pig. A TC,^ of
4800 mg/m3 for 30 minutes was calculated for humans (Clayton and Clayton, 1981).
Zinc has a low oral chronic toxicity. In a study involving dogs and cats, 175 to 1000 mg/kg
per day of ZnO, administered orally for 3 to 53 weeks, was tolerated. Some of the dogs
showed glucosuria and some of the cats showed fibrous degeneration of the pancreas. A
number of other animal feeding studies demonstrate the low oral toxicity of zinc (Clayton
and Clayton, 1981; U.S. EPA, 1987a).
Generally adverse but minor effects have been demonstrated in guinea pigs inhaling large
amounts (1-5 mg/m3) of zinc oxides (Lam et al., 1982,1985; Amdur et al., 1982). Lam et al.
(1985) measured pulmonary function in guinea pigs exposed to zinc oxide fume at 5 mg/m3
three hours daily for a period of six days. Vital capacity, functional residual capacity, alveolar
volume, and single breath diffusive capacity for carbon monoxide decreased following the
final exposure and did not return to normal after 72 hours. Flow resistance increases, and
decreases in compliance and total lung capacity returned to normal after this period.
Fibroblasts in interstitial infiltrates (including a fibrotic reaction) were observed. It was
concluded that pulmonary changes may occur with relatively few exposures at the workplace
threshold limit value.
Zinc does not appear to be teratogenic except perhaps at very high doses; intraperitoneal
injections of relatively large doses (20 mg/kg) in mice during pregnancy results in some
malformations in fetal ossifications (Chang et al., 1977).
GENOTOXICITY
Various studies have indicated that zinc is not mutagenic. In vitro analyses of zinc chloride
demonstrated that the fidelity ofDNA synthesis was unaffected (Sirover and Loeb, 1976a,b;
Miyaki et al., 1977). Zinc industry employees have shown a greater number of chromosomal
aberrations in peripheral blood lymphocytes than did controls (Bauchinger et al., 1976).
However, these workers were also exposed to other agents known to cause chromosome
structural alterations (Leonard, 1985). There is no evidence that the inhalation, ingestion
or parenteral administration of zinc induces the formation of tumors.
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APPENDIX C
RELATIVE ABSORPTION FACTORS
(RAFs)
THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK
RELATIVE ABSORPTION FACTORS
(RAFs)
The derivation of a Relative Absorption Factor (RAF) for a chemical by a specific route
and medium of exposure involves two basic steps:
(1) the identification of derived route- and medium-specific absorption efficiencies from the literature for the
chemical and
(2) the comparison of the absorption efficiency by the route and medium of exposure with the absorption
efficiency by the route and medium in the study used as the basis for the derivation of the toxicity value.
The identification of the route- and medium-specific absorption efficiencies was
accomplished through a literature search and data collection exercise.
For the oral route of exposure, the highest reported absorption efficiency for the
medium of interest was taken as the most appropriate value.
For the dermal route of exposure, a 24-hour, non-occluded exposure was selected as
the most appropriate scenario. All the dermal absorption efficiencies were
adjusted to comply with this selection.
For the inhalation route of exposure, the steady state or equilibrium absorption
efficiency was selected as the most appropriate value as the exposure scenarios of
interest in the Residential ShortForm are not acute in nature.
When no data existed for the specific medium of interest, a value was selected from the
literature which was derived by the same route (but different medium). When no data
existed for the specific route in question, the absorption efficiency for a different
substance with similar chemical and physical properties was used.
Once the appropriate route- and medium-specific absorption efficiencies were obtained,
the toxicity values were examined and the RAFs were derived.
When the toxicity value represents an APPLIED dose (or concentration), the RAF is
calculated as the ratio of the absorption efficiency by the route and medium of the
exposure scenario of interest and the absorption efficiency by the route and
medium of the study used as the basis for the derivation of the toxicity value.
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When the toxicity value represents an ABSORBED dose (or concentration), the RAF
is simply the absorption efficiency of the chemical by the route and medium of
concern.
The risk assessor is referred to the following documents for a more detailed discussion of
the Relative Absorption Factor.
Guidance for Disposal Site Riak Characterization and Related Phase II Activities - In Support of the Massachusetts
Contingency Plan, Massachusetts Department of Environmental Quality Engineering [Policy No. WSC/ORS-141-89]
(1989) APPENDIX B.
Risk Assessment Guidance For Superfund: Volume I - Human Health Evaluation Manual (Part A). U.S.
Environmental Protection Agency, Office of Emergency and Remedial Response [EPA 540/1-89/002] (December
1989) APPENDK A.
The following pages describe the derivation of the
Relative Absorption Factors for each of the
chemicals contained in the Residential ShortForm
These values will be updated periodically, and the risk
assessor should use the most current values.
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The following table of references is reproduced from Table VII- 1, and is included here to
support the chemical specific toxicity information which appear at the beginning of each
of the following sections and which are used to develop the RAFs.
References for the
ShortForm Toxicity Values
Reference # Description
1. U.S. EPA Integrated Risk Information System (IRIS). On-line search: current as of
September 2, 1992.
1m.. The oral Carcinogenic Potency Value from IRIS is used as a dermal CPV.
I.e. The chronic inhalation RfC (from IRIS) has been used here as a subchronic inhalation RfC
equivalent.
Id. This toxicity value for CHROMIUM is taken from the IRIS file for hexavalent chromium
(Cr VI).
I.e. The chronic oral RfD (from IRIS) has been used here as a subchronic oral RfD equivalent.
l.f. This oral Carcinogenic Potency Value equivalent for arsenic is back-calculated from a drinking
water Unit Risk value from IRIS.
l.g. This Carcinogenicity Potency Value or Unit Risk for benzo[a]pyrene (from IRIS) has been
applied to the seven PAH compounds which are designated as category A, Bl, B2 or C
carcinogens.
2. U.S. EPA Health Effects Assessment Summary Tables (HEAST), Annual FY- 1992.
[OERR 9200.6-303 (92-1), NTIS No. PB92-921199] March, 1992.
2a. The oral Carcinogenic Potency Value from HEAST is used as a dermal CPV.
2.b. This subchronic oral RfD (from HEAST) for naphthalene has been used as the subchronic oral
RfD equivalent for all PAH compounds for which subchronic oral RfDs are unavailable.
2.c. The chronic inhalation RfC (from HEAST) has been used here as a subchronic inhalation RfC
equivalent.
2.d. The chronic oral RfD for food (from HEAST) has been used as the oral RfD for ^Hminm
2.e. The chronic oral RfD for *»Hmiiim (from HEAST) has been used here as a subchronic oral RfD
equivalent.
2.f. The chronic oral RfD for naphthalene (from HEAST) has been used as the chronic RfD
equivalent for ail PAH compounds for which chronic oral RfDs are unavailable.
2.g. This toxicity value for CHROMIUM (taken from HEAST) is for hexavalent chromium (Cr VI).
2.h. This Carcinogenic Potency Value or Unit Risk was taken from a fact sheet distributed by the
U.S. EPA Superfund Health Risk Technical Support Center at ECAO-Cincinnati.
2.i. The oral Carcinogenic Potency Value (from the ECAO -Cincinnati fact sheet) is used as a dermal
CPV.
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3. Allowable Threshold Concentrations (ATCs) from MA DEQE (1989a), Guidance for Disposal Site
Risk Characterization and Related Phase U Activities - In Support of the Massachusetts
Contingency Plan, Appendix J.
3.a. The chronic inhalation ATC (from MA DEQE, 1989a) has been used here as a subchronic
inhalation ATC equivalent.
3.b. The ATC for "total concentration of naphthalene and 2-methylnaphthalene'' is used here as the
ATC for this chemical.
3.c. The chronic inhalation ATC for naphthalene has been used as the chronic inhalation RfC
equivalent for all PAH compounds for which chronic inhalation RfCs are unavailable.
3.d. The chronic inhalation ATC for naphthalene has been used as the subchronic inhalation RfC
equivalent for all PAH compounds for which subchronic RfCs are unavailable.
4. Developed for the Residential ShortForm by MA DEP staff. Documentation of this value may be
found in APPENDIX D.
NC Not Considered to be Carcinogenic by this Exposure Medium
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ACENAPHTHENE CAS #: 83329
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.6 mg/kg/day (2)
Chronic Oral Reference Dose: 0.06 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on oral or dermal inhalation route. Assume
same as B[a]P.
The oral and dermal chronic reference dose for acenaphthene is based on an oral gavage
study in mice. In this study, an applied dose was used.
ACENAPHTHENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for acenaphthene is based on an oral
gavage study in mice. In this study, an applied dose was used.
ACENAPHTHENE RAFs
Evaluation of Subchronic Exposures
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ACENAPHTHYLENE CAS #: 208968
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on oral or dermal route. Assume same as
B[a]P.
The oral and dermal chronic reference dose for acenaphthylene is based on an oral
naphthalene gavage study in rats. In this study, an applied dose was used.
ACENAPHTHEYLNE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for acenaphthylene is based on a
naphthalene oral gavage study in rats. In this study, an applied dose was used.
ACENAPHTHEYLNE RAFs
Evaluation of Subchronic Exposures
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ANTHRACENE CAS #: 120127
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 3 mg/kg/day (2)
Chronic Oral Reference Dose: 0.3 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on oral or inhalation route. Assume same as
B[a]P.
Percutaneous absorption of
14
C-anthracene was estimated to be 52% of the applied dose
(Yang et al., 1986). Assume this is reduced by 50% (to 26%) when compound is applied as
a complex environmental mixture.
Yang, JJ., Roy, TA and Mackerer, C.R. (1986) Percutaneous Absorption ofAnthracene in the Rat: Comparison of
in Vivo and in Vitro Results. ToxicoL Ind. Health. 2:79-84.
The oral and dermal chronic reference dose for anthracene is based on an oral gavage
study conducted in mice. In this study, an applied dose was used.
ANTHRACENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for anthracene is based on an oral gavage
study conducted in mice. In this study, an applied dose was used.
ANTHRACENE RAFs
Evaluation of Subchronic Exposures
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ARSENIC CAS#: 7440382
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.0003 mg/kg/day (2)
Chronic Oral Reference Dose: 0.0003 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 1.8 (mg/kg/day)"1 (If)
Inhalation Cancer Unit Risk: Not Volatile
Human studies support the assumption that the soluble salts of inorganic arsenic are
almost completely absorbed by the oral route. Literature sources cite an absorption
efficiency of 98% for arsenic in humans and laboratory animals (Vahter, 1983; EPA, 1984,
1985; Goyer, 1986).
Vahter, M. (1983) Metabolism ofArsenic. In: Fowler, B.A., ed. Biological and Environmental Effect of Arsenic . New
York: Elsevier, pp. 171-198.
U.S. Environmental Protection Agency (U.S. EPA) (1985) Health Advisories for 52 Chemicals Which Have Been
Detected in Drinking Water. PB86- 118338.
U.S. Environmental Protection Agency (U.S. EPA) ( 1984) Health Assessment Document for Inorganic Arsenic . Final
report. Research Triangle Park, NC: Environmental Protection Agency. EPA 600/8-83-02 IF.
Goyer, R.A. (1986) Casarett and Doull's Toxicology . (CD. Klaassen, M.O. Amdur and J. Doull, Eds.) 3rd ed., pp.
582-635, MacMillan, New York.
No quantitative studies were located to evaluate the dermal absorption of arsenic
compounds. However, clinical symptoms of arsenic poisoning have been reported in
humans after accidents where the only route of exposure was through the skin,
suggesting that dermal absorption does occur. An absorption efficiency of 3% may be
considered a conservative upper-bound based on EP toxicity studies where the extraction
of arsenic from soil (Ph 5, 24 hours) averaged 3%.
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The oral and dermal cancer potency value for arsenic is based on a drinking water
ingestion study in humans. In this study, an applied dose was used.
ARSENIC RAFs
Evaluation of Carcinogenicity
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The oral and dermal chrome reference dose for arsenic is based on a drinking water
ingestion study in humans. In this study, an applied dose was used.
ARSENIC RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for arsenic is based on a drinking water
ingestion study in rats. In this study, an applied dose was used.
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Evaluation of Subchronic Exposures
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BENZENE CAS^ 71432
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.05 mg/kg/day (4)
Chronic Oral Reference Dose: 0.005 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: 32 /ig/ms (4)
Chronic Inhalation Reference Concentration: 9 Mg/m9 (3)
Oral Cancer Potency Factor: 0.029 (mg/kg/day)"1 (1)
Inhalation Cancer Unit Risk: 0.0000083 (/zg/m3)* 1 (1)
The oral absorption efficiency of pure benzene is estimated to be essentially 100% based
on rabbit data in which 100% of an oral dose was either metabolized or exhaled
unchanged (Sabourin et al., 1986). The oral bioavailability of benzene was slightly but not
significantly increased by adsorption to clay soil (Turkall, et al., 1988). Human (Parke
and Williams, 1953) and animal studies suggest that virtually all (100%) of an oral dose of
benzene is absorbed.
Parke, D.V. and Williams, R.T. (1953) Studies in Detoxication. 49. The Metabolism ofBenzene Containing [**€]
Benzene. Biochem. J. 54:231-238.
Sabourin, P., Chen, B., Henderson, R. Lucier, G. and Birnbaum, L. (1986) Effect ofDose on Absorption and
Excretion of^C-Benzene Administered Orally or by Inhalation. The ToxicologisL 6: 163.
Turkall, R.M., Skowronski, G., Gerges, S., Von Hagen, S. and Abdel-Rahmen, M.S. (1988) Soil Adsorption Alters
Kinetics and Bioavailability ofBenzene in Orally Exposed Male Rats. Arch. Environ. Contam. ToxicoL 17:159-
164.
For dermal absorption, the controlling factor is contact time with the skin. One study
(Susten et al., 1990) estimated the non-occluded dermal absorption of benzene in hairless
mice to be approximately 1% of the applied dose in 4 hour (or 6% in 24 hours), with
volatilization occurring rapidly. In a second study (Susten et al., 1985), the dermal
absorption efficiency (non-occluded) of benzene was 1% of the applied dose in 2.5 hours
(or 10% in 24 hours). In an occluded study (Lam and Bisgaard, 1989), the dermal
absorption efficiency of 1,3-diaminobenzene was 100% of the applied dose in 24 hours for
aqueous solutions and hydrogen peroxide-based solutions of this benzene analog. This
suggests that the dermal absorption of benzene is highly dependent on whether an
occluded or non-occluded study design is utilized. An average non-occluded dermal
absorption efficiency (24 hour) of 10% was selected as a protective estimate from these
studies while an occluded 24-hr dose would be absorbed 100%. The dermal bioavailability
of benzene was slightly reduced by its adsorption to soil (Skowronski, et al., 1988). The
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dermal absorption efficiency of soil-adsorbed benzene was estimated to be approximately
12% in 36 hours (8% in 24 hours) in a non-occluded study.
Agency for Toxic Substances and Disease Registry (ATSDR) (1989) Toxicological Profile for Benzene . Agency for
Toxic Substances and Disease Registry, U.S. Public Health Service, pp. 36-38.
Skowronski, GA, Turkall, R.M. and Abdel-Rahman, M.S. (1988) Soil Adsorption Alters Bioavailability ofBenzene in
Dermally Exposed Male Rats. Am. Ind. Hyg. Assoc J. 49:506-511.
Susten, A.S., Niemeier. R.W. and Simon, S.D. (1990) In Vivo Percutaneous Absorption Studies of Volatile Organic
Solvents in Hairless Mice II. Toluene, Ethylbenzene and Aniline. J. AppL ToxicoL 10:217-225.
ljtm
i H.R. and Bisgaard, H.C. (1989) Percutaneous Absorption, Biotransformation, Retention and Excretion of 1,3-
Diaminobenzene in the Rat. Fd. Chem. ToxicoL 27:741-749.
The oral and dermal cancer potency value for benzene was derived from a human
inhalation study. In this study, an absorbed dose was used. The RAFs for all scenarios
are therefore the absorption efficiencies of benzene by the route in question.
BENZENE RAFs
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The oral and dermal chronic reference dose for benzene was derived from an animal
inhalation study. An absorption efficiency of 50% was used to calculate an absorbed dose.
The RAFs for all pathways are the absorption efficiencies of benzene by the route in
question.
BENZENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for benzene was derived from an animal
inhalation study. An absorption efficiency of 50% was used to calculate an absorbed dose.
The RAFs for all scenarios are the absorption efficiencies of benzene by the route in
question.
BENZENE RAFs
Evaluation of Subchronic Exposures
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BENZO[a]ANTHRACENE CAS #: 56553
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day)"1 (lg)
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on oral or dermal route. Assume same as
B[a]P.
The oral and dermal cancer potency value for benzo[a]anthracene is based on a dietary
study in which B[a]P was administered to mice. In this study, an applied dose was used.
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The oral and dermal chronic reference dose for benzo[a]anthracene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
BENZO[a]ANTHRACENE RAFs
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The oral and dermal subchronic reference dose for benzo[a]anthracene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
BENZO[a]ANTHRACENE RAFs
Evaluation of Subchronic Exposures
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BENZO[a]PYRENE CAS #: 50328
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day)"1 (1)
Inhalation Cancer Unit Risk: Not Volatile
The oral absorption of 14C-labeled B[a]P, dissolved in peanut oil and administered by
gavage, was studied in rats (Hecht et al., 1979). Absorption was determined by recovery
of label in urine and feces. Unchanged B[a]P recovered in feces was estimated at 9% of
the total dose, with all other fecal radioactivity (85% of applied dose) recovered as
metabolites. This suggests an oral absorption efficiency of 91%.
Hecht, S.S., Grabowski, W. and Groth, K. (1979) Analysis ofFeces for B[a)P After Consumption of Charcoal-Broiled
Beef by Rats and Humans. Food CosmeL Toxicol. 17:223-227.
The percutaneous absorption of 14C-B[a]P was studied in vivo in Swiss Webster mice
(Sanders et al., 1986) and in Sprague-Dawley rats (Yang et al., 1986). Absorption was
determined by analyzing radioactivity in urine, feces and tissues, and by analysis of
residual label at the site of application. Dermal absorption efficiency was measured as
40% (in mice) and 6% (in rats) in 24 hrs. The higher value of 40% is selected as a
protective estimate for human dermal exposure to pure compound. In vitro estimates are
lower, ranging from 0.1%-15% in humans and animals (Kao et al., 1985; Kao et al., 1988)
and are not considered applicable to human exposure. The in vivo percutaneous
absorption of soil-adsorbed B[alP was determined in rats by Yang et al. (1989). The range
of absorbed doses was 1.3% - 9.2% depending on the amount of soil applied. More
efficient absorption occurred at lower soil application rates. Wester et al. (1990) confirms
a low absorption for soil-associated B[a]P in the rhesus monkey with a range of 9% - 18%.
The upper limit of 18% is selected as a protective estimate for human exposure to B[a]P
contaminated soil.
Kao, J., Hall, J. and Helman, G. (1988) In Vitro Percutanous Absorption in Mouse Skin: Influence of Skin
Appendages. ToxiooL AppL Pharmacol. 94: 93-103.
Kao, J.K., Patterson, FJL, and Hall, J. (1985) Skin Penetration and Metabolism of Topically Applied Chemicals in
Six Mammalian Species, Including Man: An In Vitro Study With Benzo(a)pyrene and Testosterone. ToxiooL AppL
PhamaooL 81:502-518.
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Sanders, C.L., Skinner, C. and Gelman, R.H. (1986) Percutaneous Absorption of 7,10 —C-Benzo[a]pyrenc and 7,12
14
^C-Dimethylbenzla]anthracene in Mice. JEPTO 2:25-34.
Wester, R.C., Maibach, HJ., Bucks, DAW., Sedik, L., Melendres, J., Liao, C. and DiZio, S. (1990) Percutaneous
Absorption ofpCJDDT and p*C]Benzo[aJpyrene from Soil. Fund. AppL Toxicol. 15:510-516.
Yang, JJ., Roy, TA. and Mackerer, C.R. (1986) Percutaneous Absorption ofBenzolajpyrene in the Rat. Comparison
of In Vivo and In Vitro Results. Toxicol. Ind. Health 2:409-416.
Yang, JJ., Roy, TA., Krueger, AJ., Neil, W. and Mackerer, CJl. (1989) In Vitro and In Vivo Percutaneous
Absorption of Benzolajpyrene From Petroleum Crude-Fortified Soil in the Rat. BulL Environ. Contarn. ToxiooL
43:207-214.
The dermal penetration of B[a]P, applied as a complex organic mixture, seems to be
representative of the dermal penetration of other PAHs examined in this study (Dankovic
et al., 1989) including pyrene, benzanthracene, benzofluorene, methylchrysene, chrysene,
benzofluoranthene and benzo[e]pyrene. The dissapperance half-life of B[a]P was 6.7
hours with the other PAHs ranging from 5.0 - 8.8 hours. The dissappearance half-life of
B[a]P was decreased to 3 hours when pure B[a]P was applied to skin in acetone. These
data suggest a 50% decrease in dermal absorption of B[a]P when applied as an
environmental mixture (20%) rather than as neat compound (40%). This compares
closely with the upper limit of 18% dermal absorption efficiency selected from the study
of Wester et al.(1990) for soil-associated B[a]P.
Dankovic, DA., Wright, C.W., Zangar, R.C. and Springer, DX. (1989) Complex Mixture Effects on the Dermal
Absorption ofBenzo(a)pyrene and Other Polycyclic Aromatic Hydrocarbons From Mouse Skin. J. AppL ToxicoL
9:39-44.
The oral and dermal cancer potency value for benzo [a]pyrene is based on a dietary study
in mice. In this study, an applied dose was used.
BENZO[a]PYRENE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for benzo[alpyrene is based on a naphthalene
oral gavage study conducted in rats. In this study, an applied dose was used. The
chronic inhalation reference concentration for benzo[a]pyrene is based on a naphthalene
inhalation study in humans. In this study, an applied dose was used.
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The oral and dermal subchronic reference dose for benzo[alpyrene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
The subchronic inhalation reference concentration for benzo[a]pyrene is based on a
naphthalene inhalation study in humans. In this study, an applied dose was used.
BENZO[a]PYRENE RAFs
Evaluation of Subchronic Exposures
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BENZO[b]FLUORANTHENE CAS #: 205992
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day) (lg)
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on any route of exposure. Assume same as
B[a]P.
The oral and dermal cancer potency value for benzo[b]fluoranthene is based on a dietary
study in which B[a]P was administered to mice. In this study, an applied dose was used.
BENZO[b]FLUORANTHENE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chrome reference dose for benzo[b]fluoranthene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
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The oral and dermal subchronic reference dose for benzo[b]fluoranthene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
BENZO[b]FLUORANTHENE RAFs
Evaluation of Subchronic Exposures
SOIL
INGESTION
SOIL
DERMAL
WATER
INGESTION
VEGETABLE
INGESTION
0.91 0.18 0.91 0.91
0.91 0.18 = 0.91 = 0.91
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
C-24
BENZO[g,h,i]PERYLENE CAS #: 191242
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on any route of exposure. Assume same as
B[a]P.
The oral and dermal chronic reference dose for benzo[g,h,i]perylene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
BENZO[g,h,i]PERYLENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for benzo[g,h,ilperylene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
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BENZO[k]FLUORANTHENE CAS #: 207089
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day)"1 (lg)
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on any route of exposure. Assume same as
B[a]P.
The oral and dermal cancer potency value for benzo[k]fluoranthene is based on a dietary
study in which B[a]P was administered to mice. In this study, an applied dose was used.
BENZO[k]FLUORANTHENE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for benzo[k]fluoranthene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
BENZO[k]FLUORANTHENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for benzo[k]fluoranthene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
BENZO[k]FLUORANTHENE RAFs
Evaluation of Subchronic Exposures
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BIS(2-ETHYLHEXYL)PHTHAIATE CAS #: 117817
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.02 mg/kg/day (2)
Chronic Oral Reference Dose: 0.02 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 0.014 (mg/kg/day)"1 (1)
Inhalation Cancer Unit Risk: Not Volatile
.
14C-DEHP appears to be efficiently absorbed from the gastrointestinal tract of the rat
(Williams and Blanchfield, 1974). More than 90% of the radiolabel was excreted in urine.
Fecal excretion was not quantified, suggesting oral absorption is probably close to 100%.
A second study (Chadwick et al., 1982) demonstrated virtually complete absorption of 14C-
DEHP administered in the diet to F344 rats.
Chadwick, M., Bronfman, A.K. and Silveira, D.M. (1982) Dose-Dependence of and Effect of Prior Exposure on the
Metabolism of DEHP Administered in the Diet to Rats . Report to Chemical Manufacturers Association. Arthur D.
Little, Inc.
Williams, D.T. and Blanchfiels, B J. (1974) Retention, Excretion and Metabolism ofDEHP Administered Orally to the
Rat. BulL Environ. Contain. ToxicoL 11:371-387.
DEHP appears to be poorly absorbed through skin (Elsisi et al., 1985). Only 7% of an
occluded applied dose of
14C-DEHP was absorbed through shaved rat skin, as evidenced by
the appearance of radiolabel in urine, feces and tissues. In a semi-occluded study (Elsisi
et al., 1989), the shaved skin of F344 rats was exposed to
14
C-phthalates in ethanol and
covered with a perforated plastic cap. Radioactivity was monitored in urine and feces as
an index of excretion. Bis(2-ethylhexyl)phthalate was poorly absorbed with less than 2%
of the applied dose recovered in biological material (98% recovered at the site of
application). The value of 2% is selected as the most appropriate since the experimental
protocol most closely represents the human exposure scenario.
Elsisi, A. E., Carter, D. E. and Sipes, I. G. (1975). Dermal Absorption and Tissue Distribution of Phthalate Esters.
Toxioologist 5:246.
Elsisi, E., Carter, D.E. and Sipes, I.G. (1989) Dermal Absorption ofPhthalate Diesters in Rats. Fund. Appl.
ToxiooL12:70-77.
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The oral and dermal cancer potency value for bis(2-ethylhexyl)phthalate is based on an
oral feeding (dietary) study in mice. The toxicity value is based on an applied dose.
DEHPRAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference doses for DEHP is based on an oral feeding
(dietary) study in guinea pigs. In this study, an applied dose was used.
DEHPRAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference doses for DEHP is based on an oral feeding
(dietary) study in guinea pigs. In this study, an applied dose was used.
DEHPRAFs
Evaluation of Subchronic Exposures
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CADMIUM CAS #: 7440439
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.001 mg/kg/day (2e)
Chronic Oral Reference Dose: 0.001 mg/kg/day (2d)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
Human studies have measured the oral absorption efficiency of cadmium compounds with
a reported range of 1% - 7% (McLellan et al., 1978; Shaikh and Smith, 1980). The range
of reported oral absorption efficiencies in experimental animals is lower than in humans,
from 0.5% - 3% (Engstrom and Nordberg, 1979; Moore et al., 1973; Friberg et al., 1974).
Higher doses tend to be absorbed less efficiently as do doses administered in food or milk
,
when compared to aqueous doses. Iron deficiency has been observed to increase the oral
absorption of cadmium in humans and animals (ATSDR, 1989). Therefore, the upper-
bounds of 7% (humans) and 3% (animals) are selected as protective estimates.
Agency for Toxic Substances and Disease Registry (ATSDR) (1989) Toxicological Profile for Cadmium . Agency for
Toxic Substances and Disease Registry, U.S. Public Health Service, pp. 46-49,
Engstrom, B. and Nordberg, G.F. (1979) Dose-Dependence of Gastrointestinal Absorption and Biological Half-Time of
Cadmium in Mice. Toxicology 13:215-222.
Friberg, L., Piscator, M., Nordberg, G.F. and Kjelktrom, T. (1974) Cadmium in the Environment . 2nd ed. Boca
Raton, FL: CRC Press.
Mclellan, J.S., Flanagan, P.R., Chamberlain, MJ. and Valberg, L.S. (1978) Measurement of Dietary Cadmium
Absorption in Humans. J. Toxicol. Environ. Health 4:131-138.
Moore, W., Stara, JJ., Crocker, W.C., Malanchuk, M. and litis, R. (1973) Comparison of^Cd Retention in Rats
Following Different Routes ofAdministration. Environ. Res. 6:473-478.
Shaikh, ZA. and Smith, J.C (1980) Metabolism of Orally Ingested Cadmium in Humans. In: Holmstedt, B. et al.,
eds. Mechnnism« of Toxicity and Hazard Evaluation . Amsterdam: Elsevier/North-Holland, pp. 569-574.
Cadmium is poorly absorbed by the dermal route (ATSDR, 1989). An upper-bound
estimate of 1% is probably appropriate and protective for human exposure (see
chromium).
Agency for Toxic Substances and Disease Registry (ATSDR) (1989) Toxicological Profile for Cadmium . Agency for
Toxic Substances and Disease Registry, U.S. Public Health Service, pp. 46-49.
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The oral and dermal chronic reference dose for cadmium is based on an oral dietary study
in humans. In this study, an applied dose was used. The chronic inhalation reference
concentration for cadmium is based on an inhalation study in humans. In this study, an
applied dose was used.
CADMIUM RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for cadmium is based on an oral dietary
study in humans. In this study, as applied does was used.
CADMIUM RAFs
Evaluation of Subchronic Exposures
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CARBON TETRACHLORIDE CAS #: 56235
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.007 mg/kg/day (2)
Chronic Oral Reference Dose: 0.0007 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 430 Mg/m3 (3a)
Chronic Inhalation Reference Concentration: 430 ng/m* (3)
Oral Cancer Potency Factor: 0.13 (mg/kg/day)'1 (1)
Inhalation Cancer Unit Risk: 0.000015 (Mg/m3) 1 (1)
The oral absorption efficiency in animals is extensive. Studies have reported that 80-85%
of an administered dose is recovered in expired air (Marchand et al., 1970; Paul and
Rubinstein, 1963). This indicates that GI absorption is probably close to 100% since CC1<
is metabolized with metabolites appearing in urine and feces.
Marchand, C, McLean, S. and Plaa, GX. (1970) The Effect of SKF526A on the Distribution of Carbon Tetrachloride
in Rats. J. Pharmacol. Exp. Therap. 714:232-238.
Paul, B.B. and Rubenstein, D. (1963) Metabolism of Carbon Tetrachloride and Chloroform by the Rat. J.
Pharmacol. Exp. Therap. 141:141-148.
No studies were located containing quantitative information on the dermal absorption
efficiency of carbon tetrachloride. Assume that the dermal absorption is similar to that of
other volatile organics such as benzene whose dermal absorption efficiency has been
estimated to be 10% of a non-occluded applied dose in 24 hours.
The oral and dermal cancer potency value for carbon tetrachloride is based on a gavage
study in rodents. This toxicity value is based on applied dose.
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The oral and dermal chronic reference dose for carbon tetrachloride is based on an oral
gavage study (via corn oil) in rats. In this study, an applied dose was used.
CARBON TETRACHLORIDE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for carbon tetrachloride is based on an
oral gavage study (via corn oil) in rats. In this study, an applied dose was used.
CARBON TETRACHLORIDE RAFs
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CHLOROBENZENE CAS#: 108907
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.2 mg/kg/day (2)
Chronic Oral Reference Dose: 0.02 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 200 Mg/m3 (2)
Chronic Inhalation Reference Concentration: 20 ixg/rn (2)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
The oral absorption efficiency of chlorobenzene has been reported to range from at least
18% in rats to at least 31% in humans (Lindsay-Smith et al., 1972; Ogata and Shimada,
1983). These estimates are probably low since the studies failed to quantitate exhaled
compounds. A more conservative estimate may be 100%, based on its structural similarity
to benzene.
Lindsay-Smith, J.R., Shaw, B.AJ. and Foulkes, D.M. (1972) Mechanisms ofMammalian Hydroxylation: Some Novel
Metabolites of Chlorobenzene. Xenobiotics 2:215-226.
Ogata, M. and Shimada, Y. (1983) Differences in Urinary Monochlorobenzene Metabolites Between Rats and Humans.
Int. Arch. Oooup. Environ. Health 53:51-57.
No studies were located regarding the dermal absorption of chlorobenzene. Assume it to
be similar to benzene (10% non-occluded, 24 hours).
The oral and dermal chronic reference dose for chlorobenzene is based on an oral
(capsule) study in dogs. In this study, an applied dose was used.
CHLOROBENZENE
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The oral and dermal subchronic reference dose for chlorobenzene is based on an oral
(capsule) study in dogs. In this study, an applied dose was used.
CHLOROBENZENE
Evaluation of Subchronic Exposures
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CHLOROFORM CAS#: 67663
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.01 mg/kg/day (2)
Chronic Oral Reference Dose: 0.01 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 660 Mg/m3 (3a)
Chronic Inhalation Reference Concentration: 660 Mg/m3 (3)
Oral Cancer Potency Factor: 0.0061 (mg/kg/day)'1 (1)
Inhalation Cancer Unit Risk: 0,000023 (Mg/m3)" 1 (1)
Oral absorption efficiency of chloroform in humans and animals is essentially 100% (Fry
et al., 1972; Brown et al., 1974; Taylor et al., 1974).
Brown, D.M., Langley, PJ\, Smith, D. and Taylor, D.C. (1974) Metabolism of Chloroform. I. The Metabolism of^C-
Chlorofbrm by Different Species. Xenobiotioa. 4:151-163.
Fry, BJ., Taylor, T. and Hathaway, DJ2. (1972) Pulmonary Elimination of Chloroform and its Metabolites in Man.
Arch. Int. Pharmaoodyn. 196:98-11.
Taylor, D.C, Brown, D.M., Ruble, R. and Langley, P.F. (1974) Metabolism of Chloroform. II. A Sex Difference in the
Metabolism of —C-Chloroform in Mice. Xenobiotioa. 4:165-174.
Dermal absorption of chloroform is rapid and quite large (329 umol/min/cm2) across
mouse skin (Tsurata, 1975). This suggests that an occluded dose would be 100% absorbed
with a non-occluded dose being absorbed less efficiently (perhaps 10% as with benzene)
due to rapid volatilization.
Tsurata, H. ( 1975) Percutaneous Absorption of Organic Solvents. I. Comparative Study of the in Vivo Percutaneous
Absorption of Chlorinated Solvents in Mice. Ind. Health. 13:227-236.
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The oral and dermal cancer potency value for chloroform is based on an oral drinking
water study in rats. This toxicity value is not based on absorbed dose.
CHLOROFORM RAFs
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The oral and dermal chronic reference dose for chloroform is based on an oral
(toothpaste) study conducted in dogs. In this study, an applied dose was used.
CHLOROFORM RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for chloroform is based on an oral
(toothpaste) study conducted in dogs. In this study, an applied dose was used.
CHLOROFORM RAFs
Evaluation of Subchronic Exposures
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C-38
CHROMIUM CAS #: 7440473
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.02 mg/kg/day (2g)
Chronic Oral Reference Dose: 0.005 mg/kg/day (Id)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
Oral absorption in humans ranges from 0.4% (chromium HI) to 11% (chromium VI)
(Donaldson and Barreras, 1966; Anderson et al., 1983). Animal studies (Mertz et al., 1965;
Donaldson and Barreras, 1966; Ogawa, 1976) indicate the same range of oral absorption
(1.4% for chromium 111-11% for chromium VI). The upper limit of 11% will be used as
an estimate of the oral absorption efficiency of chromium in humans and experimental
animals.
Anderson, R.A., Polansky, MM., Bryden, NA., Patterson, K.Y., Veillon, C. and Glinsmann, W.H. (1983) Effects of
Chromium Supplementation on Urinary Cr Excretion ofHuman Subjects and Correlation ofCr Excretion with
Selected Clinical Parameters. J. Nutr. 113:276-281.
Donaldson, R.M. and Barreras, R.F. (1966) Intestinal Absorption of Trace Quantities of Chromium. J. Lab. Clin.
Med. 68:484-493.
Mertz, W., Roginski, E.E. and Reba, R.C. (1965) Biological Activity and Fate of Trace Quantities ofIntravenous
ChromiumOn) in the Rat. Am. J. Physiol. 209:489-494.
Ogawa, E. (1976) Experimental Study on Absorption, Distribution and Excretion of Trivalent and Hexavalent
Chromes. Jap. J. Pharmacol. 26:92-103.
Chromium can be absorbed through the intact skin of humans and animals, however, no
studies were located which quantitatively described the rate or extent of dermal
absorption. A dermal absorption efficiency of 1% for chromium contaminated soils has
been used (Sheehan et al., 1991) based on EP toxicity tests. In these tests, less than 1%
of soil-adsorbed chromium was extracted with Ph 5 solution over 24 hours. These
conditions are more conducive to extraction than dermal conditions. Therefore, this 1%
figure is taken as a conservative upper-bound estimate of dermal bioavailability.
Sheehan, P.J., Meyers, D.M., Sauer, M.M. and Paustenbach, DJ. (1991) Assessment of the Human Health Risks
Posed by Exposure to Chromium-Contaminated Soils. J. Toxicol. Environ. Health 32:161-201.
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The oral and dermal chronic reference dose for chromium is based on a drinking water
ingestion study conducted in animals. In this study, an applied dose was used.
CHROMIUM RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronie reference dose for chromium is based on a drinking
water ingestion study conducted in animals. In this study, an applied dose was used.
CHROMIUM RAFs
Evaluation of Subchronie Exposures
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CHRYSENE CAS#: 218019
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day)"1 (lg)
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on the absorption via the oral or dermal route.
Assume same as B[a]P.
The oral and dermal cancer potency value for chrysene is based on a dietary study in
which B[a]P was administered to mice. In this study, an applied dose was used.
CHRYSENE RAFs
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The oral and dermal chronic reference dose for chrysene is based on a naphthalene oral
gavage study conducted in rats. In this study, an applied dose was used.
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The oral and dermal subchronic reference dose for chrysene is based on a naphthalene
oral gavage study conducted in rats. In this study, an applied dose was used.
CHRYSENE RAFs
Evaluation of Subchronic Exposures
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CYANIDE CAS#: 57125
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.02 mg/kg/day (2)
Chronic Oral Reference Dose: 0.02 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 1 Mg/m' (4)
Chronic Inhalation Reference Concentration: 7 iig/xa (4)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
The oral absorption efficiency of cyanide is difficult to quantitate from the few existing
studies. In dogs, the absorption of cyanide (KCN) was estimated to be between 17% and
72%, with sinaller doses being absorbed more efficiently (Gettler and Baine, 1938).
However, the animals died shortly after dosing which most likely limited the absorptive
phase. In a human suicide attempt (Liebowitz and Schwartz, 1948), a very speculative
absorption efficiency of 78% was calculated based on blood levels and estimation of the
ingested dose. Both estimates may underestimate the actual absorption efficiency.
Therefore, 100% is assumed to be a more representative oral absorption efficiency.
Gettler, A.O. and Baine, J.O. (1938) The Toxicology of Cyanide. Am. J. Med. Set 195:182-198.
Liebowitz, D. and Schwartz, H. (198) Cyanide Poisoning. Am. J. Clin. Pathol. 18:965-970.
No studies were located to quantitate the dermal absorption efficiency of cyanides.
Available evidence suggests that dermal absorption does occur and may be quite extensive
in some situations (ATSDR, 1989). Assume the dermal absorption to be similar to arsenic
which was estimated at 3% based on EP toxicity studies.
Agency for Toxic Substances and Disease Registry (ATSDR) ( 1989) Toxicological Profile for Cyanide . Agency for
Toxic Substances and Disease Registry, U.S. Public Health Service, pp. 36-38.
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The oral and dermal chronic reference dose for cyanide is based on an oral feeding
(dietary) study conducted in rats. In this study, an applied dose was used.
CYANIDE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for cyanide is based on an oral feeding
(dietary) study conducted in rats. In this study, an applied dose was used.
CYANIDE RAFs
Evaluation of Subchronic Exposures
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DIBENZO[a,h]ANTHRACENE CAS #: 53703
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day)"1 (lg)
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on the oral route. Assume same as B[a]P.
Dermal absorption has been documented to occur less efficiently than B[a]P. 33% of a
dermal dose was estimated to have been absorbed after 24 hours from shaved mouse skin
compared to 83% absorption for B[a]P under similar conditions (Sanders et al., 1986).
This converts to 16% absorption of an applied dermal dose of neat compound or 8%
absorption of an applied dermal dose of a complex environmental mixture.
14,
Sanders, CX., Skinner, C. and Gelman, RA. (1986) Percutaneous Absorption of 7,10 —C-Benzo[a]pyrene and 7,12
14
^€-Dimethylbenzo[a]pyrene in Mice. JEPTO. 7:25-34.
The oral and dermal cancer potency value for dibenzo[a,hlanthracene is based on a
dietary study in which B[a]P was administered to mice. In this study, an applied dose was
used.
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The oral and dermal chronic reference dose for dibenzo[a,h]anthracene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
DIBENZO[a,hJANTHRACENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for dibenzo[a,h]anthracene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
DIBENZO[a,hlANTHRACENE RAFs
Evaluation of Subohronio Exposures
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1,1-DICHLOROETHANE CAS #: 75343
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 1 mg/kg/day (2)
Chronic Oral Reference Dose: 0.1 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: 5000 ng/m3 (2)
Chronic Inhalation Reference Concentration: 500 /xg/m3 (2)
Oral Cancer Potency Factor: Not Quantified
Inhalation Cancer Unit Risk: Not Quantified
No specific studies were located quantifying the respiratory absorption efficiency of 1,1-
dichloroethane. The blood/air partitioning coefficient of 1,1-dichloroethane is
approximately 4 times less than that of 1,2-dichloroethane suggesting less efficient
pulmonary absorption of 1,1-dichloroethane than 1,2-dichloroethane. However, assume
the 75% inhalation efficiency of 1,2-dichloroethylene is applicable.
No specific studies were located quantifying the oral absorption efficiency of 1,1-
dichloroethane. Assume it to be the same as 1,2-dichloroethane (100%).
No specific studies were located quantifying the dermal absorption efficiency of 1,1-
dichloroethane. Assume it to be similar to that of other volatile compounds (benzene)
whose dermal absorption efficiency may reach 10% of a non-occluded applied dose in 24
hours.
The oral and dermal chronic reference dose for 1,1-dichloroethane is based on an
inhalation study conducted in rats. In this study, an applied dose was used.
1,1-DCA RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for 1,1-dichloroethane is based on an
inhalation study conducted in rats. In this study, an applied dose was used.
1,1-DCA RAFs
Evaluation of Subchronic Exposures
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1,2-DICHLOROETHANE CAS#: 107062
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.2 mg/kg/day (4)
Chronic Oral Reference Dose: 0.02 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: 55 ng/m* (3a)
Chronic Inhalation Reference Concentration: 55 ng/m 3 (3)
Oral Cancer Potency Factor: 0.091 (mg/kg/day)'1 (2)
Inhalation Cancer Unit Risk: 0.000026 (/ig/m3)" 1 (2)
Studies in experimental animals indicate that the oral absorption of 1,2-dichloroethane is
rapid and complete. Reitz et al. (1980) reported complete recovery of an oral dose of 14C-
1,2-dichloroethane in the urine, carcass and expired air, suggesting 100% absorption.
Comparison of blood levels attained following intravenous and oral dosing also supports
the belief that oral absorption is 100% (Spreafico et al., 1980).
Reitz, R.H., Fox, T.R. and Domoradzski, J.Y. (1980) Pharmacokinetics and Macromolecular Interactions ofEthylene
Dichloride: Comparison of Oral and Inhalation Exposures. In: Ames, B.N., Infante, P. and Reitz, R. eds. Ethylene
Dichloride: A Potential Health Risk? Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, pp. 135-148.
Spreafico, K., Zuccato, E. and Marcucci, F. (1980) Pharmacokinetics ofEthylene Dichloride in Rats Treated by
Different Routes and its Long-term Inhalatory Toxicity. In: Ames, B.N., Infante, P. and Reitz, R. eds. Ethylene
Dichloride: A Potential Health Risk? Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, pp. 107-133.
No specific information was found to quantify the dermal absorption efficiency of 1,2-
dichloroethane. Assume it to be similar to other volatile compounds (benzene) which
may reach 10% of a non-occluded applied dose in 24 hours.
The oral and dermal cancer potency value for 1,2-dichloroethane is based on a gavage
study in rats. This toxicity value is not based on absorbed dose.
1,2-DCA RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for 1,2-dichloroethane is based on an
inhalation study conducted in rats. An absorption efficiency of 30% was used to calculate
an absorbed dose. The RAFs for all pathways are therefore the absorption efficiency of
1,2-dichloroethane by the route in question.
1,2-DCA RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for 1,2-dichloroethane is based on an
inhalation study conducted in rats. An absorption efficiency of 30% was used to calculate
an absorbed dose. The RAFs for all pathways are therefore the absorption efficiency of
1,2-dichloroethane by the route in question.
1,2-DCA RAFs
Evaluation of Subchronic Exposures
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1,1-DICHLOROETHYLENE CAS #: 75354
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.009 mg/kg/day (2)
Chronic Oral Reference Dose: 0.009 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 5 Mg/m3 (3a)
Chronic Inhalation Reference Concentration: 5 ng/m3 (3)
Oral Cancer Potency Factor: 0.6 (mg/kg/day)"1 (1)
Inhalation Cancer Unit Risk: 0.00005 (jig/m8)'1 (1)
Since 1,1-dichloroethylene is a small organic molecule with chemical and physical
properties similar to the lipid soluble anaesthetics, it is expected to penetrate the
pulmonary epithelium rapidly and efficiently. An inhalation absorption efficiency of 98%
is derived from metabolic excretion data of inhaled radiolabeled 1,1-dichloroethylene data
in the rat (McKenna et al., 1977).
McKenna, MJ., Watanabe, P.G. and Gehring, PJ. (1977) Pharmacokinetics of Vinylidene Chloride in the Rat.
Environ. Health Perspect. 21:99-105.
The oral absorption of 1,1-dichloroethylene in animals has been demonstrated to be rapid
and essentially complete (100%). (Reichert et al., 1979; Jones and Hathaway, 1978;
McKenna et al., 1978; Putcha et al., 1986).
McKenna, MJ., Zemple, JA., Madrid, E.O., Braun, W.H. and Gehring, PJ. (1978) Metabolism and Pharmacokinetic
Profile of Vinylidene Chloride in Rats Following Oral Administration. Toxiool. AppL Pharmacol. 45:821-835.
Reichert, D., Werner, H.E. and Metzler, M. (1979) Molecular Mechanism of 1,1-Dichloroethylene Toxicity: Excreted
Metabolites Reveal Different Pathways ofReactive Intermediates. Arch. Toxicol. 42: 159-169.
Jones, P.K. and Hathaway, D.E. (1978) Differences in Metabolism of Vinylidene Chloride Between Mice and Rats.
Br. J. Canoer. 37:411-417.
Putcha, L., Bruchner, J.V. and D'Soyza, R. (1986) Toxicokinetics and Bioavailability of Oral and Intravenous 1,1-
Dichloroethylene. Fund. AppL Toxiool. 6:240-250.
No studies were located regarding the dermal absorption of 1,1-dichloroethylene. Due to
its chemical and physical properties, dermal absorption is expected to be 100% of an
occluded applied dose or 10% of a non-occluded applied dose (same as benzene).
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
C-51
The oral and dermal cancer potency estimate for 1,1-dichloroethylene is based on an
inhalation study in rats. In this study, an applied dose was used.
1,1-DCE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for 1,1-dichloroethylene is based on a chronic
oral drinking water study conducted in rats. In this study, an applied dose was used.
1,1-DCE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for 1,1-dichloroethylene is based on a
chronic oral drinking water study conducted in rats. In this study, an applied dose was
used.
1,1-DCE RAFs
Evaluation of Subchronic Exposures
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1,2-DICHLOROETHYLENE CAS #: 156605
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.2 mg/kg/day (2)
Chronic Oral Reference Dose: 0.02 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 1100 ng/m* (3a)
Chronic Inhalation Reference Concentration: 1100 Mg/m3 (3)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
No studies were located addressing the oral or dermal absorption efficiency of 1,2-
dichloroethylene. Assume behavior similar to 1,1-dichloroethylene and benzene (100%
oral and 10% non-occluded dermal absorption efficiencies).
The oral and dermal chronic reference dose for 1,2-dichloroethylene is based on an oral
drinking water study conducted in mice. In this study, an applied dose was used.
1,2-DCE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for 1,2-dichloroethylene is based on an
oral drinking water study conducted in mice. In this study, an applied dose was used.
1,2-DCE RAFs
Evaluation of Subchronic Exposures
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ETHYLBENZENE CAs #: i 00414
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 1 mg/kg/day (2)
Chronic Oral Reference Dose: 0.1 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 1000 iig/m* (2)
Chronic Inhalation Reference Concentration: 1000 ng/m (1)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
Animal studies indicate that ethylbenzene is quickly and efficiently absorbed by the oral
route. Estimates range from 72%-92% in one study (El Masry et al., 1956) to 84% in a
second study (Climie et al., 1983). A value of 100% is selected since these studies
underestimated oral absorption by not controlling for respiratory volatilization following
oral absorption.
Climie, U.G., Hutson, D.H. and Stovdin, G. (1983) The Metabolism ofEthylbenzene Hydroperoxide in the Rat.
Xenobiotica 13:611-618.
El Masry, AM., Smith, J.N. and Williams, R.T. (1956) The Metabolism of Alkylbenzenes: n-Propylbenzene and n-
Butylbenzene with Further Observations on Ethylbenzene. Bioohem. J. 64:50-56.
Absorption of pure liquid ethylbenzene and aqueous solutions containing ethylbenzene
through human skin is rapid and substantial (20-30 mg/cm2/hr) (Gromiec and Piotrowski,
1984). Occluded doses could potentially be 100% absorbed. The non-occluded dermal
absorption of ethylbenzene has been measured to be 3.4% of an applied dose in 4 hours
(Susten et al., 1990). This calculates to a 24 hour dermal absorption efficiency of 20%.
Susten, A.S., Niemeier, R.W. and Simon, S.D. (1990) In Vivo Percutaneous Absorption Studies of Volatile Organic
Solvents in Hairless Mice II. Toluene, Ethylbenzene and Aniline. J. Appl. Toxicol. 10:217-225.
Gromiec, J.P. and Piotrowski, J.K. (1984). Urinary Mandelic Acid as an Exposure Test for Ethylbenzene. Int. Arch.
Oooup. Environ. Health 55:61-72.
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The oral and dermal chronic reference dose for ethylbenzene is based on an oral gavage
(via olive oil) study conducted in rats. In this study, an applied dose was used.
ETHYLBENZENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for ethylbenzene is based on an oral
gavage (via olive oil) study conducted in animals. In this study, an applied dose was used.
ETHYLBENZENE RAFs
Evaluation of Subchronic Exposures
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ETHYLENE DIBROMIDE CAS#: 106934
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.0002 mg/kg/day (4)
Chronic Oral Reference Dose: 0.00002 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: 1.2 ng/in (4)
Chronic Inhalation Reference Concentration: 0.2 ng/ma (4)
Oral Cancer Potency Factor: 85 (mg/kg/day)"1 (1)
Inhalation Cancer Unit Risk: 0.00022 (/xg/m3) ' (1)
Using 14C-l,2-dibromoethane, the oral absorption efficiency of ethylene dibromide was
estimated to be at least 75% based on excretion of radiolabel in urine and feces (Plotnick
et al., 1979). This study failed to quantitate radiolabel in expired air, therefore,
absorption is assumed to be 100% by the oral route.
Plotnick, H.B., Weigel, W.W. and Richards, D.E. (1979) The Effect ofDietary Disulfiram Upon the Tissue
Distribution and Excretion of^C-l,2-Dibromoethane in the Rat. Res. Commun. Chem. PathoL Pharmacol.
26:535-543.
No studies exist quantitating the dermal absorption of EDB. However, based on its
chemical and physical properties, it is highly likely that 100% of an occluded dermal dose
would be absorbed and 10% of a non-occluded dermal applied dose.
The oral and dermal cancer potency value for ethylene dibromide is based on a gavage
study in rats. This toxicity value is not based on absorbed dose.
ETHYLENE DIBROMIDE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose is based on an oral feeding study in bulls. In
this study, an applied dose was used.
ETHYLENE DIBROMIDE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose is based on an oral feeding study in bulls.
In this study, an applied dose was used.
ETHYLENE DIBROMIDE RAFs
Evaluation of Subchronic Exposures
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FLUORANTHENE CAS #: 206440
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.4 mg/kg/day (2)
Chronic Oral Reference Dose: 0.04 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on the absorption via the oral or dermal route.
Assume same as B[a]P.
The oral and dermal chronic reference dose for fluoranthene is based on an oral gavage
study conducted in mice. In this study, an applied dose was used.
FLUORANTHENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for fluoranthene is based on an oral
gavage study conducted in mice. In this study, an applied dose was used.
FLUORANTHENE RAFs
Evaluation of Subchronic Exposures
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FLUORENE CAS#: 86737
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.4 mg/kg/day (2)
Chronic Oral Reference Dose: 0.04 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on the absorption via oral, inhalation or
dermal route. Assume same as B[a]P.
The oral and dermal chrome reference dose for fluorene is based on an oral gavage study
conducted in mice. In this study, an applied dose was used.
FLUORENE RAFs
Evaluation of Chronio Exposures
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The oral and dermal subchronic reference dose for fluorene is based on an oral gavage
study conducted in mice. In this study, an applied dose was used.
FLUORENE RAFs
Evaluation of Subchronic Exposures
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INDENO[1,2,3-cd]PYRENE CAS#: 193395
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.3 (mg/kg/day)"1 (lg)
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on the absorption via oral, inhalation or
dermal route. Assume same as B[a]P.
The oral and dermal cancer potency value for indeno[l,2,3-cd]pyrene is based on a dietary
study in which B[a]P was administered to mice. In this study, an applied dose was used.
INDENO[l,2,3-cd]PYRENE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for indeno[l,2,3-cd]pyrene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
INDENO[l,2,3-cd]PYRENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for indeno[l,2,3-cd]pyrene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
INDENO(l,2,3-od]PYRENE RAFs
Evaluation of Subchronic Exposures
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LEAD CAS#: 7439921
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.00075 mg/kg/day (4)
Chronic Oral Reference Dose: 0.00075 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: Not Quantified
Inhalation Cancer Unit Risk: Not Volatile
The oral absorption efficiency of lead compounds in adult experimental animals and adult
humans ranges from 1% - 15% (EPA, 1986; Hammond, 1982; Chamberlain et al., 1978).
Young humans and experimental animals absorb lead with higher efficiency, estimates
ranging up to 50% (Hammond, 1982; Kostial et al., 1971, 1978; Forbes and Reina, 1972).
The estimate of 50% is considered as being a conservative upper-bound for humans and
experimental animals.
Chamberlain, A., Hard, C and Little, M.J. (1978) Investigations into Lead from Motor Vehicles . Harwell, U.K:
United Kingdom Atomic Energy Authority. Rep. No. AERE-9198.
U.S. Environmental Protection Agency (EPA) (1986) Air Quality Criteria for Lead. June 1986 and Addendum,
September. 1986 . Research Triangle Park, NC: Office of Research and Development, Office of Health and
Environmental Assessment, Environmental Criteria and Assessment Office, EPA EPA 600/8-83-0 18F.
Forbes, GJJ. and Reina, J.C (1972) Effect ofAge on Gastrointestinal Absorption (Fe, Sr, Pb) in the Rat. J. Nutr.
102:647-652.
Hammond, P.B. (1982) Metabolism ofLead. In: Chisolm, JJ. and O'Hara, D.M., eds. Lead Absorption in Children:
Management. Clinical and Environmental Aspects . Baltimore, MD: Urban and Schwarzenberg, pp. 11-20.
KJMtial, K, Simonovic, J. and Pisonic, M. (1971) Lead Absorption from the Intestine in Newborn Rats. Nature
233:664-567.
The dermal absorption efficiency for lead as lead acetate has been reported to be 0.3% (12
hours) of an applied dose in humans, or 0.6% in 24 hours (Moore et al., 1980). Organic
lead compounds are absorbed more rapidly and extensively than inorganic lead
compounds.
Moore, M.R., Meredith, P.A, Watson, W.S., Sumner, DJ., Taylor, M.K and Goldberg, A (1980) The Percutaneous
Absorption of Lead-203 in Humans from Cosmetic Preparations Containing Lead Acetate, As Assessed by Whole-Body
Counting and Other Techniques. Food. Cosmet Toxicol. 18:399-405.
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The oral and dermal chronic reference dose for lead is based on back-calculation from the
drinking water action level. In this calculation, an absorbed dose was used. Therefore,
the RAF is the absorption efficiency by the route in question.
LEADRAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for lead is based on back-calculation from
the drinking water action level. In this calculation, an absorbed dose was used. Therefore,
the RAF is the absorption efficiency by the route in question.
LEADRAFs
Evaluation of Subchronic Exposures
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MERCURY CAS#: 7439976
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.0003 mg/kg/day (2)
Chronic Oral Reference Dose: 0.0003 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: 0.3 Mg/m 3 (2)
Chronic Inhalation Reference Concentration: 0.3 Mg/m3 (2)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
MERCURY (elemental)
Oral absorption of metallic mercury has been estimated to be, at most, 0.10% (Friberg
and Nordberg, 1973). The oral absorption efficiency of 0.01% in humans and laboratory
animals is most frequently cited in the literature (Owen, 1990). The value of 0.1% is
suggested as a conservative upper limit for human exposure.
Friberg, L., Nordberg, F. (1973) Inorganic Mercury - A Toxicological and Epidemiological Appraisal. In: Miller,
M.W., Clarkson, T.W., ed. Mercury. Mercurials and Mercaptans . Springfield, Illinois: Charles C Thomas, pp. 5-22.
Owen, BA. (1990) Literature-Derived Absorption Coefficients for 39 Chemicals Via Oral and Inhalation Routes of
Exposure. ReguL Toxicol Pharmacol. 11:237-252.
Hursh et al. (1989) report maximum systemic mercury as a fraction of initial amounts of.
mercury on the skin. The average percentage absorbed (from data obtained from 5
human volunteers) can be calculated as 40% of the free mercury deposited on the skin.
Assuming that 10% of the mercury in soil could be extracted and available for dermal
absorption (Landa, 1978), a dermal absorption factor of 0.04 is obtained.
Hursh, J.B., Clarkson, T.W., Miles, E.F., et al. (1989) Percutaneous Absorption of Mercury Vapor by Man. Arch.
Environ. Health 44:120-127.
Landa, E.R. (1978) The Retention of Metallic Mercury Vapor by Soils. Geochem. Cosmochim. Acta.
42:1407-1411.
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MERCURY (inorganic)
An oral absorption efficiency of 15% is frequently cited in the literature (Owen, 1990).
The range of values is 1% (mice) - 15% (humans) (Weiss et al., 1973; Clarkson, 1971), 15%
being chosen as a protective estimate. Oral feeding of mercury-contaminated soil to mice
(5% of diet) resulted in an oral absorption efficiency of 0.4% (Revis et al., 1990), compared
to a 1% absorption efficiency for non-soil associated mercury. The form of mercury in
the soil was 88% inorganic, 7% elemental and 0.01% organic. Since the soil-associated
efficiency is approximately half the reported efficiency for non-soil associated mercury in
mice, this suggests a protective human oral absorption efficiency of soil-adsorbed mercury
of 7.5%.
Revis, N.W., Osborne, TIL, Holdsworth, G. and Hadden, C. (1990) Mercury in Soil: A Method for Assessing
Acceptable Limits. Arch. Environ. Contam. Toxicol. 19:221-226.
Agency for Toxic Substances and Disease Registry (ATSDR) (1989) Toxicological Profile for Mercury. Agency for
Toxic Substances and Disease Registry, U.S. Public Health Service, pp. 37-40.
Kostial, K, Kello, D., Jugo, S., et al. (1978) Influence ofAge on Metal Metabolism and Toxicity. Environ. Health
PerspecL 25:81-86.
Owen, BA (1990) Literature-Derived Absorption Coefficients for 39 Chemicals Via Oral and Inhalation Routes of
Exposure. ReguL Toxicol Pharmacol. 11:237-252.
Weiss, S.H., Wands, J.R., Yardley, J.H. (1973) Demonstration by Electron Detraction ofBlack Mercury Sulfide (b-
HgS) in a Case of "Melanosis coli and Black Kidneys" Caused by Chronic Inorganic Mercury Poisoning [Abstract].
Lab. Invest 5:401-402.
Clarkson, T.W. (1971) Epidemiological and Experimental Aspects ofLead and Mercury Contamination. Food
Cosmet ToxiooL 9:229-243.
Aqueous solutions of mercuric chloride applied to the skin of human volunteers were
calculated to result in the absorption of 20 to 65 percent of the applied dose (Baranowska-
Dutkiewioz, 1982). Assuming that 10% of the mercury in soil could be extracted and
available for dermal absorption (Landa, 1978), a dermal absorption factor of 0.065 (6.5%) is
obtained.
Baranowska-Dutkiewicz, B. (1982) Evaluation of the Skin Uptake ofMercuric Chloride in Man. Journal of Applied
Toxicology. 2:223-225.
Landa, E.R. (1978) The Retention of Metallic Mercury Vapor by Soils. Geochem. Cosmochim. Acta.
42:1407-1411.
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MERCURY (organic)
The oral absorption efficiency of methylmercury is reported as 95% (Aberg et al., 1969;
Owen, 1990). Other forms of organic mercury may be orally absorbed less efficiently,
with estimates ranging down to 80% (Fitzhugh et al., 1950).
Owen, B. A. (1990) Literature-Derived Absorption Coefficients for 39 Chemicals Via Oral and Inhalation Routes of
Exposure. ReguL ToxiooL Pharmacol. 11:237-252.
Aberg, B., Elkman, R., Falk, U., et al. (1969) Metabolism ofMethylmercury ^Hg) Compounds in Man: Excretion
and Distribution. Arch. Environ. Health 19:478-484.
Fitzhugh, O.G., Nelson, AA, Laug, E.P., et al. (1950) Chronic Oral Toxicities of Mercuri-phenyl and Mercuric Salts.
Arch. Ind. Hyg. Oooup. Med. 2:433-442
Methyl mercury (in water) applied to the skin of guinea pigs at two dose levels resulted
in 3.4% and 4.5% of the applied dose being absorbed (Skog and Wahlberg, 1964). Given
the lipophilicity of organomercurials, an absorption value of 4.5% was chosen.
Skog, E. and Wahlberg, J.E. (1964) A Comparative Investigation of the Percutaneous Absorption of Metal Compounds
in the Guinea Pig by Means of the Radioactive Isotopes: —Cr, —Co, —Zn, —-Ag, —^Cd, —Hg. J. Invest
DennatoL 43:187-192.
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The dermal and oral chronic reference dose for mercury is based on a human study of
blood levels of methyl mercury. In this study, an administered (applied) dose was
calculated from a blood level of 200 ng Hg/ml blood.
MERCURY RAFs
Evaluation of Chronic Exposures
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The dermal and oral subchronic reference dose for mercury was adopted from the chronic
oral RfD for methyl mercury, an estimated applied dose based upon blood levels of
methyl mercury.
MERCURY RAFs
Evaluation of Subchronic Exposures
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METHYLENE CHLORIDE CAS#: 75092
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.06 mg/kg/day (2)
Chronic Oral Reference Dose: 0.06 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 3000 Mg/m3 (2)
Chronic Inhalation Reference Concentration: 3000 ng/m3 (2)
Oral Cancer Potency Factor: 0.0075 (mg/kg/day)'1 (1)
Inhalation Cancer Unit Risk: 0.00000047 (/xg/m3) ' (1)
In rats administered single oral doses of nonradioactive methylene chloride in water
(Angelo, et al., 1986), the amount of methylene chloride remaining in the lower
gastrointestinal tract accounted for less than 2% of the administered dose. In a second
study (McKenna and Zempel, 1981), a single oral dose of 14C-DCM administered to rats
was eliminated 100% in the breath as unchanged methylene chloride and as metabolites
within 48 hours. Both studies suggest close to a 100% oral absorption efficiency.
McKenna, MJ., Zempel, J.A (1981) The Dose-Dependent Metabolism of^€ Methylene Chloride Following Oral
Administration to Rat. Food Cosraet. ToxiooL 19:73-78.
Angelo, MJ., Pritchard, A3., Hawkins, D.R., Waller, AR. and Roberts, A. (1986) The Pharmacokinetics of
Dichloromethane. 27. Disposition in Fischer 344 Rats Following Intraveous and Oral Administration. Food Chem.
ToxicoL 24:975-980.
No studies were located quantifying the dermal absorption of methylene chloride.
Assume it to be similar to the conservative estimate of 10% derived for benzene in a non-
occluded dosing protocol.
The oral and dermal cancer potency value for methylene chloride is based on an oral
drinking water study in mice. This toxicity value is not based on absorbed dose.
METHYLENE CHLORIDE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for methylene chloride is based on an oral
drinking water study in rats. In this study, an applied dose was used.
METHYLENE CHLORIDE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for methylene chloride is based on an oral
drinking water study in rats. In this study, an applied dose was used.
METHYLENE CHLORIDE RAFs
Evaluation of Subchronic Exposures
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METHYL ETHYL KETONE CAS #: 78933
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.5 mg/kg/day (2)
Chronic Oral Reference Dose: 0.05 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: 3000 iig/m* (2)
Chronic Inhalation Reference Concentration: 1000 ng/in (1)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
No information was located to quantitatively determine the oral or dermal absorption
efficiency of methyl ethyl ketone. Assume a 100% absorption efficiency by the oral route
and a 10% dermal absorption efficiency (non-occluded, 24 hour).
*
The oral and dermal chronic reference dose for methyl ethyl ketone is based on an
inhalation study conducted in rats. An absorption efficiency of 50% was used to calculate
an absorbed dose. The RAFs to be used for all exposure pathways are the absorption
efficiencies of methyl ethyl ketone by the route in question.
METHYL ETHYL KETONE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for methyl ethyl ketone is based on an
inhalation study conducted in rats. An absorption efficiency of 50% was used to calculate
an absorbed dose. The RAFs to be used for all exposure pathways are the absorption
efficiencies of methyl ethyl ketone by the route in question.
METHYL ETHYL KETONE RAFs
Evaluation of Subchronic Exposures
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METHYL TERTIARY BUTYL ETHER CAS#: 1634044
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.052 mg/kg/day (2)
Chronic Oral Reference Dose: 0.0052 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: 500 ^ig/m (lc)
Chronic Inhalation Reference Concentration: 500 lig/m (1)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
No information was located to quantitatively determine the oral or dermal absorption
efficiency of methyl tert butyl ether. Assume a 100% absorption efficiency by the oral
route and a 10% dermal absorption efficiency (non-occluded, 24 hour).
The oral and dermal chronic reference dose for methyl tert butyl ether is based on an
inhalation study conducted in rats. An absorption efficiency of 50% was used to calculate
an absorbed dose. The RAFs to be used for all exposure pathways are the absorption
efficiencies of methyl tert butyl ether by the route in question.
METHYL TERT BUTYL ETHER RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for methyl tert butyl ether is based on an
inhalation study conducted in rats. An absorption efficiency of 50% was used to calculate
an absorbed dose. The RAFs to be used for all exposure pathways are the absorption
efficiencies of methyl tert butyl ether by the route in question.
METHYL TERT BUTYL ETHER RAFs
Evaluation of Subchronic Exposures
SOIL
INGESTION
SOIL
DERMAL
WATER
INGESTION
VEGETABLE
INGESTION
1 0.1 1 1
MA DEP, ORS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
C-76
NAPHTHALENE and
2-METHYLNAPHTHALENE
CAS #: 91203
CAS #: 91576
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: 71 ng/ra (3a)
Chronic Inhalation Reference Concentration: 71 pg/in (3b)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
Oral absorption, based on fecal recovery of metabolites, has been demonstrated to be
essentially 100% in the rat (Chang, 1943).
Chang, L H. (1943) The Fecal Excretion ofPolycyclic Hydrocarbons Following Their Administration to the Rat. J.
BioL Chenx 151:93-102.
No information exists quantifying the dermal absorption efficiency of naphthalene.
However, toxicity has been documented following exposure by this suggesting absorption
has occurred. Assume 10% to represent the dermal absorption efficiency (same as non-
occlude, 24 hour benzene value).
The oral and dermal chronic reference dose for naphthalene and 2-methylnaphthalene is
based on an oral gavage study conducted in rats. In this study, an applied dose was used.
NAPHTHALENE & 2-METHYLNAPHTHALENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for naphthalene and 2-methylnaphthalene
is based on an oral gavage study conducted in the rats. In this study, an applied dose was
used.
NAPHTHALENE & 2-METHYLNAPHTHALENE RAFs
Evaluation of Subchronic Exposures
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NICKEL CAS #: 7440020
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.02 mg/kg/day (2)
Chronic Oral Reference Dose: 0.02 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
Human and animal studies indicate that the oral absorption efficiency of nickel from food
or water ranges from 1% - 10% (Christensen and Lagesson, 1981; Schroeder et al., 1974;
Tedeschi and Sunderman, 1956; Ambrose et al., 1976; Nielsen et al., 1986; Ho and Furst,
1973). The upper-bound of 10% is selected as a protective estimate of the oral absorption
efficiency of nickel.
Christensen, O.B. and Lagesson, V. (1981) Nickel Concentrations ofBlood and Urine After Oral Administration.
Ann. Clin. Lab. ScL 11:119-125.
Schroeder, HA, Mitchener, M. and Nason, AP. (1974) Life-Term Effects of Nickel in Rats: Survival, Tumors,
Interactions with Trace Elements and Tissue Levels. J. Nutr. 104:239-243.
Tedeschi, R.E. and Sunderman, F.W. (1957) Nickel Poisoning V. The Metabolism of Nickel Under Normal
Conditions and After Exposure to Nickel CarbonyL Arch. Ind. Health 16:486-488.
Ambrose, AM., Larson, P.S., Borzelleca, J.R. and Hennigar, Git. ( 1976) Long Term Toxicologic Assessment of
Nickel in Rats and Dogs. J. Food. ScL Technol. 13:181-187.
Nielsen, G.D., Andersen, O., Jensen, M. and Grandjean, P. (1986) Gastrointestinal Nickel Absorption. A New
Experimental Model Using the Gamma-Emitting Isotope —Ni. In: The Sixth UOEH Int. Svmp.. 3rd COMTOX on
Bio- and Toxicokinetics of Metals. Kitakyushu City, Japan, Int. Conf. Clin. Chem., Chem. Toxicol., July 27-31.
Ho., W. and Furst, A (1973) Nickel Excretion by Rats Following a Single Treatment. Proc West. Pharmacol. Soc
16:245-248.
Aqueous solutions of various forms of nickel can penetrate occluded human skin with
absorption efficiencies ranging from 55% - 77%, most absorption occurring in the first 24
hours (Norgaard, 1955). It is unclear whether the nickel was absorbed into the deep
layers of the skin or into the bloodstream. Studies in guinea pigs (Lloyd, 1980)
demonstrated that much of the nickel absorbed remained in the skin, primarily in the
jighly keratinized areas, while approximately 0.005 - 0.51 % of the applied nickel chloride
was recovered from the blood and urine. A more recent study on excised human skin
(Fullerton et al., 1986) indicated that 3.5% of an applied dose of nickel chloride
MA DEP, ORS & BWSC
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permeated the skin after 144 hours when the skin was occluded. Fullerton also noted
that nickelous ions from a chloride solution passed through the skin ~ 50 times faster
than nickelous ions from a sulfate solution.
An absorption value of 3.5% is selected as an realistic estimate applicable to human
exposure scenarios.
Fullerton, A., Anderson, JR., and Hoelgaard, A. et al. (1986) Permeation of nickel salts through human skin in
vitro. Cont Derma. 16:173-177.
Lloyd, G.K. (1980) Dermal absorption of nickel in relation to the induction of allergic contact dermatitis:
Preliminary results. In: Nickel Toxicology. Brown, S.S. and Sunderman, F.W., eds., Academic Press, London U.K.
Norgaard, O. (1966) Investigation with Radioactive Ni-67 Into the Resorption of Nickel Through the Skin in Normal
and in Nickel-Hypersensitive Persons. Acta. Derm. VenereoL 35:111-117.
The oral and dermal chronic reference dose for nickel is based on an oral feeding
(dietary) study conducted in rats. In this study, an applied dose was used.
NICKEL RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for nickel is based on an oral feeding
(dietary) study conducted in rats. In this study, an applied dose was used.
NICKEL RAFs
Evaluation of Subchronic Exposures
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PHENANTHRENE CAS#: 85018
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.04 mg/kg/day (2b)
Chronic Oral Reference Dose: 0.04 mg/kg/day (2f)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
No specific quantitative information found on the absorption via the oral or dermal route.
Assume same as B[a]P.
The oral and dermal chronic reference dose for phenanthrene is based on a naphthalene
oral gavage study in rats. In this study, an applied dose was used.
PHENANTHRENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for phenanthrene is based on a
naphthalene oral gavage study conducted in rats. In this study, an applied dose was used.
PHENANTHRENE RAFs
Evaluation of Subchronic Exposures
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PHENOL CAS#: 108952
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.6 mg/kg/day (2)
Chronic Oral Reference Dose: 0.6 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
Phenol is absorbed readily and efficiently from the GI tract. In humans, Capel et al.
(1972) reported that up to 98% of an oral dose was recovered as urinary metabolites
within 24 hours, suggesting 100% absorption. The oral absorption in other species
appears to be similar to humans.
Capel, IJ)., French, Mil. and Millburn, P. (1972) Fate of [—]-phenol in various speicies. Xenobiotica 2:25-34.
Phenol is absorbed quite readily from the skin. In one study (Baranowska-Dutkiewicz,
1981), the dermal absorption efficiency of aqueous phenol through human skin was shown
to be approximately 13% of the applied dose in 30 minutes (26% in one hour). The value
of 26% is assumed to be a protective estimate since volatilization of any remaining phenol
is expected to be complete after 1 hour.
Baranowska-Dutkiewicz, B. (1981) Skin absorption ofphenol from aqueous solutions in men. Int. Arch. Environ,
Health 49:99-104.
The oral and dermal chronic reference dose for phenol is based on an oral gavage study
(via water) in rats. In this study, an applied dose was used.
PHENOL RAFs
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The oral and dermal subchronic reference dose for phenol is based on an oral gavage
study (via water) in rats. In this study, an applied dose was used.
PHENOL RAFs
Evaluation of Subchronic Exposures
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PCBs CAS #: 1336363
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.000005 mg/kg/day (4)
Chronic Oral Reference Dose: 0.000005 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: 7.7 (mg/kg/day)"1 (1)
Inhalation Cancer Unit Risk: Not Volatile .
Oral (gavage) studies in rats and rhesus monkeys demonstrate a range in absorption
efficiencies of PCBs to be 90%-99% (Albro and Fishbein, 1972; Allen et al, 1974). When
administered to ferrets in food, 85% of an applied dose was seen to be absorbed (Bleavins
et al., 1984). The oral absorption efficiency of 14C-labeled PCB contaminated soil and
pure
14
C-labeled PCBs was assessed in Sprague-Dawley rats (Fries et al., 1989). The
absorption efficiencies were reported as follows:
Soil/diet Soil/gavage Non-soil/diet Non-soil/gavage
TriPCBs 82% 78%
TetraPCBs 80% 89% 91% 95%
PentaPCBs 67% 78% 86% 81%
Average 76% 82% 89% 88%
These results suggest that the presence of soil does inhibit the oral absorption of PCBs.
Fries, G.F., Marrow, G.S. and Somich, C.J. (1989) Oral Bioavailability ofAged Polychlorinated Biphenyl Residues
Contained in Soil. Bull. Environ. Contain. Toxicol. 43:683-690.
Albro, P.W. and Fishbein, L. (1972) Intestinal Absorption ofPolychlorinated Biphenyls in Rats. BulL Environ.
Contam. Toxicol. 8:26-35.
Allen, J.R., Norback, D.H., Hsu, I.C. (1974) Tissue Modifications in Monkeys as Related to Absorption, Distribution
and Excretion ofPolychlorinated Biphenyls. Arch. Envron. Contam. Toxicol. 2:86-95.
Bleavins, M.R., Breslin, WJ., Aulerich, R.J. and Ringer, R.K. (1984) Placental and Mammary Transfer of a
Polychlorinated Biphenyl Mixture (Aroclor 1254) in the European Ferret. Environ. Toxicol. Chem. 3:637-44.
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The dermal absorption efficiency (24 hour) of C-PCBs in guinea pigs ranged from 33%
56% of the applied dose, dependent on the concentration applied. The range in Rhesus
monkeys was 15% - 34% of the applied dose. These ranges were based on excretion of
radioactivity in urine and feces. Assume the upper-bound estimate of 56% is
representative and protective for human exposure to pure compound. Roy et al. (1989)
examined the dermal absorption of tetraPCBs in low organic carbon content soil in rats.
After 96 hours, 50% of the applied dose had been absorbed. Assuming linearity, this
suggests 12.5% absorption of soil-associated PCBs in 24 hours.
A recent U.S. EPA study (US EPA, 1992) recommended absorption efficiencies for PCBs
in soil for human skin between 0.6% (high carbon soils) and 6% (low carbon soils).
Roy, T.A., Yang, JJ., Krueger, A.J., Driver, J.H. and Konz, JJ. (1989) Dermal Absorption of Dioxins and PCBs
from Soil. Draft report prepared by Versar, Inc. for U.S. EPA, Office of Toxic Substances, Exposure Evaluation
Division, Exposure Assessment Branch. EPA Contract No. 68-02-4254.
US EPA (1992), Dermal Asbsorption Assessment: Principles and Applications . EPA/600/8-9 1/01 IB. Office of
Research and Development, Washington D.C.
Wester, R.C., Bucks, DAW, Maibach, H.I. and Anderson, J. (1983) Polychlorinated Bipkenyls (PCBs): Dermal
Absorption, Systemic Elimination and Dermal Wash Efficiency. J. Toxicol. Environ. Health 12:511-519.
The oral and dermal cancer potency value for PCBs is based on an oral feeding (dietary)
study in rats. This toxicity value is not based on absorbed dose.
PCBs RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for PCBs is based on an oral feeding (dietary)
study in primates. In this study, an applied dose was used.
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PCBs RAFs
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The oral and dermal subchronic reference dose for PCBs is based on an oral feeding
(dietary) study in primates. In this study, an applied dose was used.
PCBs RAFs
Evaluation of Subchronic Exposures
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PYRENE CAS#: 129000
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.3 mg/kg/day (2)
Chronic Oral Reference Dose: 0.03 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
No specific quantitative information found on the absorption via the oral or dermal route.
Assume same as B[a]P.
The oral and dermal chronic reference dose for pyrene is based on an oral gavage study
conducted in mice. In this study, an applied dose was used.
PYRENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for pyrene is based on an oral gavage
study conducted in mice. In this study, an applied dose was used.
PYRENE RAFs
Evaluation of Subchronic Exposures
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SILVER CAS#: 7440224
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.005 mg/kg/day (le)
Chronic Oral Reference Dose: 0.005 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
The oral absorption efficiency of silver compounds varies between species. Estimates
range from 1% in rats and mice, 10% in dogs (Furchner et al., 1968) and 21% in humans
(Maclntyre et al., 1978). Furchner considered their calculated equilibrium factor of 4.4%
to be a conservative estimate for the amount of silver retained by a 70 kg human. The
differences are believed to be due to differences in gastrointestinal transit times between
species.
Furchner, JJ5., Richmond, C.R. and Drake, GA (1968) Comparative Metabolism ofRadionuclides in Mammals - IV.
Retention of Silver-llOm in the Mouse, Rat, Monkey and Dog. Health Phys. 15:505-514.
Maclntyre, D., Mclay, A.L.C. and East, B.W. (1978) Silver Poisoning Associated with an Antismoking Lozenge. Br.
Med. J. 2:1749-1750.
Less than 1% of dermally-applied silver compounds are absorbed through the intact skin
of humans (Snyder et al., 1985). The amount dermally absorbed by guinea pigs was
estimated to be approximately 1% of the applied dose (Wahlberg, 1965).
Snyder, W.S., et al. ( 1975) Report of the Task Group on Reference Man . Oxford, England: Pergamon Press, pp.
407-708.
Wahlberg, J.E. (1965) Percutaneous Toxicity ofMetal Compounds. A Comparative Investigation in Guinea Pigs.
Arch- Environ. Health 11:201-204.
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The oral and dermal chronic reference dose for silver is based on a human intravenous
study converted to an applied oral dose assuming 4% oral retention.
SILVER RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for silver is based on a human
intravenous study converted to an applied oral dose assuming 4% retention.
SILVER RAFs
Evaluation of Subchronic Exposures
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TETRACHLOROETHYLENE CAS#: 127184
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.1 mg/kg/day (2)
Chronic Oral Reference Dose: 0.01 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 4600 lig/m (3a)
Chronic Inhalation Reference Concentration: 4600 pg/m3 (3)
Oral Cancer Potency Factor: 0.052 (mg/kg/day)"1 (2h)
Inhalation Cancer Unit Risk: 0.00000058 (jig/m3)"1 (2h)
Results from several animal studies (Pegg et al., 1979; Schumann et al., 1980; Frantz and
Wantanabe, 1983) indicate that tetrachloroethylene is rapidly and virtually completely
absorbed following oral administration.
Frantz, S.W. and Wantanabe, P.G. (1983) Tetrachloroethylene: Balance and Tissue Distribution in Male Sprague-
Dawley Rats by Drinking Water Administration. ToxiooL Appl. Pharmacol. 69:66-72.
Pegg, D.G., Zemple, JA., Braun, W.H. and Watanabe, P.G. (1979) Disposition of (^C)Tetrachloroethylene Following
Oral and Inhalation Exposure in Rats. Toxicol. Appl. Pharmacol. 51:465-474.
Schumann, A.M., Quast, J.F., and Watanabe, P.G. (1980) The Pharmacokinetics and Macromoleular Interactions of
Perchloroethylene in Mice and Rats as Related to Oncogenicity. Toxicol. Appl. Pharmacol. 55:207-219.
Dermal absorption of tetrachloroethylene appears to be poor (0.24 mg/cm2/nr) (Tsuruta,
1975). Therefore, the absorption efficiency by the dermal route in a non-occluded
exposure probably does not exceed 10% (see benzene).
Tsuruta, H. (1975) Percutaneous absorption of organic solvents. I. Comparative study of + 6 percutaneous
absorption of chlorinated solvents in mice. Ind. Health 13:227-236.
The oral and dermal cancer potency value for tetrachloroethylene is based on a gavage
study in mice. This toxicity value is not based on absorbed dose.
TETRACHLOROETHYLENE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for tetrachloroethylene is based on an oral
gavage (via corn oil) in mice. In this study, an applied dose was used.
TETRACHLOROETHYLENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for tetrachloroethylene is based on an oral
gavage (via corn oil) study in mice. In this study, an applied dose was used.
TETRACHLOROETHYLENE RAFs
Evaluation of Subchronic Exposures
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THALLIUM CAS#: 7440280
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.0007 mg/kg/day (2)
Chronic Oral Reference Dose: 0.00007 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
Limited human data suggest that most of an oral dose of thallium (applied as thallium
nitrate) is absorbed from the gastrointestinal tract (Barclay et al., 1953). Animal studies
suggest that thallium is completely absorbed when ingested. A single trace dose of
thallium
204
(as thallium nitrate) was administered orally to rats (Lie et al., 1960). The
body burden of thallium
204
, as percent dose, decreased with a single exponential function
which extrapolated to 100% at zero time. It was concluded that thallium is completely
absorbed from the gastrointestinal tract. A 100% oral absorption efficiency is therefore
assumed for thallium compounds.
Barclay, R.K., Pencock, W.C., Kanofey, DA. (1953) Distribution and Excretion of Radioactive Thallium in the Chick
Embryo, Rat and Man. J. Pharmacol. Exp. Ther. 107:178-187.
Lie, R., Thomas, R. and Scott, J. ( 1960) The Distribution and Excretion of Thallium— in the Rat, with Suggested
MPC's and a Bio-Assay Procedure. Health Phys. 2:334-340.
No quantitative studies were located regarding the dermal absorption of thallium in
humans or animals. Assume a dermal absorption efficiency of 1% as a conservative upper-
bound estimate (see chromium).
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The oral and dermal chronic reference dose for thallium is based on an oral study
conducted in rats. In this study, an applied dose was used.
THALLIUM RAFs
Evaluation of Chronic Exposures
SOIL
INGESTION
SOIL
DERMAL
WATER
INGESTION
VEGETABLE
INGESTION
1
... — 1
0.01
— n ni
1
— i
1
— i
1 1 1 1
The oral and dermal subchronic reference dose for thallium is based on an oral study
conducted in rats. In this study, an applied dose was used.
THALLIUM RAFs
Evaluation of Subchronic Exposures
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TOLUENE CAS #: 108883
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 2 mg/kg/day (2)
Chronic Oral Reference Dose: 0.2 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 2000 Mg/m3 (2)
Chronic Inhalation Reference Concentration: 400 lig/m
3
(1)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
Rabbit studies indicate that essentially 100% of an oral dose of toluene is either excreted
as metabolites or exhaled unchanged, implying 100% absorption efficiency by the oral
route (Smith et al., 1954; El Masry et al., 1956). Oral absorption efficiency of soil-
adsorbed toluene was not changed from that of the pure compound even though
absorption was delayed in time by the presence of sandy soil (Turkall et al., in press).
El Masry, A.M., Smith, J.N. and Williams, R.T. (1956) Studies in Detoxication 69. The Metabolism ofAlkylbenzenes:
n-Propylbenzene and n-Butylbenzene with Further Observations on Ethylbenzene. Biochem. J. 64:50-56.
Smith, J.N., Smithies, R.H. and Williams, R.T. (1954) Studies in Detoxication 55. The Metabolism ofAlkylbenzenes
.
Biochem. J. 56:317-325.
Turkall, R.M., Skowronski, GA and Abdel-Rahmen, M.S. (in press) Differences in Kinetics ofPure and Soil-
Adsorbed Toluene in Orally Exposed Male Rats. Arch. Environ. Contarn. Toxicol.
The dermal absorption of toluene has been measured to be approximately 2% of the
applied dose in 4 hours, or 12% in 24 hours (Susten et al., 1990). This study allowed for
volatilization of toluene, rapidly decreasing the actual applied dose. In a second study
(Skowronski, et al., 1989), volatilization loss was minimized to less than 10% of the
applied dose by occlusion. The dermal absorption efficiency was estimated to be
approximately 90% with volatilization loss accounting for the remainder of the dose
(essentially 100% dermal absorption). The estimate was based on recovery of radioactivity
in urine, feces and expired air. The dermal absorption of toluene was unaffected by its
adsorption to clay or sandy soils. The 24 hour non-occluded value (12%) is assumed to be
the most appropriate and protective for human exposure.
Susten, A.S., Niemeier, R.W. and Simon, S.D. (1990) In Vivo Percutaneous Absorption Studies of Volatile Organic
Solvents in Hairless Mice II. Toluene, Ethylbenzene and Aniline. J. Appl. Toxicol. 10:217-225.
Skowronski, G.A., Turkall, R.M. and Abdel-Rahman, M.S. (1989) Effects of Soil on Percutaneous Absorption of
Toluene in Male Rats. J. Toxicol. Environ. Health 26:373-384.
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The oral and dermal chronic reference dose for toluene is based on an oral gavage (via
corn oil) study conducted in rats. In this study, an applied dose was used.
TOLUENE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for toluene is based on an oral gavage (via
corn oil) study conducted in rats. In this study, an applied dose was used.
TOLUENE RAFs
Evaluation of Subchronic Exposures
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1,1,1 -TRICHLOROETHANE CAS #: 71556
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.9 mg/kg/day (2)
Chronic Oral Reference Dose: 0.09 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: 10000 Mg/m3 (2)
Chronic Inhalation Reference Concentration: 1000 Hg/m (2)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
No studies were located containing information to quantitate the oral absorption
efficiency of 1,1,1-trichloroethane. However, it can be assumed to be rapidly and
completely absorbed in a manner similar to other chlorinated volatiles.
No studies were located containing information to quantitate the dermal absorption
efficiency of 1,1,1-trichloroethane. Assume a 10% absorption efficiency (non-occluded, 24
hour), comparable to other volatile compounds.
The oral and dermal chronic reference dose for 1,1,1-trichloroethane is based on an
inhalation study conducted in guinea pigs. An absorption efficiency of 30% was used to
calculate an absorbed dose. The RAFs to be used for all exposure pathways are the
absorption efficiencies of 1,1,1-trichloroethane by the route in question.
1,1,1-TRICHLOROETHANE RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for 1,1,1-trichloroethane is based on an
inhalation study conducted in guinea pigs. An absorption efficiency of 30% was used to
calculate an absorbed dose. The RAFs to be used for all exposure pathways are the
absorption efficiencies of 1,1,1-trichloroethane by the route in question.
1,1,1-TRICHLOROETHANE RAFs
Evaluation of Subchronic Exposures
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TRICHLOROETHYLENE CAS#: 79016
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.02 mg/kg/day (4)
Chronic Oral Reference Dose: 0.002 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: 180 ng/m. (3a)
Chronic Inhalation Reference Concentration: 180 lig/m
3
(3)
k -iOral Cancer Potency Factor: 0.011 (mg/kg/day)" (2h)
Inhalation Cancer Unit Risk: 0.0000017 (Mg/m3)"1 (2h)
Oral absorption studies in experimental animals indicate that trichloroethylene is
extensively absorbed by the oral route. Absorption efficiency was measured as 91% - 98%
of an applied oral dose (Prout et al., 1985; Dekant et al., 1984) determined as radioactivity
in expired air and urine. Radioactivity in the carcass was not determined. Absorption,
therefore, is assumed to be complete.
Dekant, W., Metzler, M. and Henschler, D. (1984) Novel Metabolites of Trichloroethylene, Through Dechlorination
Reactions in Rats, Mice and Humans. Biochem. Pharmacol. 33:2021-2027.
Prout, M.S., Provan, W.M. and Green, T. (1985) Species Differences in Response to Trichloroethylene. Toxicol.
Appl. Pharmacol. 79:389-400.
No studies were located regarding the dermal absorption efficiency of trichloroethylene.
Assume 10% dermal absorption (non-occluded, 24 hour) based on physical and chemical
properties similar to the other volatile compounds.
The oral and dermal cancer potency value for trichloroethylene is based on a gavage
study in mice. This toxicity value is not based on absorbed dose.
TRICHLOROETHYLENE RAFs
Evaluation of Carcinogenicity
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The oral and dermal chronic reference dose for trichloroethylene is based on an
inhalation study in rats. An absorption factor of 30% was used to calculate an absorbed
dose. The RAFs to be used for all exposure pathways are the absorption efficiencies of
trichloroethylene by the route in question.
TRICHLOROETHYLENE RAFs
Evaluation of Chronic Expousres
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The oral and dermal subchronic reference dose for trichloroethylene is based on an
inhalation study in rats. An absorption factor of 30% was used to calculate an absorbed
dose. The RAFs to be used for all exposure pathways are the absorption efficiencies of
trichloroethylene by the route in question.
TRICHLOROETHYLENE RAFs
Evaluation of Subchronic Expousres
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VINYL CHLORIDE CAS #: 75014
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.001 mg/kg/day (4)
Chronic Oral Reference Dose: 0.001 mg/kg/day (4)
Subchronic Inhalation Reference Concentration: 17 /ig/m (3a)
Chronic Inhalation Reference Concentration: 17 Hg/m (3)
Oral Cancer Potency Factor: 1.9 (mg/kg/day)"1 (2)
Inhalation Cancer Unit Risk: 0.000084 (Mg/m3)', (2)
In young human volunteers administered vinyl chloride monomer for 6 hours, an average
retention of 42% was estimated. It was not reported whether steady state had been
achieved. Maximum retention was achieved at 15 minutes and retention declined after
30 minutes after which it increased to a relatively constant value. The percentage
retained seemed to be independent of the concentration inhaled. A range of reported
inhalation absorption efficiencies is 40% - 98%, 64% being suggested as representative and
protective (Owen, 1990)
Owen, B_A. (1990) Literature-Derived Absorption Coefficients for 39 Chemicals Via Oral and Inhalation Routes of
Exposure. Regul. Toxicol. Pharmacol. 11:237-252.
Krajewski, J., Dobecki, M. and Gromiec, J. (1980) Retention of Vinyl Chloride in the Human Lung. Br. J. Ind.
Med. 37:373-374.
Rats were administered single gavage doses of
14
C-vinyl chloride in corn oil and
radioactivity levels excreted in expired air, urine and feces, as well as the amount
remaining in the carcass, were measured at 72 hours. 0.47-2.39% of the administered
dose was recovered in the feces indicating that absorption was nearly complete. Total
recovery ranged from 82.3-91.3% suggesting a substantial loss of radioactivity. An oral
absorption efficiency of 98% is assumed to be protective for human exposure.
Watanabe, P.G., McGowan, G.R. and Gehring, P.J. (1976) Fate of [^C] Vinyl Chloride After Single Oral
Administration. Toxicol. Appl. Phamacol. 36:339-352.
Two rhesus monkeys exposed from the neck down to 14C-vinyl chloride vapor were found
to have dermal absorptions of 0.031% and 0.023%, respectively. The dermal absorption of
neat vinyl chloride or soil contaminated with vinyl chloride would be expected to be
greater due to increased time of dermal contact. Therefore, the dermal absorption
efficiency is assumed to be similar to the 10% estimate derived for other volatile
compounds (non-occluded, 24 hour).
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Hefner, R.E. Jr., Watanabe, P.G. and Gehring, PJ. (1975) Percutaneous absorption of vinyl chloride. ToxiooL
Appl. Pharmacol. 34:529-532.
The oral and dermal cancer potency value for vinyl chloride is based on an inhalation
study in rats. This toxicity value is not based on absorbed dose.
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The oral and dermal chronic reference dose for vinyl chloride is based on an oral feeding
(dietary) study in rats. In this study, an applied dose was used.
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Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for vinyl chloride is based on an oral
feeding (dietary) study in rats. In this study, an applied dose was used.
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VINYL CHLORIDE RAFs
Evaluation of Subchronic Exposures
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XYLENES CAS #: 1330207
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 4 mg/kg/day (2)
Chronic Oral Reference Dose: 2 mg/kg/day (1)
Subchronic Inhalation Reference Concentration: 300 lig/m3 (2)
Chronic Inhalation Reference Concentration: 300 Hg/m (2)
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: NC
The oral absorption efficiency of 100% is estimated from limited excretion data specifying
that more than 98% of an oral dose of p-xylene was absorbed and excreted as metabolites
in urine and expired air of the rabbit.
Bray, H.G., Humphric, B.G. and Thorpe, W.V. (1949) Metabolism of Derivatives of Toluene 3. o-,m- and p-Xylenes.
Biochem. J. 45:241-244.
The dermal absorption efficiency of m-xylene, adsorbed to either sand or clay, has been
demonstrated to be essentially 100% of an occluded dose when applied to the shaved skin
of male rats (Skowronski et al., 1990). Absorption was rapid with 50% of the dose
absorbed in less than 1 hour. Soil adsorption slightly delayed the dermal absorption of
m-xylene relative to pure parent compound. The dermal absorption of soil adsorbed
mixed xylene isomers is assumed to behave as m-xylene. No information exists on non-
occluded dermal uptake, however, it would be assumed to be similar to that of its
structural analog, toluene (12% in 24 hours).
Skowronski, GA, Turkall, R.M., Kadry, A.R.M. and Abdel-Rahmen, M.S. (1990) Effects of soil on the dermal
bioavailability of m-xylene in male rats.
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The oral and dermal chronic reference dose for xylenes is based on an oral gavage study
conducted in rats. In this study, an applied dose was used.
XYLENES RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for xylenes is based on an oral gavage
study conducted in rats. In this study, an applied dose was used.
XYLENES RAFs
Evaluation of Subchronic Exposures
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ZINC CAS #: 7440666
TOXICITY INFORMATION FROM THE RESIDENTIAL SHORTFORM:
Subchronic Oral Reference Dose: 0.2 mg/kg/day (2)
Chronic Oral Reference Dose: 0.2 mg/kg/day (2)
Subchronic Inhalation Reference Concentration: Not Volatile
Chronic Inhalation Reference Concentration: Not Volatile
Oral Cancer Potency Factor: NC
Inhalation Cancer Unit Risk: Not Volatile
The absorption of zinc in humans from the diet has been determined to range from 22% -
46% (Sandstrom et al., 1987) with the upper limit of the range suggested as an
appropriate estimate. Zinc is more efficiently absorbed from drinking water with
absorption estimates ranging up to 58% (Dinsmore et al., 1985; Farah et al., 1984; Valberg
et al., 1985).
Dinsmore, W., Callender, M.E., McMaster, D., Todd, S.J. and Love, A.H.G. (1985) Zinc Absorption in Alcoholics
Using Zinc-65. Digest. 32:238-242.
Farah, DA., Hall, M.J., Mills, P.R. and Russell, R.I. (1984) Effect of Wheat Bran on Zinc Absorption. Human Nutr.
Clin. Nutr. 380:433-441.
Sandstrom, B., Davison, L., Kivisto, B., Hasselbland, C. and Cederbland, A. (1987) The Effect of Vegetables and Beet
Fibre on the Absorption of Zinc in Humans from Composite Meals. Brit. J. Nutr. 58:49-57.
Valberg, L.S., Flanagan, P.R., Ghent, C.N. and Chemberlai, MJ. (1985) Zinc Absorption and Leukocyte Zinc in
Alcoholic and Nonalcoholic Cirrhosis. Digest. Dis. SoL 30:329-333.
No studies were located quantitatively describing the dermal absorption of zinc
compounds. Assume a dermal absorption efficiency of 1% as a conservative upper-bound
estimate (see chromium).
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The oral and dermal chronic reference dose for zinc is based on an oral human dietary
study. In this study, an applied dose was used.
ZINC RAFs
Evaluation of Chronic Exposures
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The oral and dermal subchronic reference dose for zinc is based on an oral human dietary
study. In this study, an applied dose was used.
ZINC RAFs
Evaluation of Subchronic Exposures
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APPENDIX D
MA DEP DERIVED
TOXICITY VALUES
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BENZENE
SUBCHRONIC INHALATION REFERENCE CONCENTRATION
The subchronic inhalation Reference Concentration (RflC) equivalent value was derived from
information presented in the Massachusetts DEP's Methodology to Derive Indoor Air
Guidance Levels (MA DEP, 1991). The subchronic RflC is based on a 4 week study
(Rosenthal, 1987) which examined the effect of inhaled benzene (6 hours/day, 5 days/week)
on circulating lymphocytes. The ability of exposed mice to mount a cell-mediated immune
response associated with tumor surveillance was monitored and noted to be delayed,
suggesting compromised function. A Lowest Observed Adverse Effects Level (LOAEL) of 10
ppm (32.2 mg/m3) was identified by this study as a level of benzene which still resulted in
significant impairment of the lymphocyte response. Based on this LOAEL and the
application of standard uncertainty factors, a subchronic RflC equivalent may be calculated.
UF, = 10 = LOAEL -> NOAEL
UF2 = 10 = animal -> human extrapolation
UF3 = 10 = sensitive subpopulations
RfClubchronjc = 32.2 mg/m3 * 103 /xg/mg * (1/10) * (1/10) * (1/10)
3RfC«
Jbchronic = 32 Mg/m
SUBCHRONIC ORAL REFERENCE DOSE
The subchronic oral Reference Dose equivalent value was derived from information presented
in the U.S. EPA's Benzene Health Advisory (U.S. EPA, 1987). The subchronic RfD is based
on a study by Deichman (1963) who exposed Sprague-Dawley rats to benzene by inhalation
(6 hrs/day, 4 days/week) at a broad range of concentrations and monitored their hematology
weekly. By the second week of treatment, there was definite hematological impairment,
including severe leukopenia at the 61, 65 and 831 ppm exposure concentrations and
moderate leukopenia, especially in females, at the 44 and 47 ppm exposure concentrations.
Leukopenia was not observed at 29 or 31 ppm.
Based on this data, and assuming 50% absorption of inhaled benzene (Nomiyama, 1974 a,b),
a subchronic RfD equivalent may be calculated:
NOAEL2wksexposure = 31 ppm (96 mg/m3 )
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AD
ml = 96 mg/m
3
• 4 ev/wk • 6 hr/ev • 0.26 m3/d * 0.5
0.35 kg • 168 hr/1 wk
ADrat = 5 mg/kg/day
Where:
AD^ = The calculated Absorbed Dose in the rat study. In units: mg/kg/day
96 mg/m3 = No Observed Adverse Effects Level (NOAEL)
4 events/week = dosing regimen from the study
6 hours/day = dosing regimen from the study
0.26 m /day = rat inhalation rate
0.5 = absorption efficiency
0.35 kg = rat body weight
168 hrs/week = Conversion factor
The AD^, may be converted to an allowable human absorbed subchronic reference dose
equivalent through the application of standard uncertainty factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
R^-u^ = 5 mg/kg/day * (1/10) * (1/10)
RfD-ubch^* = 0.05 mg/kg/day
CHRONIC ORAL REFERENCE DOSE
The chronic oral Reference Dose (RfD) equivalent was derived from the Deichman study
described above. The AD
mt calculated above may be converted to an allowable human
absorbed chronic reference dose equivalent through the application of standard uncertainty
factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
UF„ = 10 = subchronic -> chronic3
RfDc-on* = 5 mg/kg/day * (1/10) * (1/10) * (1/10)
RfDcwon* = 0.005 mg/kg/day
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CYANIDE
SUBCHRONIC INHALATION REFERENCE CONCENTRATION
A subchronic reference concentration (RfC) equivalent value and a chronic allowable
threshold concentration (ATC) for cyanide have been developed based on human and animal
toxicological information for all forms of inhaled cyanide. The long-term health
consequences following inhalation exposure to cyanide are primarily central nervous system
effects including deafness, visual deficits and loss of muscular coordination. Other organ
systems involved (cardiovascular, thyroid, respiratory) are believed to be secondary responses.
No evidence exists to implicate cyanide as possessing carcinogenic properties, however, it is
possible that reproductive/developmental effects would result following exposure.
Few studies exist concerning health consequences of long-term cyanide inhalation. Two
possible key studies have been identified from a thorough literature search. The study of
El Ghawabi et al. (1975) is a human epidemiological study which examined thyroid
enlargement in non-smoking workers occupationally exposed to cyanide at levels of 6.4 to
10.4 ppm for 5 to 15 years. It is possible that a chronic human LOAEL of 6.4 ppm could be
identified from this study, however, it is likely that the workers were exposed to other
volatiles and particulates during the course of their employment. A second key study
(Hugod, 1981) involved the examination of myocardial histopathology in rabbits continuously
exposed to hydrogen cyanide for 28 days. From this study a subchronic animal NOAEL of
0.5 ppm can be identified. This study is flawed since the investigator did not report a dose-
response relationship and by the criticism that other cardiac indices may be more sensitive
indicators of cardiac damage (O'Flaherty and Thomas, 1982). However, this study is the only
inhalation study available with continuous exposure to cyanide of a subchronic nature.
The subchronic animal NOAEL of 0.5 ppm hydrogen cyanide gas (0.55 mg/m3 cyanide) from
the Hugod study was adjusted according to standard EPA RfC methodology (EPA, 1990) to
derive a subchronic RfC for cyanide.
Animal NOAEL (28-day, continuous, adult) = 0.55 mg/m
Human-Equivalent Concentration (x 1.8) = 0.99 mg/m3
Human NOAEL (h- 10) = 0.099 mg/m3
Adjustment for sensitive individuals (-5- 10) = 0.0099 mg/m
Low confidence in database (? 10) = 0.00099 mg/m
SUBCHRONIC RfC = 1.0 Mg/m3
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CHRONIC INHALATION REFERENCE CONCENTRATION
According to EPA RflC methodology for gases producing extrarespiratory effects, the air
concentration should be adjusted to yield a human-equivalent concentration based on the
ratio of the inhalation rate/body weight for the animal and human according to the following
equation:
(Inhalation Rate)
mbbjt
(Body Weight)
rabbit
(Inhalation Rate)human
(Body Weight)human
The confidence in the database is low since very few inhalation studies are available. Of
those studies identified, all are either methodologically flawed or utilize high exposure levels.
The Chemical Health Effects Assessment Methodology (CHEM) (MA DEP, 1990) can be used
to derive a threshold effects level (TEL) which is a concentration in air to which the public
could be exposed for an average lifetime and experience no adverse threshold health effects.
By definition, the TEL incorporates a relative source contribution factor which, when
removed, results in an Allowable Threshold Concentration (ATC) (MA DEQE, 1989). The
ATC, therefore, is analogous to a chronic RflC.
Occupational limits are used as the basis for a TEL rather than primary toxicity studies.
The most appropriate occupational limit (MAOL) for cyanide (inorganic and gaseous forms)
of 5 mg/m3 (NIOSH/OSHA) was selected and adjusted to account for continuous exposure
and for protection of children and high-risk groups to derive an adjusted MAOL of
0.07 mg/m3 .
MAOL = 5 mg/m3
Adjustment for continuous exposure (-9- 4.2) =1.2 mg/m
3
Adjustment for childhood exposure (+ 1.75) = 0.7 mg/m
3
Adjustment for high-risk groups (-§ 10 ) = 0.07 mg/m
Adjusted MAOL = 0.07 mg/m3
The adjusted MAOL was further modified to account for reproductive/ developmental effects
and the relative source contribution which are not considered in setting the occupational
exposure limit. Based on available reproductive/developmental studies, cyanide was scored
as a category "B" chemical and assigned a threshold effects uncertainty factor (TEUF) of 10.
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• TEUF adjustment (* 10) = 0.007 mg/m3
• Relative source contribution ( x .2) = 0.0014 mg/m
TEL = 1.4 Mg/m3
Removing the relative source contribution factor of 0.2 results in the Allowable Threshold
Concentration:
ATC = 7 /xg/m3
or,
CHRONIC RfC = 7 Mg/m3
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J. Ind. Med. 32:215-219.
Hugod, C. (1981) Myocardial morphology in rabbits exposed to various gas phase
constituents of tobacco smoke - an ultrastructural study. Atherosclerosis 40:181-190.
Guidance for Disposal Site Risk Characterization and Related Phase II Activities - In
Support of the Massachusetts Contingency Plan , Massachusetts Department of
Environmental Quality Engineering. [Policy No. WSC/ORS-141-891 (1989).
The Chemical Health Effects Assessment Methodology (CHEM) and The Method to
Derive Allowable Ambient Limits (AAL), Volumes I & II . Massachusetts Department
of Environmental Protection [Office of Research and Standards Publication No. 90-1]
(1990).
O'Flaherty, E.J. and Thomas, W.C. (1982) The cardiotoxicity of hydrogen cyanide as
a component ofpolymer pyrolysis smoke. Toxicol. Appl. Pharmacol. 63: 373-381.
Interim methods for development of inhalation reference concentrations
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Environmental Protection Agency, Environmental Criteria and Assessment Office.
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1,2-DICHLOROETHANE
SUBCHRONIC ORAL REFERENCE DOSE
The subchronic oral Reference Dose equivalent value was derived from information presented
in the U.S. EPA's 1,2-Dichloroethane Health Advisory (U.S. EPA, 1987). The subchronic RfD
is based on a combination of three inhalation studies (Heppel, 1946; Spencer, 1951; Hofmann,
1971) in which variious animal species were exposed to 1,2-dichloroethane (1,2-DCA) for up
to eight months. In these studies, exposures of rats and guinea pigs to air containing
100 ppm 1,2-dichloroethane for 6 to 7 hours/day, 5 days/week resulted in no mortality and
no adverse effects as determined by general appearance, behavior, growth, organ function or
blood chemistry. However, similar exposures of rats, guinea pigs, rabbits, and monkeys to
air containing 400 to 500 ppm 1,2-dichloroethane resulted in high mortality and varying
pathological findings including pulmonary congestion, diffused myocarditis, slight to moderate
fatty degeneration of the liver, kidney, adrenal and heart, and increased plasma prothrombin
time.
Based on this data, and assuming 30% absorption (U.S. EPA, 1987) of inhaled 1,2-DCA, a
subchronic RfD equivalent may be calculated:
NOAEL
emonthexposure = 100 ppm (405 mg/m3)
AD
rat
= 405 mg/m3 * 5 ev/wk * 7 hr/ev * 0.26 m3/d * 0.3
0.35 kg * 168 hr/1 wk
AD
rat
= 19 mg/kg/day
Where:
AD^ = The calculated Absorbed Dose in the rat study. In units: mg/kg/day
405 mg/m3 = No Observed Adverse Effects Level (NOAEL)
5 events/week = dosing regimen from the study
7 hours/day = dosing regimen from the study
0.26 m /day = rat inhalation rate
0.3 = absorption efficiency
0.35 kg = rat body weight
168 hrs/week = Conversion factor
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The AD^ may be converted to an allowable human absorbed subchronic reference dose
equivalent through the application of standard uncertainty factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
Wto^^ = 19 mg/kg/day * (1/10) * (1/10)
raD-ubdvon* = 0.2 mg/kg/day
CHRONIC ORAL REFERENCE DOSE
The chronic oral Reference Dose (RfD) equivalent was derived from the combination of
studies described above. The AD^ calculated above may be converted to an allowable human
absorbed chronic reference dose equivalent through the application of standard uncertainty
factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
UF3 = 10 = subchronic -> chronic
Rro*™.* = 19 mg/kg/day * (1/10) * (1/10) * (1/10)
RTOcNon* = 0.02 mg/kg/day
REFERENCES
Heppel, L.A., Neal, P.A., Perrin, T.L., Endicott, K.M. and Porterfield, V.T. (1946) The
toxicology of 1,2-dichloroethane (ethylene dichloride). J. Ind. Hyg. Tox. 28(4): 113-120.
Hofmann H.T., Birnsteil, H. and Jobst, P. (1971) Zur inhalationtoxicitat von 1,1- and
1,2-dichloroathan. Arch. Toxikol. 27:248-265.
Spencer, H.C., Rowe, V.K, Adams, E.M., McCollister, D.D. and Irish, D.D. (1951)
Vapor toxicity ofethylene dichloride determined by experiments on laboratory animals.
Ind. Hyg. Occup. Med. 4:482-493.
1.2-Dichloroethane Health Advisory . U.S. Environmental Protection Agency, Office of
Drinking Water (1987).
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ETHYLENE DIBROMIDE
SUBCHRONIC INHALATION REFERENCE CONCENTRATION
A subchronic reference concentration (RflC) equivalent value has been developed for ethylene
dibromide (EDB) based on available human and animal toxicological information. Inhalation
of EDB vapor may cause severe acute respiratory injury, central nervous system depression
and severe vomiting (Sittig, 1981). Animal studies have indicated that EDB may produce
liver and kidney injury (Sittig, 1981). EDB has been found to be a potent carcinogen in
animals and has tested positively in a number of in vitro mutagenicity assays (NIOSH, 1977).
In addition, EDB has produced developmental and reproductive effects in animals (NIOSH,
1977).
A thorough literature search was conducted for this compound. Most of the studies retrieved
focused on carcinogenicity. The majority of studies located are summarized in the NIOSH
Criteria for a Recommended Standard .... Occupational Exposure to Ethylene Dibromide
(NIOSH, 1977) and the Agency for Toxic Substances and Disease Registry Toxicological
Profile for 1,2-Dibromoethane (ATSDR, 1991). Other noncarcinogenic studies identified
which were not cited in the above publications include:
Source Species Exp. Route Duration Effect Exp. Level
Williams New Zeal. subcut. 5 days incr. mortality; 45 mg/kg/day
et al., white liver damage; (LOAEL)
1991 rabbit signif. deer, sperm
velocity; incr. sperm
abnormalities
NTP, mice, inhal. 6hr/d, deer, weight-male 3 ppm
1982 rats 5d/wk,
13 wks
rats and male/female
mice
(LOAEL)
A critical subchronic inhalation study (NTP, 1982) was identified from this search. In this
study, mice and rats were exposed to EDB by inhalation at concentrations of 0, 3, 15, or 75
ppm for 6 hours per day, 5 days per week for 13 weeks. The study produced a dose-related
depression in weight in male rats and in male and female mice. A LOAEL of 3 ppm was
identified from this study as the basis for developing a subchronic inhalation RflC using EPA
RflC methodology (EPA, 1990). The following adjustments were made:
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• Animal LOAEL (subchronic) = 3 ppm
• Corrected for continuous exposure over the subchronic period (x 6 hrs/24 hrs x 5 days/7 days) = 0.54 ppm
3 3 **-* m 3
• Converted to mg/m (based on mg/m = ppm x M.W./24.45) = 4.1 mg/m
(Molecular Weight, M.W. = 187.88)
• Human-Equivalent Concentration (to account for absorption: (based on comparison to a rat since yields the
1 3
more conservative results of the test species used: x 2.9 )) = 11.9 mg/m
• Human-Equivalent Concentration (to account for distribution, metabolism and excretion: + 10) =1.2 mg/m
• Human NOAEL (+ 10) = 0.12 mg/m3
• Adjust for sensitive individual (+ 10) = 0.012 mg/m
• Low confidence in database (* 10) = 0.0012 mg/m
SUBCHRONIC RfC = 1.2 /xg/m3
CHRONIC INHALATION REFERENCE CONCENTRATION
The Chemical Health Effects Assessment Methodology (CHEM) (MA DEP, 1990) can be used
to derive a threshold effects exposure limit (TEL) which represents a concentration in air
to which the general public can be exposed day after day for a lifetime and experience no
adverse threshold health effects. The TEL incorporates a relative source contribution factor
which, when removed, results in an Allowable Threshold Concentration (ATC) (MA DEQE,
1989). The ATC, therefore, is analogous to a chronic RfC.
Occupational limits are used as the basis for a TEL rather than primary toxicity studies.
The OSHA occupational limit of 20 ppb (NIOSH 1978) was selected as the most appropriate
occupational exposure limit (MAOL) for ethylene dibromide. The MAOL value was adjusted
to account for continuous exposure and for protection of children and high-risk groups to
derive an adjusted MAOL of 0.2 iig/m.
• MAOL = 20 ppb
3 3
• Converted to ng/m (based on fig/m = ppb x M.W./24.45) =
153.7 /xg/m3
3
• Adjustment for continuous exposure (-* 4.2) = 36.6 /xg/m
3
• Adjustment for childhood exposure (-r 1.75) = 20.9 fig/m
• Adjustment for high-risk groups (h- 10) = 2.1 /xg/m
Adjusted MAOL = 2.1 /xg/m3
According to EPA RfC methodology for gases, the air concentration should be adjusted to yield a human-equivalent
concentration based on the ratio of alveolar ventilation rate divided by the body weight of the animal species to the same
parameters for humans. The following formula was used:
(Inhalation Rate
fat
/Body Weighty )/(Inhalation Ratehuman/Body Weighthuman )
The values used in the above^ formula include inhalation rate
rat
= 0.29 m /day; body weighty = 0.35 kg;
inhalation ratehuman = 20 m /day; body weighthuman = 70 kg
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The adjusted MAOL was further modified to account for reproductive/developmental effects
not accounted for in setting the occupational exposure limit and for relative source
contribution (which is also not considered in the derivation of the occupational limit). Based
on available developmental and reproductive studies, EDB was given a hazard score of "A"
and assigned a threshold effects uncertainty factor (TEUF) of 10.
TEUF adjustment (+ 10) = 0.2/tg/m
Relative source contribution (x 0.2) = 0.04 figjm
TEL = 0.04 /xg/m3
Removing the relative source contribution factor of 0.2 results in the Allowable Threshold
Concentration:
or,
ATC = 0.2 Mg/m3
CHRONIC RfC = 0.2 fig/m
SUBCHRONIC ORAL REFERENCE DOSE (RfD)
A subchronic oral reference dose (RfD) equivalent value for ethylene dibromide (EDB) has
been developed based on human and animal toxicologic^ information. Acute oral exposure
to EDB has produced vomiting, abdominal pain, diarrhea, nausea, anuria and death (NIOSH,
1977). Animal studies have indicated that EDB may produce liver and kidney injury (Sittig,
1981). EDB has been found to be a potent carcinogen in animals and has tested positively
in a number of in vitro mutagenicity assays (NIOSH, 1977). In addition, EDB has produced
developmental and reproductive effects in animals (NIOSH, 1977).
A thorough literature search was conducted for this compound. Most of the available studies
for EDB are either acute exposure studies or focus on carcinogenicity as an endpoint. The
majority of studies located are summarized by NIOSH (1977) and the Agency for Toxic
Substances and Disease Registry (ATSDR, 1991). Other potentially pertinent studies
investigating noncarcinogenic endpoints which were not cited in the above documents
include:
Source Species Exp. Route Duration Effect Exp. Level
Williams New Zeal. subcut. 5 days incr. mortality; 45 mg/kg/day
et al., white liver damage; (LOAEL)
1991 rabbit signif. deer, sperm
velocity; incr. sperm
abnormalities
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Several studies (NIOSH, 1977) done by the same group of investigators which are cited in
the above document focus on reproductive effects produced in bulls given oral doses of EDB.
A critical subchronic study (Amir et al., 1965) was selected as the basis for developing the
RfD. In this study, Israeli-Friesian bulls were given oral doses of EDB from age 4 days to
24 months. From to 3 months, 2 mg/kg/day was administered via ethyl alcohol in milk.
From 3-12 months, 2 mg/kg/day was dissolved in soybean oil and put into the feed. After
12 months, 4 mg/kg/day was administered orally in an oil mixture by capsule every other
day. The average daily dose for this period was 2 mg/kg/day. Effects noted included
abnormal spermatozoa and decreased spermatozoic density and motility. Based on the
results of this study, an animal LOAEL of 2 mg/kg/day has been identified. The LOAEL
has been adjusted using modified EPA RfD methodology (U.S. EPA, 1987) to derive a
subchronic RflC of 0.0002 mg/kg/day.
Animal LOAEL (subchronic) = 2 mg/kg/day
Animal NOAEL (+ 10) = 0.2 mg/kg/day
Human NOAEL (* 10) - 0.02 mg/kg/day
Adjust for sensitive individual (* 10) = 0.002 mg/kg/day
Low confidence in database (•* 10) = 0.0002 mg/kg/day
SUBCHRONIC RfD = 0.0002 mg/kg/day
The confidence in the database is low since there are few subchronic oral studies. Of the
studies located, reproductive toxicity was the only health endpoint examined. In addition,
little to no information was located regarding subchronic oral exposure in humans. No
adequate dose-response data were identified. Although standard EPA RfD methodology does
not include an uncertainty factor for low confidence in the database, an uncertainty factor
of 10 is included in the EPA methodology for developing inhalation reference concentrations
(RfCs). This factor will be adopted for development of the EDB oral RfD.
CHRONIC ORAL REFERENCE DOSE (RfD)
There were no chronic oral studies identified for EDB. Based on the approach used by EPA
to extrapolate a chronic NOAEL from a subchronic NOAEL, an additional uncertainty factor
of 10 was applied to the NOAEL to approximate a chronic RfD for this compound. Thus:
• Subchronic RfD = 0.0002 mg/kg/day
• Chronic RfD (+ 10) = 0.00002 mg/kg/day
CHRONIC RfD = 0.00002 mg/kg/day
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LEAD
CHRONIC AND SUBCHRONIC ORAL REFERENCE DOSES
The Office of Research and Standards currently recommends the use of the toxicity criteria
for lead back-calculated from the promulgated National Primary Drinking Water Regulation
Action Level of 15 Mg/L (U.S. EPA, 1991).
It should be explicit in all reports using these criteria that they are not considered risk free
levels. These criteria are described as Regulatory Daily Doses (RDDs) to distinguish them
from the U.S. EPA's Reference Doses (which are assumed to result in no adverse effects) and
the subjective term "Allowable Daily Intake".
The values are:
RDDon*^^ = 7.5 x 10" mg/kg/day
RDDon^omc = 7.5 x KT mg/kg/day
The RDDs given here are absorbed doses.
The aim of this section was to identify surrogate toxicity values which can effectively be used
in the evaluation C.21E disposal sites. It is understood that while these interim values are
not considered to be without risk of harm to health, they are within the range of "acceptable
risk" for this chemical. Many of the standards and guidelines (Table 1) used to develop the
values listed in Table 2 have undergone extensive national public review, and the risk
balancing/risk management decisions made are documented (federal drinking water
standards). Others have undergone statewide review or none at all.
Of the seven criteria considered, the two extreme toxicity values were eliminated from
further consideration: the 1991 Maximum Contaminant Level Goal was considered infeasible
(the derived toxicity value is mg/kg/day), and the Massachusetts Department of Public
Health "Dangerous Level in Soil" (MA DPH) is more representative of a trigger level for a
Short-Term Measure than a clean-up level (the derived value is 0.005 mg/kg/day).
Among the remaining five criteria, toxicity values range from 0.00025 mg/kg/day to 0.0025
mg/kg/day, a span of a factor often. Three values (from the 1985 PMCLG, the 1991 Action
Level, and the ORS manipulation of the lead model) are clustered in the range 0.00075 to
0.0013 mg/kg/day (less than a factor of two). The 1991 Action Level value was chosen
because:
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(1) The value is consistent with results of the back-calculation from the
1985 PMCLG and ORS manipulation of the computerized lead model,
(2) It is back-calculated from a standard (published in its final form in the
June 7, 1991 Federal Register) and thus represents the most recent
U.S. EPA statement as to what it considers an upper limit of an
"allowable" exposure,
(3) The use of the most current drinking water standard is consistent with
guidance that existing standards for lead be used to evaluate
noncarcinogenic risk (U.S. EPA, 1986),
This discussion is in response to a need to include quantitative evaluations of lead in the
Residential ShortForm pursuant to the Massachusetts Contingency Plan (MCP, 310 CMR 40).
These daily intakes would be used in the absence of a U.S. EPA verified Reference Dose
(RfD) or Carcinogenic Potency (Slope) Value (CPV) pending a Departmental or Bureau of
Waste Site Cleanup policy addressing such exposures.
DISCUSSION
Lead is a ubiquitous environmental contaminant in Massachusetts as a result of the historical
use of lead paint and leaded fuels, as well as those releases of lead regulated under the MCP.
The lead problem is further complicated by its toxicity: there appears to be no concentration
of lead which is free from the risk of adverse non-carcinogenic health impacts if exposure
were to occur. In addition, lead is considered to be a "probable human carcinogen" (U.S. EPA,
1989a).
The problematical regulation of lead is not limited to the the Residential ShortForm or the
Department's Bureau of Waste Site Cleanup assessment and remediation program, and
should be the subject of a Department-wide strategy to reduce all potential exposures to lead
in the Commonwealth. As with most complex issues, such a policy cannot be completed in
a matter of months. In the interim, however, it is vital that the Residential ShortForm have
some means of quantitatively assessing lead contamination at C.21E disposal sites.
Various U.S. EPA and Massachusetts regulatory actions concerning oral exposures to lead are
summarized in Table 1. Given that no exposure to lead in the environment is risk-free,
virtually all of the regulatory values presented in Table 1 involve risk management decisions
which balance the potential health impacts with technical feasibility and cost considerations.
The use of traditional methods of developing strictly health-based criteria or assessing risk
is not currently an option in the case of lead for two reasons:
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(1) there is no No Observed Adverse Effect Level (NOAEL) which is used to
derive a Reference Dose or Reference Concentration, the usual bases for
regulating chemicals with non-carcinogenic effects, and
(2) there is no Carcinogenic Potency Value, the usual basis for regulating
chemicals considered to be carcinogenic.
In the absence of these toxicity values, a risk assessor may search the toxicologic^ literature
for alternative values, or derive such alternative values from any existing standards or
guidelines for that chemical. The latter methodology is described in the Department's
Guidance for Disposal Site Risk Characterization and Related Phase IIActivities - In Support
of the Massachusetts Contingency Plan (MA DEQE, 1989) and the U.S. EPA Region I
Supplemental Risk Assessment Guidance for the Superfund Program (U.S. EPA 1989b). This
process for deriving toxicity values has been chosen for this interim approach to assessing
exposure to lead at C.21E disposal sites.
It should be noted that, in certain situations, the use of these toxicity values may indicate
a need for remediation at C.21E disposal sites where lead concentrations are at or below
"background" levels. The Massachusetts Contingency Plan addresses these circumstances in
40.545 (3)0) 2., Requirements When a Remedial Response Action is Necessary. This section
states that if the evaluation of risk indicates a need for remediation and if the levels of oil
or hazardous materials which would exist in the absence of the disposal site (i.e.,
"background") prevent achievement of guidelines, policies or total site risk limits, then the
achievement of such "background" levels may, upon approval of the Department, be
considered to meet the requirements for a permanent solution.
Table 2 summarizes these alternative toxicity values. The derivation for the chosen level
follows.
N.B.: Many of the standards and guidelines which serve as the source for
these "alternative toxicity values" incorporate risk management decisions
which considered factors beyond solely the potential health impacts.
These values should not be considered "safe", or "risk-free" levels.
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TABLE 1
U.S. EPA and MASSACHUSETTS REGULATORY ACTIONS
WATER
SOIL
U.S. EPA - Proposed (1985) Maximum Contaminant
Level Goal for Drinking Water (PMCLG)
U.S. EPA/Massachusetts - Maximum Contaminant
Level for Drinking Water (MCL)
U.S. EPA (1991) Maximum Contaminant Level Goal
for Drinking Water (MCLG)
U.S. EPA ( 1991) NPDWR Action Level (AL) (Measured
at the tap)
U.S. EPA - Ambient Water Quality Criteria (AWQC)
(Human Health)
Massachusetts - "Dangerous Level in Soil" (MA DPH)
U.S. EPA - OSWER Lead Clean-up Levels at
Superfund Sites
20/ig/L
50/ig/L
Ofig/L
15/xg/L
50/ig/L
1000 mg/kg
500 - 1000 mg/kg
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TABLE 2
SUMMARY OF ALTERNATIVE ABSORBED ORAL TOXICITY VALUES
FOR THE EVALUATION OF LEAD IN RISK CHARACTERIZATIONS
PERFORMED UNDER THE MCP
ORAL
SOURCE
back-calculated from
PMCLG = 20 Mg/L
back-calculated from
MCLG = /xg/L
back-calculated from
MCL = 50 Mg/L
back-calculated from
Action Level = 15 figfL
back-calculated from UPTAKE/BIOKINETIC MODEL
back-calculated from MA DPH
"Dangerous Level in Soil"
back-calculated from EPA OSWER Directive Levels
VALUE
0.001 mg/kg/day
mg/kg/day
0.0025 mg/kg/day
0.00075 mg/kg/day
0.0013 mg/kg/day
0.005 mg/kg/day
0.0025 mg/kg/day
DOSE ESTIMATES FROM EXISTING STANDARDS AND GUIDELINES
In the absence of a U.S. EPA verified reference dose and/or reference concentration, or
equivalent published toxicity values which could be used to evaluate risk of harm to human
health, guidance has been provided (MA DEQE, 1989; U.S. EPA, 1989b) to assist risk
assessor in the development of acceptable alternative dose. These alternative dos a are
generally back-calculated from existing standards and guidelines. While this methodology
is relatively straight-forward, it is important to remember that standards and guidelines may
consider other factors (such as cost and feasibility) in addition to health impacts. Alternative
toxicity values calculated in this manner must be accompanied by a discussion of the basis
of the standard or guideline used as a starting point.
Action Level (AL)
An Interim Maximum Contaminant Level of 0.05 mg/L was promulgated for lead by the U.S.
EPA in 1980. On June 7, 1991, the U.S. EPA promulgated the National Primary Drinking
Water Regulation for Lead (40 CFR Part 141 and 142, Federal Register Vol. 56 No. 110)
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which established an Action Level of 0.015 mg/liter. The Action Level is triggered if more
than 10% of the targeted tap samples is greater than 0.015 mg/1. [An Action Level is defined
as that concentration of lead in water that determines, in some cases, whether a water
system must install corrosion control treatment, monitor source water, replace lead service
lines, and undertake a public education process.! The Action Level is a standard based on
health considerations, but which also considers risk management issues such as technological
or economic feasibility. The following calculations detail the derivation of an Regulatory
Daily Dose (RDD) the AL (the RDD,, ).
ARDD = STND * VI -r BW
Where:
ARDD = Applied Regulatory Daily Dose (mg/kg/day) back-calculated from the Action Level
STND = the 1991 Action Level (AL: 0.015 mg/L)
VI = Daily Intake of Water for a Child, 1 L/day
BW = A Child's Body Weight, 10 kg
ARDD., = 0.015 mg/L * 1 L/day -r 10 kg
ARDD,,, = 0.0015 mg/kg/day
Assuming that 50% of the lead ingested in the drinking water is absorbed in the
gastrointestinal tract, the absorbed Regulatory Daily Doses based upon the Action Level
would be:
RDD., = 0.0015 mg/kg/day * 0.5
RDD„ = 0.00075 mg/kg/day
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METHYL TERTIARY BUTYL ETHER (MTBE)
SUBCHRONIC ORAL REFERENCE DOSE
The subchronic oral Reference Dose equivalent value was derived from information presented
in the U.S. EPA's Methvl-t-Butvl Ether Health Advisory (U.S. EPA, 1989). The subchronic
RfD is based on a 13-week inhalation study (Greenough, 1980) in which rats were exposed
for 6 hours/day, 5 days/week for 13 weeks to 0, 250, 500 or 1,000 ppm MTBE. No effects
were seen on survival, body weight, hematological, clinical chemistry or urinalysis values, or
gross or microscopic appearance of tissues or organs. A slight reduction in absolute and
relative lung weight was observed in females exposed to 1,000 ppm MTBE. The only other
effect noted by the investigators was an increasing depth of anesthesia with increasing
exposure concentration. Exposure-effect relationships for anesthesia were not further
delineated. Accordingly, 250 ppm is considered a LOAEL for anesthetic effects.
Based on this data, and assuming 50% absorption of inhaled methyl tert-butyl ether, a
subchronic RfD equivalent may be calculated:
LOAEL 13weekexposure = 250 ppm (901 mg/m3)
AD^ = 901 mg/m3 * 5 ev/wk * 6 hr/ev * 0.217 m3/d * 0.5
0.336 kg * 168 hr/1 wk
AD„, = 52 mg/kg/day
Where:
AD
mt
= The calculated Absorbed Dose in the rat study. In units: mg/kg/day
901 mg/m3 = Lowest Observed Adverse Effects Level (LOAEL)
5 events/week = dosing regimen from the study
6 hours/day = dosing regimen from the study
0.217 m /day = rat inhalation rate (based on measured body weight)
0.5 = absorption efficiency
0.336 kg = rat body weight from study
168 hrs/week = Conversion factor
The AD^ may be converted to an allowable human absorbed subchronic reference dose
equivalent through the application of standard uncertainty factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
UF3 = 10 = LOAEL -> NOAEL
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Rtt>
-ubch,onlc = 52 mg/kg/day * (1/10) * (1/10) * (1/10)
RfD-*^ = 0.052 mg/kg/day
CHRONIC ORAL REFERENCE DOSE
The chronic oral Reference Dose (RfD) equivalent was derived from the Greenough study
described above. The AD^, calculated above may be converted to an allowable human
absorbed chronic reference dose equivalent through the application of standard uncertainty
factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
UF3 = 10 = subchronic -> chronic
UF4 = 10 = LOAEL -> NOAEL
RfDch***: = 52 mg/kg/day * (1/10) * (1/10) * (1/10) * (1/10)
RfDcuon* = 0.0052 mg/kg/day
REFERENCES
Methyl tertiarv-butvl ether (Driverton) three month inhalation toxicity in rats .
Greenough, R.J., P. Mc Donald, P. Robinson, J.R. Cowie, W. Maule, F. Macnaughton,
and A. Rushton, Project No. 413038. Unpublished report submitted to Chemische
Werke Hols, AG. Marl, West Germany. 230pp. (1980)
Methvl-t-Butvl Ether Health Advisory . U.S. Environmental Protection Agency, Office
of Drinking Water (1989).
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POLYCHLORINATED BIPHENYLS
CHRONIC ORAL REFERENCE DOSE
The chronic oral reference dose equivalent value for polychlorinated biphenyls (PCBs) was
developed with information contained in the (DRAFT) Toxicological Profile for Selected PCBs
(ATSDR, 1991). One study (Tryphonas et al., 1989) looked at several immunological
parameters in monkeys fed dietary doses of Aroclor 1254 ranging from 0.005 to 0.08
mg/kg/day over a period of 133 weeks (27 months). All doses tested induced a significant
and dose-related decrease in antibody levels (IgG and IgM) in response to immunization with
SRBC-7, 14 and 21 days after immunization. The ATSDR calculated a "Minimal Risk Level"
(MRL) of 0.005 /xg/kg/day based upon this study in a manner similar to that described below.
LOAEL = 0.005 mg/kg/day
UF, = 10 = LOAEL to NOAEL extrapolation
UF2 = 10 = animal -> human extrapolation
UF3 = 10 = sensitive subpopulations
RfD-***™* = 0.005 mg/kg/day * (1/10) * (1/10) * (1/10)
Rfl>on^omc = 5 x 10* mg/kg/day
SUBCHRONIC ORAL REFERENCE DOSE
The chronic oral RfD equivalent derived above is based upon immunological effects which
have been demonstrated following shorter exposures periods (Loose et al., 1978a, 1978b;
Thomas and Hinsdill, 1978; Truelove et al., 1982) without the demonstration of a NOAEL.
As a result, the chronic oral RfD equivalent has been adopted as the subchronic oral RfD
equivalent.
Rro
ool^Wibchronic
= 5 x 10* mg/kg/day
MA DEP, OPvS & BWSC
Documentation for the Risk Assessment ShortForm Residential Scenario
versions 1.6 a & b - 10/92
D -27
REFERENCES
DRAFT Toxicological Profile for Selected PCBs . Agency for Toxic Substances and
Disease Registry, U.S. Public Health Service (1991).
Loose, L.D., Silkworth, J.B., Pittman, K.A., et al. (1978a) Impaired host resistance to
endotoxin and malaria in polychlorinated biphenyl- and hexachlorobenzene-treated
mice. Infection and Immunity 20:30-35.
Loose, L.D., Pittman, K.A., Benitz, K.F., et al. (1978b) Environmental chemical-
induced immune dysfunction. Ecotoxicol Environ Safety 2:173-198.
Thomas, P.T. and Hinsdill, R.D. (1978) Effect of polychlorinated biphenyls on the
immune responses ofrhesus monkeys and mice. Toxicol Appl Pharmacol 44:41-51.
Truelove, J., Grant, D., Mes, J. et al. (1982) Polychlorinated biphenyl toxicity in the
pregnant cynomolgus monkey: A pilot study. Arch Environ Contain Toxicol
11:583-588.
Tryphonas, H., Hayward, S., O'Grady, L., et al. (1989) Immunotoxicity studies ofPCB
(Aroclor 1254) in the adult rhesus (Macaca mulatta) monkey -preliminary report. Int
J Immunopharmacol 11:199-206.
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TRICHLOROETHYLENE
SUBCHRONIC ORAL REFERENCE DOSE
The subchronic oral Reference Dose equivalent value was derived from information presented
in the U.S. EPA's Trichloroethvlene Health Advisory (U.S. EPA, 1987). The subchronic RfD
is based on a subacute inhalation study (Kimmerle, 1973). In this study rats were exposed
to 55 ppm trichloroethvlene for 8 hours/day, 5 days/week for 14 weeks. Indices of toxicity
include hematological investigation, liver and renal function tests, blood glucose and
organ/body weight ratios. Liver weights were shown to be elevated while other test values
were not different from controls. The elevated liver weights could be interpreted to be the
result of hydropic changes or fatty accumulation. The no-observed-effect level was not
identified since only a single concentration was administered
Based on this data, and assuming 30% absorption of inhaled trichloroethvlene, a subchronic
RfD equivalent may be calculated:
LOAEL 14_kexpo9ure = 55 ppm (300 mg/m3)
AD
ral
= 300 mg/m3 * 5 ev/wk * 8 hr/ev * 0.26 m3/d • 0.3
0.35 kg • 168 hr/1 wk
AD^ = 16 mg/kg/day
Where:
AD
ra| = The calculated Absorbed Dose in the rat study. In units: mg/kg/day
300 mg/m3 = Lowest Observed Adverse Effects Level (LOAEL)
5 events/week = dosing regimen from the study
8 hours/day = dosing regimen from the study
0.26 myday = rat inhalation rate
0.3 = absorption efficiency
0.35 kg = rat body weight
168 hrs/week = Conversion factor
The AD
rat
may be converted to an allowable human absorbed subchronic reference dose
equivalent through the application of standard uncertainty factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
UF3 = 10 = LOAEL -> NOAEL
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RTO-ubcwon* = 16 mg/kg/day * (1/10) * (1/10) • (1/10)
R^bc^on* = 0.02 mg/kg/day
CHRONIC ORAL REFERENCE DOSE
The chronic oral Reference Dose (RfD) equivalent was derived from the Kimmerle study
described above. The AD^ calculated above may be converted to an allowable human
absorbed chronic reference dose equivalent through the application of standard uncertainty
factors:
UF, = 10 = animal -> human extrapolation
UF2 = 10 = sensitive subpopulations
UF3 = 10 = subchronic -> chronic
UF4 = 10 = LOAEL -> NOAEL
RTOcvooic = 16 mg/kg/day * (1/10) * (1/10) * (1/10) * (1/10)
RTOrfuon* = 0.002 mg/kg/day
REFERENCES
Kimmerle, G. and Eben, A. (1973) Metabolism, excretion and toxicology of
trichloroethylene after inhalation. 1. Experimental exposure on rats. Arch. Toxicol.
30:115.
Trichloroethylene Health Advisory
. U.S. Environmental Protection Agency, Office of
Drinking Water (1987).
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VINYL CHLORIDE
CHRONIC ORAL REFERENCE DOSE
The chronic oral Reference Dose equivalent value was derived from information presented
in the U.S. EPA's Vinyl Chloride Health Advisory (U.S. EPA, 1987). The chronic RfD is
based on a lifetime feeding study (Til, 1981). In this study Til extended earlier work (Feron,
1981) to include lower doses with basically the same protocol used in the latter study.
Carcinogenic and noncarcinogenic effects were evident with a vinyl chloride dietary level of
1.3 mhg/kg/day. At dietary levels of 0.014 and 0.13 mg/kg/day, increased incidences of
basophilic foci of cellular alteration in the liver of female rats were evident. However,
basophilic foci by themselves are concluded not to represent an adverse effect on the liver
in the absence of additional effects indicative of liver lesions such as those found in the
1.3 mg/kg/day group; and a dose-related increase in basophilic foci was not evident.
Therefore, the dose of 0.13 mg/kg/day is identified as the NOAEL for noncarcinogenic
effects.
Based on this data, a chronic RfD equivalent may be calculated:
NOAEL
r„,rte(imeexposure = 0.13 mg/kg/day (applied dose)
The NOAEL^,.,^,^ may be converted to an allowable human applied chronic reference dose
equivalent through the application of standard uncertainty factors:
UF, = 10 = animal -> human extrapolation
UF
2
= 10 = sensitive subpopulations
R^c*™* = 0-13 mg/kg/day * (1/10) * (1/10)
RfD
.*«nic = °-001 mg/kg/day (applied dose)
SUBCHRONIC ORAL REFERENCE DOSE
The chronic oral RfD is assumed to be protective of subchronic expsures, and the subchronic
oral RfD is set equal to the chronic oral RfD.
RfD
.ubeh(onic = 0-001 mg/kg/day (applied dose)
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APPENDIX E
SOFTWARE LICENSE
THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK
Use of this software shall be considered acknowledgement of the following terms and
conditions:
1. The Department may update, modify, alter or change the Risk Assessment
ShortForm and Documentation for the Residential ShortForm at any time and
issue a revised version. The User accepts responsibility for ensuring that any
given version of this material is acceptable to the Department at the time it
is employed for a regulatory purpose.
2. The User agrees not to modify or change the contents of the software or
documentation in any substantive way.
3. A person who submits or keeps information generated from the use of a
modified version of this software as part of any record, report or file required
by the Massachusetts Contingency Plan may be subject to civil or criminal
penalties for making false, inaccurate, incomplete or misleading statements
pursuant to 310 CMR 40.009.
4. The software is provided in an "as is" condition. Under no circumstances will
the Commonwealth of Massachusetts be liable for any loss or damage resulting
to the property of the User or any third party or for personal injury regardless
of the form of the action whether in contract or tort. The Commonwealth of
Massachusetts disclaims all other warranties, either express or implied,
including all warranties of merchantability or fitness for a particular purpose.
In no event will the Commonwealth of Massachusetts be liable for loss of
profits, loss of records, loss of facility or equipment use, or interruption of
business or power source, or for any special, indirect, incidental or
consequential damages of any kind, whether under this agreement or
otherwise, even if the Commonwealth of Massachusetts has been advised of
the possibility of such damages. The User agrees to indemnify the
Commonwealth ofMassachusetts for any liability resulting from the use of this
software.
Any questions concerning the use or duplication of this software and documentation should
be directed to the Massachusetts Department of Environmental Protection, Office of
Research and Standards (617)292-5570.
THE USER ACKNOWLEDGES THAT THE USER HAS READ THIS SOFTWARE
LICENSE, UNDERSTANDS IT, AND AGREES AND INTENDS TO BE BOUND BY
ITS TERMS.
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SOFTWARE LICENSE
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Protection (MA DEP) is,distributing this software and documentation free andXT^licensed to use this software without charge.
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should also be distributed as a complete package. The Massachusetts
Department ofEnvironmental Protection must be acknowledged as the source
attributed
A C°Py
°
f^ UCeD8e mU8t be induded ta the package
DUtribution of the flis* Assessment Sfewtfbrm and Documentation for the
Residential ShortForm must be done without ch„rg» You are not permittedby license to request or accept any remuneration of any kind for the
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follows:
Bulletin board systems or other electronic information services are permitted to make this softwareand documentauon available for download and charge their customary fees, ifany, for access to the
b. Users groups and other not-for-profit organizations that distribute this software may charge a
reasonable fee to cover duplication and related costs.
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